10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED March 31, 2023
OR
☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE TRANSITION PERIOD FROM _____TO

COMMISSION FILE NUMBER: 814-00802

HORIZON TECHNOLOGY FINANCE CORPORATION

(Exact name of registrant as specified in its charter)

Delaware	27-2114934
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
312 Farmington Avenue
Farmington, CT	06032
(Address of principal executive offices)	(Zip Code)

(860) 676‑8654

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☐ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b‑2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☐
Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b‑2 of the Exchange Act). Yes ☐ No ☒

The number of shares of the registrant’s common stock traded under the symbol “HRZN” on the Nasdaq Global Select Market, $0.001 par value per share, outstanding as of May 2, 2023 was 28,656,554.

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Ticker symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001 per share	HRZN	The Nasdaq Stock Market LLC
4.875% Notes due 2026	HTFB	The New York Stock Exchange
6.25% Notes due 2027	HTFC	The New York Stock Exchange

HORIZON TECHNOLOGY FINANCE CORPORATION

FORM 10‑Q

TABLE OF CONTENTS

		Page
PART I
Item 1	Consolidated Financial Statements.	3
	Consolidated Statements of Assets and Liabilities as of March 31, 2023 (unaudited) and December 31, 2022	3
	Consolidated Statements of Operations for the three months ended March 31, 2023 and 2022 (unaudited)	4
	Consolidated Statements of Changes in Net Assets for the three months ended March 31, 2023 and 2022 (unaudited)	5
	Consolidated Statements of Cash Flows for the three months ended March 31, 2023 and 2022 (unaudited)	6
	Consolidated Schedules of Investments as of March 31, 2023 (unaudited) and December 31, 2022	7
	Notes to the Consolidated Financial Statements (unaudited)	21
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	44
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	59
Item 4.	Controls and Procedures	60
PART II
Item 1.	Legal Proceedings	60
Item 1A.	Risk Factors	60
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	61
Item 3.	Defaults Upon Senior Securities	61
Item 4.	Mine Safety Disclosures	61
Item 5.	Other Information	61
Item 6.	Exhibits	61
	Signatures	62
EX‑31.1
EX‑31.2
EX‑32.1
EX‑32.2

2

PART I: FINANCIAL INFORMATION

Item 1. Consolidated Financial Statements

Horizon Technology Finance Corporation and Subsidiaries

Consolidated Statements of Assets and Liabilities

(Dollars in thousands, except share and per share data)

	March 31,			December 31,
	2023			2022
	(Unaudited)
Assets
Non-affiliate investments at fair value (cost of $724,162 and $721,248, respectively)	$	714,466		$	720,026
Non-controlled affiliate investments at fair value (cost of $0 and $0, respectively) (Note 5)		846			—
Total investments at fair value (cost of $724,162 and $721,248, respectively) (Note 4)		715,312			720,026
Cash		19,844			20,612
Investments in money market funds		23,698			7,066
Restricted investments in money market funds		2,987			2,788
Interest receivable		13,843			13,573
Other assets		2,554			2,761
Total assets	$	778,238		$	766,826
Liabilities
Borrowings (Note 7)	$	439,645		$	434,078
Distributions payable		9,365			9,159
Base management fee payable (Note 3)		1,059			1,065
Incentive fee payable (Note 3)		2,978			1,392
Other accrued expenses		3,508			2,684
Total liabilities		456,555			448,378
Commitments and contingencies (Notes 3 and 8)
Net assets
Preferred stock, par value $0.001 per share, 1,000,000 shares authorized, zero shares issued and outstanding as of March 31, 2023 and December 31, 2022		—			—
Common stock, par value $0.001 per share, 100,000,000 shares authorized, 28,544,822 and 27,920,838 shares issued and 28,377,357 and 27,753,373 shares outstanding as of March 31, 2023 and December 31, 2022, respectively		30			29
Paid-in capital in excess of par		393,312			385,921
Distributable earnings (loss)		(71,659	)		(67,502	)
Total net assets		321,683			318,448
Total liabilities and net assets	$	778,238		$	766,826
Net asset value per common share	$	11.34		$	11.47

See Notes to Consolidated Financial Statements

3

Horizon Technology Finance Corporation and Subsidiaries

Consolidated Statements of Operations (Unaudited)

(Dollars in thousands, except share and per share data)

	For the Three Months Ended
	March 31,
	2023			2022
Investment income
Interest income on non-affiliate investments	$	27,399		$	13,853
Fee income on non-affiliate investments		638			351
Total investment income		28,037			14,204
Expenses
Interest expense		7,120			3,424
Base management fee (Note 3)		3,201			2,244
Performance based incentive fee (Note 3)		2,978			1,424
Administrative fee (Note 3)		440			362
Professional fees		658			577
General and administrative		445			344
Total expenses		14,842			8,375
Net investment income before excise tax		13,195			5,829
Provision for excise tax		184			100
Net investment income		13,011			5,729
Net realized and unrealized loss
Net realized (loss) gain on non-affiliate investments		(168	)		30
Net realized (loss) gain on investments		(168	)		30
Net unrealized depreciation on non-affiliate investments		(8,383	)		(2,287	)
Net unrealized appreciation on non-controlled affiliate investments		846			—
Net unrealized appreciation on controlled affiliate investments		—			50
Net unrealized depreciation on investments		(7,537	)		(2,237	)
Net realized and unrealized loss		(7,705	)		(2,207	)
Net increase in net assets resulting from operations	$	5,306		$	3,522
Net investment income per common share	$	0.46		$	0.26
Net increase in net assets resulting from operations per common share	$	0.19		$	0.16
Distributions declared per share	$	0.33		$	0.30
Weighted average shares outstanding		28,227,100			21,904,160

See Notes to Consolidated Financial Statements

4

Horizon Technology Finance Corporation and Subsidiaries

Consolidated Statements of Changes in Net Assets (Unaudited)

(Dollars in thousands, except share data)

					Paid-In Capital
	Common Stock				in Excess of		Distributable			Total Net
	Shares		Amount		Par		Earnings			Assets
Balance at December 31, 2021		21,217,460	$	22	$	301,359		(56,046	)	$	245,335
Issuance of common stock, net of offering costs		2,750,171		3		38,184		—			38,187
Net increase in net assets resulting from operations, net of excise tax:
Net investment income, net of excise tax		—		—		—		5,729			5,729
Net realized gain on investments		—		—		—		30			30
Net unrealized depreciation on investments		—		—		—		(2,237	)		(2,237	)
Issuance of common stock under dividend reinvestment plan		9,506		—		145		—			145
Distributions declared		—		—		—		(7,200	)		(7,200	)
Balance at March 31, 2022		23,977,137		25		339,688		(59,724	)		279,989
Balance at December 31, 2022		27,753,373		29		385,921		(67,502	)		318,448
Issuance of common stock, net of offering costs		605,848		1		7,173		—			7,174
Net increase in net assets resulting from operations, net of excise tax:
Net investment income, net of excise tax		—		—		—		13,011			13,011
Net realized loss on investments		—		—		—		(168	)		(168	)
Net unrealized depreciation on investments		—		—		—		(7,537	)		(7,537	)
Issuance of common stock under dividend reinvestment plan		18,136		—		218		—			218
Distributions declared		—		—		—		(9,463	)		(9,463	)
Balance at March 31, 2023		28,377,357	$	30	$	393,312	$	(71,659	)	$	321,683

See Notes to Consolidated Financial Statements

5

Horizon Technology Finance Corporation and Subsidiaries

Consolidated Statements of Cash Flows (Unaudited)

(Dollars in thousands)

	For the three months ended March 31,
	2023			2022
Cash flows from operating activities:
Net increase in net assets resulting from operations	$	5,306		$	3,522
Adjustments to reconcile net increase in net assets resulting from operations to net cash provided by (used in) operating activities:
Amortization of debt issuance costs		478			336
Net realized loss (gain) on investments		168			(30	)
Net unrealized depreciation on investments		7,537			2,237
Purchase of investments		(47,008	)		(94,485	)
Principal payments received on investments		39,756			14,145
Payment-in-kind interest on investments		(1,204	)		—
Proceeds from sale of investments		6,520			21,280
Changes in assets and liabilities:
Decrease (increase) in interest receivable		840			(866	)
Increase in end-of-term payments		(1,017	)		(1,285	)
Decrease in unearned income		(1,148	)		(81	)
Decrease in other assets		98			652
Increase (decrease) in other accrued expenses		824			(274	)
(Decrease) increase in base management fee payable		(6	)		79
Increase (decrease) in incentive fee payable		1,586			(591	)
Net cash provided by (used in) operating activities		12,730			(55,361	)
Cash flows from financing activities:
Repayment of 2019 Asset-Backed Notes		(4,783	)		(12,352	)
Proceeds from issuance of common stock, net of offering costs		7,174			38,187
Advances on Credit Facilities		10,000			25,000
Repayment of Credit Facilities		—			(20,000	)
Debt issuance costs		(19	)		(550	)
Distributions paid		(9,039	)		(6,227	)
Net cash provided by financing activities		3,333			24,058
Net increase (decrease) in cash, cash equivalents and restricted cash		16,063			(31,303	)
Cash, cash equivalents and restricted cash:
Beginning of period		30,466			47,281
End of period	$	46,529		$	15,978
Supplemental disclosure of cash flow information:
Cash paid for interest	$	6,623		$	3,044
Supplemental non-cash investing and financing activities:
Warrant investments received and recorded as unearned income	$	141		$	1,174
Distributions payable	$	9,365		$	7,193
End-of-term payments receivable	$	10,799		$	6,522
Non-cash income	$	3,944		$	1,424

	March 31,
	2023		2022
Cash	$	19,844	$	12,452
Investments in money market funds		23,698		2,011
Restricted investments in money market funds		2,987		1,515
Total cash, cash equivalents and restricted cash	$	46,529	$	15,978

See Notes to Consolidated Financial Statements

6

Horizon Technology Finance Corporation and Subsidiaries

Consolidated Schedule of Investments (Unaudited)

March 31, 2023

(Dollars in thousands)

Portfolio Company (1)(3)	Sector	Type of Investment (7)	Cash Rate (4)			Index	Margin			Floor			Ceiling			ETP (10)			Maturity Date	Principal Amount		Cost of Investments (6)(9)		Fair Value (9)
Non-Affiliate Investments — 222.1% (8)
Non-Affiliate Debt Investments — 212.8% (8)
Non-Affiliate Debt Investments — Life Science — 95.7% (8)
Avalo Therapeutics, Inc. (2)(5)(12)	Biotechnology	Term Loan		14.25	%	Prime		6.25	%		9.50	%		-			3.00	%	January 1, 2025	$	2,913	$	2,860	$	2,779
		Term Loan		14.25	%	Prime		6.25	%		9.50	%		-			3.00	%	January 1, 2025		2,885		2,832		2,752
		Term Loan		14.25	%	Prime		6.25	%		9.50	%		-			3.00	%	January 1, 2025		1,442		1,416		1,375
		Term Loan		14.25	%	Prime		6.25	%		9.50	%		-			3.00	%	February 1, 2025		2,885		2,829		2,749
		Term Loan		14.25	%	Prime		6.25	%		9.50	%		-			3.00	%	February 1, 2025		2,885		2,829		2,749
		Term Loan		14.25	%	Prime		6.25	%		9.50	%		-			3.00	%	April 1, 2025		1,442		1,412		1,370
		Term Loan		14.25	%	Prime		6.25	%		9.50	%		-			3.00	%	April 1, 2025		1,442		1,412		1,370
Castle Creek Biosciences, Inc. (2)(12)	Biotechnology	Term Loan		12.88	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		5,000		4,895		4,895
		Term Loan		12.88	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		5,000		4,967		4,967
		Term Loan		12.88	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		3,000		2,977		2,977
		Term Loan		12.88	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		5,000		4,967		4,967
		Term Loan		12.88	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		5,000		4,970		4,970
		Term Loan		12.88	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		3,000		2,980		2,980
Emalex Biosciences, Inc. (2)(12)	Biotechnology	Term Loan		12.57	%	Libor		4.72	%		9.75	%		-			5.00	%	June 1, 2024		1,979		1,965		1,965
		Term Loan		12.57	%	Libor		4.72	%		9.75	%		-			5.00	%	June 1, 2024		1,979		1,966		1,966
		Term Loan		12.57	%	Libor		4.72	%		9.75	%		-			5.00	%	November 1, 2025		5,000		4,930		4,930
		Term Loan		12.57	%	Libor		4.72	%		9.75	%		-			5.00	%	May 1, 2026		5,000		4,921		4,921
Evelo Biosciences, Inc. (2)(5)(12)	Biotechnology	Term Loan		12.25	%	Prime		4.25	%		11.00	%		-			4.25	%	January 1, 2028		10,000		9,880		9,880
		Term Loan		12.25	%	Prime		4.25	%		11.00	%		-			4.25	%	January 1, 2028		15,000		14,819		14,819
		Term Loan		12.25	%	Prime		4.25	%		11.00	%		-			4.25	%	January 1, 2028		6,000		5,928		5,928
		Term Loan		12.25	%	Prime		4.25	%		11.00	%		-			4.25	%	January 1, 2028		6,000		5,928		5,928
		Term Loan		12.25	%	Prime		4.25	%		11.00	%		-			4.25	%	January 1, 2028		4,000		3,952		3,952
		Term Loan		12.25	%	Prime		4.25	%		11.00	%		-			4.25	%	January 1, 2028		4,000		3,952		3,952
Greenlight Biosciences, Inc. (2)(5)(12)	Biotechnology	Term Loan		13.75	%	Prime		5.75	%		9.00	%		-			3.00	%	July 1, 2025		4,500		4,371		4,352
		Term Loan		13.75	%	Prime		5.75	%		9.00	%		-			3.00	%	July 1, 2025		2,250		2,187		2,177
IMV Inc. (2)(5)(12)	Biotechnology	Term Loan		13.75	%	Prime		5.75	%		9.00	%		-			5.00	%	July 1, 2025		5,000		4,951		4,759
		Term Loan		13.75	%	Prime		5.75	%		9.00	%		-			5.00	%	July 1, 2025		2,500		2,476		2,380
		Term Loan		13.75	%	Prime		5.75	%		9.00	%		-			5.00	%	January 1, 2026		5,000		4,953		4,761
		Term Loan		13.75	%	Prime		5.75	%		9.00	%		-			5.00	%	January 1, 2026		5,000		4,953		4,761
KSQ Therapeutics, Inc. (2) (12)	Biotechnology	Term Loan		12.75	%	Prime		4.75	%		8.50	%		-			5.50	%	May 1, 2027		6,250		6,082		6,082
		Term Loan		12.75	%	Prime		4.75	%		8.50	%		-			5.50	%	May 1, 2027		6,250		6,182		6,182
Native Microbials, Inc (2) (12)	Biotechnology	Term Loan		13.25	%	Prime		5.25	%		8.50	%		-			5.00	%	November 1, 2026		3,750		3,707		3,707
		Term Loan		13.25	%	Prime		5.25	%		8.50	%		-			5.00	%	November 1, 2026		2,500		2,472		2,472
PDS Biotechnology Corporation (2)(5)(12)	Biotechnology	Term Loan		13.75	%	Prime		5.75	%		9.75	%		-			3.75	%	September 1, 2026		10,000		9,714		9,714
		Term Loan		13.75	%	Prime		5.75	%		9.75	%		-			3.75	%	September 1, 2026		3,750		3,702		3,702
		Term Loan		13.75	%	Prime		5.75	%		9.75	%		-			3.75	%	September 1, 2026		3,750		3,702		3,702
Provivi, Inc. (2)(12)	Biotechnology	Term Loan		13.17	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		4,667		4,606		4,606
		Term Loan		13.17	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		4,667		4,606		4,606
		Term Loan		13.17	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		2,333		2,287		2,287
		Term Loan		13.17	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		2,333		2,287		2,287
		Term Loan		13.17	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		2,333		2,282		2,282
		Term Loan		13.17	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		2,333		2,282		2,282

See Notes to Consolidated Financial Statements

7

Horizon Technology Finance Corporation and Subsidiaries

 

Consolidated Schedule of Investments (Unaudited)

March 31, 2023

(Dollars in thousands)

Portfolio Company (1)(3)	Sector	Type of Investment (7)	Cash Rate (4)			Index	Margin			Floor			Ceiling		ETP (10)			Maturity Date	Principal Amount		Cost of Investments (6)(9)		Fair Value (9)
Stealth Biotherapeutics Inc. (2)(12)	Biotechnology	Term Loan		13.50	%	Prime		5.50	%		8.75	%		-		6.00	%	October 1, 2025		5,000		4,922		4,922
		Term Loan		13.50	%	Prime		5.50	%		8.75	%		-		6.00	%	October 1, 2025		2,500		2,461		2,461
Aerobiotix, LLC (2)(12)	Medical Device	Term Loan		14.25	%	Prime		6.25	%		9.50	%		-		6.00	%	April 1, 2026		2,500		2,467		2,361
		Term Loan		14.25	%	Prime		6.25	%		9.50	%		-		6.00	%	April 1, 2026		2,500		2,467		2,361
Ceribell, Inc. (2)(12)	Medical Device	Term Loan		11.25	%	Prime		3.50	%		8.25	%		-		5.50	%	October 1, 2024		5,000		4,977		4,977
		Term Loan		11.25	%	Prime		3.50	%		8.25	%		-		5.50	%	October 1, 2024		5,000		4,977		4,977
		Term Loan		11.25	%	Prime		3.50	%		8.25	%		-		5.50	%	October 1, 2024		2,500		2,481		2,481
		Term Loan		11.25	%	Prime		3.50	%		8.25	%		-		5.50	%	October 1, 2024		2,500		2,481		2,481
Cognoa, Inc. (2)(12)	Medical Device	Term Loan		13.50	%	Prime		5.50	%		8.75	%		-		6.00	%	August 1, 2026		5,000		4,940		4,940
		Term Loan		13.50	%	Prime		5.50	%		8.75	%		-		6.00	%	August 1, 2026		2,500		2,470		2,470
Conventus Orthopaedics, Inc. (2)(12)	Medical Device	Term Loan		12.67	%	Libor		8.00	%		9.25	%		-		10.36	%	July 1, 2025		3,960		3,904		3,904
		Term Loan		12.67	%	Libor		8.00	%		9.25	%		-		10.36	%	July 1, 2025		3,960		3,904		3,904
Corinth Medtech, Inc. (2)(12)	Medical Device	Term Loan		13.00	% (11)	Prime		5.25	%		8.50	%		-		20.00	%	June 30, 2023		2,528		2,528		2,528
		Term Loan		13.00	% (11)	Prime		5.25	%		8.50	%		-		20.00	%	June 30, 2023		2,528		2,528		2,528
		Term Loan		13.00	% (11)	Prime		5.25	%		8.50	%		-		50.00	%	June 30, 2023		200		200		200
CSA Medical, Inc. (2)(12)	Medical Device	Term Loan		12.87	%	Libor		8.20	%		10.00	%		-		5.00	%	January 1, 2024		1,250		1,239		1,239
		Term Loan		12.87	%	Libor		8.20	%		10.00	%		-		5.00	%	January 1, 2024		83		83		83
		Term Loan		12.87	%	Libor		8.20	%		10.00	%		-		5.00	%	March 1, 2024		1,600		1,587		1,587
InfoBionic, Inc. (2)(12)	Medical Device	Term Loan		14.00	%	Prime		6.25	%		9.50	%		-		4.00	%	October 1, 2024		2,771		2,715		2,715
		Term Loan		14.00	%	Prime		6.25	%		9.50	%		-		4.00	%	June 1, 2025		1,000		977		977
Magnolia Medical Technologies, Inc. (2)(12)	Medical Device	Term Loan		12.75	%	Prime		5.00	%		9.75	%		-		4.00	%	March 1, 2025		5,000		4,946		4,946
		Term Loan		12.75	%	Prime		5.00	%		9.75	%		-		4.00	%	March 1, 2025		5,000		4,946		4,946
		Term Loan		12.75	%	Prime		5.00	%		9.75	%		-		4.00	%	March 1, 2025		5,000		4,940		4,940
		Term Loan		12.75	%	Prime		5.00	%		9.75	%		-		4.00	%	March 1, 2025		5,000		4,941		4,941
		Term Loan		12.75	%	Prime		5.00	%		9.75	%		-		4.00	%	January 1, 2027		5,000		4,920		4,920
		Term Loan		12.75	%	Prime		5.00	%		9.75	%		-		4.00	%	January 1, 2027		5,000		4,920		4,920
Robin Healthcare, Inc. (2)(12)	Medical Device	Term Loan		13.50	%	Prime		5.50	%		10.25	%		-		4.00	%	November 1, 2026		3,500		3,413		3,413
		Term Loan		13.50	%	Prime		5.50	%		10.25	%		-		4.00	%	November 1, 2026		3,500		3,463		3,463
Scientia Vascular, Inc. (2)(12)	Medical Device	Term Loan		12.50	%	Prime		4.75	%		8.50	%		-		5.00	%	January 1, 2027		3,750		3,601		3,601
		Term Loan		12.50	%	Prime		4.75	%		8.50	%		-		5.00	%	January 1, 2027		3,750		3,710		3,710
Sonex Health, Inc. (2)(12)	Medical Device	Term Loan		14.25	%	Prime		6.50	%		9.75	%		-		8.00	%	June 1, 2025		2,500		2,478		2,478
		Term Loan		14.25	%	Prime		6.50	%		9.75	%		-		8.00	%	June 1, 2025		2,500		2,478		2,478
		Term Loan		14.25	%	Prime		6.50	%		9.75	%		-		8.00	%	June 1, 2025		2,500		2,478		2,478
		Term Loan		14.25	%	Prime		6.50	%		9.75	%		-		8.00	%	April 1, 2026		2,500		2,459		2,459
		Term Loan		14.25	%	Prime		6.50	%		9.75	%		-		8.00	%	May 1, 2026		2,500		2,458		2,458
Spineology, Inc. (2)(12)	Medical Device	Term Loan		15.00	%	Prime		7.00	%		10.25	%		-		1.00	%	October 1, 2025		5,000		4,969		4,969
		Term Loan		15.00	%	Prime		7.00	%		10.25	%		-		1.00	%	April 1, 2026		2,500		2,483		2,483

See Notes to Consolidated Financial Statements

8

Horizon Technology Finance Corporation and Subsidiaries

 

Consolidated Schedule of Investments (Unaudited)

March 31, 2023

(Dollars in thousands)

Portfolio Company (1)(3)	Sector	Type of Investment (7)	Cash Rate (4)			Index	Margin			Floor			Ceiling		ETP (10)			Maturity Date	Principal Amount		Cost of Investments (6)(9)		Fair Value (9)
Swift Health Systems Inc. (2)(12)	Medical Device	Term Loan		13.00	%	Prime		5.25	%		9.00	%		-		5.00	%	July 1, 2027		3,500		3,457		3,457
		Term Loan		13.00	%	Prime		5.25	%		9.00	%		-		5.00	%	July 1, 2027		3,500		3,457		3,457
		Term Loan		13.25	%	Prime		5.25	%		9.00	%		-		5.00	%	July 1, 2027		3,500		3,447		3,447
		Term Loan		13.25	%	Prime		5.25	%		9.00	%		-		5.00	%	July 1, 2027		3,500		3,447		3,447
Total Non-Affiliate Debt Investments — Life Science																						309,108		307,749
Non-Affiliate Debt Investments — Sustainability — 25.8% (8)
Aerofarms, Inc. (2)(12)	Other Sustainability	Term Loan		14.75	%	Prime		6.75	%		10.00	%		-		3.00	%	April 1, 2026		3,750		3,704		3,585
		Term Loan		14.75	%	Prime		6.75	%		10.00	%		-		3.00	%	April 1, 2026		3,750		3,704		3,585
Nexii Building Solutions, Inc. (2)(12)	Other Sustainability	Term Loan		15.00	%	Prime		7.00	%		10.25	%		-		2.50	%	September 1, 2025		7,500		7,383		7,245
		Term Loan		15.00	%	Prime		7.00	%		10.25	%		-		2.50	%	September 1, 2025		7,500		7,383		7,245
		Term Loan		15.00	%	Prime		7.00	%		10.25	%		-		2.50	%	September 1, 2025		7,500		7,383		7,245
		Term Loan		15.00	%	Prime		7.00	%		10.25	%		-		2.50	%	July 1, 2026		5,000		4,912		4,820
		Term Loan		15.00	%	Prime		7.00	%		10.25	%		-		2.50	%	July 1, 2026		5,000		4,912		4,820
Soli Organic, Inc. (2)(12)	Other Sustainability	Term Loan		14.75	%	Prime		6.75	%		10.00	%		-		2.75	%	April 1, 2026		5,000		4,935		4,935
		Term Loan		14.75	%	Prime		6.75	%		10.00	%		-		2.75	%	April 1, 2026		2,500		2,467		2,467
		Term Loan		14.75	%	Prime		6.75	%		10.00	%		-		2.75	%	May 1, 2026		5,000		4,932		4,932
		Term Loan		14.75	%	Prime		6.75	%		10.00	%		-		2.75	%	May 1, 2026		2,500		2,466		2,466
		Term Loan		13.50	%	Prime		5.50	%		11.75	%		-		2.75	%	December 1, 2026		5,000		4,909		4,909
		Term Loan		13.50	%	Prime		5.50	%		11.75	%		-		2.75	%	December 1, 2026		2,500		2,454		2,454
Temperpack Technologies, Inc. (2)(12)	Other Sustainability	Term Loan		14.75	%	Prime		6.75	%		10.00	%		-		2.50	%	June 1, 2025		3,750		3,706		3,706
		Term Loan		14.75	%	Prime		6.75	%		10.00	%		-		2.50	%	June 1, 2025		3,750		3,720		3,720
		Term Loan		14.75	%	Prime		6.75	%		10.00	%		-		2.50	%	October 1, 2025		7,500		7,431		7,431
		Term Loan		14.75	%	Prime		6.75	%		10.00	%		-		2.50	%	October 1, 2025		3,750		3,715		3,715
		Term Loan		14.75	%	Prime		6.75	%		10.00	%		-		2.50	%	October 1, 2025		3,750		3,715		3,715
Total Non-Affiliate Debt Investments — Sustainability																						83,831		82,995
Non-Affiliate Debt Investments — Technology — 83.2% (8)
Axiom Space, Inc. (2)(12)	Communications	Term Loan		13.75	%	Prime		6.00	%		9.25	%		-		2.50	%	June 1, 2026		7,500		7,459		7,459
		Term Loan		13.75	%	Prime		6.00	%		9.25	%		-		2.50	%	June 1, 2026		7,500		7,459		7,459
		Term Loan		13.75	%	Prime		6.00	%		9.25	%		-		2.50	%	June 1, 2026		7,500		7,459		7,459
Better Place Forests Co. (12)(13)	Consumer-related Technologies	Term Loan		14.25	%	Prime		6.25	%		9.50	%		-		1.85	%	July 1, 2025		5,000		4,951		3,467
		Term Loan		14.25	%	Prime		6.25	%		9.50	%		-		1.85	%	October 1, 2025		2,500		2,474		1,733
CAMP NYC, Inc. (2)(12)	Consumer-related Technologies	Term Loan		15.25	%	Prime		7.25	%		10.50	%		-		3.00	%	May 1, 2026		3,500		3,464		3,464
Clara Foods Co. (2)(12)	Consumer-related Technologies	Term Loan		13.50	%	Prime		5.75	%		9.00	%		-		5.50	%	August 1, 2025		2,333		2,318		2,318
		Term Loan		13.50	%	Prime		5.75	%		9.00	%		-		5.50	%	August 1, 2025		2,333		2,318		2,318

See Notes to Consolidated Financial Statements

9

Horizon Technology Finance Corporation and Subsidiaries

 

Consolidated Schedule of Investments (Unaudited)

March 31, 2023

(Dollars in thousands)

Portfolio Company (1)(3)	Sector	Type of Investment (7)	Cash Rate (4)			Index	Margin			Floor			Ceiling			ETP (10)			Maturity Date	Principal Amount		Cost of Investments (6)(9)		Fair Value (9)
Divergent Technologies, Inc. (2)(12)	Consumer-related Technologies	Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		3,750		3,520		3,520
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		1,250		1,239		1,239
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		3,750		3,717		3,717
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		1,250		1,239		1,239
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		3,750		3,717		3,717
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		1,250		1,239		1,239
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	January 1, 2028		3,750		3,701		3,701
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	January 1, 2028		3,750		3,701		3,701
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	April 1, 2028		3,750		3,698		3,698
Havenly, Inc. (2)(12)	Consumer-related Technologies	Term Loan		13.00	%	Prime		5.00	%		5.00	%		-			4.00	%	March 1, 2027		2,000		1,165		1,165
		Term Loan		13.00	%	Prime		5.00	%		5.00	%		-			4.00	%	March 1, 2027		3,000		1,748		1,748
		Term Loan		11.50	%	Prime		3.50	%		10.50	%		-			7.78	%	February 1, 2028		2,813		2,813		2,813
		Term Loan		11.50	%	Prime		3.50	%		10.50	%		-			7.78	%	February 1, 2028		2,813		2,813		2,813
Interior Define, Inc. (2)(12)(13)	Consumer-related Technologies	Term Loan		14.50	%	Prime		6.50	%		9.75	%		-			4.00	%	January 1, 2026		3,246		3,162		—
		Term Loan		14.50	%	Prime		6.50	%		9.75	%		-			4.00	%	January 1, 2026		2,963		2,886		—
Lyrical Foods, Inc. (2)(12)	Consumer-related Technologies	Term Loan		10.50	%	Prime		2.50	%		8.00	%		-			-		September 1, 2027		2,598		2,586		2,330
MyForest Foods Co. (2)(12)	Consumer-related Technologies	Term Loan		14.75	%	Prime		6.75	%		10.00	%		-			3.00	%	October 1, 2025		5,000		4,961		4,961
		Term Loan		14.75	%	Prime		6.75	%		10.00	%		-			3.00	%	October 1, 2025		2,500		2,480		2,480
NextCar Holding Company, Inc. (2)(12)	Consumer-related Technologies	Term Loan		13.50	% (11)	Prime		5.75	%		9.00	%		-			5.25	%	October 31, 2023		5,169		5,121		4,883
		Term Loan		13.50	% (11)	Prime		5.75	%		9.00	%		-			5.25	%	October 31, 2023		2,067		2,050		1,955
		Term Loan		13.50	% (11)	Prime		5.75	%		9.00	%		-			5.25	%	October 31, 2023		2,584		2,564		2,446
		Term Loan		13.50	% (11)	Prime		5.75	%		9.00	%		-			5.25	%	October 31, 2023		3,101		3,076		2,934
		Term Loan		13.50	% (11)	Prime		5.75	%		9.00	%		-			5.25	%	October 31, 2023		2,584		2,548		2,430
		Term Loan		13.50	% (11)	Prime		5.75	%		9.00	%		-			5.25	%	October 31, 2023		2,584		2,548		2,430
		Term Loan		13.50	% (11)	Prime		5.75	%		9.00	%		-			5.25	%	October 31, 2023		5,169		5,093		4,859
		Term Loan		13.50	% (11)	Prime		5.75	%		9.00	%		-			5.25	%	October 31, 2023		2,584		2,545		2,428
Optoro, Inc. (2)(12)	Consumer-related Technologies	Term Loan		14.00	%	Prime		6.25	%		9.50	%		-			4.00	%	August 1, 2027		2,500		2,355		2,355
Primary Kids, Inc. (2)(12)	Consumer-related Technologies	Term Loan		15.00	%	Prime		7.25	%		10.50	%		-			3.00	%	March 1, 2025		2,300		2,277		2,277
		Term Loan		15.00	%	Prime		7.25	%		10.50	%		-			3.00	%	March 1, 2025		2,300		2,277		2,277
		Term Loan		15.00	%	Prime		7.25	%		10.50	%		-			3.00	%	September 1, 2025		2,900		2,870		2,870
Unagi, Inc. (2)(12)	Consumer-related Technologies	Term Loan		15.75	% (11)	Prime		7.75	%		11.00	%		-			-		May 1, 2027		1,065		1,041		1,041
		Term Loan		15.75	% (11)	Prime		7.75	%		11.00	%		-			-		May 1, 2027		533		520		520
		Term Loan		15.75	% (11)	Prime		7.75	%		11.00	%		-			-		May 1, 2027		533		521		521
Liqid, Inc. (2)(12)	Networking	Term Loan		14.00	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		2,833		2,793		2,793
		Term Loan		14.00	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		2,833		2,793		2,793
		Term Loan		14.00	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		1,417		1,395		1,395
		Term Loan		14.00	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		1,417		1,395		1,395
		Term Loan		14.00	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		1,417		1,371		1,371
BriteCore Holdings, Inc. (2)(12)	Software	Term Loan		14.50	%	Prime		6.75	%		10.00	%		-			5.00	%	March 1, 2026		2,500		2,488		2,488
		Term Loan		14.50	%	Prime		6.75	%		10.00	%		-			5.00	%	March 1, 2026		2,500		2,488		2,488
		Term Loan		14.50	%	Prime		6.75	%		10.00	%		-			3.00	%	March 1, 2027		2,500		2,467		2,467
		Term Loan		14.50	%	Prime		6.75	%		10.00	%		-			3.00	%	March 1, 2027		2,500		2,467		2,467
Decisyon, Inc. (12)	Software	Term Loan		17.43	%	Prime		9.43	%		12.68	%		-			50.43	%	December 31, 2022		3,284		3,284		2,750

See Notes to Consolidated Financial Statements

10

Horizon Technology Finance Corporation and Subsidiaries

 

Consolidated Schedule of Investments (Unaudited)

March 31, 2023

(Dollars in thousands)

Portfolio Company (1)(3)	Sector	Type of Investment (7)	Cash Rate (4)			Index	Margin			Floor			Ceiling			ETP (10)			Maturity Date	Principal Amount		Cost of Investments (6)(9)		Fair Value (9)
Dropoff, Inc. (2)(12)	Software	Term Loan		14.50	%	Prime		6.50	%		9.75	%		-			3.50	%	April 1, 2026		6,500		6,359		6,359
		Term Loan		14.50	%	Prime		6.50	%		9.75	%		-			3.50	%	April 1, 2026		6,000		5,869		5,869
		Term Loan		14.50	%	Prime		6.50	%		9.75	%		-			3.50	%	August 1, 2026		2,500		2,442		2,442
Engage3, LLC (2)(12)	Software	Term Loan		14.00	%	Prime		6.25	%		9.75	%		-			4.50	%	July 1, 2027		3,750		3,680		3,680
		Term Loan		14.00	%	Prime		6.25	%		9.75	%		-			4.50	%	July 1, 2027		3,750		3,720		3,720
Groundspeed Analytics, Inc. (2)(12)	Software	Term Loan		13.50	%	Prime		5.50	%		11.00	%		18.00	%		3.00	%	December 1, 2026		5,000		4,802		4,802
		Term Loan		13.50	%	Prime		5.50	%		11.00	%		18.00	%		3.00	%	December 1, 2026		5,000		4,953		4,953
		Convertible Note		15.00	%														September 10,2024		500		500		500
Kodiak Robotics, Inc. (2)(12)	Software	Term Loan		13.50	%	Prime		5.50	%		10.25	%		-			4.00	%	April 1, 2026		10,000		9,843		9,843
		Term Loan		13.50	%	Prime		5.50	%		10.25	%		-			4.00	%	April 1, 2026		10,000		9,843		9,843
		Term Loan		13.50	%	Prime		5.50	%		10.25	%		-			4.00	%	April 1, 2026		5,000		4,921		4,921
		Term Loan		13.50	%	Prime		5.50	%		10.25	%		-			4.00	%	April 1, 2026		5,000		4,921		4,921
Lemongrass Holdings, Inc. (2)(12)	Software	Term Loan		14.50	%	Prime		6.50	%		9.75	%		-			2.50	%	March 1, 2026		5,000		4,953		4,953
		Term Loan		14.50	%	Prime		6.50	%		9.75	%		-			2.50	%	March 1, 2026		2,500		2,477		2,477
Lytics, Inc. (2)(12)	Software	Term Loan		13.75	%	Prime		6.00	%		9.25	%		-			3.00	%	November 1, 2026		2,500		2,411		2,411
		Term Loan		13.75	%	Prime		6.00	%		12.25	%		-			3.00	%	December 1, 2026		1,250		1,232		1,232
		Term Loan		13.75	%	Prime		6.00	%		12.25	%		-			3.00	%	April 1, 2027		1,000		984		984
Noodle Partners, Inc. (2)(12)	Software	Term Loan		13.00	%	Prime		5.00	%		12.00	%		-			3.00	%	March 1, 2027		10,000		9,733		9,733
		Term Loan		13.00	%	Prime		5.00	%		12.00	%		-			3.00	%	March 1, 2027		5,000		4,928		4,928
		Term Loan		13.00	%	Prime		5.00	%		12.00	%		-			3.00	%	March 1, 2027		5,000		4,928		4,928
Reputation Institute, Inc. (2)(12)	Software	Term Loan		15.00	%	Prime		7.25	%		10.50	%		-			3.00	%	August 1, 2025		4,833		4,772		4,772
Slingshot Aerospace, Inc. (2)(12)	Software	Term Loan		13.75	%	Prime		5.75	%		9.75	%		-			5.00	%	August 1, 2026		5,000		4,940		4,940
		Term Loan		13.75	%	Prime		5.75	%		9.75	%		-			5.00	%	August 1, 2026		5,000		4,940		4,940
		Term Loan		13.75	%	Prime		5.75	%		9.75	%		-			5.00	%	August 1, 2026		5,000		4,875		4,875
		Term Loan		13.75	%	Prime		5.75	%		9.75	%		-			5.00	%	August 1, 2026		5,000		4,940		4,940
Supply Network Visibility Holdings LLC (2)(12)	Software	Term Loan		14.25	%	Prime		6.50	%		9.75	%		-			4.00	%	February 1, 2025		3,208		3,183		3,183
		Term Loan		14.25	%	Prime		6.50	%		9.75	%		-			4.00	%	February 1, 2025		3,208		3,183		3,183
		Term Loan		14.25	%	Prime		6.50	%		9.75	%		-			4.00	%	December 1, 2025		2,500		2,475		2,475
		Term Loan		14.25	%	Prime		6.50	%		9.75	%		-			4.00	%	December 1, 2025		2,500		2,475		2,475
Total Non-Affiliate Debt Investments — Technology																							277,916		267,673
Non-Affiliate Debt Investments — Healthcare information and services — 8.1% (8)
Hound Labs inc. (2) (12)	Diagnostics	Term Loan		14.00	%	Prime		6.00	%		9.25	%		-			3.50	%	June 1, 2026		2,500		2,388		2,388
		Term Loan		14.00	%	Prime		6.00	%		9.25	%		-			3.50	%	June 1, 2026		2,500		2,476		2,476
		Term Loan		14.00	%	Prime		6.00	%		9.25	%		-			3.50	%	June 1, 2026		5,000		4,951		4,951
Secure Transfusion Services, Inc. (12)(13)	Other Healthcare	Term Loan		13.75	%	Prime		5.75	%		9.00	%		-			4.00	%	October 1, 2025		4,719		4,658		46
		Term Loan		13.75	%	Prime		5.75	%		9.00	%		-			4.00	%	December 31, 2025		2,217		2,182		5
BrightInsight, Inc. (2)(12)	Software	Term Loan		13.25	%	Prime		5.50	%		9.50	%		-			3.00	%	August 1, 2027		7,000		6,663		6,663
		Term Loan		13.25	%	Prime		5.50	%		9.50	%		-			3.00	%	August 1, 2027		3,500		3,452		3,452
		Term Loan		13.25	%	Prime		5.50	%		9.50	%		-			3.00	%	August 1, 2027		3,500		3,452		3,452
		Term Loan		13.50	%	Prime		5.50	%		9.50	%		-			3.00	%	April 1, 2028		2,750		2,704		2,704
Total Non-Affiliate Debt Investments — Healthcare information and services																							32,926		26,137
Total Non- Affiliate Debt Investments																							703,781		684,554

See Notes to Consolidated Financial Statements

11

Horizon Technology Finance Corporation and Subsidiaries

 

Consolidated Schedule of Investments (Unaudited)

March 31, 2023

(Dollars in thousands)

					Cost of		Fair
Portfolio Company (1)(3)	Sector	Type of Investment (7)	Number of Shares		Investments (6)(9)		Value (9)
Non-Affiliate Warrant Investments — 8.0% (8)
Non-Affiliate Warrants — Life Science — 2.1% (8)
Avalo Therapeutics, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		26,444		311		—
Castle Creek Biosciences, Inc. (2)(12)	Biotechnology	Preferred Stock Warrant		7,404		214		329
Corvium, Inc. (2)(12)	Biotechnology	Preferred Stock Warrant		661,956		53		—
Emalex Biosciences, Inc. (2)(12)	Biotechnology	Preferred Stock Warrant		110,402		176		256
Evelo Biosciences, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		463,915		126		—
Greenlight Biosciences, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		47,452		366		—
Imunon, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		19,671		66		—
IMV Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		39,774		67		—
KSQ Therapeutics, Inc. (2) (12)	Biotechnology	Preferred Stock Warrant		48,076		50		56
Mustang Bio, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		252,161		141		—
Native Microbials, Inc (2)(12)	Biotechnology	Preferred Stock Warrant		103,679		64		159
PDS Biotechnology Corporation (2)(5)(12)	Biotechnology	Common Stock Warrant		299,848		160		937
Provivi, Inc. (2)(12)	Biotechnology	Preferred Stock Warrant		254,609		401		128
Rocket Pharmaceuticals Corporation (5)(12)	Biotechnology	Common Stock Warrant		7,051		17		2
Stealth Biotherapeutics Inc. (2)(12)	Biotechnology	Common Stock Warrant		318,181		264		28
vTv Therapeutics Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		95,293		44		—
Xeris Pharmaceuticals, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		126,000		72		9
AccuVein Inc. (2)(12)	Medical Device	Common Stock Warrant		1,175		24		—
Aerin Medical, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		1,818,183		66		1,196
Aerobiotix, LLC (2)(12)	Medical Device	Preferred Stock Warrant		27,330		48		31
Canary Medical Inc. (2)(12)	Medical Device	Preferred Stock Warrant		12,153		86		1,862
Ceribell, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		145,483		69		206
Cognoa, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		775,000		144		173
Conventus Orthopaedics, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		7,972,222		221		221
CSA Medical, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		1,375,727		153		148
CVRx, Inc. (2)(5)(12)	Medical Device	Common Stock Warrant		47,410		76		72
Infobionic, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		317,647		124		51

See Notes to Consolidated Financial Statements

12

Horizon Technology Finance Corporation and Subsidiaries

 

Consolidated Schedule of Investments (Unaudited)

March 31, 2023

(Dollars in thousands)

					Cost of		Fair
Portfolio Company (1)(3)	Sector	Type of Investment (7)	Number of Shares		Investments (6)(9)		Value (9)
Magnolia Medical Technologies, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		809,931		194		379
Meditrina, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		233,993		83		98
Robin Healthcare, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		86,066		16		15
Scientia Vascular, Inc (2)(12)	Medical Device	Preferred Stock Warrant		19,662		40		45
Sonex Health, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		605,313		98		120
VERO Biotech LLC (2)(12)	Medical Device	Preferred Stock Warrant		408		53		1
Swift Health Systems Inc. (2)(12)	Medical Device	Preferred Stock Warrant		135,484		71		81
Total Non-Affiliate Warrants — Life Science						4,158		6,603
Non-Affiliate Warrants — Sustainability — 0.2% (8)
Aerofarms, Inc. (2)(12)	Other Sustainability	Preferred Stock Warrant		201,537		61		72
LiquiGlide, Inc. (2)(12)	Other Sustainability	Common Stock Warrant		61,359		39		53
Nexii Building Solutions, Inc. (2)(12)	Other Sustainability	Common Stock Warrant		204,195		490		1
Soli Organic, Inc. (2)(12)	Other Sustainability	Preferred Stock Warrant		681		214		354
Temperpack Technologies, Inc. (2)(12)	Other Sustainability	Preferred Stock Warrant		34,604		118		259
Total Non-Affiliate Warrants — Sustainability						922		739
Non-Affiliate Warrants — Technology — 5.1% (8)
Axiom Space, Inc. (2)(12)	Communications	Common Stock Warrant		1,991		46		64
Intelepeer Holdings, Inc. (2)(12)	Communications	Preferred Stock Warrant		2,936,535		138		3,251
PebblePost, Inc. (2)(12)	Communications	Preferred Stock Warrant		598,850		91		170
Alula Holdings, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		20,000		93		64
Aterian, Inc. (2)(5)(12)	Consumer-related Technologies	Common Stock Warrant		76,923		195		—
Better Place Forests Co. (12)	Consumer-related Technologies	Preferred Stock Warrant		2,672		26		—
Caastle, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		268,591		68		1,057
CAMP NYC, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		17,605		22		—
Clara Foods Co. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		46,745		30		124
Divergent Technologies, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		33,742		70		237
Havenly, Inc. (2)(12)	Consumer-related Technologies	Common Stock Warrant		1,312,500		2,942		2,674
MyForest Foods Co. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		143		29		36
NextCar Holding Company, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		1,261,253		197		17
Optoro, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		6,600		104		104
Primary Kids, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		553,778		57		427
Quip NYC Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		6,191		325		532
Unagi, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		171,081		32		111
Updater, Inc.(2)(12)	Consumer-related Technologies	Common Stock Warrant		108,333		34		42
CPG Beyond, Inc. (2)(12)	Data Storage	Preferred Stock Warrant		500,000		242		903
Silk, Inc. (2)(12)	Data Storage	Preferred and Common Stock Warrant		442,110		234		399
Global Worldwide LLC (2)(12)	Internet and Media	Preferred Stock Warrant		245,810		75		—
Rocket Lawyer Incorporated (2)(12)	Internet and Media	Preferred Stock Warrant		261,721		92		352
Skillshare, Inc. (2)(12)	Internet and Media	Preferred Stock Warrant		139,074		162		1,231
Liqid, Inc. (2)(12)	Networking	Preferred Stock Warrant		344,102		364		237
Halio, Inc. (2)(12)	Power Management	Preferred Stock Warrant		5,002,574		1,585		2,808
Avalanche Technology, Inc. (2)(12)	Semiconductors	Preferred and Common Stock Warrants		6,081		57		—
BriteCore Holdings, Inc. (2)(12)	Software	Preferred Stock Warrant		77,828		21		67
Decisyon, Inc. (12)	Software	Common Stock Warrant		82,967		46		—
Dropoff, Inc. (2)(12)	Software	Common Stock Warrant		516,732		455		196
E La Carte, Inc. (2)(5)(12)	Software	Common Stock Warrant		147,361		60		—
Groundspeed Analytics, Inc. (2)(12)	Software	Preferred Stock Warrant		86,300		7		1
Kodiak Robotics, Inc. (2)(12)	Software	Preferred Stock Warrant		639,918		275		287
Lemongrass Holdings, Inc. (2)(12)	Software	Preferred Stock Warrant		101,308		35		40
Lotame Solutions, Inc. (2)(12)	Software	Preferred Stock Warrant		71,305		19		53
Lytics, Inc. (2)(12)	Software	Preferred Stock Warrant		85,543		43		46
Noodle Partners, Inc. (2)(12)	Software	Preferred Stock Warrant		84,037		116		116
Reputation Institute, Inc. (2)(12)	Software	Preferred Stock Warrant		3,731		61		46
Revinate Holdings, Inc. (2)(12)	Software	Preferred Stock Warrant		682,034		44		97
Riv Data Corp. (2)(12)	Software	Preferred Stock Warrant		321,428		12		296
SIGNiX, Inc. (12)	Software	Preferred Stock Warrant		186,235		225		—
Slingshot Aerospace, Inc. (2)(12)	Software	Preferred Stock Warrant		309,208		123		135
Supply Network Visibility Holdings LLC (2)(12)	Software	Preferred Stock Warrant		682		64		140
Topia Mobility, Inc. (2)(12)	Software	Preferred Stock Warrant		3,049,607		138		—
xAd, Inc. (2)(12)	Software	Preferred Stock Warrant		4,343,348		177		11
Total Non-Affiliate Warrants — Technology						9,231		16,371

See Notes to Consolidated Financial Statements

13

Horizon Technology Finance Corporation and Subsidiaries

 

Consolidated Schedule of Investments (Unaudited)

March 31, 2023

(Dollars in thousands)

					Cost of		Fair
Portfolio Company (1)(3)	Sector	Type of Investment (7)	Number of Shares		Investments (6)(9)		Value (9)
Non-Affiliate Warrants — Healthcare information and services — 0.6% (8)
Hound Labs, Inc (2) (12)	Diagnostics	Preferred Stock Warrant		159,893		47		53
Kate Farms, Inc. (2)(12)	Other Healthcare	Preferred Stock Warrant		82,965		102		1,363
Secure Transfusion Services, Inc. (12)	Other Healthcare	Preferred Stock Warrant		77,690		48		—
BrightInsight, Inc. (2)(12)	Software	Preferred Stock Warrant		85,066		167		175
Medsphere Systems Corporation (2)(12)	Software	Preferred Stock Warrant		7,097,792		60		354
Total Non-Affiliate Warrants — Healthcare information and services						424		1,945
Total Non-Affiliate Warrants						14,735		25,658
Non-Affiliate Other Investments — 0.4% (8)
Lumithera, Inc. (12)	Medical Device	Royalty Agreement				1,200		1,100
ZetrOZ, Inc. (12)	Medical Device	Royalty Agreement				—		200
Total Non-Affiliate Other Investments						1,200		1,300
Non-Affiliate Equity — 0.9% (8)
Castle Creek Biosciences, Inc. (12)	Biotechnology	Common Stock		1,162		250		250
Emalex Biosciences, Inc. (12)	Biotechnology	Common Stock		32,831		356		356
Getaround, Inc. (2)(5)	Consumer-related Technologies	Common Stock		87,082		253		25
SnagAJob.com, Inc. (12)	Consumer-related Technologies	Common Stock		82,974		9		83
Lumithera, Inc. (12)	Medical Device	Common Stock		392,651		2,000		1,700
Tigo Energy, Inc. (12)	Other Sustainability	Preferred Stock		22,313		8		27
Branded Online, Inc. (2)(5)	Software	Common Stock		5,398		1,075		14
Decisyon, Inc. (12)	Software	Preferred and Common Stock		72,638,663		229		—
Lotame, Inc. (12)	Software	Preferred Stock		66,127		5		193
Axiom Space, Inc. (12)	Technology	Preferred Stock		1,810		261		306
Total Non-Affiliate Equity						4,446		2,954
Total Non-Affiliate Portfolio Investment Assets					$	724,162	$	714,466
Non-controlled Affiliate Investments — 0.3% (8)
Non-controlled Affiliate Equity — Life Science —0.3% (8)
Cadrenal Therapeutics, Inc. (5)	Biotechnology	Common Stock		600,000		—		846
Total Non-Controlled Affiliate Equity					$	—		846
Total Non-Controlled Affiliate Portfolio Investment Assets					$	—		846
Total Portfolio Investment Assets — 222.4% (8)					$	724,162	$	715,312

(1) All investments of the Company are in entities which are organized under the laws of the United States and have a principal place of business in the United States.

(2) Has been pledged as collateral under the revolving credit facility (the “Key Facility”) with KeyBank National Association (“Key”), the Note Funding Agreement (the “NYL Facility”, together with the Key Facility, the "Credit Facilities") with several entities owned or affiliated with New York Life Insurance Company (“NYL Noteholders”), the term debt securitization in connection with which an affiliate of the Company made an offering of $100.0 million in aggregate principal amount of fixed rate asset-backed notes that were issued in conjunction with the $160.0 million securitization of secured loans the Company completed on August 13, 2019 (the “2019 Asset-Backed Notes”), and/or the term debt securitization in connection with which an affiliate of the Company made an offering of $100.0 million in aggregate principal amount of fixed rate asset-backed notes that were issued in conjunction with the $157.8 million securitization of secured loans the Company completed on November 9, 2022 (the “2022 Asset-Backed Notes”).

(3) All non-affiliate investments are investments in which the Company owns less than 5% of the voting securities of the portfolio company. All non-controlled affiliate investments are investments in which the Company owns 5% or more of the voting securities of the portfolio company but not more than 25% of the voting securities of the portfolio company. All controlled affiliate investments are investments in which the Company owns more than 25% of the portfolio company’s outstanding voting securities or has the power to exercise control over management or policies of such portfolio company (including through a management agreement).

(4) All interest is payable in cash due monthly in arrears, unless otherwise indicated, and applies only to the Company’s debt investments. Interest rate is the annual interest rate on the debt investment and does not include end-of-term payments (“ETPs”), and any additional fees related to the investments, such as deferred interest, commitment fees or prepayment fees. Debt investments are at variable rates for the term of the debt investment, unless otherwise indicated. All debt investments based on the London InterBank Offered Rate (“LIBOR”) are based on one-month LIBOR. For each debt investment, the current interest rate in effect as of  March 31, 2023 is provided.

(5) Portfolio company is a public company.

(6) For debt investments, represents principal balance less unearned income.

(7) Warrants, Equity and Other Investments are non-income producing.

(8) Value as a percent of net assets.

(9) As of March 31, 2023, 6.3% and 6.2% of the Company’s total assets on a cost and fair value basis, respectively, are in non-qualifying assets. Under the 1940 Act, the Company may not acquire any non-qualifying assets unless, at the time the acquisition is made, qualifying assets represent at least 70% of the Company’s total assets.

(10) ETPs are contractual fixed-interest payments due in cash at the maturity date of the applicable debt investment, including upon any prepayment, and are a fixed percentage of the original principal balance of the debt investments unless otherwise noted. Interest will accrue during the life of the debt investment on each ETP and will be recognized as non-cash income until it is actually paid. Therefore, a portion of the incentive fee the Company may pay its Advisor will be based on income that the Company has not yet received in cash.

(11) Debt investment has a payment-in-kind (“PIK”) feature.

(12) The fair value of the investment was valued using significant unobservable inputs.

(13) Debt investment is on non-accrual status as of March 31, 2023.

See Notes to Consolidated Financial Statements

14

Horizon Technology Finance Corporation and Subsidiaries

 

Consolidated Schedule of Investments

December 31, 2022

(Dollars in thousands)

Portfolio Company (1)(3)	Sector	Type of Investment (7)	Cash Rate (4)			Index	Margin			Floor			Ceiling			ETP (10)			Maturity Date	Principal Amount		Cost of Investments (6)(9)		Fair Value (9)
Non-Affiliate Investments — 226.1% (8)
Non-Affiliate Debt Investments — 215.5% (8)
Non-Affiliate Debt Investments — Life Science — 99.7% (8)
Avalo Therapeutics, Inc. (2)(5)(12)	Biotechnology	Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			3.00	%	January 1, 2025	$	2,885	$	2,853	$	2,777
		Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			3.00	%	January 1, 2025		2,885		2,823		2,750
		Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			3.00	%	January 1, 2025		1,442		1,411		1,374
		Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			3.00	%	February 1, 2025		2,885		2,821		2,748
		Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			3.00	%	February 1, 2025		2,885		2,821		2,748
		Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			3.00	%	April 1, 2025		1,442		1,408		1,371
		Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			3.00	%	April 1, 2025		1,442		1,408		1,371
Castle Creek Biosciences, Inc. (2)(12)	Biotechnology	Term Loan		12.50	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		5,000		4,891		4,891
		Term Loan		12.50	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		5,000		4,963		4,963
		Term Loan		12.50	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		3,000		2,978		2,978
		Term Loan		12.50	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		5,000		4,963		4,963
		Term Loan		12.50	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		5,000		4,963		4,963
		Term Loan		12.50	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		3,000		2,978		2,978
Emalex Biosciences, Inc. (2)(12)	Biotechnology	Term Loan		12.07	%	Libor		7.90	%		9.75	%		-			5.00	%	June 1, 2024		1,979		1,962		1,962
		Term Loan		12.07	%	Libor		7.90	%		9.75	%		-			5.00	%	June 1, 2024		1,979		1,963		1,963
		Term Loan		12.07	%	Libor		7.90	%		9.75	%		-			5.00	%	November 1, 2025		5,000		4,923		4,923
		Term Loan		12.07	%	Libor		7.90	%		9.75	%		-			5.00	%	May 1, 2026		5,000		4,912		4,912
Evelo Biosciences, Inc. (2)(5)(12)	Biotechnology	Term Loan		11.75	%	Prime		4.75	%		11.00	%		-			4.25	%	January 1, 2028		10,000		9,872		9,872
		Term Loan		11.75	%	Prime		4.75	%		11.00	%		-			4.25	%	January 1, 2028		15,000		14,808		14,808
		Term Loan		11.75	%	Prime		4.75	%		11.00	%		-			4.25	%	January 1, 2028		6,000		5,923		5,923
		Term Loan		11.75	%	Prime		4.75	%		11.00	%		-			4.25	%	January 1, 2028		6,000		5,923		5,923
		Term Loan		11.75	%	Prime		4.75	%		11.00	%		-			4.25	%	January 1, 2028		4,000		3,949		3,949
		Term Loan		11.75	%	Prime		4.75	%		11.00	%		-			4.25	%	January 1, 2028		4,000		3,949		3,949
F-Star Therapeutics, Inc. (2)(5)(12)	Biotechnology	Term Loan		13.25	%	Prime		6.25	%		9.50	%		-			4.00	%	April 1, 2025		2,500		2,476		2,476
		Term Loan		13.25	%	Prime		6.25	%		9.50	%		-			4.00	%	July 1, 2025		2,500		2,473		2,473
Greenlight Biosciences, Inc. (2)(5)(12)	Biotechnology	Term Loan		13.25	%	Prime		5.75	%		9.00	%		-			3.00	%	July 1, 2025		5,000		4,857		4,857
		Term Loan		13.25	%	Prime		5.75	%		9.00	%		-			3.00	%	July 1, 2025		2,500		2,430		2,430
IMV Inc. (2)(5)(12)	Biotechnology	Term Loan		13.25	%	Prime		5.75	%		9.00	%		-			5.00	%	July 1, 2025		5,000		4,946		4,946
		Term Loan		13.25	%	Prime		5.75	%		9.00	%		-			5.00	%	July 1, 2025		2,500		2,473		2,473
		Term Loan		13.25	%	Prime		5.75	%		9.00	%		-			5.00	%	January 1, 2026		5,000		4,947		4,947
		Term Loan		13.25	%	Prime		5.75	%		9.00	%		-			5.00	%	January 1, 2026		5,000		4,947		4,947
KSQ Therapeutics, Inc. (2) (12)	Biotechnology	Term Loan		12.25	%	Prime		4.75	%		8.50	%		-			5.50	%	May 1, 2027		6,250		6,077		6,077
		Term Loan		12.25	%	Prime		4.75	%		8.50	%		-			5.50	%	May 1, 2027		6,250		6,177		6,177
Native Microbials, Inc (2) (12)	Biotechnology	Term Loan		12.75	%	Prime		5.25	%		8.50	%		-			5.00	%	November 1, 2026		3,750		3,630		3,630
		Term Loan		12.75	%	Prime		5.25	%		8.50	%		-			5.00	%	November 1, 2026		2,500		2,469		2,469
PDS Biotechnology Corporation (2)(5)(12)	Biotechnology	Term Loan		13.25	%	Prime		5.75	%		9.75	%		-			3.75	%	September 1, 2026		10,000		9,701		9,701
		Term Loan		13.25	%	Prime		5.75	%		9.75	%		-			3.75	%	September 1, 2026		3,750		3,697		3,697
		Term Loan		13.25	%	Prime		5.75	%		9.75	%		-			3.75	%	September 1, 2026		3,750		3,697		3,697
Provivi, Inc. (2)(12)	Biotechnology	Term Loan		12.67	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		4,667		4,597		4,597
		Term Loan		12.67	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		4,667		4,597		4,597
		Term Loan		12.67	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		2,333		2,280		2,280
		Term Loan		12.67	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		2,333		2,280		2,280
		Term Loan		12.67	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		2,333		2,274		2,274
		Term Loan		12.67	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		2,333		2,274		2,274
Stealth Biotherapeutics Inc. (2)(12)	Biotechnology	Term Loan		13.00	%	Prime		5.50	%		8.75	%		-			6.00	%	October 1, 2025		5,000		4,914		4,914
		Term Loan		13.00	%	Prime		5.50	%		8.75	%		-			6.00	%	October 1, 2025		2,500		2,457		2,457
Aerobiotix, LLC (2)(12)	Medical Device	Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			6.00	%	April 1, 2026		2,500		2,463		2,364
		Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			6.00	%	April 1, 2026		2,500		2,463		2,364
Canary Medical Inc. (2)(12)	Medical Device	Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			7.00	%	November 1, 2024		2,500		2,475		2,475
		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			7.00	%	November 1, 2024		2,500		2,489		2,489
		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			7.00	%	November 1, 2024		2,500		2,473		2,473
Ceribell, Inc. (2)(12)	Medical Device	Term Loan		10.50	%	Prime		3.50	%		8.25	%		-			5.50	%	October 1, 2024		5,000		4,973		4,973
		Term Loan		10.50	%	Prime		3.50	%		8.25	%		-			5.50	%	October 1, 2024		5,000		4,973		4,973
		Term Loan		10.50	%	Prime		3.50	%		8.25	%		-			5.50	%	October 1, 2024		2,500		2,478		2,478
		Term Loan		10.50	%	Prime		3.50	%		8.25	%		-			5.50	%	October 1, 2024		2,500		2,478		2,478
Cognoa, Inc. (2)(12)	Medical Device	Term Loan		13.00	%	Prime		5.50	%		8.75	%		-			6.00	%	August 1, 2026		2,500		2,466		2,466
		Term Loan		13.00	%	Prime		5.50	%		8.75	%		-			6.00	%	August 1, 2026		5,000		4,932		4,932
Conventus Orthopaedics, Inc. (2)(12)	Medical Device	Term Loan		12.17	%	Libor		8.00	%		9.25	%		-			10.36	%	July 1, 2025		3,960		3,898		3,898
		Term Loan		12.17	%	Libor		8.00	%		9.25	%		-			10.36	%	July 1, 2025		3,960		3,898		3,898

See Notes to Consolidated Financial Statements

15

Horizon Technology Finance Corporation and Subsidiaries

 

Consolidated Schedule of Investments

December 31, 2022

(Dollars in thousands)

Portfolio Company (1)(3)	Sector	Type of Investment (7)	Cash Rate (4)			Index	Margin			Floor			Ceiling		ETP (10)			Maturity Date	Principal Amount		Cost of Investments (6)(9)		Fair Value (9)
Corinth Medtech, Inc. (2)(12)	Medical Device	Term Loan		12.25	%	Prime		5.25	%		8.50	%		-		20.00	%	September 15, 2022		2,500		2,500		2,500
		Term Loan		12.25	%	Prime		5.25	%		8.50	%		-		20.00	%	September 15, 2022		2,500		2,500		2,500
CSA Medical, Inc. (2)(12)	Medical Device	Term Loan		12.37	%	Libor		8.20	%		10.00	%		-		5.00	%	January 1, 2024		1,625		1,610		1,610
		Term Loan		12.37	%	Libor		8.20	%		10.00	%		-		5.00	%	January 1, 2024		108		107		107
		Term Loan		12.37	%	Libor		8.20	%		10.00	%		-		5.00	%	March 1, 2024		2,000		1,983		1,983
Embody, Inc. (2)(12)	Medical Device	Term Loan		14.00	%	Prime		6.50	%		9.75	%		-		28.00	%	August 1, 2026		2,500		2,482		2,482
InfoBionic, Inc. (2)(12)	Medical Device	Term Loan		13.25	%	Prime		6.25	%		9.50	%		-		4.00	%	October 1, 2024		3,208		3,143		3,143
		Term Loan		13.25	%	Prime		6.25	%		9.50	%		-		4.00	%	June 1, 2025		1,000		974		974
Magnolia Medical Technologies, Inc. (2)(12)	Medical Device	Term Loan		12.00	%	Prime		5.00	%		9.75	%		-		4.00	%	March 1, 2025		5,000		4,939		4,939
		Term Loan		12.00	%	Prime		5.00	%		9.75	%		-		4.00	%	March 1, 2025		5,000		4,939		4,939
		Term Loan		12.00	%	Prime		5.00	%		9.75	%		-		4.00	%	March 1, 2025		5,000		4,933		4,933
		Term Loan		12.00	%	Prime		5.00	%		9.75	%		-		4.00	%	March 1, 2025		5,000		4,933		4,933
		Term Loan		12.50	%	Prime		5.00	%		9.75	%		-		4.00	%	January 1, 2027		5,000		4,913		4,913
		Term Loan		12.50	%	Prime		5.00	%		9.75	%		-		4.00	%	January 1, 2027		5,000		4,913		4,913
Robin Healthcare, Inc. (2)(12)	Medical Device	Term Loan		13.00	%	Prime		5.50	%		10.25	%		-		4.00	%	November 1, 2026		3,500		3,360		3,360
		Term Loan		13.00	%	Prime		5.50	%		10.25	%		-		4.00	%	November 1, 2026		3,500		3,460		3,460
Scientia Vascular, Inc. (2)(12)	Medical Device	Term Loan		11.75	%	Prime		4.75	%		8.50	%		-		5.00	%	January 1, 2027		3,750		3,597		3,597
		Term Loan		11.75	%	Prime		4.75	%		8.50	%		-		5.00	%	January 1, 2027		3,750		3,706		3,706
Sonex Health, Inc. (2)(12)	Medical Device	Term Loan		13.50	%	Prime		6.50	%		9.75	%		-		8.00	%	June 1, 2025		2,500		2,476		2,476
		Term Loan		13.50	%	Prime		6.50	%		9.75	%		-		8.00	%	June 1, 2025		2,500		2,476		2,476
		Term Loan		13.50	%	Prime		6.50	%		9.75	%		-		8.00	%	June 1, 2025		2,500		2,476		2,476
		Term Loan		13.50	%	Prime		6.50	%		9.75	%		-		8.00	%	April 1, 2026		2,500		2,453		2,453
		Term Loan		13.50	%	Prime		6.50	%		9.75	%		-		8.00	%	May 1, 2026		2,500		2,455		2,455
Spineology, Inc. (2)(12)	Medical Device	Term Loan		14.50	%	Prime		7.00	%		10.25	%		-		1.00	%	October 1, 2025		5,000		4,966		4,966
		Term Loan		14.50	%	Prime		7.00	%		10.25	%		-		1.00	%	April 1, 2026		2,500		2,481		2,481
Swift Health Systems Inc. (2)(12)	Medical Device	Term Loan		12.25	%	Prime		5.25	%		9.00	%		-		5.00	%	July 1, 2027		3,500		3,349		3,349
		Term Loan		12.25	%	Prime		5.25	%		9.00	%		-		5.00	%	July 1, 2027		3,500		3,454		3,454
Total Non-Affiliate Debt Investments — Life Science																						318,172		317,568
Non-Affiliate Debt Investments — Sustainability — 26.3% (8)
Aerofarms, Inc. (2)(12)	Other Sustainability	Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		3.00	%	April 1, 2026		3,750		3,699		3,699
		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		3.00	%	April 1, 2026		3,750		3,699		3,699
Nexii Building Solutions, Inc. (2)(12)	Other Sustainability	Term Loan		14.50	%	Prime		7.00	%		10.25	%		-		2.50	%	September 1, 2025		7,500		7,371		7,371
		Term Loan		14.50	%	Prime		7.00	%		10.25	%		-		2.50	%	September 1, 2025		7,500		7,371		7,371
		Term Loan		14.50	%	Prime		7.00	%		10.25	%		-		2.50	%	September 1, 2025		7,500		7,371		7,371
		Term Loan		14.50	%	Prime		7.00	%		10.25	%		-		2.50	%	July 1, 2026		5,000		4,903		4,903
		Term Loan		14.50	%	Prime		7.00	%		10.25	%		-		2.50	%	July 1, 2026		5,000		4,903		4,903
Soli Organic, Inc. (2)(12)	Other Sustainability	Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.75	%	April 1, 2026		2,500		2,463		2,463
		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.75	%	April 1, 2026		5,000		4,927		4,927
		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.75	%	May 1, 2026		5,000		4,924		4,924
		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.75	%	May 1, 2026		2,500		2,462		2,462
		Term Loan		13.00	%	Prime		5.50	%		10.00	%		-		2.75	%	December 1, 2026		5,000		4,900		4,900
		Term Loan		13.00	%	Prime		5.50	%		10.00	%		-		2.75	%	December 1, 2026		2,500		2,450		2,450
Temperpack Technologies, Inc. (2)(12)	Other Sustainability	Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.50	%	June 1, 2025		3,750		3,697		3,697
		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.50	%	June 1, 2025		3,750		3,717		3,717
		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.50	%	October 1, 2025		7,500		7,424		7,424
		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.50	%	October 1, 2025		3,750		3,712		3,712
		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.50	%	October 1, 2025		3,750		3,712		3,712
Total Non-Affiliate Debt Investments — Sustainability																						83,705		83,705
Non-Affiliate Debt Investments — Technology — 81.4% (8)
Axiom Space, Inc. (2)(12)	Communications	Term Loan		13.00	%	Prime		6.00	%		9.25	%		-		2.50	%	June 1, 2026		7,500		7,455		7,455
		Term Loan		13.00	%	Prime		6.00	%		9.25	%		-		2.50	%	June 1, 2026		7,500		7,455		7,455
		Term Loan		13.00	%	Prime		6.00	%		9.25	%		-		2.50	%	June 1, 2026		7,500		7,455		7,455
		Convertible Note		3.00	%													July 1, 2023		250		250		306
Alula Holdings, Inc. (2)(12)	Consumer-related Technologies	Term Loan		13.75	%	Prime		6.75	%		10.00	%		-		3.00	%	January 1, 2025		5,000		4,966		4,966
		Term Loan		13.75	%	Prime		6.75	%		10.00	%		-		3.00	%	January 1, 2025		5,000		4,966		4,966
		Term Loan		13.75	%	Prime		6.75	%		10.00	%		-		3.00	%	January 1, 2025		3,000		2,979		2,979
		Term Loan		13.75	%	Prime		6.75	%		10.00	%		-		3.00	%	December 1, 2025		1,000		976		976
		Term Loan		13.75	%	Prime		6.75	%		10.00	%		-		3.00	%	February 1, 2026		1,000		977		977
Better Place Forests Co. (2)(12)(13)	Consumer-related Technologies	Term Loan		13.75	%	Prime		6.25	%		9.50	%		-		1.85	%	July 1, 2025		5,000		4,951		3,834
		Term Loan		13.75	%	Prime		6.25	%		9.50	%		-		1.85	%	October 1, 2025		2,500		2,474		1,916
CAMP NYC, Inc. (2)(12)	Consumer-related Technologies	Term Loan		14.75	%	Prime		7.25	%		10.50	%		-		3.00	%	May 1, 2026		3,500		3,461		3,461
Clara Foods Co. (2)(12)	Consumer-related Technologies	Term Loan		12.75	%	Prime		5.75	%		9.00	%		-		5.50	%	August 1, 2025		2,500		2,482		2,482
		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-		5.50	%	August 1, 2025		2,500		2,482		2,482

See Notes to Consolidated Financial Statements

16

Horizon Technology Finance Corporation and Subsidiaries

 

Consolidated Schedule of Investments

December 31, 2022

(Dollars in thousands)

Portfolio Company (1)(3)	Sector	Type of Investment (7)	Cash Rate (4)			Index	Margin			Floor			Ceiling			ETP (10)			Maturity Date	Principal Amount		Cost of Investments (6)(9)		Fair Value (9)
Divergent Technologies, Inc. (2)(12)	Consumer-related Technologies	Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		3,750		3,478		3,478
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		1,250		1,238		1,238
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		3,750		3,715		3,715
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		1,250		1,238		1,238
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		3,750		3,715		3,715
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		1,250		1,238		1,238
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	January 1, 2028		3,750		3,698		3,698
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	January 1, 2028		3,750		3,698		3,698
Havenly, Inc. (2)(12)	Consumer-related Technologies	Term Loan		12.50	%	Prime		5.00	%		5.00	%		-			4.00	%	March 1, 2027		2,000		1,082		1,082
		Term Loan		12.50	%	Prime		5.00	%		5.00	%		-			4.00	%	March 1, 2027		3,000		1,623		1,623
		Term Loan		11.00	%	Prime		3.50	%		10.50	%		-			7.78	%	February 1, 2028		2,813		2,813		2,813
		Term Loan		11.00	%	Prime		3.50	%		10.50	%		-			7.78	%	February 1, 2028		2,813		2,813		2,813
Interior Define, Inc. (2)(12)(13)	Consumer-related Technologies	Term Loan		13.50	%	Prime		6.50	%		9.75	%		-			4.00	%	January 1, 2026		3,210		3,151		—
		Term Loan		13.50	%	Prime		6.50	%		9.75	%		-			4.00	%	January 1, 2026		2,963		2,886		—
Lyrical Foods, Inc. (2)(12)	Consumer-related Technologies	Term Loan		10.00	%	Prime		6.75	%		10.00	%		-			-		September 1, 2027		2,500		2,588		2,279
MyForest Foods Co. (2)(12)	Consumer-related Technologies	Term Loan		14.25	%	Prime		6.75	%		10.00	%		-			3.00	%	October 1, 2025		5,000		4,954		4,954
		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-			3.00	%	October 1, 2025		2,500		2,477		2,477
NextCar Holding Company, Inc. (2)(12)	Consumer-related Technologies	Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			2.00	%	December 30, 2022		5,000		4,943		4,715
		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			2.00	%	December 30, 2022		2,000		1,981		1,890
		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			2.00	%	December 30, 2022		2,500		2,477		2,363
		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			2.00	%	December 30, 2022		3,000		2,971		2,835
		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			2.00	%	December 30, 2022		2,500		2,459		2,345
		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			2.00	%	December 30, 2022		2,500		2,459		2,345
		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			2.00	%	December 30, 2022		5,000		4,914		4,688
		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			2.00	%	December 30, 2022		2,500		2,456		2,342
Optoro, Inc. (2)(12)	Consumer-related Technologies	Term Loan		13.25	%	Prime		6.25	%		9.50	%		-			4.00	%	August 1, 2027		2,500		2,347		2,347
Primary Kids, Inc. (2)(12)	Consumer-related Technologies	Term Loan		14.25	%	Prime		7.25	%		10.50	%		-			3.00	%	March 1, 2025		2,700		2,673		2,673
		Term Loan		14.25	%	Prime		7.25	%		10.50	%		-			3.00	%	March 1, 2025		2,700		2,673		2,673
		Term Loan		14.25	%	Prime		7.25	%		10.50	%		-			3.00	%	September 1, 2025		3,000		2,967		2,967
Unagi, Inc. (2)(12)	Consumer-related Technologies	Term Loan		15.25	%	Prime		7.75	%		11.00	%		-			-		July 1, 2025		2,500		2,473		2,473
		Term Loan		15.25	%	Prime		7.75	%		11.00	%		-			-		July 1, 2025		1,250		1,236		1,236
		Term Loan		15.25	%	Prime		7.75	%		11.00	%		-			-		July 1, 2025		1,250		1,236		1,236
Liqid, Inc. (2)(12)	Networking	Term Loan		13.25	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		3,333		3,286		3,286
		Term Loan		13.25	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		3,333		3,286		3,286
		Term Loan		13.25	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		1,667		1,641		1,641
		Term Loan		13.25	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		1,667		1,641		1,641
		Term Loan		13.25	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		1,667		1,613		1,613
BriteCore Holdings, Inc. (2)(12)	Software	Term Loan		13.75	%	Prime		6.75	%		10.00	%		-			5.00	%	March 1, 2026		2,500		2,421		2,421
		Term Loan		13.75	%	Prime		6.75	%		10.00	%		-			5.00	%	March 1, 2026		2,500		2,487		2,487
Decisyon, Inc. (12)	Software	Term Loan		16.93	%	Prime		9.43	%		12.68	%		-			50.43	%	December 31, 2022		3,295		3,295		3,295
Dropoff, Inc. (2)(12)	Software	Term Loan		14.00	%	Prime		6.50	%		9.75	%		-			3.50	%	April 1, 2026		6,500		6,347		6,347
		Term Loan		14.00	%	Prime		6.50	%		9.75	%		-			3.50	%	April 1, 2026		6,000		5,859		5,859
		Term Loan		14.00	%	Prime		6.50	%		9.75	%		-			3.50	%	August 1, 2026		2,500		2,436		2,436
Engage3, LLC (2)(12)	Software	Term Loan		13.25	%	Prime		6.25	%		9.75	%		-			4.50	%	July 1, 2027		3,750		3,678		3,678
		Term Loan		13.25	%	Prime		6.25	%		9.75	%		-			4.50	%	July 1, 2027		3,750		3,718		3,718
Groundspeed Analytics, Inc. (2)(12)	Software	Term Loan		13.00	%	Prime		5.50	%		11.00	%		18.00	%		3.00	%	December 1, 2026		5,000		4,798		4,798
		Term Loan		13.00	%	Prime		5.50	%		11.00	%		18.00	%		3.00	%	December 1, 2026		5,000		4,948		4,948
Kodiak Robotics, Inc. (2)(12)	Software	Term Loan		13.00	%	Prime		5.50	%		10.25	%		-			4.00	%	April 1, 2026		10,000		9,826		9,826
		Term Loan		13.00	%	Prime		5.50	%		10.25	%		-			4.00	%	April 1, 2026		10,000		9,826		9,826
		Term Loan		13.00	%	Prime		5.50	%		10.25	%		-			4.00	%	April 1, 2026		5,000		4,913		4,913
		Term Loan		13.00	%	Prime		5.50	%		10.25	%		-			4.00	%	April 1, 2026		5,000		4,913		4,913
Lemongrass Holdings, Inc. (2)(12)	Software	Term Loan		14.00	%	Prime		6.50	%		9.75	%		-			2.50	%	March 1, 2026		5,000		4,947		4,947
		Term Loan		14.00	%	Prime		6.50	%		9.75	%		-			2.50	%	March 1, 2026		2,500		2,474		2,474
Lytics, Inc. (2)(12)	Software	Term Loan		13.00	%	Prime		6.00	%		9.25	%		-			3.00	%	July 1, 2025		2,500		2,396		2,396
		Term Loan		13.00	%	Prime		6.00	%		12.25	%		-			3.00	%	December 1, 2026		1,250		1,231		1,231
Reputation Institute, Inc. (2)(12)	Software	Term Loan		14.25	%	Prime		7.25	%		10.50	%		-			3.00	%	August 1, 2025		5,000		4,932		4,932
Slingshot Aerospace, Inc. (2)(12)	Software	Term Loan		13.25	%	Prime		5.75	%		9.75	%		-			5.00	%	August 1, 2026		5,000		4,870		4,870
		Term Loan		13.25	%	Prime		5.75	%		9.75	%		-			5.00	%	August 1, 2026		5,000		4,933		4,933
		Term Loan		13.25	%	Prime		5.75	%		9.75	%		-			5.00	%	August 1, 2026		5,000		4,933		4,933
		Term Loan		13.25	%	Prime		5.75	%		9.75	%		-			5.00	%	August 1, 2026		5,000		4,933		4,933
Supply Network Visiblity Holdings LLC (2)(12)	Software	Term Loan		13.50	%	Prime		6.50	%		9.75	%		-			4.00	%	February 1, 2025		3,500		3,472		3,472
		Term Loan		13.50	%	Prime		6.50	%		9.75	%		-			4.00	%	February 1, 2025		3,500		3,472		3,472
		Term Loan		13.50	%	Prime		6.50	%		9.75	%		-			4.00	%	December 1, 2025		2,500		2,472		2,472
		Term Loan		13.50	%	Prime		6.50	%		9.75	%		-			4.00	%	December 1, 2025		2,500		2,472		2,472
Total Non-Affiliate Debt Investments — Technology																							268,468		259,366
Non-Affiliate Debt Investments — Healthcare information and services — 8.1% (8)
Hound Labs inc. (2) (12)	Diagnostics	Term Loan		13.50	%	Prime		6.00	%		9.25	%		-			3.50	%	June 1, 2026		2,500		2,385		2,385
		Term Loan		13.50	%	Prime		6.00	%		9.25	%		-			3.50	%	June 1, 2026		2,500		2,473		2,473
		Term Loan		13.50	%	Prime		6.00	%		9.25	%		-			3.50	%	June 1, 2026		5,000		4,946		4,946
Secure Transfusion Services, Inc. (2)(12)(13)	Other Healthcare	Term Loan		13.25	%	Prime		5.75	%		9.00	%		-			4.00	%	October 1, 2025		4,943		4,943		1,668
		Term Loan		13.25	%	Prime		5.75	%		9.00	%		-			4.00	%	December 31, 2025		2,500		2,467		832
BrightInsight, Inc. (2)(12)	Software	Term Loan		12.50	%	Prime		5.50	%		9.50	%		-			3.00	%	August 1, 2027		7,000		6,619		6,619
		Term Loan		12.50	%	Prime		5.50	%		9.50	%		-			3.00	%	August 1, 2027		3,500		3,448		3,448
		Term Loan		12.50	%	Prime		5.50	%		9.50	%		-			3.00	%	August 1, 2027		3,500		3,448		3,448
Total Non-Affiliate Debt Investments — Healthcare information and services																							30,729		25,819
Total Non- Affiliate Debt Investments																							701,074		686,458

See Notes to Consolidated Financial Statements

17

Horizon Technology Finance Corporation and Subsidiaries

 

Consolidated Schedule of Investments

December 31, 2022

(Dollars in thousands)

					Cost of		Fair
Portfolio Company (1)(3)	Sector	Type of Investment (7)	Number of Shares		Investments (6)(9)		Value (9)
Non-Affiliate Warrant Investments — 9.4% (8)
Non-Affiliate Warrants — Life Science — 3.1% (8)
Avalo Therapeutics, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		26,442		311		—
Castle Creek Biosciences, Inc. (2)(12)	Biotechnology	Preferred Stock Warrant		7,404		214		335
Corvium, Inc. (2)(12)	Biotechnology	Preferred Stock Warrant		661,956		53		—
Emalex Biosciences, Inc. (2)(12)	Biotechnology	Preferred Stock Warrant		110,402		176		263
Evelo Biosciences, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		463,915		126		125
F-Star Therapeutics, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		21,120		35		—
Greenlight Biosciences, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		47,452		366		—
Imunon, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		16,502		66		—
IMV Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		39,774		67		—
KSQ Therapeutics, Inc. (2) (12)	Biotechnology	Preferred Stock Warrant		48,077		51		60
Mustang Bio, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		252,161		146		—
Native Microbials, Inc (2) (12)	Biotechnology	Preferred Stock Warrant		103,679		64		162
PDS Biotechnology Corporation (2)(5)(12)	Biotechnology	Common Stock Warrant		299,848		160		3,024
Provivi, Inc. (2)(12)	Biotechnology	Preferred Stock Warrant		203,017		399		648
Rocket Pharmaceuticals Corporation (5)(12)	Biotechnology	Common Stock Warrant		7,051		17		14
Stealth Biotherapeutics Inc. (2)(12)	Biotechnology	Common Stock Warrant		318,181		264		37
vTv Therapeutics Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		95,293		44		—
Xeris Pharmaceuticals, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		126,000		72		3
AccuVein Inc. (2)(12)	Medical Device	Common Stock Warrant		1,175		24		—
Aerin Medical, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		1,818,183		64		1,200
Aerobiotix, LLC (2)(12)	Medical Device	Preferred Stock Warrant		27,330		48		31
Canary Medical Inc. (2)(12)	Medical Device	Preferred Stock Warrant		12,153		84		1,864
Ceribell, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		145,483		69		209
Cognoa, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		775,000		148		179
Conventus Orthopaedics, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		7,972,222		221		226
CSA Medical, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		1,375,727		153		150
CVRx, Inc. (2)(5)(12)	Medical Device	Common Stock Warrant		47,410		76		394
Infobionic, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		317,647		124		113
Magnolia Medical Technologies, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		809,931		194		385
Meditrina, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		233,993		83		101
Robin Healthcare, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		86,066		16		16
Scientia Vascular, Inc (2)(12)	Medical Device	Preferred Stock Warrant		19,662		40		46
Sonex Health, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		605,313		98		123
VERO Biotech LLC (2)(12)	Medical Device	Preferred Stock Warrant		408		53		1
Swift Health Systems Inc. (2)(12)	Medical Device	Preferred Stock Warrant		135,484		71		83
Total Non-Affiliate Warrants — Life Science						4,197		9,792
Non-Affiliate Warrants — Sustainability — 0.6% (8)
Aerofarms, Inc. (2)(12)	Other Sustainability	Preferred Stock Warrant		201,537		61		74
LiquiGlide, Inc. (2)(12)	Other Sustainability	Common Stock Warrant		61,539		39		55
Nexii Building Solutions, Inc. (2)(12)	Other Sustainability	Common Stock Warrant		204,832		488		1,061
Soli Organic, Inc. (2)(12)	Other Sustainability	Preferred Stock Warrant		681		214		361
Temperpack Technologies, Inc. (2)(12)	Other Sustainability	Preferred Stock Warrant		35,906		126		268
Total Non-Affiliate Warrants — Sustainability						928		1,819

See Notes to Consolidated Financial Statements

18

Horizon Technology Finance Corporation and Subsidiaries

 

Consolidated Schedule of Investments

December 31, 2022

(Dollars in thousands)

					Cost of		Fair
Portfolio Company (1)(3)	Sector	Type of Investment (7)	Number of Shares		Investments (6)(9)		Value (9)
Non-Affiliate Warrants — Technology — 5.1% (8)
Axiom Space, Inc. (2)(12)	Communications	Common Stock Warrant		1,991		46		67
Intelepeer Holdings, Inc. (2)(12)	Communications	Preferred Stock Warrant		2,936,535		139		3,265
PebblePost, Inc. (2)(12)	Communications	Preferred Stock Warrant		598,850		92		173
Alula Holdings, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		20,000		93		64
Aterian, Inc. (2)(5)(12)	Consumer-related Technologies	Common Stock Warrant		76,923		195		—
Better Place Forests Co. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		10,690		26		—
Caastle, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		268,591		68		1,069
CAMP NYC, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		17,605		20		61
Clara Foods Co. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		46,745		30		125
Divergent Technologies, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		31,966		56		233
Havenly, Inc. (2)(12)	Consumer-related Technologies	Common Stock Warrant		1,312,500		2,947		2,947
Interior Define, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		553,710		103		—
MyForest Foods Co. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		143		29		37
NextCar Holding Company, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		1,261,253		197		17
Optoro, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		6,600		104		104
Primary Kids, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		553,778		57		429
Quip NYC Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		6,191		325		534
Unagi, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		171,081		32		22
Updater, Inc.(2)(12)	Consumer-related Technologies	Common Stock Warrant		108,333		34		42
CPG Beyond, Inc. (2)(12)	Data Storage	Preferred Stock Warrant		500,000		242		909
Silk, Inc. (2)(12)	Data Storage	Preferred Stock Warrant		442,110		234		407
Global Worldwide LLC (2)(12)	Internet and Media	Preferred Stock Warrant		245,810		75		—
Rocket Lawyer Incorporated (2)(12)	Internet and Media	Preferred Stock Warrant		261,721		92		357
Skillshare, Inc. (2)(12)	Internet and Media	Preferred Stock Warrant		139,074		162		802
Liqid, Inc. (2)(12)	Networking	Preferred Stock Warrant		344,102		364		243
Halio, Inc. (2)(12)	Power Management	Preferred Stock Warrant		5,002,574		1,585		2,610
Avalanche Technology, Inc. (2)(12)	Semiconductors	Preferred and Common Stock Warrants		6,081		56		—
BriteCore Holdings, Inc. (2)(12)	Software	Preferred Stock Warrant		77,828		21		69
Decisyon, Inc. (12)	Software	Common Stock Warrant		82,967		46		—
Dropoff, Inc. (2)(12)	Software	Common Stock Warrant		516,732		455		197
E La Carte, Inc. (2)(5)(12)	Software	Common Stock Warrant		147,361		60		3
Groundspeed Analytics, Inc. (2)(12)	Software	Preferred Stock Warrant		86,300		6		6
Kodiak Robotics, Inc. (2)(12)	Software	Preferred Stock Warrant		639,918		273		296
Lemongrass Holdings, Inc. (2)(12)	Software	Preferred Stock Warrant		101,308		34		41
Lotame Solutions, Inc. (2)(12)	Software	Preferred Stock Warrant		288,115		22		312
Lytics, Inc. (2)(12)	Software	Preferred Stock Warrant		80,197		40		44
Reputation Institute, Inc. (2)(12)	Software	Preferred Stock Warrant		3,731		56		39
Revinate Holdings, Inc. (2)(12)	Software	Preferred Stock Warrant		682,034		46		99
Riv Data Corp. (2)(12)	Software	Preferred Stock Warrant		321,428		12		296
SIGNiX, Inc. (12)	Software	Preferred Stock Warrant		186,235		225		—
Skyword, Inc. (12)	Software	Preferred and Common Stock Warrants		301,055		48		1
Slingshot Aerospace, Inc. (2)(12)	Software	Preferred Stock Warrant		309,208		123		133
Supply Network Visiblity Holdings LLC (2)(12)	Software	Preferred Stock Warrant		682		64		83
Topia Mobility, Inc. (2)(12)	Software	Preferred Stock Warrant		3,049,607		138		—
xAd, Inc. (2)(12)	Software	Preferred Stock Warrant		4,343,348		177		12
Total Non-Affiliate Warrants — Technology						9,249		16,148
Non-Affiliate Warrants — Healthcare information and services — 0.6% (8)
Hound Labs, Inc (2) (12)	Diagnostics	Preferred Stock Warrant		159,893		47		54
Kate Farms, Inc. (2)(12)	Other Healthcare	Preferred Stock Warrant		82,965		102		1,370
Secure Transfusion Services, Inc. (2)(12)	Other Healthcare	Preferred Stock Warrant		77,690		47		—
BrightInsight, Inc. (2)(12)	Software	Preferred Stock Warrant		80,544		160		170
Medsphere Systems Corporation (2)(12)	Software	Preferred Stock Warrant		7,097,792		60		359
Total Non-Affiliate Warrants — Healthcare information and services						416		1,953
Total Non-Affiliate Warrants						14,790		29,712
Non-Affiliate Other Investments — 0.4% (8)
Lumithera, Inc. (2)	Medical Device	Royalty Agreement				1,200		1,100
ZetrOZ, Inc. (12)	Medical Device	Royalty Agreement				—		200
Total Non-Affiliate Other Investments						1,200		1,300
Non-Affiliate Equity — 0.8% (8)
Castle Creek Biosciences, Inc. (12)	Biotechnology	Common Stock		1,162		250		250
Emalex Biosciences, Inc. (2)(12)	Biotechnology	Common Stock		32,831		356		356
Getaround, Inc. (2)(5)	Consumer-related Technologies	Common Stock		87,082		253		57
SnagAJob.com, Inc. (12)	Consumer-related Technologies	Common Stock		82,974		8		83
Lumithera, Inc. (2)	Medical Device	Common Stock		392,651		2,000		1,700
Tigo Energy, Inc. (2)	Other Sustainability	Preferred		22,313		8		27
Branded Online, Inc. (2)(5)	Software	Common Stock		108,004		1,079		83
Decisyon, Inc. (12)	Software	Preferred and Common Stock		72,638,663		230		—
Total Non-Affiliate Equity						4,184		2,556
Total Non-Affiliate Portfolio Investment Assets					$	721,248	$	720,026
Total Portfolio Investment Assets — 226.1% (8)					$	721,248	$	720,026

(1) All investments of the Company are in entities which are organized under the laws of the United States and have a principal place of business in the United States.

(2) Has been pledged as collateral under the Key Facility, the NYL Facility the 2019 Asset-Backed Notes and/or the 2022 Asset-Backed Notes.

See Notes to Consolidated Financial Statements

19

Horizon Technology Finance Corporation and Subsidiaries

 

Consolidated Schedule of Investments

December 31, 2022

(Dollars in thousands)

(3) All non-affiliate investments are investments in which the Company owns less than 5% of the voting securities of the portfolio company. All non-controlled affiliate investments are investments in which the Company owns 5% or more of the voting securities of the portfolio company but not more than 25% of the voting securities of the portfolio company. All controlled affiliate investments are investments in which the Company owns more than 25% of the portfolio company’s outstanding voting securities or has the power to exercise control over management or policies of such portfolio company (including through a management agreement).

(4) All interest is payable in cash due monthly in arrears, unless otherwise indicated, and applies only to the Company’s debt investments. Interest rate is the annual interest rate on the debt investment and does not include ETPs, and any additional fees related to the investments, such as deferred interest, commitment fees or prepayment fees. Debt investments are at variable rates for the term of the debt investment, unless otherwise indicated. All debt investments based on the LIBOR are based on one-month LIBOR. For each debt investment, the current interest rate in effect as of  December 31, 2022 is provided.

(5) Portfolio company is a public company.

(6) For debt investments, represents principal balance less unearned income.

(7) Warrants, Equity and Other Investments are non-income producing.

(8) Value as a percent of net assets.

(9) As of December 31, 2022, 6.5% and 6.6% of the Company's total assets on a cost and fair value basis, respectively, are in non-qualifying assets. Under the 1940 Act, the Company may not acquire any non-qualifying assets unless, at the time the acquisition is made, qualifying assets represent at least 70% of the Company’s total assets.

(10) ETPs are contractual fixed-interest payments due in cash at the maturity date of the applicable debt investment, including upon any prepayment, and are a fixed percentage of the original principal balance of the debt investments unless otherwise noted. Interest will accrue during the life of the debt investment on each ETP and will be recognized as non-cash income until it is actually paid. Therefore, a portion of the incentive fee the Company may pay its Advisor will be based on income that the Company has not yet received in cash.

(11) Debt investment has a PIK feature.

(12) The fair value of the investment was valued using significant unobservable inputs.

(13) Debt investment is on non-accrual status as of December 31, 2022.

See Notes to Consolidated Financial Statements

20

Horizon Technology Finance Corporation and Subsidiaries

Notes to Consolidated Financial Statements

 

Note 1. Organization

Horizon Technology Finance Corporation (the “Company”) was organized as a Delaware corporation on March 16, 2010 and is an externally managed, non-diversified, closed-end investment company. The Company has elected to be regulated as a business development company (“BDC”) under the 1940 Act. In addition, for tax purposes, the Company has elected to be treated as a regulated investment company (“RIC”) as defined under Subchapter M of the Internal Revenue Code of 1986, as amended (the “Code”). As a RIC, the Company generally is not subject to corporate-level federal income tax on the portion of its taxable income (including net capital gains) the Company distributes to its stockholders. The Company primarily makes secured debt investments to development-stage companies in the technology, life science, healthcare information and services and sustainability industries. All of the Company’s debt investments consist of loans secured by all of, or a portion of, the applicable debtor company’s tangible and intangible assets.

On October 28, 2010, the Company completed an initial public offering (“IPO”) and its common stock trades on the Nasdaq Global Select Market under the symbol “HRZN”.

Horizon Credit II LLC (“Credit II”) was formed as a Delaware limited liability company on June 28, 2011, with the Company as its sole equity member. Credit II is a special purpose bankruptcy-remote entity and is a separate legal entity from the Company. Any assets conveyed to Credit II are not available to creditors of the Company or any other entity other than Credit II’s lenders.

The Company formed Horizon Funding 2019‑1 LLC (“2019‑1 LLC”) as a Delaware limited liability company on May 2, 2019 and Horizon Funding Trust 2019‑1 on May 15, 2019 (“2019‑1 Trust” and, together with the 2019‑1 LLC, the “2019‑1 Entities”). The 2019‑1 Entities are special purpose bankruptcy remote entities and are separate legal entities from the Company. The Company formed the 2019‑1 Entities for purposes of securitizing the 2019 Asset-Backed Notes.

Horizon Funding I, LLC (“HFI”) was formed as a Delaware limited liability company on May 9, 2018, with Horizon Secured Loan Fund I LLC, a Delaware limited liability company (“HSLFI”) as its sole member. HFI is a special purpose bankruptcy-remote entity and is a separate legal entity from HSLFI. Any assets conveyed to HFI are not available to creditors of HSLFI or any other entity other than HFI’s lenders. As of April 21, 2020, HSLFI and its subsidiary, HFI, are consolidated by the Company.

The Company formed Horizon Funding 2022‑1 LLC (“2022‑1 LLC”) as a Delaware limited liability company on September 30, 2022 and Horizon Funding Trust 2022‑1 on October 18, 2022 (“2022‑1 Trust” and, together with the 2022‑1 LLC, the “2022‑1 Entities”). The 2022‑1 Entities are special purpose bankruptcy remote entities and are separate legal entities from the Company. The Company formed the 2022‑1 Entities for purposes of securitizing the 2022 Asset-Backed Notes.

The Company has also established an additional wholly owned subsidiary, which is structured as a Delaware limited liability company, to hold the assets of a portfolio company acquired in connection with foreclosure or bankruptcy, which is a separate legal entity from the Company.

The Company’s investment strategy is to maximize the investment portfolio’s return by generating current income from the debt investments the Company makes and capital appreciation from the warrants the Company receives when making such debt investments. The Company has entered into an investment management agreement (the “Investment Management Agreement”) with Horizon Technology Finance Management LLC (the “Advisor”) under which the Advisor manages the day-to-day operations of, and provides investment advisory services to, the Company.

21

Horizon Technology Finance Corporation and Subsidiaries

Notes to Consolidated Financial Statements

 

Note 2. Basis of presentation and significant accounting policies

The consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and pursuant to the requirements for reporting on Form 10‑Q and Articles 6 and 10 of Regulation S-X (“Regulation S-X”) under the Securities Act of 1933, as amended (the “Securities Act”). In the opinion of management, the consolidated financial statements reflect all adjustments and reclassifications, consisting solely of normal recurring accruals, that are necessary for the fair presentation of financial results as of and for the periods presented. All intercompany balances and transactions have been eliminated. The current period’s results of operations are not necessarily indicative of results that ultimately may be achieved for the year. Therefore, the unaudited financial statements and notes should be read in conjunction with the audited financial statements and notes thereto for the year ended December 31, 2022.

Principles of consolidation

As required under GAAP and Regulation S-X, the Company will generally consolidate its investment in a company that is an investment company subsidiary or a controlled operating company whose business consists of providing services to the Company. Accordingly, the Company consolidated the results of the Company’s wholly-owned subsidiaries in its consolidated financial statements.

Assets related to transactions that do not meet Accounting Standards Codification (“ASC”) Topic 860, Transfers and Servicing requirements for accounting sale treatment are reflected in the Company’s Consolidated Statements of Assets and Liabilities as investments. Those assets are owned by special purpose entities, including 2019‑1 Entities and 2022-1 Entities, that are consolidated in the Company’s consolidated financial statements. The creditors of the special purpose entities have received security interests in such assets and such assets are not intended to be available to the creditors of the Company (or any affiliate of the Company).

Use of estimates

In preparing the consolidated financial statements in accordance with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosures of contingent assets and liabilities, as of the date of the balance sheet and income and expenses for the period. Actual results could differ from those estimates. Material estimates that are particularly susceptible to significant change in the near term relate to the valuation of investments.

Fair value

The Company records all of its investments at fair value in accordance with relevant GAAP, which establishes a framework used to measure fair value and requires disclosures for fair value measurements. The Company has categorized its investments carried at fair value, based on the priority of the valuation technique, into a three-level fair value hierarchy as more fully described in Note 6. Fair value is a market-based measure considered from the perspective of the market participant who holds the financial instrument rather than an entity specific measure. Therefore, when market assumptions are not readily available, the Company’s own assumptions are set to reflect those that management believes market participants would use in pricing the financial instrument at the measurement date.

The availability of observable inputs can vary depending on the financial instrument and is affected by a wide variety of factors, including, for example, the type of product, whether the product is new, whether the product is traded on an active exchange or in the secondary market and the current market conditions. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for financial instruments classified as Level 3.

See Note 6 for additional information regarding fair value.

22

Horizon Technology Finance Corporation and Subsidiaries

Notes to Consolidated Financial Statements

 

Segments

The Company has determined that it has a single reporting segment and operating unit structure. The Company lends to and invests in portfolio companies in various technology, life science, healthcare information and services and sustainability industries. The Company separately evaluates the performance of each of its lending and investment relationships. However, because each of these debt investments and investment relationships has similar business and economic characteristics, they have been aggregated into a single lending and investment segment.

Investments

Investments are recorded at fair value. Pursuant to the amended SEC Rule 2a-5 of the 1940 Act, on July 29, 2022, the Company's board of directors (the “Board”) designated the Advisor as the Company’s “valuation designee.” The valuation designee determines the fair value of the Company’s portfolio investments and the Board oversees the valuation designee. The Company has the intent to hold its debt investments for the foreseeable future or until maturity or payoff.

Interest on debt investments is accrued and included in income based on contractual rates applied to principal amounts outstanding. Interest income is determined using a method that results in a level rate of return on principal amounts outstanding. Generally, when a debt investment becomes 90 days or more past due, or if the Company otherwise does not expect to receive interest and principal repayments, the debt investment is placed on non-accrual status and the recognition of interest income may be discontinued. Interest payments received on non-accrual debt investments may be recognized as income, on a cash basis, or applied to principal depending upon management’s judgment at the time the debt investment is placed on non-accrual status. As of March 31, 2023, there were three investments on nonaccrual status with a cost of $20.3 million and a fair value of $5.3 million. As of December 31, 2022, there were three investments on non-accrual status with a cost of $20.9 million and a fair value of $8.3 million. For the three months ended March 31, 2023 and 2022, the Company did not recognize any interest income received from debt investments on non-accrual status.

The Company receives a variety of fees from borrowers in the ordinary course of conducting its business, including advisory fees, commitment fees, amendment fees, non-utilization fees, success fees and prepayment fees. In a limited number of cases, the Company may also receive a non-refundable deposit earned upon the termination of a transaction. Debt investment origination fees, net of certain direct origination costs, are deferred and, along with unearned income, are amortized as a level-yield adjustment over the respective term of the debt investment. All other income is recognized when earned. Fees for counterparty debt investment commitments with multiple debt investments are allocated to each debt investment based upon each debt investment’s relative fair value. When a debt investment is placed on non-accrual status, the amortization of the related fees and unearned income is discontinued until the debt investment is returned to accrual status.

Certain debt investment agreements also require the borrower to make an ETP, that is accrued into interest receivable and taken into income over the life of the debt investment to the extent such amounts are expected to be collected. The Company will generally cease accruing the income if there is insufficient value to support the accrual or the Company does not expect the borrower to be able to pay the ETP when due. The proportion of the Company’s total investment income that resulted from the portion of ETPs not received in cash for the three months ended  March 31, 2023 and 2022 was 6.3% and 9.5%, respectively. 

In connection with substantially all lending arrangements, the Company receives warrants to purchase shares of stock from the borrower. The warrants are recorded as assets at estimated fair value on the grant date using the Black-Scholes valuation model. The warrants are considered loan fees and are recorded as unearned income on the grant date. The unearned income is recognized as interest income over the contractual life of the related debt investment in accordance with the Company’s income recognition policy. Subsequent to debt investment origination, the fair value of the warrants is determined using the Black-Scholes valuation model. Any adjustment to fair value is recorded through earnings as net unrealized appreciation or depreciation on investments. Gains and losses from the disposition of the warrants or stock acquired from the exercise of warrants are recognized as realized gains and losses on investments.

23

Horizon Technology Finance Corporation and Subsidiaries

Notes to Consolidated Financial Statements

 

Realized gains or losses on the sale of investments, or upon the determination that an investment balance, or portion thereof, is not recoverable, are calculated using the specific identification method. The Company measures realized gains or losses by calculating the difference between the net proceeds from the repayment or sale and the amortized cost basis of the investment. Net change in unrealized appreciation or depreciation reflects the change in the fair values of the Company’s portfolio investments during the reporting period, including any reversal of previously recorded unrealized appreciation or depreciation when gains or losses are realized.

Debt issuance costs

Debt issuance costs are fees and other direct incremental costs incurred by the Company in obtaining debt financing from its lenders and issuing debt securities. The unamortized balance of debt issuance costs as of  March 31, 2023 and  December 31, 2022 was $6.6 million and $7.1 million, respectively. These amounts are amortized and included in interest expense in the consolidated statements of operations over the life of the borrowings. The accumulated amortization balances as of March 31, 2023 and  December 31, 2022 were $5.3 million and $4.8 million, respectively. The amortization expense for the three months ended March 31, 2023 and 2022 was $0.5 million and $0.3 million, respectively. 

Income taxes

As a BDC, the Company has elected to be treated as a RIC under Subchapter M of the Code and operates in a manner so as to qualify for the tax treatment applicable to RICs. In order to qualify as a RIC and to avoid the imposition of corporate-level income tax on the portion of its taxable income distributed to stockholders, among other things, the Company is required to meet certain source of income and asset diversification requirements and to timely distribute dividends out of assets legally available for distribution to its stockholders of an amount generally at least equal to 90% of its investment company taxable income, as defined by the Code and determined without regard to any deduction for dividends paid, for each tax year. The Company, among other things, has made and intends to continue to make the requisite distributions to its stockholders, which generally relieves the Company from corporate-level U.S. federal income taxes. Accordingly, no provision for federal income tax has been recorded in the financial statements. Differences between taxable income and net increase in net assets resulting from operations either can be temporary, meaning they will reverse in the future, or permanent. In accordance with ASC Topic 946, Financial Services—Investment Companies, as amended, of the Financial Accounting Standards Board (“FASB”), permanent tax differences, such as non-deductible excise taxes paid, are reclassified from distributions in excess of net investment income and net realized loss on investments to paid-in-capital at the end of each fiscal year. These permanent book-to-tax differences are reclassified on the consolidated statements of changes in net assets to reflect their tax character but have no impact on total net assets. 

Depending on the level of taxable income earned in a tax year, the Company may choose to carry forward taxable income in excess of current year distributions into the next tax year and incur a 4% U.S. federal excise tax on such income, as required. To the extent that the Company determines that its estimated current year annual taxable income will be in excess of estimated current year distributions, the Company accrues excise tax, if any, on estimated excess taxable income as taxable income is earned. For the three months ended March 31, 2023 and 2022, $0.2 million and $0.1 million, respectively, was accrued for U.S. federal excise tax. 

24

Horizon Technology Finance Corporation and Subsidiaries

Notes to Consolidated Financial Statements

 

The Company evaluates tax positions taken in the course of preparing the Company’s tax returns to determine whether the tax positions are “more-likely-than-not” to be sustained by the applicable tax authority in accordance with ASC Topic 740, Income Taxes, as modified by ASC Topic 946. Tax benefits of positions not deemed to meet the more-likely-than-not threshold, or uncertain tax positions, would be recorded as a tax expense in the current year. It is the Company’s policy to recognize accrued interest and penalties related to uncertain tax benefits in income tax expense. The Company had no material uncertain tax positions at March 31, 2023 and  December 31, 2022. The Company’s income tax returns for the 2021, 2020 and 2019 tax years remain subject to examination by U.S. federal and state tax authorities.

Distributions

Distributions to common stockholders are recorded on the declaration date. The amount to be paid out as distributions is determined by the Board. Net realized capital gains, if any, may be distributed, although the Company may decide to retain such net realized gains for investment.

The Company has adopted a dividend reinvestment plan that provides for reinvestment of cash distributions on behalf of its stockholders, unless a stockholder elects to receive cash. As a result, if the Board declares a cash distribution, then stockholders who have not “opted out” of the dividend reinvestment plan will have their cash distributions automatically reinvested in additional shares of the Company’s common stock, rather than receiving the cash distribution. The Company may issue new shares or purchase shares in the open market to fulfill its obligations under the plan.

Stockholders’ Equity

On August 2, 2021, the Company entered into an At-The-Market (“ATM”) sales agreement (the “2021 Equity Distribution Agreement”), with Goldman Sachs & Co. LLC and B. Riley FBR, Inc. (each a “Sales Agent” and, collectively, the “Sales Agents”). The 2021 Equity Distribution Agreement provides that the Company may offer and sell its shares from time to time through the Sales Agents up to $100.0 million worth of its common stock, in amounts and at times to be determined by the Company. Sales of the Company’s common stock, if any, may be made in negotiated transactions or transactions that are deemed to be “at-the-market,” as defined in Rule 415 under the Securities Act, including sales made directly on the Nasdaq or similar securities exchange or sales made to or through a market maker other than on an exchange, at prices related to the prevailing market prices or at negotiated prices.

During the three months ended March 31, 2023, the Company sold 605,848 shares of common stock under the 2021 Equity Distribution Agreement. For the same period, the Company received total accumulated net proceeds of approximately $7.2 million, including $0.2 million of offering expenses, from these sales.

During the three months ended March 31, 2022, the Company sold 250,171 shares of common stock under the 2021 Equity Distribution Agreement. For the same period, the Company received total accumulated net proceeds of approximately $3.9 million, including $0.1 million of offering expenses, from these sales.

On  March 14, 2022, the Company completed a follow-on public offering of 2,500,000 shares of its common stock at a public offering price of $14.35 per share, for total net proceeds to the Company of $34.3 million, after deducting underwriting commission and discounts and other offering expenses.

25

Horizon Technology Finance Corporation and Subsidiaries

Notes to Consolidated Financial Statements

 

The Company generally uses net proceeds from these offerings to make investments, to pay down liabilities and for general corporate purposes. As of March 31, 2023, shares representing approximately $24.1 million of its common stock remain available for issuance and sale under the 2021 Equity Distribution Agreement.

Stock Repurchase Program

On April 28, 2023, the Board extended a previously authorized stock repurchase program which allows the Company to repurchase up to $5.0 million of its common stock at prices below the Company’s net asset value per share as reported in its most recent consolidated financial statements. Under the repurchase program, the Company may, but is not obligated to, repurchase shares of its outstanding common stock in the open market or in privately negotiated transactions from time to time. Any repurchases by the Company will comply with the requirements of Rule 10b‑18 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and any applicable requirements of the 1940 Act. Unless extended by the Board, the repurchase program will terminate on the earlier of June 30, 2024 or the repurchase of $5.0 million of the Company’s common stock. During the three months ended March 31, 2023 and 2022, the Company did not make any repurchases of its common stock. From the inception of the stock repurchase program through March 31, 2023, the Company repurchased 167,465 shares of its common stock at an average price of $11.22 on the open market at a total cost of $1.9 million.

Transfers of financial assets

Assets related to transactions that do not meet the requirements under ASC Topic 860, Transfers and Servicing for sale treatment under GAAP are reflected in the Company’s consolidated statements of assets and liabilities as investments. Those assets are owned by special purpose entities that are consolidated in the Company’s financial statements. The creditors of the special purpose entities have received security interests in such assets and such assets are not intended to be available to the creditors of the Company (or any other affiliate of the Company).

Transfers of financial assets are accounted for as sales when control over the assets has been surrendered. Control over transferred assets is deemed to be surrendered when (1) the assets have been isolated from the Company — put presumptively beyond the reach of the transferor and its creditors, even in bankruptcy or other receivership, (2) the transferee obtains the right (free of conditions that constrain it from taking advantage of that right) to pledge or exchange the transferred assets and (3) the transferor does not maintain effective control over the transferred assets through either (a) an agreement that both entitles and obligates the transferor to repurchase or redeem the assets before maturity or (b) the ability to unilaterally cause the holder to return specific assets, other than through a cleanup call.

Recently issued accounting pronouncement

In June 2022, the FASB issued Accounting Standards Update No. 2022-03, Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU 2022-03”). ASU 2022-03 clarifies the guidance when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of the security. The amendments in ASU 2022-03 are effective for public companies for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The Company is currently assessing the impact of ASU 2022-03 on its consolidated financial statements.

26

Horizon Technology Finance Corporation and Subsidiaries

Notes to Consolidated Financial Statements

 

Note 3. Related party transactions

Investment Management Agreement

At a special meeting of the stockholders on October 30, 2018, the stockholders approved a new Investment Management Agreement which became effective on March 7, 2019. The new Investment Management Agreement replaced the previously effective Amended and Restated Investment Management Agreement dated as of October 28, 2010 and amended effective July 1, 2014. On October 28, 2022, the Board unanimously approved the renewal of the Investment Management Agreement. Under the terms of the Investment Management Agreement, the Advisor determines the composition of the Company’s investment portfolio, the nature and timing of the changes to the investment portfolio and the manner of implementing such changes; identifies, evaluates and negotiates the structure of the investments the Company makes (including performing due diligence on the Company’s prospective portfolio companies); and closes, monitors and administers the investments the Company makes, including the exercise of any voting or consent rights.

On February 23, 2023, the Company announced that an affiliate of Monroe Capital LLC (“Monroe Capital”) has entered into a definitive purchase agreement to acquire one hundred percent (100%) of the membership interests of the Advisor and that the Company’s Board has unanimously approved a new investment management agreement with the Advisor, subject to stockholder approval at the annual meeting of stockholders to be held on May 25, 2023 and the closing of the purchase transaction. The Company is not a party to the definitive purchase agreement. Additional information on the approval of the new investment management agreement can be found in the Company’s proxy statement mailed to stockholders on or around April 6, 2023, and is available on the SEC’s website at http://www.sec.gov, or on the Company’s website at http://www.horizontechfinance.com.  

The Advisor’s services under the Investment Management Agreement are not exclusive to the Company, and the Advisor is free to furnish similar services to other entities so long as its services to the Company are not impaired. The Advisor is a registered investment adviser with the SEC. The Advisor receives fees for providing services to the Company under the Investment Management Agreement, consisting of two components, a base management fee and an incentive fee.

The base management fee was and will be calculated at an annual rate of 2.00% of the Company’s gross assets (less cash and cash equivalents) including any assets acquired with the proceeds of leverage; provided, that, to the extent the Company’s gross assets (less cash and cash equivalents) exceed $250 million, the base management fee on the amount of such excess over $250 million will be calculated at an annual rate of 1.60% of the Company’s gross assets (less cash and cash equivalents) including any assets acquired with the proceeds of leverage. The base management fee is payable monthly in arrears and is prorated for any partial month.

The base management fee payable at March 31, 2023 and  December 31, 2022 was $1.1 million. The base management fee expense was $3.2 million and $2.2 million for the three months ended March 31, 2023 and 2022, respectively. 

The incentive fee has two parts, as follows:

The first part, which is subject to the Incentive Fee Cap and Deferral Mechanism, as defined below, is calculated and payable quarterly in arrears based on the Company’s Pre-Incentive Fee Net Investment Income for the immediately preceding calendar quarter. For this purpose, “Pre-Incentive Fee Net Investment Income” means interest income, dividend income and any other income (including any other fees (other than fees for providing managerial assistance), such as commitment, origination, structuring, diligence and consulting fees or other fees received from portfolio companies) accrued during the calendar quarter, minus expenses for the quarter (including the base management fee, expenses payable under the Administration Agreement (as defined below), and any interest expense and any dividends paid on any issued and outstanding preferred stock, but excluding the incentive fee). Pre-Incentive Fee Net Investment Income includes, in the case of investments with a deferred interest feature (such as original issue discount, debt instruments with PIK interest and zero coupon securities), accrued income the Company has not yet received in cash. The incentive fee with respect to the Pre-Incentive Fee Net Investment Income is 20.00% of the amount, if any, by which the Pre-Incentive Fee Net Investment Income for the immediately preceding calendar quarter exceeds a hurdle rate of 1.75% (which is 7.00% annualized) of the Company’s net assets at the end of the immediately preceding calendar quarter, adjusted for any share issuances or repurchases during the relevant quarter, subject to a “catch-up” provision measured as of the end of each calendar quarter. Under this provision, in any calendar quarter, the Advisor receives no incentive fee until the Pre-Incentive Fee Net Investment Income equals the hurdle rate of 1.75%, but then receives, as a “catch-up,” 100.00% of the Pre-Incentive Fee Net Investment Income with respect to that portion of such Pre-Incentive Fee Net Investment Income, if any, that exceeds the hurdle rate but is less than 2.1875% quarterly (which is 8.75% annualized). The effect of this “catch-up” provision is that, if Pre-Incentive Fee Net Investment Income exceeds 2.1875% in any calendar quarter, the Advisor will receive 20.00% of the Pre-Incentive Fee Net Investment Income as if the hurdle rate did not apply.

27

Horizon Technology Finance Corporation and Subsidiaries

Notes to Consolidated Financial Statements

 

Pre-Incentive Fee Net Investment Income does not include any realized capital gains, realized capital losses or unrealized capital appreciation or depreciation. Because of the structure of the incentive fee, it is possible that the Company may pay an incentive fee in a quarter in which the Company incurs a loss. For example, if the Company receives Pre-Incentive Fee Net Investment Income in excess of the quarterly minimum hurdle rate, the Company will pay the applicable incentive fee up to the Incentive Fee Cap, defined below, even if the Company has incurred a loss in that quarter due to realized and unrealized capital losses. The Company’s net investment income used to calculate this part of the incentive fee is also included in the amount of the Company’s gross assets used to calculate the 2.00% base management fee. These calculations are appropriately prorated for any period of less than three months and adjusted for any share issuances or repurchases during the current quarter.

The incentive fee on Pre-Incentive Fee Net Investment Income is subject to a fee cap and deferral mechanism which is determined based upon a look-back period of up to three years and is expensed when incurred. For this purpose, the look-back period for the incentive fee based on Pre-Incentive Fee Net Investment Income (the “Incentive Fee Look-back Period”) includes the relevant calendar quarter and the 11 preceding full calendar quarters. Each quarterly incentive fee payable on Pre-Incentive Fee Net Investment Income is subject to a cap (the “Incentive Fee Cap”) and a deferral mechanism through which the Advisor may recoup a portion of such deferred incentive fees (collectively, the “Incentive Fee Cap and Deferral Mechanism”). The Incentive Fee Cap is equal to (a) 20.00% of Cumulative Pre-Incentive Fee Net Return (as defined below) during the Incentive Fee Look-back Period less (b) cumulative incentive fees of any kind paid to the Advisor during the Incentive Fee Look-back Period. To the extent the Incentive Fee Cap is zero or a negative value in any calendar quarter, the Company will not pay an incentive fee on Pre-Incentive Fee Net Investment Income to the Advisor in that quarter. To the extent that the payment of incentive fees on Pre-Incentive Fee Net Investment Income is limited by the Incentive Fee Cap, the payment of such fees will be deferred and paid in subsequent calendar quarters up to three years after their date of deferment, subject to certain limitations, which are set forth in the Investment Management Agreement. The Company only pays incentive fees on Pre-Incentive Fee Net Investment Income to the extent allowed by the Incentive Fee Cap and Deferral Mechanism. “Cumulative Pre-Incentive Fee Net Return” during any Incentive Fee Look-back Period means the sum of (a) Pre-Incentive Fee Net Investment Income and the base management fee for each calendar quarter during the Incentive Fee Look-back Period and (b) the sum of cumulative realized capital gains and losses, cumulative unrealized capital appreciation and cumulative unrealized capital depreciation during the applicable Incentive Fee Look-back Period.

The second part of the incentive fee is determined and payable in arrears as of the end of each calendar year (or, upon termination of the Investment Management Agreement, as of the termination date), and equals 20.00% of the Company’s realized capital gains, if any, on a cumulative basis from the date of the election to be a BDC through the end of each calendar year, computed net of all realized capital losses and unrealized capital depreciation on a cumulative basis through the end of such year, less all previous amounts paid in respect of the capital gain incentive fee. However, in accordance with GAAP, the Company is required to include the aggregate unrealized capital appreciation on investments in the calculation and accrue a capital gain incentive fee on a quarterly basis, as if such unrealized capital appreciation were realized, even though such unrealized capital appreciation is not permitted to be considered in calculating the fee actually payable under the Investment Management Agreement.

The performance based incentive fee expense was $3.0 million and $1.4 million for the three months ended March 31, 2023 and 2022, respectively. The incentive fee on Pre-Incentive Fee Net Investment Income was subject to the Incentive Fee Cap and Deferral Mechanism for the three months ended March 31, 2023, which resulted in $0.2 million of reduced expense and additional net investment income. This deferral represents a contingent future liability and may be paid up to three years after the date of deferment. The total contingent future liability as of March 31, 2023 was $1.3 million. The incentive fee on Pre-Incentive Fee Net Investment Income was not subject to the Incentive Fee Cap and Deferral Mechanism for the three months ended March 31, 2022. The performance based incentive fee payable as of March 31, 2023 and  December 31, 2022 was $3.0 million and $1.4 million, respectively. The entire incentive fee payable as of March 31, 2023 and  December 31, 2022 represented part one of the incentive fee.

28

Horizon Technology Finance Corporation and Subsidiaries

Notes to Consolidated Financial Statements

 

Administration Agreement

The Company entered into an administration agreement (the “Administration Agreement”) with the Advisor to provide administrative services to the Company. For providing these services, facilities and personnel, the Company reimburses the Advisor for the Company’s allocable portion of overhead and other expenses incurred by the Advisor in performing its obligations under the Administration Agreement, including rent, the fees and expenses associated with performing compliance functions and the Company’s allocable portion of the costs of compensation and related expenses of the Company’s Chief Financial Officer and Chief Compliance Officer and their respective staffs. The administrative fee expense was $0.4 million for the three months ended March 31, 2023 and 2022. 

Note 4. Investments

The following table shows the Company’s investments as of March 31, 2023 and  December 31, 2022:

	March 31, 2023				December 31, 2022
	Cost		Fair Value		Cost		Fair Value
	(In thousands)
Investments
Debt	$	703,781	$	684,554	$	701,074	$	686,458
Warrants		14,735		25,658		14,790		29,712
Other		1,200		1,300		1,200		1,300
Equity		4,446		3,800		4,184		2,556
Total investments	$	724,162	$	715,312	$	721,248	$	720,026

29

Horizon Technology Finance Corporation and Subsidiaries

Notes to Consolidated Financial Statements

 

The following table shows the Company’s investments by industry sector as of March 31, 2023 and  December 31, 2022:

	March 31, 2023				December 31, 2022
	Cost		Fair Value		Cost		Fair Value
	(In thousands)
Life Science
Biotechnology	$	187,970	$	186,981	$	193,372	$	195,006
Medical Device		129,102		131,823		132,803		135,960
Technology
Communications		22,913		26,168		22,892		26,176
Consumer-Related		107,802		99,140		121,961		114,050
Data Storage		476		1,302		476		1,316
Internet and Media		329		1,583		329		1,159
Networking		10,111		9,984		11,831		11,710
Power Management		1,585		2,808		1,585		2,610
Semiconductors		57		—		56		—
Software		145,706		143,680		120,157		118,716
Sustainability
Energy Efficiency		8		27		8		27
Other Sustainability		84,753		83,734		84,633		85,524
Healthcare Information and Services
Diagnostics		9,862		9,868		9,851		9,858
Other		6,990		1,414		7,559		3,870
Software		16,498		16,800		13,735		14,044
Total investments	$	724,162	$	715,312	$	721,248	$	720,026

Note 5. Transactions with affiliated companies

A non-controlled affiliated company is generally a portfolio company in which the Company owns 5% or more of such portfolio company’s voting securities but not more than 25% of such portfolio company’s voting securities.

Transactions related to investments in non-controlled affiliated companies for the three months ended March 31, 2023 were as follows:  

					Three months ended March 31, 2023
	Fair value at						Transfers				Net				Fair value at
Portfolio	December 31,				Principal		in/(out) at		Discount		unrealized		Net realized		March 31,		Interest
Company	2022		Purchases		Payments		fair value		accretion		gain/(loss)		gain/(loss)		2023		income
	(In thousands)
Cadrenal Therapeutics, Inc.	$	—	$	—	$	—	$	—	$	—	$	846	$	—	$	846	$	—
Total non-controlled affiliates	$	—	$	—	$	—	$	—	$	—	$	846	$	—	$	846	$	—

For the three months ended March 31, 2022, there were no transactions related to investments in non-controlled affiliated companies.

A controlled affiliated company is generally a portfolio company in which the Company owns more than 25% of such portfolio company’s voting securities or has the power to exercise control over management or policies of such portfolio company (including through a management agreement).

For the three months ended March 31, 2023, there were no transactions related to investments in controlled affiliated companies. 

30

Horizon Technology Finance Corporation and Subsidiaries

Notes to Consolidated Financial Statements

 

Transactions related to investments in controlled affiliated companies for the three months ended March 31, 2022 were as follows:

					Three months ended March 31, 2022
	Fair value at							Transfers				Net				Fair value at
Portfolio	December 31,							in/(out) at		Dividends		unrealized		Net realized		March 31,		Dividend
Company	2021		Purchases		Sales			fair value		declared		gain/(loss)		gain/(loss)		2022		income
	(In thousands)
HESP LLC		—		—		(50	)		—		—		50		—		—		—
Total controlled affiliates	$	—	$	—	$	(50	)	$	—	$	—	$	50	$	—	$	—	$	—

Note 6. Fair value

Prior to July 30, 2022, the Board determined the fair value of the Company’s investments. Pursuant to the amended SEC Rule 2a-5 of the 1940 Act, on July 29, 2022, the Board designated the Advisor as the Company’s “valuation designee.” The Board is responsible for oversight of the valuation designee. The valuation designee has established a Valuation Committee to determine in good faith the fair value of the Company’s investments, based on input from the Advisor’s management and personnel and independent valuation firms which are engaged at the direction of the Valuation Committee to assist in the valuation of certain portfolio investments lacking a readily available market quotation at least once during a trailing twelve-month period. The Valuation Committee determines fair values pursuant to a valuation policy approved by the Board and pursuant to a consistently applied valuation process. This valuation process is conducted at the end of each fiscal quarter, with at least 25% (based on fair value) of the Company’s valuation of portfolio companies lacking readily available market quotations subject to review by an independent valuation firm.

The Company uses fair value measurements made by the valuation designee to record fair value adjustments to certain assets and liabilities and to determine fair value disclosures. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is best determined based upon quoted market prices. However, in certain instances, there are no quoted market prices for certain assets or liabilities. In cases where quoted market prices are not available, fair values are based on estimates using present value or other valuation techniques. Those techniques are significantly affected by the assumptions used, including the discount rate and estimates of future cash flows. Accordingly, the fair value estimates may not be realized in an immediate settlement of the asset or liability.

Fair value measurements focus on exit prices in an orderly transaction (that is, not a forced liquidation or distressed sale) between market participants at the measurement date under current market conditions. If there has been a significant decrease in the volume and level of activity for the asset or liability, a change in valuation technique or the use of multiple valuation techniques may be appropriate. In such instances, determining the price at which willing market participants would transact at the measurement date under current market conditions depends on the facts and circumstances and requires the use of significant judgment.

The Company’s fair value measurements are classified into a fair value hierarchy in accordance with ASC Topic 820, Fair Value Measurement, based on the markets in which the assets and liabilities are traded and the reliability of the assumptions used to determine fair value. The three categories within the hierarchy are as follows:

Level 1 Quoted prices in active markets for identical assets and liabilities.

Level 2 Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities in active markets, quoted prices in markets that are not active, and model-based valuation techniques for which all significant inputs are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation.

31

Horizon Technology Finance Corporation and Subsidiaries

Notes to Consolidated Financial Statements

 

Due to the inherent uncertainty of determining the fair value of investments that do not have a readily available market value, the fair value of the Company’s investments may fluctuate from period to period. Additionally, the fair value of the Company’s investments may differ significantly from the values that would have been used had a ready market existed for such investments and may differ materially from the values that the Company may ultimately realize. Further, such investments are generally subject to legal and other restrictions on resale or otherwise are less liquid than publicly traded securities. If the Company was required to liquidate a portfolio investment in a forced or liquidation sale, the Company could realize significantly less than the value at which the Company has recorded such portfolio investment.

Cash and interest receivable: The carrying amount is a reasonable estimate of fair value. These financial instruments are not recorded at fair value on a recurring basis and are categorized as Level 1 within the fair value hierarchy described above.

Money market funds:  The carrying amounts are valued at their net asset value as of the close of business on the day of valuation. These financial instruments are recorded at fair value on a recurring basis and are categorized as Level 2 within the fair value hierarchy described above as these funds can be redeemed daily.

Debt investments: The fair value of debt investments is estimated by discounting the expected future cash flows using the period end rates at which similar debt investments would be made to borrowers with similar credit ratings and for the same remaining maturities. Significant increases (decreases) in this unobservable input would result in a significantly lower (higher) fair value measurement. These assets are recorded at fair value on a recurring basis and are categorized as Level 3 within the fair value hierarchy described above.

Under certain circumstances, the Company  may use an alternative technique to value debt investments that better reflects its fair value such as the use of multiple probability weighted cash flow models when the expected future cash flows contain elements of variability.

Warrant investments: The Company values its warrants using the Black-Scholes valuation model incorporating the following material assumptions:

● Underlying asset value of the issuer is estimated based on information available, including any information regarding the most recent rounds of borrower funding. Significant increases (decreases) in this unobservable input would result in a significantly higher (lower) fair value measurement.

● Volatility, or the amount of uncertainty or risk about the size of the changes in the warrant price, is based on indices of publicly traded companies similar in nature to the underlying company issuing the warrant. A total of seven such indices are used. Significant increases (decreases) in this unobservable input would result in a significantly higher (lower) fair value measurement.

● The risk-free interest rates are derived from the U.S. Treasury yield curve. The risk-free interest rates are calculated based on a weighted average of the risk-free interest rates that correspond closest to the expected remaining life of the warrant.

● Other adjustments, including a marketability discount on private company warrants, are estimated based on management’s judgment about the general industry environment.

32

Horizon Technology Finance Corporation and Subsidiaries

Notes to Consolidated Financial Statements

 

● Historical portfolio experience on cancellations and exercises of the Company’s warrants are utilized as the basis for determining the estimated time to exit of the warrants in each financial reporting period. Warrants may be exercised in the event of acquisitions, mergers or initial public offerings, and cancelled due to events such as bankruptcies, restructuring activities or additional financings. These events cause the expected remaining life assumption to be shorter than the contractual term of the warrants. Significant increases (decreases) in this unobservable input would result in significantly higher (lower) fair value measurement.

Under certain circumstances the Company may use an alternative technique to value warrants that better reflects the warrants’ fair value, such as an expected settlement of a warrant in the near term or a model that incorporates a put feature associated with the warrant. The fair value may be determined based on the expected proceeds to be received from such settlement or based on the net present value of the expected proceeds from the put option.

The fair value of the Company’s warrants held in publicly traded companies is determined based on inputs that are readily available in public markets or can be derived from information available in public markets. Therefore, the Company has categorized these warrants as Level 2 within the fair value hierarchy described above. The fair value of the Company’s warrants held in private companies is determined using both observable and unobservable inputs and represents management’s best estimate of what market participants would use in pricing the warrants at the measurement date. Therefore, the Company has categorized these warrants as Level 3 within the fair value hierarchy described above. These assets are recorded at fair value on a recurring basis.

Equity investments: The fair value of an equity investment in a privately held company is initially the face value of the amount invested. The Company adjusts the fair value of equity investments in private companies upon the completion of a new third-party round of equity financing. The Company may make adjustments to fair value, absent a new equity financing event, based upon positive or negative changes in a portfolio company’s financial or operational performance. Significant increases (decreases) in this unobservable input would result in a significantly higher (lower) fair value measurement. The Company has categorized these equity investments as Level 3 within the fair value hierarchy described above. The fair value of an equity investment in a publicly traded company is based upon the closing public share price on the date of measurement. Therefore, the Company has categorized these equity investments as Level 1 within the fair value hierarchy described above. These assets are recorded at fair value on a recurring basis.

Other investments: Other investments are valued based on the facts and circumstances of the underlying contractual agreement. The Company currently values these contractual agreements using a multiple probability weighted cash flow model as the contractual future cash flows contain elements of variability. Significant changes in the estimated cash flows and probability weightings would result in a significantly higher or lower fair value measurement. The Company has categorized these other investments as Level 3 within the fair value hierarchy described above. These other investments are recorded at fair value on a recurring basis.

The following tables detail the investments that are carried at fair value and measured at fair value on a recurring basis as of March 31, 2023 and  December 31, 2022 and indicate the fair value hierarchy of the valuation techniques utilized by the Company to determine the fair value:

	March 31, 2023
	Level 1		Level 2		Level 3		Total
	(In thousands)
Debt investments	$	—	$	—	$	684,554	$	684,554
Warrant investments		—		1,020		24,638		25,658
Other investments		—		—		1,300		1,300
Equity investments		885		—		2,915		3,800
Total investments	$	885	$	1,020	$	713,407	$	715,312

 

	December 31, 2022
	Level 1		Level 2		Level 3		Total
	(In thousands)
Debt investments	$	—	$	—	$	686,458	$	686,458
Warrant investments		—		3,567		26,145		29,712
Other investments		—		—		1,300		1,300
Equity investments		140		—		2,416		2,556
Total investments	$	140	$	3,567	$	716,319	$	720,026

The following tables provide a summary of quantitative information about the Company’s Level 3 fair value measurements of the Company’s investments as of March 31, 2023 and  December 31, 2022. In addition to the techniques and inputs noted in the table below, according to the Company’s valuation policy, the Company may also use other valuation techniques and methodologies when determining its fair value measurements.

33

Horizon Technology Finance Corporation and Subsidiaries

Notes to Consolidated Financial Statements

 

The following table is not intended to be all-inclusive, but rather provides information on the significant Level 3 inputs as they relate to the Company’s fair value measurements as of March 31, 2023:

March 31, 2023
	Fair		Valuation Techniques/	Unobservable		Weighted
Investment Type	Value		Methodologies	Input	Range	Average(1)
			(Dollars in thousands, except per share data)
Debt investments	$	644,854	Discounted Expected Future Cash Flows	Hypothetical Market Yield	11% – 20%		14	%
		39,700	Multiple Probability Weighted Cash Flow Model	Probability Weighting	10% - 100%		43	%
Warrant investments		24,638	Black-Scholes Valuation Model	Price Per Share	0.100 –1,89999	$	62.82
				Average Industry Volatility	28%		28	%
				Marketability Discount	20%		20	%
				Estimated Time to Exit (in years)	1 to 5		3
Other investments		1,300	Multiple Probability Weighted Cash Flow Model	Discount Rate	25%		25	%
				Probability Weighting	100%		100	%
Equity investments		2,915	Last Equity Financing	Price Per Share	$1.00– $215.03	$	40.27
Total Level 3 investments	$	713,407

(1) Weighted average is calculated by multiplying (a) the unobservable input for each investment in the investment type by (b) (1) the fair value of the related investment in the investment type divided by (2) the total fair value of the investment type.

The following table is not intended to be all-inclusive, but rather provides information on the significant Level 3 inputs as they relate to the Company’s fair value measurements as of December 31, 2022:

December 31, 2022
	Fair		Valuation Techniques/	Unobservable		Weighted
Investment Type	Value		Methodologies	Input	Range	Average(1)
			(Dollars in thousands, except per share data)
Debt investments	$	669,617	Discounted Expected Future Cash Flows	Hypothetical Market Yield	3% – 22%		14	%
		16,545	Multiple Probability Weighted Cash Flow Model	Probability Weighting	10% - 75%		31	%
		296	Convertible Note Analysis	Price Per Share	$168.93	$	168.93
Warrant investments		26,145	Black-Scholes Valuation Model	Price Per Share	0.000 –1.89999	$	58.52
				Average Industry Volatility	28%		28	%
				Marketability Discount	20%		20	%
				Estimated Time to Exit (in years)	1 to 5		3
Other investments		1,300	Multiple Probability Weighted Cash Flow Model	Discount Rate	25%		25	%
				Probability Weighting	100%		100	%
Equity investments		2,416	Last Equity Financing	Price Per Share	$1.00– $215.03	$	26.93
Total Level 3 investments	$	716,319

(1) Weighted average is calculated by multiplying (a) the unobservable input for each investment in the investment type by (b) (1) the fair value of the related investment in the investment type divided by (2) the total fair value of the investment type.

Borrowings: The Key Facility and the NYL Facility approximate fair value due to the variable interest rate of the facilities and are categorized as Level 2 within the fair value hierarchy described above. Additionally, the Company considers its creditworthiness in determining the fair value of such borrowings. The fair value of the fixed-rate 2026 Notes (as defined in Note 7) is based on the closing public share price on the date of measurement. On March 31, 2023, the closing price of the 2026 Notes on the New York Stock Exchange was $23.39 per note and had an aggregate fair value of $53.8 million. Therefore, the Company has categorized this borrowing as Level 1 within the fair value hierarchy described above. The fair value of the fixed-rate 2027 Notes (as defined in Note 7) is based on the closing public share price on the date of measurement. On March 31, 2023, the closing price of the 2027 Notes on the New York Stock Exchange was $24.00 per note and had an aggregate fair value of $55.2 million. Therefore, the Company has categorized this borrowing as Level 1 within the fair value hierarchy described above. Based on market quotations on March 31, 2023, the 2019 Asset-Backed Notes were trading at par value, or $37.8 million, and are categorized as Level 3 within the fair value hierarchy described above. Based on market quotations on March 31, 2023, the 2022 Asset-Backed Notes were trading at par value, or $100.0 million, and are categorized as Level 3 within the fair value hierarchy described above. These borrowings are not recorded at fair value on a recurring basis.

Off-balance-sheet instruments: Fair values for off-balance-sheet lending commitments are based on fees currently charged to enter into similar agreements, taking into account the remaining terms of the agreements and the counterparties’ credit standings. Therefore, the Company has categorized these instruments as Level 3 within the fair value hierarchy described above.

34

Horizon Technology Finance Corporation and Subsidiaries

Notes to Consolidated Financial Statements

 

The following table shows a reconciliation of the beginning and ending balances for Level 3 assets measured at fair value on a recurring basis for the three months ended March 31, 2023:

	Three months ended March 31, 2023
	Debt			Warrant			Equity		Other
	Investments			Investments			Investments		Investments		Total
	(In thousands)
Level 3 assets, beginning of period	$	686,458		$	26,145		$	2,416	$	1,300	$	716,319
Purchase of investments		46,998			—			10		—		47,008
Warrants received and classified as Level 3		—			141			—		—		141
Principal payments received on investments		(39,756	)		—			—		—		(39,756	)
Payment-in-kind interest on investments		1,204			—			—		—		1,204
Proceeds from sale of investments		(6,508	)		(12	)		—		—		(6,520	)
Net realized gain (loss) on investments		7			(141	)		—		—		(134	)
Unrealized (depreciation) appreciation included in earnings		(4,566	)		(1,490	)		189		—		(5,867	)
Transfer out of debt investments		(295	)		(5	)		300		—		—
Other		1,012			—			—		—		1,012
Level 3 assets, end of period	$	684,554		$	24,638		$	2,915	$	1,300	$	713,407

During the three months ended March 31, 2023, there were no transfers in or out of Level 3.

The change in unrealized depreciation included in the consolidated statement of operations attributable to Level 3 investments still held at March 31, 2023 includes $4.6 million in unrealized depreciation on debt and other investments, $1.4 million in unrealized depreciation on warrant investments and $0.2 million in unrealized appreciation on equity investments.

The following table shows a reconciliation of the beginning and ending balances for Level 3 assets measured at fair value on a recurring basis for the three months ended March 31, 2022:

	Three months ended March 31, 2022
	Debt			Warrant			Equity		Other
	Investments			Investments			Investments		Investments			Total
	(In thousands)
Level 3 assets, beginning of period	$	437,317		$	19,837		$	203	$	200		$	457,557
Purchase of investments		94,485			—			—		—			94,485
Warrants received and classified as Level 3		—			808			—		—			808
Principal payments received on investments		(14,095	)		—			—		(50	)		(14,145	)
Proceeds from sale of investments		(21,250	)		(30	)		—		—			(21,280	)
Net realized gain on investments		—			30			—		—			30
Unrealized (depreciation) appreciation included in earnings		(3,170	)		1,000			—		50			(2,120	)
Other		(1,093	)		—			—		—			(1,093	)
Level 3 assets, end of period	$	492,194		$	21,645		$	203	$	200		$	514,242

During the three months ended March 31, 2022, there were no transfers in or out of Level 3.

The change in unrealized depreciation included in the consolidated statement of operations attributable to Level 3 investments still held at March 31, 2022 includes $3.3 million in unrealized depreciation on debt and other investments and $1.0 million in unrealized appreciation on warrant investments.

35

Horizon Technology Finance Corporation and Subsidiaries

Notes to Consolidated Financial Statements

 

The Company discloses fair value information about financial instruments, whether or not recognized in the consolidated statement of assets and liabilities, for which it is practicable to estimate that value. Certain financial instruments are excluded from the disclosure requirements. Accordingly, the aggregate fair value amounts presented do not represent the underlying value of the Company.

The fair value amounts have been measured as of the reporting date and have not been reevaluated or updated for purposes of these financial statements subsequent to that date. As such, the fair values of these financial instruments subsequent to the reporting date may be different than amounts reported.

As of March 31, 2023 and  December 31, 2022, all of the balances of all the Company’s financial instruments were recorded at fair value, except for the Company’s borrowings, as previously described.

Market risk

The Company assumes interest rate risk (the risk that general interest rate levels will change) as a result of its normal operations. As a result, the fair values of the Company’s financial instruments will change when interest rate levels change, and that change may be either favorable or unfavorable to the Company. Management attempts to match maturities of assets and liabilities to the extent believed necessary to minimize interest rate risk. Management monitors rates and maturities of assets and liabilities and attempts to minimize interest rate risk by adjusting terms of new debt investments and by investing in securities with terms that mitigate the Company’s overall interest rate risk.

Note 7. Borrowings

The following table shows the Company’s borrowings as of March 31, 2023 and  December 31, 2022:

	March 31, 2023							December 31, 2022
	Total		Balance			Unused		Total		Balance			Unused
	Commitment		Outstanding			Commitment		Commitment		Outstanding			Commitment
	(In thousands)
Key Facility	$	125,000	$	15,000		$	110,000	$	125,000	$	5,000		$	120,000
NYL Facility		200,000		176,750			23,250		200,000		176,750			23,250
2019 Asset-Backed Notes		37,791		37,791			—		42,573		42,573			—
2022 Asset-Backed Notes		100,000		100,000			—		100,000		100,000			—
2027 Notes		57,500		57,500			—		57,500		57,500			—
2026 Notes		57,500		57,500			—		57,500		57,500			—
Total before debt issuance costs		577,791		444,541			133,250		582,573		439,323			143,250
Unamortized debt issuance costs attributable to term borrowings		—		(4,896	)		—		—		(5,245	)		—
Total borrowings outstanding, net	$	577,791	$	439,645		$	133,250	$	582,573	$	434,078		$	143,250

As of March 31, 2023, with certain limited exceptions, the Company, as a BDC, is only allowed to borrow amounts such that the Company’s asset coverage, as defined in the 1940 Act, is at least 150% after such borrowings. As of March 31, 2023, the asset coverage for borrowed amounts was 172%.

36

Horizon Technology Finance Corporation and Subsidiaries

Notes to Consolidated Financial Statements

 

Credit Facilities

Key Facility

The Company entered into the Key Facility with Key effective November 4, 2013. On June 22, 2021, the Company amended the Key Facility, among other things, to amend the interest rate applied to the outstanding principal balance and to extend the period during which the Company  may request advances under the Key Facility to June 22, 2024. The Key Facility has an accordion feature which allows for an increase in the total loan commitment to $150 million from the $125 million commitment. The Key Facility is collateralized by all debt investments and warrants held by Credit II and permits an advance rate of up to 60% of eligible debt investments held by Credit II. The Key Facility contains covenants that, among other things, require the Company to maintain a minimum net worth and to restrict the debt investments securing the Key Facility to certain criteria for qualified debt investments and includes portfolio company concentration limits as defined in the related loan agreement. The Key Facility is scheduled to mature on June 22, 2026. The interest rate on the Key Facility is based on the rate of interest published in The Wall Street Journal as the prime rate in the United States plus 0.25%, with a prime rate floor of 4.25%. The prime rate was 8.00% and 7.50% on March 31, 2023 and  December 31, 2022, respectively. The average interest rate on the Key Facility for the three months ended March 31, 2023 and 2022 was 7.94% and 4.25%, respectively. The Key Facility requires the payment of an unused line fee in an amount up to 0.50% on an annualized basis of any unborrowed amount available under the facility. As of March 31, 2023 and  December 31, 2022, the Company had borrowing capacity under the Key Facility of $110.0 million and $120.0 million, respectively. At March 31, 2023 and  December 31, 2022, $47.7 million and $40.2 million, respectively, was available for borrowing, subject to existing terms and advance rates.

NYL Facility

On April 21, 2020, the Company purchased all of the limited liability company interests of Arena in HSLFI, which is a party to the NYL Facility. HFI entered into the NYL Facility with the NYL Noteholders for an aggregate purchase price of up to $100.0 million, with an accordion feature of up to $200.0 million at the mutual discretion and agreement of HSLFI and the NYL Noteholders. On June 1, 2018, HSLFI sold or contributed to HFI certain secured loans made to certain portfolio companies pursuant to the Sale and Servicing Agreement. Any notes issued by HFI are collateralized by all investments held by HFI and permit an advance rate of up to 67% of the aggregate principal amount of eligible debt investments. The notes were issued pursuant to the Indenture. The interest rate on the notes issued under the NYL Facility was based on the three year USD mid-market swap rate plus a margin of between 3.55% and 5.15% with an interest rate floor, depending on the rating of such notes at the time of issuance.

On February 25, 2022, the Company amended its NYL Facility, increasing the commitment by $100.0 million to enable its wholly-owned subsidiary to issue up to $200.0 million of secured notes. The amendment to the NYL Facility extends the investment period to June 2023 and the maturity date to June 2028. In addition, the amendment, among other things, reduces the applicable margin used to calculate the credit facility’s interest rate on the Company’s borrowings above $100.0 million. Such borrowings will be priced at the three-year USD mid-market swap rate plus 3.00%.

There were $176.8 million in advances made by the NYL Noteholders as of March 31, 2023 and  December 31, 2022. The interest rate as of March 31, 2023 and  December 31, 2022 was 5.57%. As of March 31, 2023 and  December 31, 2022, the Company had borrowing capacity under the NYL Facility of $23.2 million. At March 31, 2023 and  December 31, 2022, $21.1 million and $23.2 million, respectively, was available for borrowing, subject to existing terms and advance rates.

Under the terms of the NYL Facility, the Company is required to maintain a reserve cash balance, which may be used to pay monthly interest and principal payments on the NYL Facility. The Company has segregated these funds and classified them as restricted investments in money market funds. At  March 31, 2023 and December 31, 2022, there were approximately $1.3 million and $1.0 million, respectively, of restricted investments.

Securitizations

2019 Asset-Backed Notes

On August 13, 2019, the Company completed a term debt securitization in connection with which an affiliate of the Company made an offering of the 2019 Asset-Backed Notes. The 2019 Asset-Backed Notes were rated A+(sf) by Morningstar Credit Ratings, LLC. There has been no change in the rating since August 13, 2019.

The 2019 Asset-Backed Notes were issued by the 2019‑1 Trust pursuant to a note purchase agreement, dated as of August 13, 2019, by and among the Company and Keybanc Capital Markets Inc. as Initial Purchaser, and are backed by a pool of loans made to certain portfolio companies of the Company and secured by certain assets of those portfolio companies and are to be serviced by the Company. Interest on the 2019 Asset-Backed Notes will be paid, to the extent of funds available, at a fixed rate of 4.21% per annum. The reinvestment period of the 2019 Asset-Backed Notes ended July 15, 2021 and the maturity date is September 15, 2027.

As of March 31, 2023 and  December 31, 2022, the 2019 Asset-Backed Notes had an outstanding principal balance of $37.8 million and $42.6 million, respectively.

Under the terms of the 2019 Asset-Backed Notes, the Company is required to maintain a reserve cash balance, funded through proceeds from the sale of the 2019 Asset-Backed Notes, which may be used to pay monthly interest and principal payments on the 2019 Asset-Backed Notes. The Company has segregated these funds and classified them as restricted investments in money market funds. At March 31, 2023 and  December 31, 2022, there were approximately $0.5 million and $0.6 million of restricted investments, respectively.

37

Horizon Technology Finance Corporation and Subsidiaries

Notes to Consolidated Financial Statements

 

2022 Asset-Backed Notes

On November 9, 2022, the Company completed a term debt securitization in connection with which an affiliate of the Company made an offering of the 2022 Asset-Backed Notes. The 2022 Asset-Backed Notes were rated A by DRBS, Inc. There has been no change in the rating since November 9, 2022.

The 2022 Asset-Backed Notes were issued by the 2022‑1 Trust pursuant to a note purchase agreement, dated as of November 9, 2022, by and among the Company and Keybanc Capital Markets Inc. as Initial Purchaser, and are backed by a pool of loans made to certain portfolio companies of the Company and secured by certain assets of those portfolio companies and are to be serviced by the Company. Interest on the 2022 Asset-Backed Notes will be paid, to the extent of funds available, at a fixed rate of 7.56% per annum. The reinvestment period of the 2022 Asset-Backed Notes ends November 15, 2024 and the maturity date is November 15, 2030.

As of  March 31, 2023 and  December 31, 2022, the 2022 Asset-Backed Notes had an outstanding principal balance of $100.0 million.

Under the terms of the 2022 Asset-Backed Notes, the Company is required to maintain a reserve cash balance, funded through proceeds from the sale of the 2022 Asset-Backed Notes, which may be used to pay monthly interest and principal payments on the 2022 Asset-Backed Notes. The Company has segregated these funds and classified them as restricted investments in money market funds. At  March 31, 2023 and  December 31, 2022, there were approximately $1.1 million and $1.0 million of restricted investments, respectively.

Unsecured Notes

2026 Notes

On March 30, 2021, the Company issued and sold an aggregate principal amount of $57.5 million of 4.875% notes due in 2026 (the “2026 Notes”). The amount of 2026 Notes issued and sold included the full exercise by the underwriters of their option to purchase $7.5 million in aggregate principal of additional notes. The 2026 Notes have a stated maturity of March 30, 2026 and may be redeemed in whole or in part at the Company’s option at any time or from time to time on or after March 30, 2023 at a redemption price of $25 per security plus accrued and unpaid interest. The 2026 Notes bear interest at a rate of 4.875% per year, payable quarterly on March 30, June 30, September 30 and December 30 of each year. The 2026 Notes are the Company’s direct unsecured obligations and (i) rank equally in right of payment with the Company’s current and future unsecured indebtedness; (ii) are senior in right of payment to any of the Company’s future indebtedness that expressly provides it is subordinated to the 2026 Notes; (iii) are effectively subordinated to all of the Company’s existing and future secured indebtedness (including indebtedness that is initially unsecured to which the Company subsequently grants security), to the extent of the value of the assets securing such indebtedness, and (iv) are structurally subordinated to all existing and future indebtedness and other obligations of any of the Company’s subsidiaries. As of March 31, 2023, the Company was in material compliance with the terms of the 2026 Notes. The 2026 Notes are listed on the New York Stock Exchange under the symbol “HTFB”.

2027 Notes

On June 15, 2022, the Company issued and sold an aggregate principal amount of $50.0 million of 6.25% notes due in 2027 and on July 11, 2022, pursuant to the underwriters’ 30 day option to purchase additional notes, the Company sold an additional $7.5 million of such notes (collectively, the “2027 Notes”). The 2027 Notes have a stated maturity of June 15, 2027 and may be redeemed in whole or in part at the Company’s option at any time or from time to time on or after June 15, 2024 at a redemption price of $25 per security plus accrued and unpaid interest. The 2027 Notes bear interest at a rate of 6.25% per year, payable quarterly on March 30, June 30, September 30 and December 30 of each year, commencing on September 30, 2022. The 2027 Notes are the Company’s direct unsecured obligations and (i) rank equally in right of payment with the Company’s current and future unsecured indebtedness; (ii) are senior in right of payment to any of the Company’s future indebtedness that expressly provides it is subordinated to the 2027 Notes; (iii) are effectively subordinated to all of the Company’s existing and future secured indebtedness (including indebtedness that is initially unsecured to which the Company subsequently grants security), to the extent of the value of the assets securing such indebtedness, and (iv) are structurally subordinated to all existing and future indebtedness and other obligations of any of the Company’s subsidiaries. As of March 31, 2023, the Company was in material compliance with the terms of the 2027 Notes. The 2027 Notes are listed on the New York Stock Exchange under the symbol “HTFC”.

38

Horizon Technology Finance Corporation and Subsidiaries

Notes to Consolidated Financial Statements

 

Note 8. Financial instruments with off-balance-sheet risk

In the normal course of business, the Company is party to financial instruments with off-balance-sheet risk to meet the financing needs of its borrowers. These financial instruments include commitments to extend credit and involve, to varying degrees, elements of credit risk in excess of the amount recognized in the consolidated statement of assets and liabilities. The Company attempts to limit its credit risk by conducting extensive due diligence and obtaining collateral where appropriate.

The balance of unfunded commitments to extend credit was $166.2 million and $190.0 million as of March 31, 2023 and  December 31, 2022, respectively. Commitments to extend credit consist principally of the unused portions of commitments that obligate the Company to extend credit, often subject to financial or non-financial milestones and other conditions to borrow that must be achieved before the commitment can be drawn. In addition, the commitments generally have fixed expiration dates or other termination clauses. Since commitments may expire without being drawn upon, the total commitment amounts do not necessarily represent future cash requirements. 

The following table provides the Company’s unfunded commitments by portfolio company as of March 31, 2023:

	March 31, 2023				December 31, 2022
			Fair Value of				Fair Value of
			Unfunded				Unfunded
	Principal		Commitment		Principal		Commitment
	Balance		Liability		Balance		Liability
	(In thousands)				(In thousands)
BrightInsight, Inc.	$	18,250	$	241	$	21,000	$	278
Britecore Holdings, Inc.		—		—		5,000		66
Castle Creek Biosciences		4,000		72		4,000		72
Corinth Medtech, Inc.		200		—		—		—
Divergent Technologies, Inc.		18,750		197		22,500		236
Engage3, LLC		8,000		40		8,000		40
Groundspeed Analytics, Inc.		15,500		150		15,000		150
Hound Labs, Inc.		7,500		88		7,500		88
KSQ Therapeutics, Inc.		10,000		100		10,000		100
Lytics, Inc.		4,000		52		5,000		65
Native Microbials, Inc.		—		—		7,500		72
Noodle Partners, Inc.		10,000		123		—		—
Optoro, Inc.		15,000		38		15,000		38
PDS Biotechnology Corporation		10,000		158		10,000		158
Robin Healthcare, Inc.		5,000		50		10,000		100
Scientia Vascular, Inc.		10,000		110		10,000		110
Slingshot Aerospace, Inc.		5,000		63		5,000		64
Swift Health Systems Inc.		18,500		—		25,500		105
Temperpack Technologies, Inc.		6,500		14		9,000		19
Total	$	166,200	$	1,496	$	190,000	$	1,761

The table above also provides the fair value of the Company’s unfunded commitment liability as of March 31, 2023 and December 31, 2022, which totaled $1.5 million and $1.8 million, respectively. The fair value at inception of the delay draw credit agreements is equal to the fees and/or warrants received to enter into these agreements, taking into account the remaining terms of the agreements and the counterparties’ credit profile. The unfunded commitment liability reflects the fair value of these future funding commitments and is included in the Company’s consolidated statement of assets and liabilities.

39

Horizon Technology Finance Corporation and Subsidiaries

Notes to Consolidated Financial Statements

 

Note 9. Concentrations of credit risk

The Company’s debt investments consist primarily of loans to development-stage companies at various stages of development in the technology, life science, healthcare information and services and sustainability industries. Many of these companies may have relatively limited operating histories and also may experience variation in operating results. Many of these companies conduct business in regulated industries and could be affected by changes in government regulations. Most of the Company’s borrowers will need additional capital to satisfy their continuing working capital needs and other requirements, and in many instances, to service the interest and principal payments on the loans.

The Company’s largest debt investments may vary from period to period as new debt investments are recorded and existing debt investments are repaid. The Company’s five largest debt investments, at cost and fair value, represented 23% of total debt investments outstanding as of March 31, 2023 and  December 31, 2022. No single debt investment represented more than 10% of the total debt investments at cost or fair value as of March 31, 2023 and  December 31, 2022. Investment income, consisting of interest and fees, can fluctuate significantly upon repayment of large debt investments. Interest income from the five largest debt investments at cost and fair value accounted for 22% and 26% of total interest and fee income on investments for the three months ended March 31, 2023 and 2022, respectively. 

40

Horizon Technology Finance Corporation and Subsidiaries

Notes to Consolidated Financial Statements

 

Note 10. Distributions

The Company’s distributions are recorded on the declaration date. The following table summarizes the Company’s distribution activity for the three months ended March 31, 2023 and for the year ended December 31, 2022:

							DRIP		DRIP
Date			Amount		Cash		Shares		Share
Declared	Record Date	Payment Date	Per Share		Distribution		Issued		Value
			(In thousands, except share and per share data)
Three Months Ended March 31, 2023
2/23/2023	5/18/23	6/14/23	$	0.11	$	—		—	$	—
2/23/2023	4/18/23	5/16/23		0.11		—		—		—
2/23/2023	3/17/23	4/14/23		0.11		3,035		6,894		81
			$	0.33	$	3,035		6,894	$	81
Year Ended December 31, 2022
10/28/2022	2/17/23	3/15/23	$	0.11	$	3,040		6,764	$	75
10/28/2022	1/18/23	2/15/23		0.11		3,021		5,754		74
10/28/2022	12/19/22	1/13/23		0.11		2,978		5,618		69
10/28/2022	11/17/22	12/15/22		0.05		1,319		2,171		27
7/29/2022	11/17/22	12/15/22		0.10		2,638		4,341		57
7/29/2022	10/18/22	11/15/22		0.10		2,580		4,621		60
7/29/2022	9/19/22	10/14/22		0.10		2,558		7,703		81
4/29/2022	8/18/22	9/15/22		0.10		2,528		4,925		60
4/29/2022	7/19/22	8/16/22		0.10		2,484		3,939		55
4/29/2022	6/17/22	7/15/22		0.10		2,434		4,286		51
2/25/2022	5/18/22	6/15/22		0.10		2,378		4,428		50
2/25/2022	4/19/22	5/16/22		0.10		2,349		4,088		49
2/25/2022	3/18/22	4/14/22		0.10		2,352		3,221		46
			$	1.28	$	32,659		61,859	$	754

On April 28, 2023, the Board declared monthly distributions per share, payable as set forth in the following table:

Monthly distributions

Ex-Dividend Date	Record Date	Payment Date	Distributions Declared
June 15, 2023	June 16, 2023	July 14, 2023	$	0.11
July 17, 2023	July 18, 2023	August 15, 2023	$	0.11
August 16, 2023	August 17, 2023	September 15, 2023	$	0.11

After paying distributions of $0.33 per share and earning net investment income of $0.46 per share for the quarter, the Company’s undistributed spillover income as of March 31, 2023 was $0.81 per share. Spillover income includes any ordinary income and net capital gains from the preceding tax years that were not distributed during such tax years.

41

Horizon Technology Finance Corporation and Subsidiaries

Notes to Consolidated Financial Statements

 

Note 11. Financial highlights

The following table shows financial highlights for the Company:

	Three months ended March 31,
	2023				2022
	(In thousands, except share and per share data)
Per share data:
Net asset value at beginning of period	$	11.47			$	11.56
Net investment income		0.46				0.26
Realized loss		(0.01	)			—
Unrealized depreciation on investments		(0.26	)			(0.10	)
Net increase in net assets resulting from operations		0.19				0.16
Distributions declared (1)		(0.33	)			(0.30	)
From net investment income		(0.33	)			(0.30	)
From net realized gain on investments		—				—
Return of capital		—				—
Other (2)		0.01				0.26
Net asset value at end of period	$	11.34			$	11.68
Per share market value, beginning of period	$	11.60			$	15.92
Per share market value, end of period	$	11.28			$	13.90
Total return based on a market value (3)		0.1	%			(10.8	)%
Shares outstanding at end of period		28,377,357				23,977,137
Ratios to average net assets:
Expenses without incentive value (4)		14.8	%			10.6	%
Incentive fees (4)		3.7	%			2.2	%
Net expenses (4)		18.5	%			12.8	%
Net investment income with incentive fees (4)		16.3	%			8.7	%
Net assets at the end of the period	$	321,683			$	279,989
Average net asset value	$	320,066			$	262,662
Average debt per share	$	15.61			$	12.21
Portfolio turnover ratio		4.2	%	(5)		2.6	%	(5)

(1) Distributions are determined based on taxable income calculated in accordance with income tax regulations, which may differ from amounts determined under GAAP due to (i) changes in unrealized appreciation and depreciation, (ii) temporary and permanent differences in income and expense recognition, and (iii) the amount of spillover income carried over from a given tax year for distribution in the following tax year. The final determination of taxable income for each tax year, as well as the tax attributes for distributions in such tax year, will be made after the close of the tax year.

(2) Includes the impact of the different share amounts as a result of calculating per share data based on the weighted average basic shares outstanding during the period and certain per share data based on the shares outstanding as of a period end or transaction date. The issuance of common stock on a per share basis reflects the incremental net asset value changes as a result of the issuance of common stock in the Company’s continuous public offering and pursuant to the Company’s distribution reinvestment plan. The issuance of common stock at an offering price, net of sales commissions and dealer manager fees, that is greater than the net asset value per share results in an increase in net asset value per share.

(3) The total return equals the change in the ending market value over the beginning of period price per share plus distributions paid per share during the period, divided by the beginning price.

(4) Annualized.

(5) Calculated by dividing the lesser of purchases or the sum of (1) principal prepayments and (2) maturities by the monthly average debt investment balance.

42

Horizon Technology Finance Corporation and Subsidiaries

Notes to Consolidated Financial Statements

 

Note 12. Subsequent Events

In  April 2023, the Company sold 272,303 shares of common stock under the 2021 Equity Distribution Agreement. For the same period, the Company received total accumulated net proceeds of approximately $3.1 million, including $0.1 million of offering expenses, from these sales.

IMV Inc. (“IMV”) (NASDAQ: IMV; TSX: IMV), announced on May 1, 2023 that the Nova Scotia Supreme Court has issued an initial order (the “Initial Order”) granting IMV and its subsidiaries protection under the Companies’ Creditors Arrangement Act (R.S.C., 1985, c. C-36) and IMV will seek the recognition of the Initial Order in the United States by filing a petition commencing proceedings under the Chapter 15 of the United States Bankruptcy Code.

43

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

In this quarterly report on Form 10‑Q, except where the context suggests otherwise, the terms “we,” “us,” “our” and “Horizon Technology Finance” refer to Horizon Technology Finance Corporation and its consolidated subsidiaries. The information contained in this section should be read in conjunction with our consolidated financial statements and related notes thereto appearing elsewhere in this quarterly report on Form 10‑Q.

Forward-looking statements

This quarterly report on Form 10‑Q, including the Management’s Discussion and Analysis of Financial Condition and Results of Operations, contains statements that constitute forward-looking statements, which relate to future events or our future performance or financial condition. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our industry, our beliefs and our assumptions. The forward-looking statements contained in this quarterly report on Form 10‑Q involve risks and uncertainties, including statements as to:

● our future operating results, including the performance of our existing debt investments, warrants and other investments;

● the introduction, withdrawal, success and timing of business initiatives and strategies;

● general economic and political trends and other external factors, including continuing supply chain disruptions, increased inflation and a general slowdown in economic activity;

● the relative and absolute investment performance and operations of our Advisor;

● the impact of increased competition;

● the impact of investments we intend to make and future acquisitions and divestitures;

● the unfavorable resolution of legal proceedings;

● our business prospects and the prospects of our portfolio companies, including our and their ability to achieve our respective objectives as a result of the COVID-19 pandemic;

● turmoil in Ukraine and Russia and the potential for volatility in energy prices and its impact on the industries in which we invest;

● the impact, extent and timing of technological changes and the adequacy of intellectual property protection;

● our regulatory structure and tax status;

● changes in the general interest rate environment;

● our ability to qualify and maintain qualification as a RIC and as a BDC;

● the adequacy of our cash resources and working capital;

● any losses or operations disruptions caused by us, our Advisor or our portfolio companies holding cash balances at financial institutions that exceed federally insured limits or by disruptions in the financial services industry;

● the timing of cash flows, if any, from the operations of our portfolio companies;

● the impact of interest rate volatility on our results, particularly if we use leverage as part of our investment strategy;

44

● the ability of our portfolio companies to achieve their objective;

● the impact of legislative and regulatory actions and reforms and regulatory supervisory or enforcement actions of government agencies relating to us or our Advisor;

● our contractual arrangements and relationships with third parties;

● our ability to access capital and any future financings by us;

● our use of financial leverage;

● the ability of our Advisor to attract and retain highly talented professionals;

● the impact of changes to tax legislation and, generally, our tax position; and

● our ability to fund unfunded commitments.

We use words such as “anticipates,” “believes,” “expects,” “intends,” “seeks” and similar expressions to identify forward-looking statements. Undue influence should not be placed on the forward looking statements as our actual results could differ materially from those projected in the forward-looking statements for any reason, including the factors in “Risk Factors” and elsewhere in our annual report on Form 10‑K for the year ended December 31, 2022, and elsewhere in this quarterly report on Form 10‑Q.

We have based the forward-looking statements included in this quarterly report on Form 10-Q on information available to us on the date of this quarterly report on Form 10-Q, and we assume no obligation to update any such forward-looking statements. Although we undertake no obligation to revise or update any forward-looking statements in this quarterly report on Form 10‑Q, whether as a result of new information, future events or otherwise, you are advised to consult any additional disclosures that we may make directly to you or through reports that we in the future may file with the U.S. Securities and Exchange Commission, or the SEC, including periodic reports on Form 10‑Q and Form 10‑K and current reports on Form 8‑K.

Overview

We are a specialty finance company that lends to and invests in development-stage companies in the technology, life science, healthcare information and services and sustainability industries, which we refer to as our “Target Industries.” Our investment objective is to maximize our investment portfolio’s total return by generating current income from the debt investments we make and capital appreciation from the warrants we receive when making such debt investments. We are focused on making secured debt investments, which we refer to collectively as “Venture Loans,” to venture capital and private equity backed companies and publicly traded companies in our Target Industries, which we refer to as “Venture Lending.” Our debt investments are typically secured by first liens or first liens behind a secured revolving line of credit, or collectively “Senior Term Loans.” Some of our debt investments may also be subordinated to term debt provided by third parties. As of March 31, 2023, 86.7%, or $593.6 million, of our debt investment portfolio at fair value consisted of Senior Term Loans. Venture Lending is typically characterized by (1) the making of a secured debt investment after a venture capital or equity investment in the portfolio company has been made, which investment provides a source of cash to fund the portfolio company’s debt service obligations under the Venture Loan, (2) the senior priority of the Venture Loan which requires repayment of the Venture Loan prior to the equity investors realizing a return on their capital, (3) the amortization of the Venture Loan and (4) the lender’s receipt of warrants or other success fees with the making of the Venture Loan.

We are an externally managed, closed-end, non-diversified management investment company that has elected to be regulated as a BDC under the Investment Company Act of 1940, as amended, or the 1940 Act. In addition, for U.S. federal income tax purposes, we have elected to be treated as a RIC under Subchapter M of the Code. As a BDC, we are required to comply with regulatory requirements, including limitations on our use of debt. We are permitted to, and expect to, finance our investments through borrowings subject to a 150% asset coverage test. As defined in the 1940 Act, asset coverage of 150% means that for every $100 of net assets a BDC holds, it may raise up to $200 from borrowing and issuing senior securities. The amount of leverage that we may employ will depend on our assessment of market conditions and other factors at the time of any proposed borrowing. As a RIC, we generally are not subject to corporate-level income taxes on our investment company taxable income, determined without regard to any deductions for dividends paid, and our net capital gain that we distribute as dividends for U.S. federal income tax purposes to our stockholders as long as we meet certain source-of-income, distribution, asset diversification and other requirements.

45

We were formed in March 2010 and completed an initial public offering.

Our investment activities, and our day-to-day operations, are managed by our Advisor and supervised by our Board, of which a majority of the members are independent of us. Under the Investment Management Agreement, we have agreed to pay our Advisor a base management fee and an incentive fee for its advisory services to us. We have also entered into the Administration Agreement with our Advisor under which we have agreed to reimburse our Advisor for our allocable portion of overhead and other expenses incurred by our Advisor in performing its obligations under the Administration Agreement.

Portfolio composition and investment activity

The following table shows our portfolio by type of investment as of March 31, 2023 and December 31, 2022:

	March 31, 2023						December 31, 2022
				Percentage of						Percentage of
	Number of	Fair		Total			Number of	Fair		Total
	Investments	Value		Portfolio			Investments	Value		Portfolio
	(Dollars in thousands)
Debt investments	57	$	684,554		95.7	%	60	$	686,458		95.3	%
Warrants	88		25,658		3.6		90		29,712		4.1
Other investments	2		1,300		0.2		2		1,300		0.2
Equity	11		3,800		0.5		8		2,556		0.4
Total		$	715,312		100.0	%		$	720,026		100.0	%

The following table shows total portfolio investment activity as of and for the three months ended March 31, 2023 and 2022:

	For the three months ended
	March 31,
	2023			2022
Beginning portfolio	$	720,026		$	458,075
New debt investments		47,008			94,485
Principal payments received on investments		(6,815	)		(2,095	)
Payment-in-kind interest on investments		1,204			—
Early pay-offs and principal paydowns		(32,941	)		(12,050	)
Accretion of debt investment fees		1,448			1,006
New debt investment fees		(300	)		(925	)
Proceeds from sale of investments		(6,520	)		(21,280	)
Net (loss) gain on investments		(168	)		30
Net unrealized depreciation on investments		(7,537	)		(2,237	)
Other		(93	)		—
Ending portfolio	$	715,312		$	515,009

We receive payments on our debt investments based on scheduled amortization of the outstanding balances. In addition, we receive repayments of some of our debt investments prior to their scheduled maturity date. The frequency or volume of these repayments may fluctuate significantly from period to period.

46

The following table shows our debt investments by industry sector as of March 31, 2023 and December 31, 2022:

	March 31, 2023					December 31, 2022
	Debt		Percentage of			Debt		Percentage of
	Investments at		Total			Investments at		Total
	Fair Value		Portfolio			Fair Value		Portfolio
	(Dollars in thousands)
Life Science
Biotechnology	$	183,625		26.8	%	$	189,729		27.6	%
Medical Device		124,124		18.1			127,839		18.6
Technology
Communications		22,377		3.3			22,671		3.3
Consumer-Related		93,607		13.7			108,226		15.8
Networking		9,747		1.4			11,467		1.7
Software		141,942		20.7			117,002		17.0
Sustainability
Other Sustainability		82,995		12.1			83,705		12.2
Healthcare Information and Services
Diagnostics		9,815		1.4			9,804		1.4
Other Healthcare		51		0.1			2,500		0.4
Software		16,271		2.4			13,515		2.0
Total	$	684,554		100.0	%	$	686,458		100.0	%

The largest debt investments in our portfolio may vary from period to period as new debt investments are originated and existing debt investments are repaid. Our five largest debt investments at cost and fair value represented 23% of total debt investments outstanding as of March 31, 2023 and December 31, 2022. No single debt investment at cost or fair value represented more than 10% of our total debt investments as of March 31, 2023 and December 31, 2022.

Debt investment asset quality

We use an internal credit rating system which rates each debt investment on a scale of 4 to 1, with 4 being the highest credit quality rating and 3 being the rating for a standard level of risk. A rating of 2 represents an increased level of risk and, while no loss is currently anticipated for a 2‑rated debt investment, there is potential for future loss of principal. A rating of 1 represents a deteriorating credit quality and a high degree of risk of loss of principal. Our internal credit rating system is not a national credit rating system. As of March 31, 2023 and December 31, 2022, our debt investments had a weighted average credit rating of 3.0 and 3.1, respectively. The following table shows the classification of our debt investment portfolio by credit rating as of March 31, 2023 and December 31, 2022:

	March 31, 2023							December 31, 2022
			Debt		Percentage					Debt		Percentage
	Number of		Investments at		of Debt			Number of		Investments at		of Debt
	Investments		Fair Value		Investments			Investments		Fair Value		Investments
	(Dollars in thousands)
Credit Rating
4		9	$	108,482		15.8	%		8	$	93,832		13.7	%
3		38		483,615		70.6			47		557,554		81.2
2		7		87,206		12.7			2		26,822		3.9
1		3		5,251		0.9			3		8,250		1.2
Total		57	$	684,554		100.0	%		60	$	686,458		100.0	%

As of March 31, 2023, there were three debt investments with an internal credit rating of 1, with an aggregate cost of $20.3 million and an aggregate fair value of $5.3 million. As of December 31, 2022, there were three debt investments with an internal credit rating of 1, with an aggregate cost of $20.9 million and an aggregate fair value of $8.3 million.

47

Consolidated results of operations

As a BDC and a RIC, we are subject to certain constraints on our operations, including limitations imposed by the 1940 Act and the Code. The consolidated results of operations described below may not be indicative of the results we report in future periods.

Comparison of the three months ended March 31, 2023 and 2022

The following table shows consolidated results of operations for the three months ended March 31, 2023 and 2022:

	For the three months ended
	March 31,
	2023			2022
	(In thousands)
Total investment income	$	28,037		$	14,204
Total expenses		14,842			8,375
Net investment income before excise tax		13,195			5,829
Provision for excise tax		184			100
Net investment income		13,011			5,729
Net realized (loss) gain		(168	)		30
Net unrealized depreciation on investments		(7,537	)		(2,237	)
Net increase in net assets resulting from operations	$	5,306		$	3,522
Average debt investments, at fair value	$	687,602		$	459,386
Average gross assets less cash	$	737,826		$	498,363
Average borrowings outstanding	$	440,695		$	267,376

Net increase in net assets resulting from operations can vary substantially from period to period for various reasons, including, without limitation, the recognition of realized gains and losses and unrealized appreciation and depreciation on investments. As a result, quarterly comparisons of net increase in net assets resulting from operations may not be meaningful.

Investment income

Total investment income increased by $13.8 million, or 97.4%, to $28.0 million for the three months ended March 31, 2023 as compared to the three months ended March 31, 2022. For the three months ended March 31, 2023, total investment income consisted primarily of $27.4 million in interest income from investments, which included $4.3 million in income from the accretion of origination fees and end of term payments, or ETPs, and $0.6 million in fee income. Interest income on debt investments increased by $13.5 million, or 97.8%, to $27.4 million, for the three months ended March 31, 2023 compared to the three months ended March 31, 2022. Interest income on debt investments for the three months ended March 31, 2023 as compared to the three months ended March 31, 2022 increased primarily due to an increase of $228.2 million, or 49.7%, in the average size of our debt investment portfolio and an increase in the prime rate which is the base rate for most of our variable rate debt investments. Fee income, which includes success fee, other fee and prepayment fee income on debt investments, increased by $0.3 million, or 81.8%, to $0.6 million for the three months ended March 31, 2023 compared to the three months ended March 31, 2022 primarily due to a higher aggregate amount of principal prepayments for the three months ended March 31, 2023.

The following table shows our dollar-weighted annualized yield for the three months ended March 31, 2023 and 2022:

	For the three months ended
	March 31,
Investment type:	2023			2022
Debt investments(1)		16.3	%		12.4	%
All investments(1)		15.5	%		11.8	%

(1) We calculate the dollar-weighted annualized yield on average investment type for any period as (1) total related investment income during the period divided by (2) the average of the fair value of the investment type outstanding on (a) the last day of the calendar month immediately preceding the first day of the period and (b) the last day of each calendar month during the period. The dollar-weighted annualized yield on average investment type is higher than what investors will realize because it does not reflect our expenses or any sales load paid by investors.

Investment income, consisting of interest income and fees on debt investments, can fluctuate significantly upon repayment of large debt investments. Interest income from the five largest debt investments at cost and fair value in the aggregate accounted for 22% and 26% of investment income for the three months ended March 31, 2023 and 2022, respectively.

48

Expenses

Total expenses increased by $6.5 million, or 77.2%, to $14.8 million for the three months ended March 31, 2023 as compared to the three months ended March 31, 2022. Total expenses for each period consisted of interest expense, base management fee, incentive and administrative fees, professional fees and general and administrative expenses.

Interest expense increased by $3.7 million, or 107.9%, to $7.1 million for the three months ended March 31, 2023 as compared to the three months ended March 31, 2022. Interest expense, which includes the amortization of debt issuance costs, increased primarily due to an increase in average borrowings of $173.3 million, or 64.8%, for the three months ended March 31, 2023 as compared to the three months ended March 31, 2022 and an increase in our effective cost of debt for the three months ended March 31, 2023 as compared to the three months ended March 31, 2022.

Base management fee expense increased by $1.0 million, or 42.6%, to $3.2 million for the three months ended March 31, 2023 as compared to the three months ended March 31, 2022. Base management fee increased primarily due to an increase of $228.2 million, or 49.7%, in average debt investments for the three months ended March 31, 2023 as compared to the three months ended March 31, 2022. 

Performance based incentive fee expense increased by $1.6 million, or 109.1%, to $3.0 million for the three months ended March 31, 2023 as compared to the three months ended March 31, 2022. This increase was due to an increase of $8.8 million, or 123.5%, in Pre-Incentive Fee Net Investment Income for the three months ended March 31, 2023 compared to the three months ended March 31, 2022 offset by an Incentive Fee Cap calculated based on the Incentive Fee Cap and Deferral Mechanism in our Investment Management Agreement of $0.2 million for the three months ended March 31, 2023 compared to the three months ended March 31, 2022. The Incentive Fee Cap and Deferral Mechanism resulted in $0.2 million of reduced incentive fee expense and increased net investment income for the three months ended March 31, 2023. The incentive fee on Pre-Incentive Fee Net Investment Income was subject to the Incentive Fee Cap for the three months ended March 31, 2023 due to the cumulative incentive fees paid exceeding 20% of cumulative pre-incentive fee net return during the applicable quarter and the 11 preceding full calendar quarters.

Administrative fee expense, professional fees and general and administrative expenses were $1.5 million and $1.3 million for the three months ended March 31, 2023 and 2022, respectively. 

Net realized gains and losses and net unrealized appreciation and depreciation

Realized gains or losses on investments are measured by the difference between the net proceeds from the repayment or sale and the cost basis of our investments without regard to unrealized appreciation or depreciation previously recognized. Realized gains or losses on investments include investments charged off during the period, net of recoveries. The net change in unrealized appreciation or depreciation on investments primarily reflects the change in portfolio investment fair values during the reporting period, including the reversal of previously recorded unrealized appreciation or depreciation when gains or losses are realized.

During the three months ended March 31, 2023, we realized net losses on investments totaling $0.2 million primarily due to the write off of warrants in three portfolio companies. During the three months ended March 31, 2022, we realized net gains on investments totaling $0.03 million primarily due to the realized gain from the consideration we received from the exercise and sale of two of our warrant investments.

During the three months ended March 31, 2023, net unrealized depreciation on investments totaled $7.5 million which was primarily due to the unrealized depreciation on five of our debt investments and the unrealized depreciation on our warrant investments. During the three months ended March 31, 2022, net unrealized depreciation on investments totaled $2.2 million which was primarily due to the unrealized depreciation on three of our debt investments partially offset by the unrealized appreciation on our warrant investments.

49

Liquidity and capital resources

As of March 31, 2023 and December 31, 2022, we had cash and investments in money market funds of $43.5 million and $27.7 million, respectively. Cash and investments in money market funds are available to fund new investments, reduce borrowings, pay expenses, repurchase common stock and pay distributions. In addition, as of March 31, 2023 and December 31, 2022, we had $3.0 million and $2.8 million, respectively, of restricted investments in money market funds. Restricted investments in money market funds may be used to make monthly interest and principal payments on our 2019 Asset-Backed Notes, 2022 Asset-Backed Notes, or our NYL Facility. Our primary sources of capital have been from our public and private equity offerings, use of our revolving credit facility (the “Key Facility”) with KeyBank National Association (“Key”) and the Note Funding Agreement (the “NYL Facility”, together with the Key Facility, the “Credit Facilities”) with several entities owned or affiliated with New York Life Insurance Company, and issuance of our public debt offerings. In the current economic environment, such avenues for liquidity may not be available in the future, or may be available on less attractive terms.

On August 2, 2021, we entered into an At-The-Market (“ATM”) sales agreement (the “2021 Equity Distribution Agreement”) with Goldman Sachs & Co. LLC and B. Riley FBR, Inc., (each a “Sales Agent” and, collectively, the “Sales Agents”). The 2021 Equity Distribution Agreement provides that we may offer and sell our shares from time to time through the Sales Agents up to $100.0 million worth of our common stock, in amounts and at times to be determined by us. Sales of our common stock, if any, may be made in negotiated transactions or transactions that are deemed to be “at-the-market,” as defined in Rule 415 under the Securities Act, including sales made directly on the NASDAQ or similar securities exchange or sales made to or through a market maker other than on an exchange, at prices related to the prevailing market prices or at negotiated prices.

During the three months ended March 31, 2023, we sold 605,848 shares of common stock under the 2021 Equity Distribution Agreement. For the same period, we received total accumulated net proceeds of approximately $7.2 million, including $0.2 million of offering expenses, from these sales.

During the three months ended March 31, 2022, we sold 250,171 shares of common stock under the 2021 Equity Distribution Agreement. For the same period, we received total accumulated net proceeds of approximately $3.9 million, including $0.1 million of offering expenses, from these sales.

50

On April 28, 2023, our Board extended a previously authorized stock repurchase program which allows us to repurchase up to $5.0 million of our common stock at prices below our net asset value (“NAV”) per share as reported in our most recent consolidated financial statements. Under the repurchase program, we may, but are not obligated to, repurchase shares of our outstanding common stock in the open market or in privately negotiated transactions from time to time. Any repurchases by us will comply with the requirements of Rule 10b‑18 under the Exchange Act and any applicable requirements of the 1940 Act. Unless extended by our Board, the repurchase program will terminate on the earlier of June 30, 2024 or the repurchase of $5.0 million of our common stock. During the three months ended March 31, 2023 and 2022, we did not make any repurchases of our common stock. From the inception of the stock repurchase program through March 31, 2023, we repurchased 167,465 shares of our common stock at an average price of $11.22 on the open market at a total cost of $1.9 million.

At March 31, 2023 and December 31, 2022, the outstanding principal balance under our Key Facility was $15.0 million and $5.0 million, respectively. As of March 31, 2023 and December 31, 2022, we had borrowing capacity under the Key Facility of $110.0 million and $120.0 million, respectively. At March 31, 2023 and December 31, 2022, $47.7 million and $40.2 million, respectively, was available, subject to existing terms and advance rates.

At March 31, 2023 and December 31, 2022, the outstanding principal balance under the NYL Facility was $176.8 million. As of March 31, 2023 and December 31, 2022, we had borrowing capacity under the NYL Facility of $23.2 million. At March 31, 2023 and December 31, 2022, $21.1 million and $23.2 million, respectively, was available, subject to existing terms and advance rates.

Our operating activities provided cash of $12.7 million for the three months ended March 31, 2023, and our financing activities provided cash of $3.3 million for the same period. Our operating activities provided cash from principal payments received on our debt investments partially offset by cash used to purchase investments in portfolio companies. Our financing activities provided cash primarily from advances on our Credit Facilities and the sale of shares through our ATM for net proceeds of $7.2 million, partially offset by cash used to repay our 2019 Asset-Backed Notes and to pay distributions to our stockholders.

Our operating activities used cash of $55.4 million for the three months ended March 31, 2022, and our financing activities provided cash of $24.1 million for the same period. Our operating activities used cash to purchase investments in portfolio companies partially offset by principal payments received on our debt investments. Our financing activities provided cash primarily from the completion of a follow-on public offering of 2.5 million shares of common stock for net proceeds of $34.3 million, after deducting underwriting commission and discounts and other offering expenses and advances on our Credit Facilities, partially offset by cash used to repay our Key Facility and pay distributions to our stockholders. 

Our primary use of available funds is to make debt investments in portfolio companies and for general corporate purposes. We expect to raise additional equity and debt capital opportunistically as needed and, subject to market conditions, to support our future growth to the extent permitted by the 1940 Act.

In order to remain subject to taxation as a RIC, we intend to distribute to our stockholders all or substantially all of our investment company taxable income. In addition, as a BDC, we are required to maintain asset coverage of at least 150%. This requirement limits the amount that we may borrow.

We believe that our current cash, cash generated from operations, and funds available from our Credit Facilities will be sufficient to meet our working capital and capital expenditure commitments for at least the next 12 months.

51

Current borrowings

The following table shows our borrowings as of March 31, 2023 and December 31, 2022:

	March 31, 2023							December 31, 2022
	Total		Balance			Unused		Total		Balance			Unused
	Commitment		Outstanding			Commitment		Commitment		Outstanding			Commitment
	(In thousands)
Key Facility	$	125,000	$	15,000		$	110,000	$	125,000	$	5,000		$	120,000
NYL Facility		200,000		176,750			23,250		200,000		176,750			23,250
2019 Asset-Backed Notes		37,791		37,791			—		42,573		42,573			—
2022 Asset-Backed Notes		100,000		100,000			—		100,000		100,000			—
2027 Notes		57,500		57,500			—		57,500		57,500			—
2026 Notes		57,500		57,500			—		57,500		57,500			—
Total before debt issuance costs		577,791		444,541			133,250		582,573		439,323			143,250
Unamortized debt issuance costs attributable to term borrowings		—		(4,896	)		—		—		(5,245	)		—
Total borrowings outstanding, net	$	577,791	$	439,645		$	133,250	$	582,573	$	434,078		$	143,250

Credit Facilities

Key Facility

We entered into the Key Facility effective November 4, 2013. Through June 21, 2021, the interest rate on the Key Facility was based upon the one-month LIBOR plus a spread of 3.25%, with a LIBOR floor of 1.00%. From and after June 30, 2021, the interest rate on the Key Facility is based on the rate of interest published in The Wall Street Journal as the prime rate in the United States plus 0.25%, with a prime rate floor of 4.25%. The prime rate was 8.00% and 7.50% as of March 31, 2023 and December 31, 2022, respectively. The interest rates in effect were 8.25% and 7.75% as of March 31, 2023 and December 31, 2022, respectively. The Key Facility requires the payment of an unused line fee in an amount equal to 0.50% of any unborrowed amount available under the facility annually.

The Key Facility has an accordion feature which allows for an increase in the total loan commitment to $150 million. On June 22, 2021, we amended the Key Facility, among other things, to amend the interest rate applied to the outstanding principal balance and to extend the period during which we may request advances under the Key Facility (or the “Revolving Period”), to June 22, 2024. The Key Facility is collateralized by debt investments held by Credit II and permits an advance rate of up to sixty percent (60%) of eligible debt investments held by Credit II. The Key Facility contains covenants that, among other things, require us to maintain a minimum net worth, to restrict the debt investments securing the Key Facility to certain criteria for qualified debt investments and to comply with portfolio company concentration limits as defined in the related loan agreement. After the Revolving Period, we may not request new advances, and we must repay the outstanding advances under the Key Facility as of such date, at such times and in such amounts as are necessary to maintain compliance with the terms and conditions of the Key Facility, particularly the condition that the principal balance of the Key Facility not exceed sixty percent (60%) of the aggregate principal balance of our eligible debt investments to our portfolio companies. The maturity date of the Key Facility, the date on which all outstanding advances under the Key Facility are due and payable, is June 22, 2026.

NYL Facility

On April 21, 2020, we purchased all of the limited liability company interests of Arena in HSLFI. HFI is a wholly-owned subsidiary of HSLFI. HFI entered into the NYL Facility with the NYL Noteholders for an aggregate purchase price of up to $100.0 million, with an accordion feature of up to $200.0 million at the mutual discretion and agreement of HSLFI and the NYL Noteholders. On June 1, 2018, HSLFI sold or contributed to HFI certain secured loans made to certain portfolio companies pursuant to the Sale and Servicing Agreement. Any notes issued by HFI are collateralized by all investments held by HFI and permit an advance rate of up to 67% of the aggregate principal amount of eligible debt investments.

On February 25, 2022, we amended the NYL Facility, increasing the commitment by $100 million to enable our wholly-owned subsidiary to issue up to $200 million of secured notes. The amendment to the NYL Facility extends the investment period to June 2023 and the maturity date to June 2028. In addition, the amendment, among other things, reduces the applicable margin used to calculate the NYL Facility’s interest rate on our borrowings above $100 million. Such borrowings will be priced at the three-year USD mid-market swap rate plus 3.00%.

Under the terms of the NYL Facility, we are required to maintain a reserve cash balance, which may be used to pay monthly interest and principal payments on the NYL Facility. We have segregated these funds and classified them as restricted investments in money market funds. At March 31, 2023, and December 31, 2022, there were approximately $1.3 million and $1.0 million, respectively, of restricted investments.

There were $176.8 million in notes issued to the NYL Noteholders as of March 31, 2023 and December 31, 2022 at an interest rate of 5.57%. As of March 31, 2023 and December 31, 2022, we had borrowing capacity under the NYL Facility of $23.2 million. At March 31, 2023 and December 31, 2022, $21.1 million and $23.2 million, respectively, was available for borrowing, subject to existing terms and advance rates.

52

Securitizations

2019 Asset-Backed Notes 

On August 13, 2019, the 2019 Asset-Backed Notes were issued by the 2019‑1 Trust pursuant to a note purchase agreement, dated as of August 13, 2019, by and among us and Keybanc Capital Markets Inc. as Initial Purchaser, and are backed by a pool of loans made to certain portfolio companies of ours and secured by certain assets of those portfolio companies and are to be serviced by us. Interest on the 2019 Asset-Backed Notes will be paid, to the extent of funds available, at a fixed rate of 4.21% per annum. The 2019 Asset-Backed Notes had a two-year reinvestment period and a stated maturity of September 15, 2027. The 2019 Asset-Backed Notes were rated A+(sf) by Morningstar Credit Ratings, LLC on August 13, 2019. There has been no change in the rating since August 13, 2019.

At March 31, 2023, and December 31, 2022, the 2019 Asset-Backed Notes had an outstanding principal balance of $37.8 million and $42.6 million, respectively.

Under the terms of the 2019 Asset-Backed Notes, we are required to maintain a reserve cash balance, funded through proceeds from the sale of the 2019 Asset-Backed Notes, which may be used to pay monthly interest and principal payments on the 2019 Asset-Backed Notes. We have segregated these funds and classified them as restricted investments in money market funds. At March 31, 2023, and December 31, 2022, there were approximately $0.5 million and $0.6 million, respectively, of restricted investments.

2022 Asset-Backed Notes

On November 9, 2022, the 2022 Asset-Backed Notes were issued by the 2022‑1 Trust pursuant to a note purchase agreement, dated as of November 9, 2022, by and among us and Keybanc Capital Markets Inc. as Initial Purchaser, and are backed by a pool of loans made to certain portfolio companies of ours and secured by certain assets of those portfolio companies and are to be serviced by us. Interest on the 2022 Asset-Backed Notes will be paid, to the extent of funds available, at a fixed rate of 7.56% per annum. The 2022 Asset-Backed Notes have a two-year reinvestment period and a stated maturity of November 15, 2030. The 2022 Asset-Backed Notes were rated A by Morningstar Credit Ratings, LLC on November 9, 2022. There has been no change in the rating since November 9, 2022.

As of March 31, 2023 and December 31, 2022, the 2022 Asset-Backed Notes had an outstanding principal balance of $100.0 million.

Under the terms of the 2022 Asset-Backed Notes, we are required to maintain a reserve cash balance, funded through proceeds from the sale of the 2022 Asset-Backed Notes, which may be used to pay monthly interest and principal payments on the 2022 Asset-Backed Notes. We have segregated these funds and classified them as restricted investments in money market funds. At March 31, 2023, and December 31, 2022, there were approximately $1.1 million and $1.2 million, respectively, of restricted investments.

Unsecured Notes

2026 Notes

On March 30, 2021, we issued and sold an aggregate principal amount of $57.5 million of 4.875% notes due in 2026, or the 2026 Notes. The amount of 2026 Notes issued and sold included the full exercise by the underwriters of their option to purchase $7.5 million in aggregate principal of additional notes. The 2026 Notes have a stated maturity of March 30, 2026 and may be redeemed in whole or in part at our option at any time or from time to time on or after March 30, 2023 at a redemption price of $25 per security plus accrued and unpaid interest. The 2026 Notes bear interest at a rate of 4.875% per year, payable quarterly on March 30, June 30, September 30 and December 30 of each year. The 2026 Notes are our direct unsecured obligations and (i) rank equally in right of payment with our current and future unsecured indebtedness; (ii) are senior in right of payment to any of our future indebtedness that expressly provides it is subordinated to the 2026 Notes; (iii) are effectively subordinated to all of our existing and future secured indebtedness (including indebtedness that is initially unsecured to which we subsequently grant security), to the extent of the value of the assets securing such indebtedness, and (iv) are structurally subordinated to all existing and future indebtedness and other obligations of any of our subsidiaries. As of March 31, 2023, we were in material compliance with the terms of the 2026 Notes. The 2026 Notes are listed on the New York Stock Exchange under the symbol “HTFB”.

2027 Notes

On June 15, 2022, we issued and sold an aggregate principal amount of $50.0 million of 6.25% notes due in 2027 and on July 11, 2022, pursuant to the underwriters’ 30 day option to purchase additional notes, we sold an additional $7.5 million of such notes, or collectively, the 2027 Notes. The 2027 Notes have a stated maturity of June 15, 2027 and may be redeemed in whole or in part at our option at any time or from time to time on or after June 15, 2024 at a redemption price of $25 per security plus accrued and unpaid interest. The 2027 Notes bear interest at a rate of 6.25% per year, payable quarterly on March 30, June 30, September 30 and December 30 of each year, commencing on September 30, 2022. The 2027 Notes are our direct unsecured obligations and (i) rank equally in right of payment with our current and future unsecured indebtedness; (ii) are senior in right of payment to any of our future indebtedness that expressly provides it is subordinated to the 2027 Notes; (iii) are effectively subordinated to all of our existing and future secured indebtedness (including indebtedness that is initially unsecured to which we subsequently grant security), to the extent of the value of the assets securing such indebtedness, and (iv) are structurally subordinated to all existing and future indebtedness and other obligations of any of our subsidiaries. As of March 31, 2023, we were in material compliance with the terms of the 2027 Notes. The 2027 Notes are listed on the New York Stock Exchange under the symbol “HTFC”.

53

Other assets

As of March 31, 2023 and December 31, 2022, other assets were $2.6 million and $2.8 million, respectively, which is primarily comprised of debt issuance costs and prepaid expenses.

Contractual obligations and off-balance sheet arrangements

The following table shows our significant contractual payment obligations and off-balance sheet arrangements as of March 31, 2023:

	Payments due by period
			Less than		1 – 3		3 – 5		After 5
	Total		1 year		Years		Years		years
	(In thousands)
Borrowings	$	444,541	$	35,217	$	284,192	$	125,132	$	—
Unfunded commitments		166,200		143,700		22,500		—		—
Incentive fee deferral		1,255		—		1,255		—		—
Total	$	611,996	$	178,917	$	307,947	$	125,132	$	—

In the normal course of business, we are party to financial instruments with off-balance sheet risk. These consist primarily of unfunded commitments to extend credit, in the form of loans, to our portfolio companies. Unfunded commitments to provide funds to portfolio companies are not reflected on our balance sheet. Our unfunded commitments may be significant from time to time. As of March 31, 2023, we had unfunded commitments of $166.2 million. This includes no undrawn revolver commitments. These commitments are subject to the same underwriting and ongoing portfolio maintenance requirements as are the financial instruments that we hold on our balance sheet. In addition, these commitments are often subject to financial or non-financial milestones and other conditions to borrowing that must be achieved before the commitment can be drawn. Since these commitments may expire without being drawn upon, the total commitment amount does not necessarily represent future cash requirements. We regularly monitor our unfunded commitments and anticipated refinancings, maturities and capital raising, to ensure that we have sufficient liquidity to fund unfunded commitments. As of March 31, 2023, we reasonably believed that our assets would provide adequate financial resources to satisfy all of our unfunded commitments.

In addition to the Credit Facilities, we have certain commitments pursuant to our Investment Management Agreement entered into with our Advisor. We have agreed to pay a fee for investment advisory and management services consisting of two components (1) a base management fee equal to a percentage of the value of our gross assets less cash or cash equivalents, and (2) a two-part incentive fee. We have also entered into a contract with our Advisor to serve as our administrator. Payments under the Administration Agreement are equal to an amount based upon our allocable portion of our Advisor’s overhead in performing its obligations under the agreement, including rent, fees and other expenses inclusive of our allocable portion of the compensation of our Chief Financial Officer and Chief Compliance Officer and their respective staffs. See Note 3 to our consolidated financial statements for additional information regarding our Investment Management Agreement and our Administration Agreement.

54

The incentive fee on Pre-Incentive Fee Net Investment Income is subject to a fee cap and deferral mechanism which is determined based upon a look-back period of up to three years and is expensed when incurred. For this purpose, the Incentive Fee Look-back Period includes the relevant calendar quarter and the 11 preceding full calendar quarters. Each quarterly incentive fee payable on Pre-Incentive Fee Net Investment Income is subject to the Incentive Fee Cap and Deferral Mechanism. The Incentive Fee Cap is equal to (a) 20.00% of Cumulative Pre-Incentive Fee Net Return during the Incentive Fee Look-back Period less (b) cumulative incentive fees of any kind paid to our Advisor during the Incentive Fee Look-back Period. To the extent the Incentive Fee Cap is zero or a negative value in any calendar quarter, we will not pay an incentive fee on Pre-Incentive Fee Net Investment Income to our Advisor in that quarter. To the extent that the payment of incentive fees on Pre-Incentive Fee Net Investment Income is limited by the Incentive Fee Cap, the payment of such fees will be deferred and paid in subsequent calendar quarters up to three years after their date of deferment, subject to certain limitations, which are set forth in the Investment Management Agreement. During the three months ended March 31, 2023, the Incentive Fee Cap and Deferral Mechanism resulted in deferral of $0.2 million of incentive fee which may become subject to payment up to three years after the date of deferment. As of March 31, 2023, the total amount subject to recoupment was $1.3 million.

Distributions

In order to qualify and be subject to tax as a RIC, we must meet certain source-of-income, asset diversification and annual distribution requirements. Generally, in order to qualify as a RIC, we must derive at least 90% of our gross income for each tax year from dividends, interest, payments with respect to certain securities, loans, gains from the sale or other disposition of stock, securities or foreign currencies, income derived from certain publicly traded partnerships, or other income derived with respect to our business of investing in stock or other securities. We must also meet certain asset diversification requirements at the end of each quarter of each tax year. Failure to meet these diversification requirements on the last day of a quarter may result in us having to dispose of certain investments quickly in order to prevent the loss of RIC status. Any such dispositions could be made at disadvantageous prices or times, and may cause us to incur substantial losses.

In addition, in order to be subject to tax as a RIC and to avoid the imposition of corporate-level tax on the income and gains we distribute to our stockholders in respect of any tax year, we are required under the Code to distribute as dividends to our stockholders out of assets legally available for distribution each tax year an amount generally at least equal to 90% of the sum of our net ordinary income and net short-term capital gains in excess of net long-term capital losses, if any. Additionally, in order to avoid the imposition of a U.S. federal excise tax, we are required to distribute, in respect of each calendar year, dividends to our stockholders of an amount at least equal to the sum of 98% of our calendar year net ordinary income (taking into account certain deferrals and elections); 98.2% of our capital gain net income (adjusted for certain ordinary losses) for the one year period ending on October 31 of such calendar year; and any net ordinary income and capital gain net income for preceding calendar years that were not distributed during such calendar years and on which we previously did not incur any U.S. federal income tax. If we fail to qualify as a RIC for any reason and become subject to corporate tax, the resulting corporate taxes could substantially reduce our net assets, the amount of income available for distribution and the amount of our distributions. Such a failure would have a material adverse effect on us and our stockholders. In addition, we could be required to recognize unrealized gains, incur substantial taxes and interest and make substantial distributions in order to re-qualify as a RIC. We cannot assure stockholders that they will receive any distributions.

To the extent our taxable earnings in a tax year fall below the total amount of our distributions made to stockholders in respect of such tax year, a portion of those distributions may be deemed a return of capital to our stockholders for U.S. federal income tax purposes. Thus, the source of a distribution to our stockholders may be the original capital invested by the stockholder rather than our income or gains. Stockholders should review any written disclosure accompanying a distribution payment carefully and should not assume that the source of any distribution is our ordinary income or gains.

We have adopted an “opt out” dividend reinvestment plan, or DRIP, for our common stockholders. As a result, if we declare a distribution, then stockholders’ cash distributions will be automatically reinvested in additional shares of our common stock unless a stockholder specifically “opts out” of our DRIP. If a stockholder opts out, that stockholder will receive cash distributions. Although distributions paid in the form of additional shares of our common stock will generally be subject to U.S. federal, state and local taxes, stockholders participating in our DRIP will not receive any corresponding cash distributions with which to pay any such applicable taxes. If our common stock is trading above NAV, a stockholder receiving distributions in the form of additional shares of our common stock will be treated as receiving a distribution of an amount equal to the fair market value of such shares of our common stock. We may use newly issued shares to implement the DRIP, or we may purchase shares in the open market in connection with our obligations under the DRIP.

Related party transactions

We have entered into the Investment Management Agreement with our Advisor. Our Advisor is registered as an investment adviser under the Investment Advisers Act of 1940, as amended. Our investment activities are managed by our Advisor and supervised by our Board, the majority of whom are independent directors. Under the Investment Management Agreement, we have agreed to pay our Advisor a base management fee as well as an incentive fee. During the three months ended March 31, 2023 and 2022, our Advisor earned $6.2 million and $3.7 million, respectively, pursuant to the Investment Management Agreement.

55

Horizon Technology Finance Principals LLC f/k/a Horizon Technology Finance, LLC (“HTF Principals”), owns more than seventy percent (70%) of our Advisor. Our Chief Executive Officer, Robert D. Pomeroy Jr. and our President, Gerald A. Michaud own one hundred percent (100%) of HTF Principals. By virtue of their ownership interest in HTF Principals, Mr. Pomeroy and Mr. Michaud control our Advisor.

On February 22, 2023, our Advisor, HTF Principals and Horizon Technology Finance Employees LLC (“HTF Employees”) entered into a Membership Interest Purchase Agreement (the “Purchase Agreement”)  with MCH Holdco LLC (“MCH Holdco”), an affiliate of Monroe Capital LLC (“Monroe Capital”), and Monroe Capital Investment Holdings, L.P., an affiliate of Monroe Capital and the sole stockholder of MCH Holdco, pursuant to which HTF Principals and HTF Employees will sell all of their membership interests in our Advisor (which constitute one hundred percent (100%) of the membership interests of our Advisor) to MCH Holdco and our Advisor will become a direct wholly owned subsidiary of MCH Holdco and an affiliate of Monroe Capital (the “Transaction”).  Subject to customary closing conditions, the Transaction is expected to close around the end of May 2023. A significant portion of the consideration payable by Monroe Capital to HTF Principals and HTF Employees pursuant to the Purchase Agreement is in the form of earnout payments contingent upon our performance in 2023, 2024, and 2025, aligning the incentives of our Advisor’s current officers with our stockholders.

We have also entered into the Administration Agreement with our Advisor. Under the Administration Agreement, we have agreed to reimburse our Advisor for our allocable portion of overhead and other expenses incurred by our Advisor in performing its obligations under the Administration Agreement, including rent and our allocable portion of the costs of compensation and related expenses of our Chief Financial Officer and Chief Compliance Officer and their respective staffs. In addition, pursuant to the terms of the Administration Agreement our Advisor provides us with the office facilities and administrative services necessary to conduct our day-to-day operations. During the three months ended March 31, 2023 and 2022, our Advisor earned $0.4 million pursuant to the Administration Agreement. 

HTF Principals has granted us a non-exclusive, royalty-free license to use the name “Horizon Technology Finance.”

We believe that we derive substantial benefits from our relationship with our Advisor. Our Advisor may manage other investment vehicles, or Advisor Funds, with the same investment strategy as us. Our Advisor may provide us an opportunity to co-invest with the Advisor Funds. Under the 1940 Act, absent receipt of exemptive relief from the SEC, we and our affiliates are precluded from co-investing in negotiated investments. On November 27, 2017, we were granted exemptive relief from the SEC which permits us to co-invest with the Advisor Funds, subject to certain conditions.

Critical accounting policies

The discussion of our financial condition and results of operation is based upon our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP. The preparation of these consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. Changes in the economic environment, financial markets and any other parameters used in determining such estimates could cause actual results to differ. In addition to the discussion below, we describe our significant accounting policies in the notes to our consolidated financial statements.

We have identified the following items as critical accounting policies.

Valuation of investments

Investments are recorded at fair value. Prior to July 30, 2022, our Board determined the fair value of our investments. Pursuant to the amended SEC Rule 2a-5 of the 1940 Act, on July 29, 2022, our Board designated our Advisor as our “valuation designee.” Our Board is responsible for oversight of the valuation designee. The valuation designee has established a Valuation Committee to determine in good faith the fair value of our investments, based on input of our Advisor’s management and personnel and independent valuation firms which are engaged at the direction of the Valuation Committee to assist in the valuation of certain portfolio investments lacking a readily available market quotation at least once during a trailing twelve-month period. The Valuation Committee determines fair values pursuant to a valuation policy approved by our Board and pursuant to a consistently applied valuation process. This valuation process is conducted at the end of each fiscal quarter, with at least 25% (based on fair value) of our valuation of portfolio companies lacking readily available market quotations subject to review by an independent valuation firm. We apply fair value to substantially all of our investments in accordance with Topic 820, Fair Value Measurement, of the Financial Accounting Standards Board’s, or FASB’s, Accounting Standards Codification as amended, or ASC, which establishes a framework used to measure fair value and requires disclosures for fair value measurements. We have categorized our investments carried at fair value, based on the priority of the valuation technique, into a three-level fair value hierarchy. Fair value is a market-based measure considered from the perspective of the market participant who holds the financial instrument rather than an entity specific measure. Therefore, when market assumptions are not readily available, our own assumptions are set to reflect those that we believe market participants would use in pricing the financial instrument at the measurement date. 

56

The availability of observable inputs can vary depending on the financial instrument and is affected by a wide variety of factors, including, for example, the type of product, whether the product is new, whether the product is traded on an active exchange or in the secondary market and the current market conditions. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. The three categories within the hierarchy are as follows:

Level 1 Quoted prices in active markets for identical assets and liabilities.

Level 2 Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities in active markets, quoted prices in markets that are not active and model-based valuation techniques for which all significant inputs are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation.

Income recognition

Interest on debt investments is accrued and included in income based on contractual rates applied to principal amounts outstanding. Interest income is determined using a method that results in a level rate of return on principal amounts outstanding. Generally, when a debt investment becomes 90 days or more past due, or if we otherwise do not expect to receive interest and principal repayments, the debt investment is placed on non-accrual status and the recognition of interest income may be discontinued. Interest payments received on non-accrual debt investments may be recognized as income, on a cash basis, or applied to principal depending upon management’s judgment at the time the debt investment is placed on non-accrual status. For the three months ended March 31, 2023 and 2022, we did not recognize any interest income from debt investments on non-accrual status. 

We receive a variety of fees from borrowers in the ordinary course of conducting our business, including advisory fees, commitment fees, amendment fees, non-utilization fees, success fees and prepayment fees. In a limited number of cases, we may also receive a non-refundable deposit earned upon the termination of a transaction. Debt investment origination fees, net of certain direct origination costs, are deferred, and along with unearned income, are amortized as a level yield adjustment over the respective term of the debt investment. All other income is recorded into income when earned. Fees for counterparty debt investment commitments with multiple debt investments are allocated to each debt investment based upon each debt investment’s relative fair value. When a debt investment is placed on non-accrual status, the amortization of the related fees and unearned income is discontinued until the debt investment is returned to accrual status.

Certain debt investment agreements also require the borrower to make an ETP that is accrued into income over the life of the debt investment to the extent such amounts are expected to be collected. We will generally cease accruing the income if there is insufficient value to support the accrual or if we do not expect the borrower to be able to pay all principal and interest due.

In connection with substantially all lending arrangements, we receive warrants to purchase shares of stock from the borrower. We record the warrants as assets at estimated fair value on the grant date using the Black-Scholes valuation model. We consider the warrants as loan fees and record them as unearned income on the grant date. The unearned income is recognized as interest income over the contractual life of the related debt investment in accordance with our income recognition policy. Subsequent to origination, the warrants are also measured at fair value using the Black-Scholes valuation model. Any adjustment to fair value is recorded through earnings as net unrealized gain or loss on investments. Gains and losses from the disposition of the warrants or stock acquired from the exercise of warrants are recognized as realized gains and losses on investments.

57

Realized gains or losses on the sale of investments, or upon the determination that an investment balance, or portion thereof, is not recoverable, are calculated using the specific identification method. We measure realized gains or losses by calculating the difference between the net proceeds from the repayment or sale and the amortized cost basis of the investment. Net change in unrealized appreciation or depreciation reflects the change in the fair values of our portfolio investments during the reporting period, including any reversal of previously recorded unrealized appreciation or depreciation, when gains or losses are realized.

Income taxes

We have elected to be treated as a RIC under Subchapter M of the Code and operate in a manner so as to qualify for the tax treatment applicable to RICs. In order to qualify as a RIC and to avoid the imposition of corporate-level U.S. federal income tax on the amounts we distribute to our stockholders, among other things, we are required to meet certain source of income and asset diversification requirements, and we must timely distribute dividends to our stockholders out of assets legally available for distribution each tax year of an amount generally equal to at least 90% of our investment company taxable income, as defined by the Code and determined without regard to any deduction for dividends paid. We, among other things, have made and intend to continue to make the requisite distributions to our stockholders, which will generally relieve us from incurring any material liability for U.S. federal income taxes.

Depending on the level of taxable income earned in a tax year, we may choose to carry forward taxable income in excess of current year distributions into the next tax year and incur a 4% excise tax on such income, as required. To the extent that we determine that our estimated current year annual taxable income will be in excess of estimated current year distributions, we will accrue excise tax, if any, on estimated excess taxable income as taxable income is earned.

We evaluate tax positions taken in the course of preparing our tax returns to determine whether the tax positions are “more-likely-than-not” to be sustained by the applicable tax authority in accordance with ASC Topic 740, Income Taxes, as modified by ASC Topic 946, Financial Services — Investment Companies. Tax benefits of positions not deemed to meet the more-likely-than-not threshold, or uncertain tax positions, are recorded as a tax expense in the current year. It is our policy to recognize accrued interest and penalties related to uncertain tax benefits in income tax expense. We had no material uncertain tax positions at March 31, 2023 and December 31, 2022.

Recent developments

In April 2023, we sold 272,303 shares of common stock under the 2021 Equity Distribution Agreement. For the same period, we received total accumulated net proceeds of approximately $3.1 million, including $0.1 million of offering expenses, from these sales.

IMV Inc. (“IMV”) (NASDAQ: IMV; TSX: IMV), announced on May 1, 2023 that the Nova Scotia Supreme Court has issued an initial order (the “Initial Order”) granting IMV and its subsidiaries protection under the Companies’ Creditors Arrangement Act (R.S.C., 1985, c. C-36) and IMV will seek the recognition of the Initial Order in the United States by filing a petition commencing proceedings under the Chapter 15 of the United States Bankruptcy Code.

58

Recently issued accounting pronouncement

In June 2022, the FASB issued Accounting Standards Update No. 2022-03, Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions, or ASU 2022-03. ASU 2022-03 clarifies the guidance when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of the security. The amendments in ASU 2022-03 are effective for public companies for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. We are currently assessing the impact of ASU 2022-03 on our consolidated financial statements.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

We are subject to financial market risks, including changes in interest rates. During the periods covered by our financial statements, the interest rates on the debt investments within our portfolio were primarily at floating rates. We expect that our debt investments in the future will primarily have floating interest rates. As of March 31, 2023 and December 31, 2022, 96% and 100%, respectively, of the outstanding principal amount of our debt investments bore interest at floating rates. New commitments to lend to our portfolio companies are typically based on the Prime Rate as published in The Wall Street Journal.

Based on our March 31, 2023 consolidated statement of assets and liabilities (without adjustment for potential changes in the credit market, credit quality, size and composition of assets on the consolidated statement of assets and liabilities or other business developments that could affect net income) and the base index rates at March 31, 2023, the following table shows the annual impact on the change in net assets resulting from operations of changes in interest rates, which assumes no changes in our investments and borrowings:

	Investment			Interest			Change in Net
Change in basis points	Income			Expense			Assets(1)
	(In thousands)
Up 300 basis points	$	19,440		$	456		$	18,984
Up 200 basis points	$	13,014		$	304		$	12,710
Up 100 basis points	$	6,556		$	152		$	6,404
Down 300 basis points	$	(18,326	)	$	(456	)	$	(17,870	)
Down 200 basis points	$	(12,740	)	$	(304	)	$	(12,436	)
Down 100 basis points	$	(6,389	)	$	(152	)	$	(6,237	)

(1) Excludes the impact of incentive fees based on Pre-Incentive Fee Net Investment Income.

While our 2027 Notes, our 2026 Notes, our 2019 Asset-Backed Notes and our 2022 Asset-Backed Notes bear interest at a fixed rate, our Credit Facilities have a floating interest rate provision. The Key Facility is subject to a floor of 0.25% per annum, based on a prime rate index which resets monthly and the NYL Facility is based on the three year USD mid-market swap rate plus a margin of between 3.55% and 5.15% with an interest rate floor, depending on the rating of such notes at the time of issuance. Any other credit facilities into which we enter in the future may have floating interest rate provisions. We have used hedging instruments in the past to protect us against interest rate fluctuations, and we may use them in the future. Such instruments may include caps, swaps, futures, options and forward contracts. While hedging activities may insulate us against adverse changes in interest rates, they may also limit our ability to participate in the benefits of lower interest rates with respect to the investments in our portfolio with fixed interest rates. Engaging in commodity interest transactions such as swap transactions or futures contracts on our behalf may cause our Advisor to fall within the definition of “commodity pool operator” under the Commodity Exchange Act (the “CEA”), and related Commodity Futures Trading Commission (the "CFTC"), regulations. On January 31, 2020, our Advisor claimed an exclusion from the definition of the term “commodity pool operator” under the CEA and the CFTC regulations in connection with its management of us and, therefore, is not subject to CFTC registration or regulation under the CEA as a commodity pool operator with respect to its management of us.

59

Because we currently fund, and expect to continue to fund, our investments with borrowings, our net income is dependent upon the difference between the rate at which we borrow funds and the rate at which we invest the funds borrowed. Accordingly, there can be no assurance that a significant change in market interest rates will not have a material adverse effect on our net income. In periods of rising interest rates, our cost of funds could increase, which would reduce our net investment income.

Inflation and Supply Chain Risk

Economic activity has continued to accelerate across sectors and regions. Nevertheless, due to global supply chain issues, geopolitical events, a rise in energy prices and strong consumer demand as economies continue to reopen, inflation is showing signs of acceleration in the U.S. and globally. Inflation is likely to continue in the near to medium-term, particularly in the U.S., with the possibility that monetary policy may tighten in response. Persistent inflationary pressures could affect our portfolio companies’ profit margins.

Item 4. Controls and Procedures

(a) Evaluation of disclosure controls and procedures

As of March 31, 2023, we, including our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a‑15(e) under the Exchange Act). Based on that evaluation, our management, including our Chief Executive Officer and Chief Financial Officer, concluded that our disclosure controls and procedures were effective and provided reasonable assurance that information required to be disclosed in our periodic SEC filings is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. However, in evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated can provide only reasonable assurance of achieving the desired control objectives, and management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of such possible controls and procedures.

(b) Changes in internal controls over financial reporting.

There have been no material changes in our internal control over financial reporting (as defined in Rules 13a‑15(f) and 15d‑15(f) under the Exchange Act) during our most recently completed fiscal quarter, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II

Item 1: Legal Proceedings.

We are not currently subject to any material legal proceedings, nor, to our knowledge, are any material legal proceeding threatened against us. From time to time, we may be a party to certain legal proceedings in the ordinary course of business, including proceedings relating to the enforcement of our rights under contracts with our portfolio companies. Our business is also subject to extensive regulation, which may result in regulatory proceedings against us. While the outcome of any such future legal or regulatory proceedings cannot be predicted with certainty, we do not expect that any such future proceedings will have a material effect upon our financial condition or results of operations. 

Item 1A: Risk Factors.

In addition to other information set forth in this quarterly report on Form 10-Q, you should carefully consider the factors set forth in “Item 1A Risk Factors” in our annual report on Form 10‑K for the year ended December 31, 2022, which could materially affect our business, financial condition and/or operating results. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially affect our business, financial condition and/or operating results. There have been no material changes during the three months ended March 31, 2023 to the risk factors set forth in “Item 1A. Risk Factors” of our annual report on Form 10-K for the year ended December 31, 2022, except as set forth below.

We, our Advisor, and our portfolio companies may maintain cash balances at financial institutions that exceed federally insured limits and may otherwise be materially affected by adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults or non-performance by financial institutions or transactional counterparties

Our cash and our Advisor’s cash is held in accounts at U.S. banking institutions that we believe are of high quality. Cash held by us, our Advisor and by our portfolio companies in non-interest-bearing and interest-bearing operating accounts may exceed the Federal Deposit Insurance Corporation (“FDIC”) insurance limits. If such banking institutions were to fail, we, our Advisor, or our portfolio companies could lose all or a portion of those amounts held in excess of such insurance limitations. In addition, actual events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems, which could adversely affect our, our Advisor’s and our portfolio companies’ business, financial condition, results of operations, or prospects.

Although we and our Advisor assess our and our portfolio companies’ banking relationships as we believe necessary or appropriate, our and our portfolio companies’ access to funding sources and other credit arrangements in amounts adequate to finance or capitalize our respective current and projected future business operations could be significantly impaired by factors that affect us, our Advisor or our portfolio companies, the financial institutions with which we, our Advisor or our portfolio companies have arrangements directly, or the financial services industry or economy in general. These factors could include, among others, events such as liquidity constraints or failures, the ability to perform obligations under various types of financial, credit or liquidity agreements or arrangements, disruptions or instability in the financial services industry or financial markets, or concerns or negative expectations about the prospects for companies in the financial services industry. These factors could involve financial institutions or financial services industry companies with which we, our Advisor or our portfolio companies have financial or business relationships, but could also include factors involving financial markets or the financial services industry generally.

In addition, investor concerns regarding the U.S. or international financial systems could result in less favorable commercial financing terms, including higher interest rates or costs and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it more difficult for us, our Advisor, or our portfolio companies to acquire financing on acceptable terms or at all.

60

Item 2: Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3: Defaults Upon Senior Securities

None.

Item 4: Mine Safety Disclosures

Not applicable

Item 5: Other Information

None.

Item 6: Exhibits

EXHIBIT INDEX

Exhibit  No.	Description
31.1*	Certifications by Chief Executive Officer pursuant to Exchange Act Rule 13a‑14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, as amended
31.2*	Certifications by Chief Financial Officer pursuant to Exchange Act Rule 13a‑14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, as amended
32.1*	Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, as amended
32.2*	Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, as amended
101.INS	Inline XBRL Instance Document (the Instance Document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)
101.SCH	Inline XBRL Taxonomy Extension Schema Document
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

*         Filed herewith

61

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Quarterly Report on Form 10‑Q to be signed on its behalf by the undersigned, thereunto duly authorized.

	HORIZON TECHNOLOGY FINANCE CORPORATION
Date: May 2, 2023	By:	/s/ Robert D. Pomeroy, Jr.
	Name:	Robert D. Pomeroy, Jr.
	Title:	Chief Executive Officer and Chairman of the Board
Date: May 2, 2023	By:	/s/ Daniel R. Trolio
	Name:	Daniel R. Trolio
	Title:	Chief Financial Officer

62

EX-31.1

EXHIBIT 31.1

CERTIFICATION PURSUANT TO EXCHANGE ACT

RULES 13a-14 AND 15d-14, AS ADOPTED PURSUANT

TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

CHIEF EXECUTIVE OFFICER CERTIFICATION

I, Robert D. Pomeroy, Jr., as Chief Executive Officer and Chairman of the Board of Horizon Technology Finance Corporation, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Horizon Technology Finance Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 2, 2023

By:	/s/ Robert D. Pomeroy, Jr.
	Chief Executive Officer and
	Chairman of the Board

EX-31.2

EXHIBIT 31.2

CERTIFICATION PURSUANT TO EXCHANGE ACT

RULES 13a-14 AND 15d-14, AS ADOPTED PURSUANT

TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

CHIEF FINANCIAL OFFICER CERTIFICATION

I, Daniel R. Trolio, as Chief Financial Officer of Horizon Technology Finance Corporation, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Horizon Technology Finance Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 2, 2023

By:	/s/ Daniel R. Trolio
	Daniel R. Trolio
	Chief Financial Officer

EX-32.1

EXHIBIT 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

Pursuant to

Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350)

In connection with the Quarterly Report on Form 10-Q of Horizon Technology Finance Corporation (the “Company”) for the quarterly period ended March 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Robert D. Pomeroy, Jr., as Chief Executive Officer and Chairman of the Board, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of Sarbanes-Oxley Act of 2002, as amended, that to my knowledge:

(1)  The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2)  The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Robert D. Pomeroy, Jr.
Name:	Robert D. Pomeroy, Jr.
Title:	Chief Executive Officer and Chairman of the Board
Date:	May 2, 2023

EX-32.2

EXHIBIT 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

Pursuant to

Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350)

In connection with the Quarterly Report on Form 10-Q of Horizon Technology Finance Corporation (the “Company”) for the quarterly period ended March 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Daniel R. Trolio, as Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of Sarbanes-Oxley Act of 2002, as amended, that to my knowledge:

(1)  The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2)  The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Daniel R. Trolio
Name:	Daniel R. Trolio
Title:	Chief Financial Officer
Date:	May 2, 2023

XML

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2023	May 02, 2023
Document Information [Line Items]
Entity Central Index Key	0001487428
Entity Registrant Name	Horizon Technology Finance Corp
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2023
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2023
Document Transition Report	false
Entity File Number	814-00802
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	27-2114934
Entity Address, Address Line One	312 Farmington Avenue
Entity Address, City or Town	Farmington
Entity Address, State or Province	CT
Entity Address, Postal Zip Code	06032
City Area Code	860
Local Phone Number	676‑8654
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		28,656,554
The 6.25% Notes due 2027 [Member]
Document Information [Line Items]
Title of 12(b) Security	6.25% Notes due 2027
Trading Symbol	HTFC
Security Exchange Name	NYSE
The 4.875% Notes due 2026 [Member]
Document Information [Line Items]
Title of 12(b) Security	4.875% Notes due 2026
Trading Symbol	HTFB
Security Exchange Name	NYSE
Common Stock [Member]
Document Information [Line Items]
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	HRZN
Security Exchange Name	NASDAQ

XML

Consolidated Statements of Assets and Liabilities (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Assets
Investments at fair value	$ 715,312	$ 720,026
Cash	19,844	20,612
Investments in money market funds	23,698	7,066
Restricted investments in money market funds	2,987	2,788
Interest receivable	13,843	13,573
Other assets	2,554	2,761
Total assets	778,238	766,826
Liabilities
Borrowings (Note 7)	439,645	434,078
Distributions payable	9,365	9,159
Base management fee payable (Note 3)	1,059	1,065
Incentive fee payable (Note 3)	2,978	1,392
Other accrued expenses	3,508	2,684
Total liabilities	456,555	448,378
Commitments and contingencies (Notes 3 and 8)
Net assets
Preferred stock, par value $0.001 per share, 1,000,000 shares authorized, zero shares issued and outstanding as of March 31, 2023 and December 31, 2022	0	0
Common stock, par value $0.001 per share, 100,000,000 shares authorized, 28,544,822 and 27,920,838 shares issued and 28,377,357 and 27,753,373 shares outstanding as of March 31, 2023 and December 31, 2022, respectively	30	29
Paid-in capital in excess of par	393,312	385,921
Distributable earnings (loss)	(71,659)	(67,502)
Total net assets	321,683	318,448
Total liabilities and net assets	$ 778,238	$ 766,826
Net asset value per common share (in dollars per share)	$ 11.34	$ 11.47
Investment, Unaffiliated Issuer [Member]
Assets
Investments at fair value	$ 714,466	$ 720,026
Investment, Affiliated Issuer, Noncontrolled [Member]
Assets
Investments at fair value	$ 846	$ 0

XML

Consolidated Statements of Assets and Liabilities (Current Period Unaudited) (Parentheticals) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Investments at cost	$ 724,162	$ 721,248
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	1,000,000	1,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares oustanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	28,544,822	27,920,838
Common stock, shares outstanding (in shares)	28,377,357	27,753,373
Investment, Unaffiliated Issuer [Member]
Investments at cost	$ 724,162	$ 721,248
Investment, Affiliated Issuer, Noncontrolled [Member]
Investments at cost	$ 0	$ 0

XML

Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Investment income
Total investment income	$ 28,037	$ 14,204
Expenses
Interest expense	7,120	3,424
Base management fee (Note 3)	3,201	2,244
Performance based incentive fee (Note 3)	2,978	1,424
Administrative fee (Note 3)	440	362
Professional fees	658	577
General and administrative	445	344
Total expenses	14,842	8,375
Net investment income before excise tax	13,195	5,829
Provision for excise tax	184	100
Net investment income	13,011	5,729
Net realized and unrealized loss
Net realized (loss) gain on investments	(168)	30
Net unrealized (depreciation) appreciation on investments	(7,537)	(2,237)
Net realized and unrealized loss	(7,705)	(2,207)
Net increase in net assets resulting from operations	$ 5,306	$ 3,522
Net investment income per common share (in dollars per share)	$ 0.46	$ 0.26
Net increase in net assets resulting from operations per common share (in dollars per share)	0.19	0.16
Distributions declared per share (in dollars per share)	$ 0.33	$ 0.30
Weighted average shares outstanding (in shares)	28,227,100	21,904,160
Investment, Unaffiliated Issuer [Member]
Investment income
Interest income on non-affiliate investments	$ 27,399	$ 13,853
Fee income on non-affiliate investments	638	351
Net realized and unrealized loss
Net realized (loss) gain on investments	(168)	30
Net unrealized (depreciation) appreciation on investments	(8,383)	(2,287)
Investment, Affiliated Issuer, Noncontrolled [Member]
Net realized and unrealized loss
Net realized (loss) gain on investments	0
Net unrealized (depreciation) appreciation on investments	846	0
Investment, Affiliated Issuer, Controlled [Member]
Net realized and unrealized loss
Net realized (loss) gain on investments		0
Net unrealized (depreciation) appreciation on investments	$ 0	$ 50

XML

Consolidated Statements of Changes in Net Assets (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Common Stock Outstanding [Member]
Balance (in shares)	27,753,373	21,217,460
Issuance of common stock, net of offering costs (in shares)	605,848	2,750,171
Issuance of common stock under dividend reinvestment plan (in shares)	18,136	9,506
Balance (in shares)	28,377,357	23,977,137
Common Stock [Member]
Balance	$ 29	$ 22
Issuance of common stock, net of offering costs	1	3
Net investment income, net of excise tax	0	0
Net realized gain (loss) on investments	0	0
Net unrealized depreciation on investments	0	0
Issuance of common stock under dividend reinvestment plan	0	0
Distributions declared	0	0
Balance	30	25
Additional Paid-in Capital [Member]
Balance	385,921	301,359
Issuance of common stock, net of offering costs	7,173	38,184
Net investment income, net of excise tax	0	0
Net realized gain (loss) on investments	0	0
Net unrealized depreciation on investments	0	0
Issuance of common stock under dividend reinvestment plan	218	145
Distributions declared	0	0
Balance	393,312	339,688
Retained Earnings [Member]
Balance	(67,502)	(56,046)
Issuance of common stock, net of offering costs	0	0
Net investment income, net of excise tax	13,011	5,729
Net realized gain (loss) on investments	(168)	30
Net unrealized depreciation on investments	(7,537)	(2,237)
Issuance of common stock under dividend reinvestment plan	0	0
Distributions declared	(9,463)	(7,200)
Balance	(71,659)	(59,724)
Balance	318,448	245,335
Issuance of common stock, net of offering costs	7,174	38,187
Net investment income, net of excise tax	13,011	5,729
Net realized gain (loss) on investments	(168)	30
Net unrealized depreciation on investments	(7,537)	(2,237)
Issuance of common stock under dividend reinvestment plan	218	145
Distributions declared	(9,463)	(7,200)
Balance	$ 321,683	$ 279,989

XML

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flows from operating activities:
Net increase in net assets resulting from operations	$ 5,306	$ 3,522
Adjustments to reconcile net increase in net assets resulting from operations to net cash provided by (used in) operating activities:
Amortization of debt issuance costs	478	336
Net realized loss (gain) on investments	168	(30)
Net unrealized depreciation on investments	7,537	2,237
Purchase of investments	(47,008)	(94,485)
Principal payments received on investments	39,756	14,145
Payment-in-kind interest on investments	(1,204)	0
Proceeds from sale of investments	6,520	21,280
Changes in assets and liabilities:
Decrease (increase) in interest receivable	840	(866)
Increase in end-of-term payments	(1,017)	(1,285)
Decrease in unearned income	(1,148)	(81)
Decrease in other assets	98	652
Increase (decrease) in other accrued expenses	824	(274)
(Decrease) increase in base management fee payable	(6)	79
Increase (decrease) in incentive fee payable	1,586	(591)
Net cash provided by (used in) operating activities	12,730	(55,361)
Cash flows from financing activities:
Proceeds from issuance of common stock, net of offering costs	7,174	38,187
Advances on Credit Facilities	10,000	25,000
Repayment of Credit Facilities	0	(20,000)
Debt issuance costs	(19)	(550)
Distributions paid	(9,039)	(6,227)
Net cash provided by financing activities	3,333	24,058
Net increase (decrease) in cash, cash equivalents and restricted cash	16,063	(31,303)
Cash, cash equivalents and restricted cash:
Beginning of period	30,466	47,281
End of period	46,529	15,978
Supplemental disclosure of cash flow information:
Cash paid for interest	6,623	3,044
Supplemental non-cash investing and financing activities:
Warrant investments received and recorded as unearned income	141	1,174
Distributions payable	9,365	7,193
End-of-term payments receivable	10,799	6,522
Non-cash income	3,944	1,424
Cash	19,844	12,452
Investments in money market funds	23,698	2,011
Restricted investments in money market funds	2,987	1,515
Total cash, cash equivalents and restricted cash	46,529	15,978
Asset-backed Notes 2019 [Member]
Cash flows from financing activities:
Repayment of notes	$ (4,783)	$ (12,352)

XML

Consolidated Schedule of Investments (Unaudited)

3 Months Ended

Mar. 31, 2023

Notes to Financial Statements

Schedule of Investments [Text Block]

March 31, 2023

(Dollars in thousands)

Portfolio Company (1)(3)	Sector	Type of Investment (7)	Cash Rate (4)			Index	Margin			Floor			Ceiling			ETP (10)			Maturity Date	Principal Amount		Cost of Investments (6)(9)		Fair Value (9)
Non-Affiliate Investments — 222.1% (8)
Non-Affiliate Debt Investments — 212.8% (8)
Non-Affiliate Debt Investments — Life Science — 95.7% (8)
Avalo Therapeutics, Inc. (2)(5)(12)	Biotechnology	Term Loan		14.25	%	Prime		6.25	%		9.50	%		-			3.00	%	January 1, 2025	$	2,913	$	2,860	$	2,779
		Term Loan		14.25	%	Prime		6.25	%		9.50	%		-			3.00	%	January 1, 2025		2,885		2,832		2,752
		Term Loan		14.25	%	Prime		6.25	%		9.50	%		-			3.00	%	January 1, 2025		1,442		1,416		1,375
		Term Loan		14.25	%	Prime		6.25	%		9.50	%		-			3.00	%	February 1, 2025		2,885		2,829		2,749
		Term Loan		14.25	%	Prime		6.25	%		9.50	%		-			3.00	%	February 1, 2025		2,885		2,829		2,749
		Term Loan		14.25	%	Prime		6.25	%		9.50	%		-			3.00	%	April 1, 2025		1,442		1,412		1,370
		Term Loan		14.25	%	Prime		6.25	%		9.50	%		-			3.00	%	April 1, 2025		1,442		1,412		1,370
Castle Creek Biosciences, Inc. (2)(12)	Biotechnology	Term Loan		12.88	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		5,000		4,895		4,895
		Term Loan		12.88	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		5,000		4,967		4,967
		Term Loan		12.88	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		3,000		2,977		2,977
		Term Loan		12.88	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		5,000		4,967		4,967
		Term Loan		12.88	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		5,000		4,970		4,970
		Term Loan		12.88	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		3,000		2,980		2,980
Emalex Biosciences, Inc. (2)(12)	Biotechnology	Term Loan		12.57	%	Libor		4.72	%		9.75	%		-			5.00	%	June 1, 2024		1,979		1,965		1,965
		Term Loan		12.57	%	Libor		4.72	%		9.75	%		-			5.00	%	June 1, 2024		1,979		1,966		1,966
		Term Loan		12.57	%	Libor		4.72	%		9.75	%		-			5.00	%	November 1, 2025		5,000		4,930		4,930
		Term Loan		12.57	%	Libor		4.72	%		9.75	%		-			5.00	%	May 1, 2026		5,000		4,921		4,921
Evelo Biosciences, Inc. (2)(5)(12)	Biotechnology	Term Loan		12.25	%	Prime		4.25	%		11.00	%		-			4.25	%	January 1, 2028		10,000		9,880		9,880
		Term Loan		12.25	%	Prime		4.25	%		11.00	%		-			4.25	%	January 1, 2028		15,000		14,819		14,819
		Term Loan		12.25	%	Prime		4.25	%		11.00	%		-			4.25	%	January 1, 2028		6,000		5,928		5,928
		Term Loan		12.25	%	Prime		4.25	%		11.00	%		-			4.25	%	January 1, 2028		6,000		5,928		5,928
		Term Loan		12.25	%	Prime		4.25	%		11.00	%		-			4.25	%	January 1, 2028		4,000		3,952		3,952
		Term Loan		12.25	%	Prime		4.25	%		11.00	%		-			4.25	%	January 1, 2028		4,000		3,952		3,952
Greenlight Biosciences, Inc. (2)(5)(12)	Biotechnology	Term Loan		13.75	%	Prime		5.75	%		9.00	%		-			3.00	%	July 1, 2025		4,500		4,371		4,352
		Term Loan		13.75	%	Prime		5.75	%		9.00	%		-			3.00	%	July 1, 2025		2,250		2,187		2,177
IMV Inc. (2)(5)(12)	Biotechnology	Term Loan		13.75	%	Prime		5.75	%		9.00	%		-			5.00	%	July 1, 2025		5,000		4,951		4,759
		Term Loan		13.75	%	Prime		5.75	%		9.00	%		-			5.00	%	July 1, 2025		2,500		2,476		2,380
		Term Loan		13.75	%	Prime		5.75	%		9.00	%		-			5.00	%	January 1, 2026		5,000		4,953		4,761
		Term Loan		13.75	%	Prime		5.75	%		9.00	%		-			5.00	%	January 1, 2026		5,000		4,953		4,761
KSQ Therapeutics, Inc. (2) (12)	Biotechnology	Term Loan		12.75	%	Prime		4.75	%		8.50	%		-			5.50	%	May 1, 2027		6,250		6,082		6,082
		Term Loan		12.75	%	Prime		4.75	%		8.50	%		-			5.50	%	May 1, 2027		6,250		6,182		6,182
Native Microbials, Inc (2) (12)	Biotechnology	Term Loan		13.25	%	Prime		5.25	%		8.50	%		-			5.00	%	November 1, 2026		3,750		3,707		3,707
		Term Loan		13.25	%	Prime		5.25	%		8.50	%		-			5.00	%	November 1, 2026		2,500		2,472		2,472
PDS Biotechnology Corporation (2)(5)(12)	Biotechnology	Term Loan		13.75	%	Prime		5.75	%		9.75	%		-			3.75	%	September 1, 2026		10,000		9,714		9,714
		Term Loan		13.75	%	Prime		5.75	%		9.75	%		-			3.75	%	September 1, 2026		3,750		3,702		3,702
		Term Loan		13.75	%	Prime		5.75	%		9.75	%		-			3.75	%	September 1, 2026		3,750		3,702		3,702
Provivi, Inc. (2)(12)	Biotechnology	Term Loan		13.17	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		4,667		4,606		4,606
		Term Loan		13.17	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		4,667		4,606		4,606
		Term Loan		13.17	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		2,333		2,287		2,287
		Term Loan		13.17	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		2,333		2,287		2,287
		Term Loan		13.17	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		2,333		2,282		2,282
		Term Loan		13.17	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		2,333		2,282		2,282

See Notes to Consolidated Financial Statements

Consolidated Schedule of Investments (Unaudited)

March 31, 2023

(Dollars in thousands)

Portfolio Company (1)(3)	Sector	Type of Investment (7)	Cash Rate (4)			Index	Margin			Floor			Ceiling		ETP (10)			Maturity Date	Principal Amount		Cost of Investments (6)(9)		Fair Value (9)
Stealth Biotherapeutics Inc. (2)(12)	Biotechnology	Term Loan		13.50	%	Prime		5.50	%		8.75	%		-		6.00	%	October 1, 2025		5,000		4,922		4,922
		Term Loan		13.50	%	Prime		5.50	%		8.75	%		-		6.00	%	October 1, 2025		2,500		2,461		2,461
Aerobiotix, LLC (2)(12)	Medical Device	Term Loan		14.25	%	Prime		6.25	%		9.50	%		-		6.00	%	April 1, 2026		2,500		2,467		2,361
		Term Loan		14.25	%	Prime		6.25	%		9.50	%		-		6.00	%	April 1, 2026		2,500		2,467		2,361
Ceribell, Inc. (2)(12)	Medical Device	Term Loan		11.25	%	Prime		3.50	%		8.25	%		-		5.50	%	October 1, 2024		5,000		4,977		4,977
		Term Loan		11.25	%	Prime		3.50	%		8.25	%		-		5.50	%	October 1, 2024		5,000		4,977		4,977
		Term Loan		11.25	%	Prime		3.50	%		8.25	%		-		5.50	%	October 1, 2024		2,500		2,481		2,481
		Term Loan		11.25	%	Prime		3.50	%		8.25	%		-		5.50	%	October 1, 2024		2,500		2,481		2,481
Cognoa, Inc. (2)(12)	Medical Device	Term Loan		13.50	%	Prime		5.50	%		8.75	%		-		6.00	%	August 1, 2026		5,000		4,940		4,940
		Term Loan		13.50	%	Prime		5.50	%		8.75	%		-		6.00	%	August 1, 2026		2,500		2,470		2,470
Conventus Orthopaedics, Inc. (2)(12)	Medical Device	Term Loan		12.67	%	Libor		8.00	%		9.25	%		-		10.36	%	July 1, 2025		3,960		3,904		3,904
		Term Loan		12.67	%	Libor		8.00	%		9.25	%		-		10.36	%	July 1, 2025		3,960		3,904		3,904
Corinth Medtech, Inc. (2)(12)	Medical Device	Term Loan		13.00	% (11)	Prime		5.25	%		8.50	%		-		20.00	%	June 30, 2023		2,528		2,528		2,528
		Term Loan		13.00	% (11)	Prime		5.25	%		8.50	%		-		20.00	%	June 30, 2023		2,528		2,528		2,528
		Term Loan		13.00	% (11)	Prime		5.25	%		8.50	%		-		50.00	%	June 30, 2023		200		200		200
CSA Medical, Inc. (2)(12)	Medical Device	Term Loan		12.87	%	Libor		8.20	%		10.00	%		-		5.00	%	January 1, 2024		1,250		1,239		1,239
		Term Loan		12.87	%	Libor		8.20	%		10.00	%		-		5.00	%	January 1, 2024		83		83		83
		Term Loan		12.87	%	Libor		8.20	%		10.00	%		-		5.00	%	March 1, 2024		1,600		1,587		1,587
InfoBionic, Inc. (2)(12)	Medical Device	Term Loan		14.00	%	Prime		6.25	%		9.50	%		-		4.00	%	October 1, 2024		2,771		2,715		2,715
		Term Loan		14.00	%	Prime		6.25	%		9.50	%		-		4.00	%	June 1, 2025		1,000		977		977
Magnolia Medical Technologies, Inc. (2)(12)	Medical Device	Term Loan		12.75	%	Prime		5.00	%		9.75	%		-		4.00	%	March 1, 2025		5,000		4,946		4,946
		Term Loan		12.75	%	Prime		5.00	%		9.75	%		-		4.00	%	March 1, 2025		5,000		4,946		4,946
		Term Loan		12.75	%	Prime		5.00	%		9.75	%		-		4.00	%	March 1, 2025		5,000		4,940		4,940
		Term Loan		12.75	%	Prime		5.00	%		9.75	%		-		4.00	%	March 1, 2025		5,000		4,941		4,941
		Term Loan		12.75	%	Prime		5.00	%		9.75	%		-		4.00	%	January 1, 2027		5,000		4,920		4,920
		Term Loan		12.75	%	Prime		5.00	%		9.75	%		-		4.00	%	January 1, 2027		5,000		4,920		4,920
Robin Healthcare, Inc. (2)(12)	Medical Device	Term Loan		13.50	%	Prime		5.50	%		10.25	%		-		4.00	%	November 1, 2026		3,500		3,413		3,413
		Term Loan		13.50	%	Prime		5.50	%		10.25	%		-		4.00	%	November 1, 2026		3,500		3,463		3,463
Scientia Vascular, Inc. (2)(12)	Medical Device	Term Loan		12.50	%	Prime		4.75	%		8.50	%		-		5.00	%	January 1, 2027		3,750		3,601		3,601
		Term Loan		12.50	%	Prime		4.75	%		8.50	%		-		5.00	%	January 1, 2027		3,750		3,710		3,710
Sonex Health, Inc. (2)(12)	Medical Device	Term Loan		14.25	%	Prime		6.50	%		9.75	%		-		8.00	%	June 1, 2025		2,500		2,478		2,478
		Term Loan		14.25	%	Prime		6.50	%		9.75	%		-		8.00	%	June 1, 2025		2,500		2,478		2,478
		Term Loan		14.25	%	Prime		6.50	%		9.75	%		-		8.00	%	June 1, 2025		2,500		2,478		2,478
		Term Loan		14.25	%	Prime		6.50	%		9.75	%		-		8.00	%	April 1, 2026		2,500		2,459		2,459
		Term Loan		14.25	%	Prime		6.50	%		9.75	%		-		8.00	%	May 1, 2026		2,500		2,458		2,458
Spineology, Inc. (2)(12)	Medical Device	Term Loan		15.00	%	Prime		7.00	%		10.25	%		-		1.00	%	October 1, 2025		5,000		4,969		4,969
		Term Loan		15.00	%	Prime		7.00	%		10.25	%		-		1.00	%	April 1, 2026		2,500		2,483		2,483

See Notes to Consolidated Financial Statements

Consolidated Schedule of Investments (Unaudited)

March 31, 2023

(Dollars in thousands)

Portfolio Company (1)(3)	Sector	Type of Investment (7)	Cash Rate (4)			Index	Margin			Floor			Ceiling		ETP (10)			Maturity Date	Principal Amount		Cost of Investments (6)(9)		Fair Value (9)
Swift Health Systems Inc. (2)(12)	Medical Device	Term Loan		13.00	%	Prime		5.25	%		9.00	%		-		5.00	%	July 1, 2027		3,500		3,457		3,457
		Term Loan		13.00	%	Prime		5.25	%		9.00	%		-		5.00	%	July 1, 2027		3,500		3,457		3,457
		Term Loan		13.25	%	Prime		5.25	%		9.00	%		-		5.00	%	July 1, 2027		3,500		3,447		3,447
		Term Loan		13.25	%	Prime		5.25	%		9.00	%		-		5.00	%	July 1, 2027		3,500		3,447		3,447
Total Non-Affiliate Debt Investments — Life Science																						309,108		307,749
Non-Affiliate Debt Investments — Sustainability — 25.8% (8)
Aerofarms, Inc. (2)(12)	Other Sustainability	Term Loan		14.75	%	Prime		6.75	%		10.00	%		-		3.00	%	April 1, 2026		3,750		3,704		3,585
		Term Loan		14.75	%	Prime		6.75	%		10.00	%		-		3.00	%	April 1, 2026		3,750		3,704		3,585
Nexii Building Solutions, Inc. (2)(12)	Other Sustainability	Term Loan		15.00	%	Prime		7.00	%		10.25	%		-		2.50	%	September 1, 2025		7,500		7,383		7,245
		Term Loan		15.00	%	Prime		7.00	%		10.25	%		-		2.50	%	September 1, 2025		7,500		7,383		7,245
		Term Loan		15.00	%	Prime		7.00	%		10.25	%		-		2.50	%	September 1, 2025		7,500		7,383		7,245
		Term Loan		15.00	%	Prime		7.00	%		10.25	%		-		2.50	%	July 1, 2026		5,000		4,912		4,820
		Term Loan		15.00	%	Prime		7.00	%		10.25	%		-		2.50	%	July 1, 2026		5,000		4,912		4,820
Soli Organic, Inc. (2)(12)	Other Sustainability	Term Loan		14.75	%	Prime		6.75	%		10.00	%		-		2.75	%	April 1, 2026		5,000		4,935		4,935
		Term Loan		14.75	%	Prime		6.75	%		10.00	%		-		2.75	%	April 1, 2026		2,500		2,467		2,467
		Term Loan		14.75	%	Prime		6.75	%		10.00	%		-		2.75	%	May 1, 2026		5,000		4,932		4,932
		Term Loan		14.75	%	Prime		6.75	%		10.00	%		-		2.75	%	May 1, 2026		2,500		2,466		2,466
		Term Loan		13.50	%	Prime		5.50	%		11.75	%		-		2.75	%	December 1, 2026		5,000		4,909		4,909
		Term Loan		13.50	%	Prime		5.50	%		11.75	%		-		2.75	%	December 1, 2026		2,500		2,454		2,454
Temperpack Technologies, Inc. (2)(12)	Other Sustainability	Term Loan		14.75	%	Prime		6.75	%		10.00	%		-		2.50	%	June 1, 2025		3,750		3,706		3,706
		Term Loan		14.75	%	Prime		6.75	%		10.00	%		-		2.50	%	June 1, 2025		3,750		3,720		3,720
		Term Loan		14.75	%	Prime		6.75	%		10.00	%		-		2.50	%	October 1, 2025		7,500		7,431		7,431
		Term Loan		14.75	%	Prime		6.75	%		10.00	%		-		2.50	%	October 1, 2025		3,750		3,715		3,715
		Term Loan		14.75	%	Prime		6.75	%		10.00	%		-		2.50	%	October 1, 2025		3,750		3,715		3,715
Total Non-Affiliate Debt Investments — Sustainability																						83,831		82,995
Non-Affiliate Debt Investments — Technology — 83.2% (8)
Axiom Space, Inc. (2)(12)	Communications	Term Loan		13.75	%	Prime		6.00	%		9.25	%		-		2.50	%	June 1, 2026		7,500		7,459		7,459
		Term Loan		13.75	%	Prime		6.00	%		9.25	%		-		2.50	%	June 1, 2026		7,500		7,459		7,459
		Term Loan		13.75	%	Prime		6.00	%		9.25	%		-		2.50	%	June 1, 2026		7,500		7,459		7,459
Better Place Forests Co. (12)(13)	Consumer-related Technologies	Term Loan		14.25	%	Prime		6.25	%		9.50	%		-		1.85	%	July 1, 2025		5,000		4,951		3,467
		Term Loan		14.25	%	Prime		6.25	%		9.50	%		-		1.85	%	October 1, 2025		2,500		2,474		1,733
CAMP NYC, Inc. (2)(12)	Consumer-related Technologies	Term Loan		15.25	%	Prime		7.25	%		10.50	%		-		3.00	%	May 1, 2026		3,500		3,464		3,464
Clara Foods Co. (2)(12)	Consumer-related Technologies	Term Loan		13.50	%	Prime		5.75	%		9.00	%		-		5.50	%	August 1, 2025		2,333		2,318		2,318
		Term Loan		13.50	%	Prime		5.75	%		9.00	%		-		5.50	%	August 1, 2025		2,333		2,318		2,318

See Notes to Consolidated Financial Statements

Consolidated Schedule of Investments (Unaudited)

March 31, 2023

(Dollars in thousands)

Portfolio Company (1)(3)	Sector	Type of Investment (7)	Cash Rate (4)			Index	Margin			Floor			Ceiling			ETP (10)			Maturity Date	Principal Amount		Cost of Investments (6)(9)		Fair Value (9)
Divergent Technologies, Inc. (2)(12)	Consumer-related Technologies	Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		3,750		3,520		3,520
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		1,250		1,239		1,239
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		3,750		3,717		3,717
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		1,250		1,239		1,239
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		3,750		3,717		3,717
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		1,250		1,239		1,239
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	January 1, 2028		3,750		3,701		3,701
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	January 1, 2028		3,750		3,701		3,701
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	April 1, 2028		3,750		3,698		3,698
Havenly, Inc. (2)(12)	Consumer-related Technologies	Term Loan		13.00	%	Prime		5.00	%		5.00	%		-			4.00	%	March 1, 2027		2,000		1,165		1,165
		Term Loan		13.00	%	Prime		5.00	%		5.00	%		-			4.00	%	March 1, 2027		3,000		1,748		1,748
		Term Loan		11.50	%	Prime		3.50	%		10.50	%		-			7.78	%	February 1, 2028		2,813		2,813		2,813
		Term Loan		11.50	%	Prime		3.50	%		10.50	%		-			7.78	%	February 1, 2028		2,813		2,813		2,813
Interior Define, Inc. (2)(12)(13)	Consumer-related Technologies	Term Loan		14.50	%	Prime		6.50	%		9.75	%		-			4.00	%	January 1, 2026		3,246		3,162		—
		Term Loan		14.50	%	Prime		6.50	%		9.75	%		-			4.00	%	January 1, 2026		2,963		2,886		—
Lyrical Foods, Inc. (2)(12)	Consumer-related Technologies	Term Loan		10.50	%	Prime		2.50	%		8.00	%		-			-		September 1, 2027		2,598		2,586		2,330
MyForest Foods Co. (2)(12)	Consumer-related Technologies	Term Loan		14.75	%	Prime		6.75	%		10.00	%		-			3.00	%	October 1, 2025		5,000		4,961		4,961
		Term Loan		14.75	%	Prime		6.75	%		10.00	%		-			3.00	%	October 1, 2025		2,500		2,480		2,480
NextCar Holding Company, Inc. (2)(12)	Consumer-related Technologies	Term Loan		13.50	% (11)	Prime		5.75	%		9.00	%		-			5.25	%	October 31, 2023		5,169		5,121		4,883
		Term Loan		13.50	% (11)	Prime		5.75	%		9.00	%		-			5.25	%	October 31, 2023		2,067		2,050		1,955
		Term Loan		13.50	% (11)	Prime		5.75	%		9.00	%		-			5.25	%	October 31, 2023		2,584		2,564		2,446
		Term Loan		13.50	% (11)	Prime		5.75	%		9.00	%		-			5.25	%	October 31, 2023		3,101		3,076		2,934
		Term Loan		13.50	% (11)	Prime		5.75	%		9.00	%		-			5.25	%	October 31, 2023		2,584		2,548		2,430
		Term Loan		13.50	% (11)	Prime		5.75	%		9.00	%		-			5.25	%	October 31, 2023		2,584		2,548		2,430
		Term Loan		13.50	% (11)	Prime		5.75	%		9.00	%		-			5.25	%	October 31, 2023		5,169		5,093		4,859
		Term Loan		13.50	% (11)	Prime		5.75	%		9.00	%		-			5.25	%	October 31, 2023		2,584		2,545		2,428
Optoro, Inc. (2)(12)	Consumer-related Technologies	Term Loan		14.00	%	Prime		6.25	%		9.50	%		-			4.00	%	August 1, 2027		2,500		2,355		2,355
Primary Kids, Inc. (2)(12)	Consumer-related Technologies	Term Loan		15.00	%	Prime		7.25	%		10.50	%		-			3.00	%	March 1, 2025		2,300		2,277		2,277
		Term Loan		15.00	%	Prime		7.25	%		10.50	%		-			3.00	%	March 1, 2025		2,300		2,277		2,277
		Term Loan		15.00	%	Prime		7.25	%		10.50	%		-			3.00	%	September 1, 2025		2,900		2,870		2,870
Unagi, Inc. (2)(12)	Consumer-related Technologies	Term Loan		15.75	% (11)	Prime		7.75	%		11.00	%		-			-		May 1, 2027		1,065		1,041		1,041
		Term Loan		15.75	% (11)	Prime		7.75	%		11.00	%		-			-		May 1, 2027		533		520		520
		Term Loan		15.75	% (11)	Prime		7.75	%		11.00	%		-			-		May 1, 2027		533		521		521
Liqid, Inc. (2)(12)	Networking	Term Loan		14.00	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		2,833		2,793		2,793
		Term Loan		14.00	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		2,833		2,793		2,793
		Term Loan		14.00	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		1,417		1,395		1,395
		Term Loan		14.00	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		1,417		1,395		1,395
		Term Loan		14.00	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		1,417		1,371		1,371
BriteCore Holdings, Inc. (2)(12)	Software	Term Loan		14.50	%	Prime		6.75	%		10.00	%		-			5.00	%	March 1, 2026		2,500		2,488		2,488
		Term Loan		14.50	%	Prime		6.75	%		10.00	%		-			5.00	%	March 1, 2026		2,500		2,488		2,488
		Term Loan		14.50	%	Prime		6.75	%		10.00	%		-			3.00	%	March 1, 2027		2,500		2,467		2,467
		Term Loan		14.50	%	Prime		6.75	%		10.00	%		-			3.00	%	March 1, 2027		2,500		2,467		2,467
Decisyon, Inc. (12)	Software	Term Loan		17.43	%	Prime		9.43	%		12.68	%		-			50.43	%	December 31, 2022		3,284		3,284		2,750

See Notes to Consolidated Financial Statements

Consolidated Schedule of Investments (Unaudited)

March 31, 2023

(Dollars in thousands)

Portfolio Company (1)(3)	Sector	Type of Investment (7)	Cash Rate (4)			Index	Margin			Floor			Ceiling			ETP (10)			Maturity Date	Principal Amount		Cost of Investments (6)(9)		Fair Value (9)
Dropoff, Inc. (2)(12)	Software	Term Loan		14.50	%	Prime		6.50	%		9.75	%		-			3.50	%	April 1, 2026		6,500		6,359		6,359
		Term Loan		14.50	%	Prime		6.50	%		9.75	%		-			3.50	%	April 1, 2026		6,000		5,869		5,869
		Term Loan		14.50	%	Prime		6.50	%		9.75	%		-			3.50	%	August 1, 2026		2,500		2,442		2,442
Engage3, LLC (2)(12)	Software	Term Loan		14.00	%	Prime		6.25	%		9.75	%		-			4.50	%	July 1, 2027		3,750		3,680		3,680
		Term Loan		14.00	%	Prime		6.25	%		9.75	%		-			4.50	%	July 1, 2027		3,750		3,720		3,720
Groundspeed Analytics, Inc. (2)(12)	Software	Term Loan		13.50	%	Prime		5.50	%		11.00	%		18.00	%		3.00	%	December 1, 2026		5,000		4,802		4,802
		Term Loan		13.50	%	Prime		5.50	%		11.00	%		18.00	%		3.00	%	December 1, 2026		5,000		4,953		4,953
		Convertible Note		15.00	%														September 10,2024		500		500		500
Kodiak Robotics, Inc. (2)(12)	Software	Term Loan		13.50	%	Prime		5.50	%		10.25	%		-			4.00	%	April 1, 2026		10,000		9,843		9,843
		Term Loan		13.50	%	Prime		5.50	%		10.25	%		-			4.00	%	April 1, 2026		10,000		9,843		9,843
		Term Loan		13.50	%	Prime		5.50	%		10.25	%		-			4.00	%	April 1, 2026		5,000		4,921		4,921
		Term Loan		13.50	%	Prime		5.50	%		10.25	%		-			4.00	%	April 1, 2026		5,000		4,921		4,921
Lemongrass Holdings, Inc. (2)(12)	Software	Term Loan		14.50	%	Prime		6.50	%		9.75	%		-			2.50	%	March 1, 2026		5,000		4,953		4,953
		Term Loan		14.50	%	Prime		6.50	%		9.75	%		-			2.50	%	March 1, 2026		2,500		2,477		2,477
Lytics, Inc. (2)(12)	Software	Term Loan		13.75	%	Prime		6.00	%		9.25	%		-			3.00	%	November 1, 2026		2,500		2,411		2,411
		Term Loan		13.75	%	Prime		6.00	%		12.25	%		-			3.00	%	December 1, 2026		1,250		1,232		1,232
		Term Loan		13.75	%	Prime		6.00	%		12.25	%		-			3.00	%	April 1, 2027		1,000		984		984
Noodle Partners, Inc. (2)(12)	Software	Term Loan		13.00	%	Prime		5.00	%		12.00	%		-			3.00	%	March 1, 2027		10,000		9,733		9,733
		Term Loan		13.00	%	Prime		5.00	%		12.00	%		-			3.00	%	March 1, 2027		5,000		4,928		4,928
		Term Loan		13.00	%	Prime		5.00	%		12.00	%		-			3.00	%	March 1, 2027		5,000		4,928		4,928
Reputation Institute, Inc. (2)(12)	Software	Term Loan		15.00	%	Prime		7.25	%		10.50	%		-			3.00	%	August 1, 2025		4,833		4,772		4,772
Slingshot Aerospace, Inc. (2)(12)	Software	Term Loan		13.75	%	Prime		5.75	%		9.75	%		-			5.00	%	August 1, 2026		5,000		4,940		4,940
		Term Loan		13.75	%	Prime		5.75	%		9.75	%		-			5.00	%	August 1, 2026		5,000		4,940		4,940
		Term Loan		13.75	%	Prime		5.75	%		9.75	%		-			5.00	%	August 1, 2026		5,000		4,875		4,875
		Term Loan		13.75	%	Prime		5.75	%		9.75	%		-			5.00	%	August 1, 2026		5,000		4,940		4,940
Supply Network Visibility Holdings LLC (2)(12)	Software	Term Loan		14.25	%	Prime		6.50	%		9.75	%		-			4.00	%	February 1, 2025		3,208		3,183		3,183
		Term Loan		14.25	%	Prime		6.50	%		9.75	%		-			4.00	%	February 1, 2025		3,208		3,183		3,183
		Term Loan		14.25	%	Prime		6.50	%		9.75	%		-			4.00	%	December 1, 2025		2,500		2,475		2,475
		Term Loan		14.25	%	Prime		6.50	%		9.75	%		-			4.00	%	December 1, 2025		2,500		2,475		2,475
Total Non-Affiliate Debt Investments — Technology																							277,916		267,673
Non-Affiliate Debt Investments — Healthcare information and services — 8.1% (8)
Hound Labs inc. (2) (12)	Diagnostics	Term Loan		14.00	%	Prime		6.00	%		9.25	%		-			3.50	%	June 1, 2026		2,500		2,388		2,388
		Term Loan		14.00	%	Prime		6.00	%		9.25	%		-			3.50	%	June 1, 2026		2,500		2,476		2,476
		Term Loan		14.00	%	Prime		6.00	%		9.25	%		-			3.50	%	June 1, 2026		5,000		4,951		4,951
Secure Transfusion Services, Inc. (12)(13)	Other Healthcare	Term Loan		13.75	%	Prime		5.75	%		9.00	%		-			4.00	%	October 1, 2025		4,719		4,658		46
		Term Loan		13.75	%	Prime		5.75	%		9.00	%		-			4.00	%	December 31, 2025		2,217		2,182		5
BrightInsight, Inc. (2)(12)	Software	Term Loan		13.25	%	Prime		5.50	%		9.50	%		-			3.00	%	August 1, 2027		7,000		6,663		6,663
		Term Loan		13.25	%	Prime		5.50	%		9.50	%		-			3.00	%	August 1, 2027		3,500		3,452		3,452
		Term Loan		13.25	%	Prime		5.50	%		9.50	%		-			3.00	%	August 1, 2027		3,500		3,452		3,452
		Term Loan		13.50	%	Prime		5.50	%		9.50	%		-			3.00	%	April 1, 2028		2,750		2,704		2,704
Total Non-Affiliate Debt Investments — Healthcare information and services																							32,926		26,137
Total Non- Affiliate Debt Investments																							703,781		684,554

See Notes to Consolidated Financial Statements

Consolidated Schedule of Investments (Unaudited)

March 31, 2023

(Dollars in thousands)

					Cost of		Fair
Portfolio Company (1)(3)	Sector	Type of Investment (7)	Number of Shares		Investments (6)(9)		Value (9)
Non-Affiliate Warrant Investments — 8.0% (8)
Non-Affiliate Warrants — Life Science — 2.1% (8)
Avalo Therapeutics, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		26,444		311		—
Castle Creek Biosciences, Inc. (2)(12)	Biotechnology	Preferred Stock Warrant		7,404		214		329
Corvium, Inc. (2)(12)	Biotechnology	Preferred Stock Warrant		661,956		53		—
Emalex Biosciences, Inc. (2)(12)	Biotechnology	Preferred Stock Warrant		110,402		176		256
Evelo Biosciences, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		463,915		126		—
Greenlight Biosciences, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		47,452		366		—
Imunon, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		19,671		66		—
IMV Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		39,774		67		—
KSQ Therapeutics, Inc. (2) (12)	Biotechnology	Preferred Stock Warrant		48,076		50		56
Mustang Bio, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		252,161		141		—
Native Microbials, Inc (2)(12)	Biotechnology	Preferred Stock Warrant		103,679		64		159
PDS Biotechnology Corporation (2)(5)(12)	Biotechnology	Common Stock Warrant		299,848		160		937
Provivi, Inc. (2)(12)	Biotechnology	Preferred Stock Warrant		254,609		401		128
Rocket Pharmaceuticals Corporation (5)(12)	Biotechnology	Common Stock Warrant		7,051		17		2
Stealth Biotherapeutics Inc. (2)(12)	Biotechnology	Common Stock Warrant		318,181		264		28
vTv Therapeutics Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		95,293		44		—
Xeris Pharmaceuticals, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		126,000		72		9
AccuVein Inc. (2)(12)	Medical Device	Common Stock Warrant		1,175		24		—
Aerin Medical, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		1,818,183		66		1,196
Aerobiotix, LLC (2)(12)	Medical Device	Preferred Stock Warrant		27,330		48		31
Canary Medical Inc. (2)(12)	Medical Device	Preferred Stock Warrant		12,153		86		1,862
Ceribell, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		145,483		69		206
Cognoa, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		775,000		144		173
Conventus Orthopaedics, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		7,972,222		221		221
CSA Medical, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		1,375,727		153		148
CVRx, Inc. (2)(5)(12)	Medical Device	Common Stock Warrant		47,410		76		72
Infobionic, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		317,647		124		51

See Notes to Consolidated Financial Statements

Consolidated Schedule of Investments (Unaudited)

March 31, 2023

(Dollars in thousands)

					Cost of		Fair
Portfolio Company (1)(3)	Sector	Type of Investment (7)	Number of Shares		Investments (6)(9)		Value (9)
Magnolia Medical Technologies, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		809,931		194		379
Meditrina, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		233,993		83		98
Robin Healthcare, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		86,066		16		15
Scientia Vascular, Inc (2)(12)	Medical Device	Preferred Stock Warrant		19,662		40		45
Sonex Health, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		605,313		98		120
VERO Biotech LLC (2)(12)	Medical Device	Preferred Stock Warrant		408		53		1
Swift Health Systems Inc. (2)(12)	Medical Device	Preferred Stock Warrant		135,484		71		81
Total Non-Affiliate Warrants — Life Science						4,158		6,603
Non-Affiliate Warrants — Sustainability — 0.2% (8)
Aerofarms, Inc. (2)(12)	Other Sustainability	Preferred Stock Warrant		201,537		61		72
LiquiGlide, Inc. (2)(12)	Other Sustainability	Common Stock Warrant		61,359		39		53
Nexii Building Solutions, Inc. (2)(12)	Other Sustainability	Common Stock Warrant		204,195		490		1
Soli Organic, Inc. (2)(12)	Other Sustainability	Preferred Stock Warrant		681		214		354
Temperpack Technologies, Inc. (2)(12)	Other Sustainability	Preferred Stock Warrant		34,604		118		259
Total Non-Affiliate Warrants — Sustainability						922		739
Non-Affiliate Warrants — Technology — 5.1% (8)
Axiom Space, Inc. (2)(12)	Communications	Common Stock Warrant		1,991		46		64
Intelepeer Holdings, Inc. (2)(12)	Communications	Preferred Stock Warrant		2,936,535		138		3,251
PebblePost, Inc. (2)(12)	Communications	Preferred Stock Warrant		598,850		91		170
Alula Holdings, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		20,000		93		64
Aterian, Inc. (2)(5)(12)	Consumer-related Technologies	Common Stock Warrant		76,923		195		—
Better Place Forests Co. (12)	Consumer-related Technologies	Preferred Stock Warrant		2,672		26		—
Caastle, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		268,591		68		1,057
CAMP NYC, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		17,605		22		—
Clara Foods Co. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		46,745		30		124
Divergent Technologies, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		33,742		70		237
Havenly, Inc. (2)(12)	Consumer-related Technologies	Common Stock Warrant		1,312,500		2,942		2,674
MyForest Foods Co. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		143		29		36
NextCar Holding Company, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		1,261,253		197		17
Optoro, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		6,600		104		104
Primary Kids, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		553,778		57		427
Quip NYC Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		6,191		325		532
Unagi, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		171,081		32		111
Updater, Inc.(2)(12)	Consumer-related Technologies	Common Stock Warrant		108,333		34		42
CPG Beyond, Inc. (2)(12)	Data Storage	Preferred Stock Warrant		500,000		242		903
Silk, Inc. (2)(12)	Data Storage	Preferred and Common Stock Warrant		442,110		234		399
Global Worldwide LLC (2)(12)	Internet and Media	Preferred Stock Warrant		245,810		75		—
Rocket Lawyer Incorporated (2)(12)	Internet and Media	Preferred Stock Warrant		261,721		92		352
Skillshare, Inc. (2)(12)	Internet and Media	Preferred Stock Warrant		139,074		162		1,231
Liqid, Inc. (2)(12)	Networking	Preferred Stock Warrant		344,102		364		237
Halio, Inc. (2)(12)	Power Management	Preferred Stock Warrant		5,002,574		1,585		2,808
Avalanche Technology, Inc. (2)(12)	Semiconductors	Preferred and Common Stock Warrants		6,081		57		—
BriteCore Holdings, Inc. (2)(12)	Software	Preferred Stock Warrant		77,828		21		67
Decisyon, Inc. (12)	Software	Common Stock Warrant		82,967		46		—
Dropoff, Inc. (2)(12)	Software	Common Stock Warrant		516,732		455		196
E La Carte, Inc. (2)(5)(12)	Software	Common Stock Warrant		147,361		60		—
Groundspeed Analytics, Inc. (2)(12)	Software	Preferred Stock Warrant		86,300		7		1
Kodiak Robotics, Inc. (2)(12)	Software	Preferred Stock Warrant		639,918		275		287
Lemongrass Holdings, Inc. (2)(12)	Software	Preferred Stock Warrant		101,308		35		40
Lotame Solutions, Inc. (2)(12)	Software	Preferred Stock Warrant		71,305		19		53
Lytics, Inc. (2)(12)	Software	Preferred Stock Warrant		85,543		43		46
Noodle Partners, Inc. (2)(12)	Software	Preferred Stock Warrant		84,037		116		116
Reputation Institute, Inc. (2)(12)	Software	Preferred Stock Warrant		3,731		61		46
Revinate Holdings, Inc. (2)(12)	Software	Preferred Stock Warrant		682,034		44		97
Riv Data Corp. (2)(12)	Software	Preferred Stock Warrant		321,428		12		296
SIGNiX, Inc. (12)	Software	Preferred Stock Warrant		186,235		225		—
Slingshot Aerospace, Inc. (2)(12)	Software	Preferred Stock Warrant		309,208		123		135
Supply Network Visibility Holdings LLC (2)(12)	Software	Preferred Stock Warrant		682		64		140
Topia Mobility, Inc. (2)(12)	Software	Preferred Stock Warrant		3,049,607		138		—
xAd, Inc. (2)(12)	Software	Preferred Stock Warrant		4,343,348		177		11
Total Non-Affiliate Warrants — Technology						9,231		16,371

See Notes to Consolidated Financial Statements

Consolidated Schedule of Investments (Unaudited)

March 31, 2023

(Dollars in thousands)

					Cost of		Fair
Portfolio Company (1)(3)	Sector	Type of Investment (7)	Number of Shares		Investments (6)(9)		Value (9)
Non-Affiliate Warrants — Healthcare information and services — 0.6% (8)
Hound Labs, Inc (2) (12)	Diagnostics	Preferred Stock Warrant		159,893		47		53
Kate Farms, Inc. (2)(12)	Other Healthcare	Preferred Stock Warrant		82,965		102		1,363
Secure Transfusion Services, Inc. (12)	Other Healthcare	Preferred Stock Warrant		77,690		48		—
BrightInsight, Inc. (2)(12)	Software	Preferred Stock Warrant		85,066		167		175
Medsphere Systems Corporation (2)(12)	Software	Preferred Stock Warrant		7,097,792		60		354
Total Non-Affiliate Warrants — Healthcare information and services						424		1,945
Total Non-Affiliate Warrants						14,735		25,658
Non-Affiliate Other Investments — 0.4% (8)
Lumithera, Inc. (12)	Medical Device	Royalty Agreement				1,200		1,100
ZetrOZ, Inc. (12)	Medical Device	Royalty Agreement				—		200
Total Non-Affiliate Other Investments						1,200		1,300
Non-Affiliate Equity — 0.9% (8)
Castle Creek Biosciences, Inc. (12)	Biotechnology	Common Stock		1,162		250		250
Emalex Biosciences, Inc. (12)	Biotechnology	Common Stock		32,831		356		356
Getaround, Inc. (2)(5)	Consumer-related Technologies	Common Stock		87,082		253		25
SnagAJob.com, Inc. (12)	Consumer-related Technologies	Common Stock		82,974		9		83
Lumithera, Inc. (12)	Medical Device	Common Stock		392,651		2,000		1,700
Tigo Energy, Inc. (12)	Other Sustainability	Preferred Stock		22,313		8		27
Branded Online, Inc. (2)(5)	Software	Common Stock		5,398		1,075		14
Decisyon, Inc. (12)	Software	Preferred and Common Stock		72,638,663		229		—
Lotame, Inc. (12)	Software	Preferred Stock		66,127		5		193
Axiom Space, Inc. (12)	Technology	Preferred Stock		1,810		261		306
Total Non-Affiliate Equity						4,446		2,954
Total Non-Affiliate Portfolio Investment Assets					$	724,162	$	714,466
Non-controlled Affiliate Investments — 0.3% (8)
Non-controlled Affiliate Equity — Life Science —0.3% (8)
Cadrenal Therapeutics, Inc. (5)	Biotechnology	Common Stock		600,000		—		846
Total Non-Controlled Affiliate Equity					$	—		846
Total Non-Controlled Affiliate Portfolio Investment Assets					$	—		846
Total Portfolio Investment Assets — 222.4% (8)					$	724,162	$	715,312

(1) All investments of the Company are in entities which are organized under the laws of the United States and have a principal place of business in the United States.

(2) Has been pledged as collateral under the revolving credit facility (the “Key Facility”) with KeyBank National Association (“Key”), the Note Funding Agreement (the “NYL Facility”, together with the Key Facility, the "Credit Facilities") with several entities owned or affiliated with New York Life Insurance Company (“NYL Noteholders”), the term debt securitization in connection with which an affiliate of the Company made an offering of $100.0 million in aggregate principal amount of fixed rate asset-backed notes that were issued in conjunction with the $160.0 million securitization of secured loans the Company completed on August 13, 2019 (the “2019 Asset-Backed Notes”), and/or the term debt securitization in connection with which an affiliate of the Company made an offering of $100.0 million in aggregate principal amount of fixed rate asset-backed notes that were issued in conjunction with the $157.8 million securitization of secured loans the Company completed on November 9, 2022 (the “2022 Asset-Backed Notes”).

(3) All non-affiliate investments are investments in which the Company owns less than 5% of the voting securities of the portfolio company. All non-controlled affiliate investments are investments in which the Company owns 5% or more of the voting securities of the portfolio company but not more than 25% of the voting securities of the portfolio company. All controlled affiliate investments are investments in which the Company owns more than 25% of the portfolio company’s outstanding voting securities or has the power to exercise control over management or policies of such portfolio company (including through a management agreement).

(4) All interest is payable in cash due monthly in arrears, unless otherwise indicated, and applies only to the Company’s debt investments. Interest rate is the annual interest rate on the debt investment and does not include end-of-term payments (“ETPs”), and any additional fees related to the investments, such as deferred interest, commitment fees or prepayment fees. Debt investments are at variable rates for the term of the debt investment, unless otherwise indicated. All debt investments based on the London InterBank Offered Rate (“LIBOR”) are based on one-month LIBOR. For each debt investment, the current interest rate in effect as of  March 31, 2023 is provided.

(5) Portfolio company is a public company.

(6) For debt investments, represents principal balance less unearned income.

(7) Warrants, Equity and Other Investments are non-income producing.

(8) Value as a percent of net assets.

(9) As of March 31, 2023, 6.3% and 6.2% of the Company’s total assets on a cost and fair value basis, respectively, are in non-qualifying assets. Under the 1940 Act, the Company may not acquire any non-qualifying assets unless, at the time the acquisition is made, qualifying assets represent at least 70% of the Company’s total assets.

(10) ETPs are contractual fixed-interest payments due in cash at the maturity date of the applicable debt investment, including upon any prepayment, and are a fixed percentage of the original principal balance of the debt investments unless otherwise noted. Interest will accrue during the life of the debt investment on each ETP and will be recognized as non-cash income until it is actually paid. Therefore, a portion of the incentive fee the Company may pay its Advisor will be based on income that the Company has not yet received in cash.

(11) Debt investment has a payment-in-kind (“PIK”) feature.

(12) The fair value of the investment was valued using significant unobservable inputs.

(13) Debt investment is on non-accrual status as of March 31, 2023.

See Notes to Consolidated Financial Statements

Consolidated Schedule of Investments

December 31, 2022

(Dollars in thousands)

Portfolio Company (1)(3)	Sector	Type of Investment (7)	Cash Rate (4)			Index	Margin			Floor			Ceiling			ETP (10)			Maturity Date	Principal Amount		Cost of Investments (6)(9)		Fair Value (9)
Non-Affiliate Investments — 226.1% (8)
Non-Affiliate Debt Investments — 215.5% (8)
Non-Affiliate Debt Investments — Life Science — 99.7% (8)
Avalo Therapeutics, Inc. (2)(5)(12)	Biotechnology	Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			3.00	%	January 1, 2025	$	2,885	$	2,853	$	2,777
		Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			3.00	%	January 1, 2025		2,885		2,823		2,750
		Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			3.00	%	January 1, 2025		1,442		1,411		1,374
		Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			3.00	%	February 1, 2025		2,885		2,821		2,748
		Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			3.00	%	February 1, 2025		2,885		2,821		2,748
		Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			3.00	%	April 1, 2025		1,442		1,408		1,371
		Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			3.00	%	April 1, 2025		1,442		1,408		1,371
Castle Creek Biosciences, Inc. (2)(12)	Biotechnology	Term Loan		12.50	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		5,000		4,891		4,891
		Term Loan		12.50	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		5,000		4,963		4,963
		Term Loan		12.50	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		3,000		2,978		2,978
		Term Loan		12.50	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		5,000		4,963		4,963
		Term Loan		12.50	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		5,000		4,963		4,963
		Term Loan		12.50	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		3,000		2,978		2,978
Emalex Biosciences, Inc. (2)(12)	Biotechnology	Term Loan		12.07	%	Libor		7.90	%		9.75	%		-			5.00	%	June 1, 2024		1,979		1,962		1,962
		Term Loan		12.07	%	Libor		7.90	%		9.75	%		-			5.00	%	June 1, 2024		1,979		1,963		1,963
		Term Loan		12.07	%	Libor		7.90	%		9.75	%		-			5.00	%	November 1, 2025		5,000		4,923		4,923
		Term Loan		12.07	%	Libor		7.90	%		9.75	%		-			5.00	%	May 1, 2026		5,000		4,912		4,912
Evelo Biosciences, Inc. (2)(5)(12)	Biotechnology	Term Loan		11.75	%	Prime		4.75	%		11.00	%		-			4.25	%	January 1, 2028		10,000		9,872		9,872
		Term Loan		11.75	%	Prime		4.75	%		11.00	%		-			4.25	%	January 1, 2028		15,000		14,808		14,808
		Term Loan		11.75	%	Prime		4.75	%		11.00	%		-			4.25	%	January 1, 2028		6,000		5,923		5,923
		Term Loan		11.75	%	Prime		4.75	%		11.00	%		-			4.25	%	January 1, 2028		6,000		5,923		5,923
		Term Loan		11.75	%	Prime		4.75	%		11.00	%		-			4.25	%	January 1, 2028		4,000		3,949		3,949
		Term Loan		11.75	%	Prime		4.75	%		11.00	%		-			4.25	%	January 1, 2028		4,000		3,949		3,949
F-Star Therapeutics, Inc. (2)(5)(12)	Biotechnology	Term Loan		13.25	%	Prime		6.25	%		9.50	%		-			4.00	%	April 1, 2025		2,500		2,476		2,476
		Term Loan		13.25	%	Prime		6.25	%		9.50	%		-			4.00	%	July 1, 2025		2,500		2,473		2,473
Greenlight Biosciences, Inc. (2)(5)(12)	Biotechnology	Term Loan		13.25	%	Prime		5.75	%		9.00	%		-			3.00	%	July 1, 2025		5,000		4,857		4,857
		Term Loan		13.25	%	Prime		5.75	%		9.00	%		-			3.00	%	July 1, 2025		2,500		2,430		2,430
IMV Inc. (2)(5)(12)	Biotechnology	Term Loan		13.25	%	Prime		5.75	%		9.00	%		-			5.00	%	July 1, 2025		5,000		4,946		4,946
		Term Loan		13.25	%	Prime		5.75	%		9.00	%		-			5.00	%	July 1, 2025		2,500		2,473		2,473
		Term Loan		13.25	%	Prime		5.75	%		9.00	%		-			5.00	%	January 1, 2026		5,000		4,947		4,947
		Term Loan		13.25	%	Prime		5.75	%		9.00	%		-			5.00	%	January 1, 2026		5,000		4,947		4,947
KSQ Therapeutics, Inc. (2) (12)	Biotechnology	Term Loan		12.25	%	Prime		4.75	%		8.50	%		-			5.50	%	May 1, 2027		6,250		6,077		6,077
		Term Loan		12.25	%	Prime		4.75	%		8.50	%		-			5.50	%	May 1, 2027		6,250		6,177		6,177
Native Microbials, Inc (2) (12)	Biotechnology	Term Loan		12.75	%	Prime		5.25	%		8.50	%		-			5.00	%	November 1, 2026		3,750		3,630		3,630
		Term Loan		12.75	%	Prime		5.25	%		8.50	%		-			5.00	%	November 1, 2026		2,500		2,469		2,469
PDS Biotechnology Corporation (2)(5)(12)	Biotechnology	Term Loan		13.25	%	Prime		5.75	%		9.75	%		-			3.75	%	September 1, 2026		10,000		9,701		9,701
		Term Loan		13.25	%	Prime		5.75	%		9.75	%		-			3.75	%	September 1, 2026		3,750		3,697		3,697
		Term Loan		13.25	%	Prime		5.75	%		9.75	%		-			3.75	%	September 1, 2026		3,750		3,697		3,697
Provivi, Inc. (2)(12)	Biotechnology	Term Loan		12.67	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		4,667		4,597		4,597
		Term Loan		12.67	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		4,667		4,597		4,597
		Term Loan		12.67	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		2,333		2,280		2,280
		Term Loan		12.67	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		2,333		2,280		2,280
		Term Loan		12.67	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		2,333		2,274		2,274
		Term Loan		12.67	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		2,333		2,274		2,274
Stealth Biotherapeutics Inc. (2)(12)	Biotechnology	Term Loan		13.00	%	Prime		5.50	%		8.75	%		-			6.00	%	October 1, 2025		5,000		4,914		4,914
		Term Loan		13.00	%	Prime		5.50	%		8.75	%		-			6.00	%	October 1, 2025		2,500		2,457		2,457
Aerobiotix, LLC (2)(12)	Medical Device	Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			6.00	%	April 1, 2026		2,500		2,463		2,364
		Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			6.00	%	April 1, 2026		2,500		2,463		2,364
Canary Medical Inc. (2)(12)	Medical Device	Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			7.00	%	November 1, 2024		2,500		2,475		2,475
		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			7.00	%	November 1, 2024		2,500		2,489		2,489
		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			7.00	%	November 1, 2024		2,500		2,473		2,473
Ceribell, Inc. (2)(12)	Medical Device	Term Loan		10.50	%	Prime		3.50	%		8.25	%		-			5.50	%	October 1, 2024		5,000		4,973		4,973
		Term Loan		10.50	%	Prime		3.50	%		8.25	%		-			5.50	%	October 1, 2024		5,000		4,973		4,973
		Term Loan		10.50	%	Prime		3.50	%		8.25	%		-			5.50	%	October 1, 2024		2,500		2,478		2,478
		Term Loan		10.50	%	Prime		3.50	%		8.25	%		-			5.50	%	October 1, 2024		2,500		2,478		2,478
Cognoa, Inc. (2)(12)	Medical Device	Term Loan		13.00	%	Prime		5.50	%		8.75	%		-			6.00	%	August 1, 2026		2,500		2,466		2,466
		Term Loan		13.00	%	Prime		5.50	%		8.75	%		-			6.00	%	August 1, 2026		5,000		4,932		4,932
Conventus Orthopaedics, Inc. (2)(12)	Medical Device	Term Loan		12.17	%	Libor		8.00	%		9.25	%		-			10.36	%	July 1, 2025		3,960		3,898		3,898
		Term Loan		12.17	%	Libor		8.00	%		9.25	%		-			10.36	%	July 1, 2025		3,960		3,898		3,898

See Notes to Consolidated Financial Statements

Consolidated Schedule of Investments

December 31, 2022

(Dollars in thousands)

Portfolio Company (1)(3)	Sector	Type of Investment (7)	Cash Rate (4)			Index	Margin			Floor			Ceiling		ETP (10)			Maturity Date	Principal Amount		Cost of Investments (6)(9)		Fair Value (9)
Corinth Medtech, Inc. (2)(12)	Medical Device	Term Loan		12.25	%	Prime		5.25	%		8.50	%		-		20.00	%	September 15, 2022		2,500		2,500		2,500
		Term Loan		12.25	%	Prime		5.25	%		8.50	%		-		20.00	%	September 15, 2022		2,500		2,500		2,500
CSA Medical, Inc. (2)(12)	Medical Device	Term Loan		12.37	%	Libor		8.20	%		10.00	%		-		5.00	%	January 1, 2024		1,625		1,610		1,610
		Term Loan		12.37	%	Libor		8.20	%		10.00	%		-		5.00	%	January 1, 2024		108		107		107
		Term Loan		12.37	%	Libor		8.20	%		10.00	%		-		5.00	%	March 1, 2024		2,000		1,983		1,983
Embody, Inc. (2)(12)	Medical Device	Term Loan		14.00	%	Prime		6.50	%		9.75	%		-		28.00	%	August 1, 2026		2,500		2,482		2,482
InfoBionic, Inc. (2)(12)	Medical Device	Term Loan		13.25	%	Prime		6.25	%		9.50	%		-		4.00	%	October 1, 2024		3,208		3,143		3,143
		Term Loan		13.25	%	Prime		6.25	%		9.50	%		-		4.00	%	June 1, 2025		1,000		974		974
Magnolia Medical Technologies, Inc. (2)(12)	Medical Device	Term Loan		12.00	%	Prime		5.00	%		9.75	%		-		4.00	%	March 1, 2025		5,000		4,939		4,939
		Term Loan		12.00	%	Prime		5.00	%		9.75	%		-		4.00	%	March 1, 2025		5,000		4,939		4,939
		Term Loan		12.00	%	Prime		5.00	%		9.75	%		-		4.00	%	March 1, 2025		5,000		4,933		4,933
		Term Loan		12.00	%	Prime		5.00	%		9.75	%		-		4.00	%	March 1, 2025		5,000		4,933		4,933
		Term Loan		12.50	%	Prime		5.00	%		9.75	%		-		4.00	%	January 1, 2027		5,000		4,913		4,913
		Term Loan		12.50	%	Prime		5.00	%		9.75	%		-		4.00	%	January 1, 2027		5,000		4,913		4,913
Robin Healthcare, Inc. (2)(12)	Medical Device	Term Loan		13.00	%	Prime		5.50	%		10.25	%		-		4.00	%	November 1, 2026		3,500		3,360		3,360
		Term Loan		13.00	%	Prime		5.50	%		10.25	%		-		4.00	%	November 1, 2026		3,500		3,460		3,460
Scientia Vascular, Inc. (2)(12)	Medical Device	Term Loan		11.75	%	Prime		4.75	%		8.50	%		-		5.00	%	January 1, 2027		3,750		3,597		3,597
		Term Loan		11.75	%	Prime		4.75	%		8.50	%		-		5.00	%	January 1, 2027		3,750		3,706		3,706
Sonex Health, Inc. (2)(12)	Medical Device	Term Loan		13.50	%	Prime		6.50	%		9.75	%		-		8.00	%	June 1, 2025		2,500		2,476		2,476
		Term Loan		13.50	%	Prime		6.50	%		9.75	%		-		8.00	%	June 1, 2025		2,500		2,476		2,476
		Term Loan		13.50	%	Prime		6.50	%		9.75	%		-		8.00	%	June 1, 2025		2,500		2,476		2,476
		Term Loan		13.50	%	Prime		6.50	%		9.75	%		-		8.00	%	April 1, 2026		2,500		2,453		2,453
		Term Loan		13.50	%	Prime		6.50	%		9.75	%		-		8.00	%	May 1, 2026		2,500		2,455		2,455
Spineology, Inc. (2)(12)	Medical Device	Term Loan		14.50	%	Prime		7.00	%		10.25	%		-		1.00	%	October 1, 2025		5,000		4,966		4,966
		Term Loan		14.50	%	Prime		7.00	%		10.25	%		-		1.00	%	April 1, 2026		2,500		2,481		2,481
Swift Health Systems Inc. (2)(12)	Medical Device	Term Loan		12.25	%	Prime		5.25	%		9.00	%		-		5.00	%	July 1, 2027		3,500		3,349		3,349
		Term Loan		12.25	%	Prime		5.25	%		9.00	%		-		5.00	%	July 1, 2027		3,500		3,454		3,454
Total Non-Affiliate Debt Investments — Life Science																						318,172		317,568
Non-Affiliate Debt Investments — Sustainability — 26.3% (8)
Aerofarms, Inc. (2)(12)	Other Sustainability	Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		3.00	%	April 1, 2026		3,750		3,699		3,699
		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		3.00	%	April 1, 2026		3,750		3,699		3,699
Nexii Building Solutions, Inc. (2)(12)	Other Sustainability	Term Loan		14.50	%	Prime		7.00	%		10.25	%		-		2.50	%	September 1, 2025		7,500		7,371		7,371
		Term Loan		14.50	%	Prime		7.00	%		10.25	%		-		2.50	%	September 1, 2025		7,500		7,371		7,371
		Term Loan		14.50	%	Prime		7.00	%		10.25	%		-		2.50	%	September 1, 2025		7,500		7,371		7,371
		Term Loan		14.50	%	Prime		7.00	%		10.25	%		-		2.50	%	July 1, 2026		5,000		4,903		4,903
		Term Loan		14.50	%	Prime		7.00	%		10.25	%		-		2.50	%	July 1, 2026		5,000		4,903		4,903
Soli Organic, Inc. (2)(12)	Other Sustainability	Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.75	%	April 1, 2026		2,500		2,463		2,463
		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.75	%	April 1, 2026		5,000		4,927		4,927
		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.75	%	May 1, 2026		5,000		4,924		4,924
		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.75	%	May 1, 2026		2,500		2,462		2,462
		Term Loan		13.00	%	Prime		5.50	%		10.00	%		-		2.75	%	December 1, 2026		5,000		4,900		4,900
		Term Loan		13.00	%	Prime		5.50	%		10.00	%		-		2.75	%	December 1, 2026		2,500		2,450		2,450
Temperpack Technologies, Inc. (2)(12)	Other Sustainability	Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.50	%	June 1, 2025		3,750		3,697		3,697
		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.50	%	June 1, 2025		3,750		3,717		3,717
		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.50	%	October 1, 2025		7,500		7,424		7,424
		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.50	%	October 1, 2025		3,750		3,712		3,712
		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.50	%	October 1, 2025		3,750		3,712		3,712
Total Non-Affiliate Debt Investments — Sustainability																						83,705		83,705
Non-Affiliate Debt Investments — Technology — 81.4% (8)
Axiom Space, Inc. (2)(12)	Communications	Term Loan		13.00	%	Prime		6.00	%		9.25	%		-		2.50	%	June 1, 2026		7,500		7,455		7,455
		Term Loan		13.00	%	Prime		6.00	%		9.25	%		-		2.50	%	June 1, 2026		7,500		7,455		7,455
		Term Loan		13.00	%	Prime		6.00	%		9.25	%		-		2.50	%	June 1, 2026		7,500		7,455		7,455
		Convertible Note		3.00	%													July 1, 2023		250		250		306
Alula Holdings, Inc. (2)(12)	Consumer-related Technologies	Term Loan		13.75	%	Prime		6.75	%		10.00	%		-		3.00	%	January 1, 2025		5,000		4,966		4,966
		Term Loan		13.75	%	Prime		6.75	%		10.00	%		-		3.00	%	January 1, 2025		5,000		4,966		4,966
		Term Loan		13.75	%	Prime		6.75	%		10.00	%		-		3.00	%	January 1, 2025		3,000		2,979		2,979
		Term Loan		13.75	%	Prime		6.75	%		10.00	%		-		3.00	%	December 1, 2025		1,000		976		976
		Term Loan		13.75	%	Prime		6.75	%		10.00	%		-		3.00	%	February 1, 2026		1,000		977		977
Better Place Forests Co. (2)(12)(13)	Consumer-related Technologies	Term Loan		13.75	%	Prime		6.25	%		9.50	%		-		1.85	%	July 1, 2025		5,000		4,951		3,834
		Term Loan		13.75	%	Prime		6.25	%		9.50	%		-		1.85	%	October 1, 2025		2,500		2,474		1,916
CAMP NYC, Inc. (2)(12)	Consumer-related Technologies	Term Loan		14.75	%	Prime		7.25	%		10.50	%		-		3.00	%	May 1, 2026		3,500		3,461		3,461
Clara Foods Co. (2)(12)	Consumer-related Technologies	Term Loan		12.75	%	Prime		5.75	%		9.00	%		-		5.50	%	August 1, 2025		2,500		2,482		2,482
		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-		5.50	%	August 1, 2025		2,500		2,482		2,482

See Notes to Consolidated Financial Statements

Consolidated Schedule of Investments

December 31, 2022

(Dollars in thousands)

Portfolio Company (1)(3)	Sector	Type of Investment (7)	Cash Rate (4)			Index	Margin			Floor			Ceiling			ETP (10)			Maturity Date	Principal Amount		Cost of Investments (6)(9)		Fair Value (9)
Divergent Technologies, Inc. (2)(12)	Consumer-related Technologies	Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		3,750		3,478		3,478
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		1,250		1,238		1,238
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		3,750		3,715		3,715
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		1,250		1,238		1,238
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		3,750		3,715		3,715
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		1,250		1,238		1,238
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	January 1, 2028		3,750		3,698		3,698
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	January 1, 2028		3,750		3,698		3,698
Havenly, Inc. (2)(12)	Consumer-related Technologies	Term Loan		12.50	%	Prime		5.00	%		5.00	%		-			4.00	%	March 1, 2027		2,000		1,082		1,082
		Term Loan		12.50	%	Prime		5.00	%		5.00	%		-			4.00	%	March 1, 2027		3,000		1,623		1,623
		Term Loan		11.00	%	Prime		3.50	%		10.50	%		-			7.78	%	February 1, 2028		2,813		2,813		2,813
		Term Loan		11.00	%	Prime		3.50	%		10.50	%		-			7.78	%	February 1, 2028		2,813		2,813		2,813
Interior Define, Inc. (2)(12)(13)	Consumer-related Technologies	Term Loan		13.50	%	Prime		6.50	%		9.75	%		-			4.00	%	January 1, 2026		3,210		3,151		—
		Term Loan		13.50	%	Prime		6.50	%		9.75	%		-			4.00	%	January 1, 2026		2,963		2,886		—
Lyrical Foods, Inc. (2)(12)	Consumer-related Technologies	Term Loan		10.00	%	Prime		6.75	%		10.00	%		-			-		September 1, 2027		2,500		2,588		2,279
MyForest Foods Co. (2)(12)	Consumer-related Technologies	Term Loan		14.25	%	Prime		6.75	%		10.00	%		-			3.00	%	October 1, 2025		5,000		4,954		4,954
		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-			3.00	%	October 1, 2025		2,500		2,477		2,477
NextCar Holding Company, Inc. (2)(12)	Consumer-related Technologies	Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			2.00	%	December 30, 2022		5,000		4,943		4,715
		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			2.00	%	December 30, 2022		2,000		1,981		1,890
		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			2.00	%	December 30, 2022		2,500		2,477		2,363
		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			2.00	%	December 30, 2022		3,000		2,971		2,835
		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			2.00	%	December 30, 2022		2,500		2,459		2,345
		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			2.00	%	December 30, 2022		2,500		2,459		2,345
		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			2.00	%	December 30, 2022		5,000		4,914		4,688
		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			2.00	%	December 30, 2022		2,500		2,456		2,342
Optoro, Inc. (2)(12)	Consumer-related Technologies	Term Loan		13.25	%	Prime		6.25	%		9.50	%		-			4.00	%	August 1, 2027		2,500		2,347		2,347
Primary Kids, Inc. (2)(12)	Consumer-related Technologies	Term Loan		14.25	%	Prime		7.25	%		10.50	%		-			3.00	%	March 1, 2025		2,700		2,673		2,673
		Term Loan		14.25	%	Prime		7.25	%		10.50	%		-			3.00	%	March 1, 2025		2,700		2,673		2,673
		Term Loan		14.25	%	Prime		7.25	%		10.50	%		-			3.00	%	September 1, 2025		3,000		2,967		2,967
Unagi, Inc. (2)(12)	Consumer-related Technologies	Term Loan		15.25	%	Prime		7.75	%		11.00	%		-			-		July 1, 2025		2,500		2,473		2,473
		Term Loan		15.25	%	Prime		7.75	%		11.00	%		-			-		July 1, 2025		1,250		1,236		1,236
		Term Loan		15.25	%	Prime		7.75	%		11.00	%		-			-		July 1, 2025		1,250		1,236		1,236
Liqid, Inc. (2)(12)	Networking	Term Loan		13.25	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		3,333		3,286		3,286
		Term Loan		13.25	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		3,333		3,286		3,286
		Term Loan		13.25	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		1,667		1,641		1,641
		Term Loan		13.25	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		1,667		1,641		1,641
		Term Loan		13.25	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		1,667		1,613		1,613
BriteCore Holdings, Inc. (2)(12)	Software	Term Loan		13.75	%	Prime		6.75	%		10.00	%		-			5.00	%	March 1, 2026		2,500		2,421		2,421
		Term Loan		13.75	%	Prime		6.75	%		10.00	%		-			5.00	%	March 1, 2026		2,500		2,487		2,487
Decisyon, Inc. (12)	Software	Term Loan		16.93	%	Prime		9.43	%		12.68	%		-			50.43	%	December 31, 2022		3,295		3,295		3,295
Dropoff, Inc. (2)(12)	Software	Term Loan		14.00	%	Prime		6.50	%		9.75	%		-			3.50	%	April 1, 2026		6,500		6,347		6,347
		Term Loan		14.00	%	Prime		6.50	%		9.75	%		-			3.50	%	April 1, 2026		6,000		5,859		5,859
		Term Loan		14.00	%	Prime		6.50	%		9.75	%		-			3.50	%	August 1, 2026		2,500		2,436		2,436
Engage3, LLC (2)(12)	Software	Term Loan		13.25	%	Prime		6.25	%		9.75	%		-			4.50	%	July 1, 2027		3,750		3,678		3,678
		Term Loan		13.25	%	Prime		6.25	%		9.75	%		-			4.50	%	July 1, 2027		3,750		3,718		3,718
Groundspeed Analytics, Inc. (2)(12)	Software	Term Loan		13.00	%	Prime		5.50	%		11.00	%		18.00	%		3.00	%	December 1, 2026		5,000		4,798		4,798
		Term Loan		13.00	%	Prime		5.50	%		11.00	%		18.00	%		3.00	%	December 1, 2026		5,000		4,948		4,948
Kodiak Robotics, Inc. (2)(12)	Software	Term Loan		13.00	%	Prime		5.50	%		10.25	%		-			4.00	%	April 1, 2026		10,000		9,826		9,826
		Term Loan		13.00	%	Prime		5.50	%		10.25	%		-			4.00	%	April 1, 2026		10,000		9,826		9,826
		Term Loan		13.00	%	Prime		5.50	%		10.25	%		-			4.00	%	April 1, 2026		5,000		4,913		4,913
		Term Loan		13.00	%	Prime		5.50	%		10.25	%		-			4.00	%	April 1, 2026		5,000		4,913		4,913
Lemongrass Holdings, Inc. (2)(12)	Software	Term Loan		14.00	%	Prime		6.50	%		9.75	%		-			2.50	%	March 1, 2026		5,000		4,947		4,947
		Term Loan		14.00	%	Prime		6.50	%		9.75	%		-			2.50	%	March 1, 2026		2,500		2,474		2,474
Lytics, Inc. (2)(12)	Software	Term Loan		13.00	%	Prime		6.00	%		9.25	%		-			3.00	%	July 1, 2025		2,500		2,396		2,396
		Term Loan		13.00	%	Prime		6.00	%		12.25	%		-			3.00	%	December 1, 2026		1,250		1,231		1,231
Reputation Institute, Inc. (2)(12)	Software	Term Loan		14.25	%	Prime		7.25	%		10.50	%		-			3.00	%	August 1, 2025		5,000		4,932		4,932
Slingshot Aerospace, Inc. (2)(12)	Software	Term Loan		13.25	%	Prime		5.75	%		9.75	%		-			5.00	%	August 1, 2026		5,000		4,870		4,870
		Term Loan		13.25	%	Prime		5.75	%		9.75	%		-			5.00	%	August 1, 2026		5,000		4,933		4,933
		Term Loan		13.25	%	Prime		5.75	%		9.75	%		-			5.00	%	August 1, 2026		5,000		4,933		4,933
		Term Loan		13.25	%	Prime		5.75	%		9.75	%		-			5.00	%	August 1, 2026		5,000		4,933		4,933
Supply Network Visiblity Holdings LLC (2)(12)	Software	Term Loan		13.50	%	Prime		6.50	%		9.75	%		-			4.00	%	February 1, 2025		3,500		3,472		3,472
		Term Loan		13.50	%	Prime		6.50	%		9.75	%		-			4.00	%	February 1, 2025		3,500		3,472		3,472
		Term Loan		13.50	%	Prime		6.50	%		9.75	%		-			4.00	%	December 1, 2025		2,500		2,472		2,472
		Term Loan		13.50	%	Prime		6.50	%		9.75	%		-			4.00	%	December 1, 2025		2,500		2,472		2,472
Total Non-Affiliate Debt Investments — Technology																							268,468		259,366
Non-Affiliate Debt Investments — Healthcare information and services — 8.1% (8)
Hound Labs inc. (2) (12)	Diagnostics	Term Loan		13.50	%	Prime		6.00	%		9.25	%		-			3.50	%	June 1, 2026		2,500		2,385		2,385
		Term Loan		13.50	%	Prime		6.00	%		9.25	%		-			3.50	%	June 1, 2026		2,500		2,473		2,473
		Term Loan		13.50	%	Prime		6.00	%		9.25	%		-			3.50	%	June 1, 2026		5,000		4,946		4,946
Secure Transfusion Services, Inc. (2)(12)(13)	Other Healthcare	Term Loan		13.25	%	Prime		5.75	%		9.00	%		-			4.00	%	October 1, 2025		4,943		4,943		1,668
		Term Loan		13.25	%	Prime		5.75	%		9.00	%		-			4.00	%	December 31, 2025		2,500		2,467		832
BrightInsight, Inc. (2)(12)	Software	Term Loan		12.50	%	Prime		5.50	%		9.50	%		-			3.00	%	August 1, 2027		7,000		6,619		6,619
		Term Loan		12.50	%	Prime		5.50	%		9.50	%		-			3.00	%	August 1, 2027		3,500		3,448		3,448
		Term Loan		12.50	%	Prime		5.50	%		9.50	%		-			3.00	%	August 1, 2027		3,500		3,448		3,448
Total Non-Affiliate Debt Investments — Healthcare information and services																							30,729		25,819
Total Non- Affiliate Debt Investments																							701,074		686,458

See Notes to Consolidated Financial Statements

Consolidated Schedule of Investments

December 31, 2022

(Dollars in thousands)

					Cost of		Fair
Portfolio Company (1)(3)	Sector	Type of Investment (7)	Number of Shares		Investments (6)(9)		Value (9)
Non-Affiliate Warrant Investments — 9.4% (8)
Non-Affiliate Warrants — Life Science — 3.1% (8)
Avalo Therapeutics, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		26,442		311		—
Castle Creek Biosciences, Inc. (2)(12)	Biotechnology	Preferred Stock Warrant		7,404		214		335
Corvium, Inc. (2)(12)	Biotechnology	Preferred Stock Warrant		661,956		53		—
Emalex Biosciences, Inc. (2)(12)	Biotechnology	Preferred Stock Warrant		110,402		176		263
Evelo Biosciences, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		463,915		126		125
F-Star Therapeutics, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		21,120		35		—
Greenlight Biosciences, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		47,452		366		—
Imunon, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		16,502		66		—
IMV Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		39,774		67		—
KSQ Therapeutics, Inc. (2) (12)	Biotechnology	Preferred Stock Warrant		48,077		51		60
Mustang Bio, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		252,161		146		—
Native Microbials, Inc (2) (12)	Biotechnology	Preferred Stock Warrant		103,679		64		162
PDS Biotechnology Corporation (2)(5)(12)	Biotechnology	Common Stock Warrant		299,848		160		3,024
Provivi, Inc. (2)(12)	Biotechnology	Preferred Stock Warrant		203,017		399		648
Rocket Pharmaceuticals Corporation (5)(12)	Biotechnology	Common Stock Warrant		7,051		17		14
Stealth Biotherapeutics Inc. (2)(12)	Biotechnology	Common Stock Warrant		318,181		264		37
vTv Therapeutics Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		95,293		44		—
Xeris Pharmaceuticals, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		126,000		72		3
AccuVein Inc. (2)(12)	Medical Device	Common Stock Warrant		1,175		24		—
Aerin Medical, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		1,818,183		64		1,200
Aerobiotix, LLC (2)(12)	Medical Device	Preferred Stock Warrant		27,330		48		31
Canary Medical Inc. (2)(12)	Medical Device	Preferred Stock Warrant		12,153		84		1,864
Ceribell, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		145,483		69		209
Cognoa, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		775,000		148		179
Conventus Orthopaedics, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		7,972,222		221		226
CSA Medical, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		1,375,727		153		150
CVRx, Inc. (2)(5)(12)	Medical Device	Common Stock Warrant		47,410		76		394
Infobionic, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		317,647		124		113
Magnolia Medical Technologies, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		809,931		194		385
Meditrina, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		233,993		83		101
Robin Healthcare, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		86,066		16		16
Scientia Vascular, Inc (2)(12)	Medical Device	Preferred Stock Warrant		19,662		40		46
Sonex Health, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		605,313		98		123
VERO Biotech LLC (2)(12)	Medical Device	Preferred Stock Warrant		408		53		1
Swift Health Systems Inc. (2)(12)	Medical Device	Preferred Stock Warrant		135,484		71		83
Total Non-Affiliate Warrants — Life Science						4,197		9,792
Non-Affiliate Warrants — Sustainability — 0.6% (8)
Aerofarms, Inc. (2)(12)	Other Sustainability	Preferred Stock Warrant		201,537		61		74
LiquiGlide, Inc. (2)(12)	Other Sustainability	Common Stock Warrant		61,539		39		55
Nexii Building Solutions, Inc. (2)(12)	Other Sustainability	Common Stock Warrant		204,832		488		1,061
Soli Organic, Inc. (2)(12)	Other Sustainability	Preferred Stock Warrant		681		214		361
Temperpack Technologies, Inc. (2)(12)	Other Sustainability	Preferred Stock Warrant		35,906		126		268
Total Non-Affiliate Warrants — Sustainability						928		1,819

See Notes to Consolidated Financial Statements

Consolidated Schedule of Investments

December 31, 2022

(Dollars in thousands)

					Cost of		Fair
Portfolio Company (1)(3)	Sector	Type of Investment (7)	Number of Shares		Investments (6)(9)		Value (9)
Non-Affiliate Warrants — Technology — 5.1% (8)
Axiom Space, Inc. (2)(12)	Communications	Common Stock Warrant		1,991		46		67
Intelepeer Holdings, Inc. (2)(12)	Communications	Preferred Stock Warrant		2,936,535		139		3,265
PebblePost, Inc. (2)(12)	Communications	Preferred Stock Warrant		598,850		92		173
Alula Holdings, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		20,000		93		64
Aterian, Inc. (2)(5)(12)	Consumer-related Technologies	Common Stock Warrant		76,923		195		—
Better Place Forests Co. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		10,690		26		—
Caastle, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		268,591		68		1,069
CAMP NYC, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		17,605		20		61
Clara Foods Co. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		46,745		30		125
Divergent Technologies, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		31,966		56		233
Havenly, Inc. (2)(12)	Consumer-related Technologies	Common Stock Warrant		1,312,500		2,947		2,947
Interior Define, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		553,710		103		—
MyForest Foods Co. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		143		29		37
NextCar Holding Company, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		1,261,253		197		17
Optoro, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		6,600		104		104
Primary Kids, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		553,778		57		429
Quip NYC Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		6,191		325		534
Unagi, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		171,081		32		22
Updater, Inc.(2)(12)	Consumer-related Technologies	Common Stock Warrant		108,333		34		42
CPG Beyond, Inc. (2)(12)	Data Storage	Preferred Stock Warrant		500,000		242		909
Silk, Inc. (2)(12)	Data Storage	Preferred Stock Warrant		442,110		234		407
Global Worldwide LLC (2)(12)	Internet and Media	Preferred Stock Warrant		245,810		75		—
Rocket Lawyer Incorporated (2)(12)	Internet and Media	Preferred Stock Warrant		261,721		92		357
Skillshare, Inc. (2)(12)	Internet and Media	Preferred Stock Warrant		139,074		162		802
Liqid, Inc. (2)(12)	Networking	Preferred Stock Warrant		344,102		364		243
Halio, Inc. (2)(12)	Power Management	Preferred Stock Warrant		5,002,574		1,585		2,610
Avalanche Technology, Inc. (2)(12)	Semiconductors	Preferred and Common Stock Warrants		6,081		56		—
BriteCore Holdings, Inc. (2)(12)	Software	Preferred Stock Warrant		77,828		21		69
Decisyon, Inc. (12)	Software	Common Stock Warrant		82,967		46		—
Dropoff, Inc. (2)(12)	Software	Common Stock Warrant		516,732		455		197
E La Carte, Inc. (2)(5)(12)	Software	Common Stock Warrant		147,361		60		3
Groundspeed Analytics, Inc. (2)(12)	Software	Preferred Stock Warrant		86,300		6		6
Kodiak Robotics, Inc. (2)(12)	Software	Preferred Stock Warrant		639,918		273		296
Lemongrass Holdings, Inc. (2)(12)	Software	Preferred Stock Warrant		101,308		34		41
Lotame Solutions, Inc. (2)(12)	Software	Preferred Stock Warrant		288,115		22		312
Lytics, Inc. (2)(12)	Software	Preferred Stock Warrant		80,197		40		44
Reputation Institute, Inc. (2)(12)	Software	Preferred Stock Warrant		3,731		56		39
Revinate Holdings, Inc. (2)(12)	Software	Preferred Stock Warrant		682,034		46		99
Riv Data Corp. (2)(12)	Software	Preferred Stock Warrant		321,428		12		296
SIGNiX, Inc. (12)	Software	Preferred Stock Warrant		186,235		225		—
Skyword, Inc. (12)	Software	Preferred and Common Stock Warrants		301,055		48		1
Slingshot Aerospace, Inc. (2)(12)	Software	Preferred Stock Warrant		309,208		123		133
Supply Network Visiblity Holdings LLC (2)(12)	Software	Preferred Stock Warrant		682		64		83
Topia Mobility, Inc. (2)(12)	Software	Preferred Stock Warrant		3,049,607		138		—
xAd, Inc. (2)(12)	Software	Preferred Stock Warrant		4,343,348		177		12
Total Non-Affiliate Warrants — Technology						9,249		16,148
Non-Affiliate Warrants — Healthcare information and services — 0.6% (8)
Hound Labs, Inc (2) (12)	Diagnostics	Preferred Stock Warrant		159,893		47		54
Kate Farms, Inc. (2)(12)	Other Healthcare	Preferred Stock Warrant		82,965		102		1,370
Secure Transfusion Services, Inc. (2)(12)	Other Healthcare	Preferred Stock Warrant		77,690		47		—
BrightInsight, Inc. (2)(12)	Software	Preferred Stock Warrant		80,544		160		170
Medsphere Systems Corporation (2)(12)	Software	Preferred Stock Warrant		7,097,792		60		359
Total Non-Affiliate Warrants — Healthcare information and services						416		1,953
Total Non-Affiliate Warrants						14,790		29,712
Non-Affiliate Other Investments — 0.4% (8)
Lumithera, Inc. (2)	Medical Device	Royalty Agreement				1,200		1,100
ZetrOZ, Inc. (12)	Medical Device	Royalty Agreement				—		200
Total Non-Affiliate Other Investments						1,200		1,300
Non-Affiliate Equity — 0.8% (8)
Castle Creek Biosciences, Inc. (12)	Biotechnology	Common Stock		1,162		250		250
Emalex Biosciences, Inc. (2)(12)	Biotechnology	Common Stock		32,831		356		356
Getaround, Inc. (2)(5)	Consumer-related Technologies	Common Stock		87,082		253		57
SnagAJob.com, Inc. (12)	Consumer-related Technologies	Common Stock		82,974		8		83
Lumithera, Inc. (2)	Medical Device	Common Stock		392,651		2,000		1,700
Tigo Energy, Inc. (2)	Other Sustainability	Preferred		22,313		8		27
Branded Online, Inc. (2)(5)	Software	Common Stock		108,004		1,079		83
Decisyon, Inc. (12)	Software	Preferred and Common Stock		72,638,663		230		—
Total Non-Affiliate Equity						4,184		2,556
Total Non-Affiliate Portfolio Investment Assets					$	721,248	$	720,026
Total Portfolio Investment Assets — 226.1% (8)					$	721,248	$	720,026

(1) All investments of the Company are in entities which are organized under the laws of the United States and have a principal place of business in the United States.

(2) Has been pledged as collateral under the Key Facility, the NYL Facility the 2019 Asset-Backed Notes and/or the 2022 Asset-Backed Notes.

See Notes to Consolidated Financial Statements

Consolidated Schedule of Investments

December 31, 2022

(Dollars in thousands)

(3) All non-affiliate investments are investments in which the Company owns less than 5% of the voting securities of the portfolio company. All non-controlled affiliate investments are investments in which the Company owns 5% or more of the voting securities of the portfolio company but not more than 25% of the voting securities of the portfolio company. All controlled affiliate investments are investments in which the Company owns more than 25% of the portfolio company’s outstanding voting securities or has the power to exercise control over management or policies of such portfolio company (including through a management agreement).

(4) All interest is payable in cash due monthly in arrears, unless otherwise indicated, and applies only to the Company’s debt investments. Interest rate is the annual interest rate on the debt investment and does not include ETPs, and any additional fees related to the investments, such as deferred interest, commitment fees or prepayment fees. Debt investments are at variable rates for the term of the debt investment, unless otherwise indicated. All debt investments based on the LIBOR are based on one-month LIBOR. For each debt investment, the current interest rate in effect as of  December 31, 2022 is provided.

(5) Portfolio company is a public company.

(6) For debt investments, represents principal balance less unearned income.

(7) Warrants, Equity and Other Investments are non-income producing.

(8) Value as a percent of net assets.

(9) As of December 31, 2022, 6.5% and 6.6% of the Company's total assets on a cost and fair value basis, respectively, are in non-qualifying assets. Under the 1940 Act, the Company may not acquire any non-qualifying assets unless, at the time the acquisition is made, qualifying assets represent at least 70% of the Company’s total assets.

(10) ETPs are contractual fixed-interest payments due in cash at the maturity date of the applicable debt investment, including upon any prepayment, and are a fixed percentage of the original principal balance of the debt investments unless otherwise noted. Interest will accrue during the life of the debt investment on each ETP and will be recognized as non-cash income until it is actually paid. Therefore, a portion of the incentive fee the Company may pay its Advisor will be based on income that the Company has not yet received in cash.

(11) Debt investment has a PIK feature.

(12) The fair value of the investment was valued using significant unobservable inputs.

(13) Debt investment is on non-accrual status as of December 31, 2022.

See Notes to Consolidated Financial Statements

XML

Note 1 - Organization

3 Months Ended

Mar. 31, 2023

Notes to Financial Statements

Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]

Note 1. Organization

Horizon Technology Finance Corporation (the “Company”) was organized as a Delaware corporation on March 16, 2010 and is an externally managed, non-diversified, closed-end investment company. The Company has elected to be regulated as a business development company (“BDC”) under the 1940 Act. In addition, for tax purposes, the Company has elected to be treated as a regulated investment company (“RIC”) as defined under Subchapter M of the Internal Revenue Code of 1986, as amended (the “Code”). As a RIC, the Company generally is not subject to corporate-level federal income tax on the portion of its taxable income (including net capital gains) the Company distributes to its stockholders. The Company primarily makes secured debt investments to development-stage companies in the technology, life science, healthcare information and services and sustainability industries. All of the Company’s debt investments consist of loans secured by all of, or a portion of, the applicable debtor company’s tangible and intangible assets.

On October 28, 2010, the Company completed an initial public offering (“IPO”) and its common stock trades on the Nasdaq Global Select Market under the symbol “HRZN”.

Horizon Credit II LLC (“Credit II”) was formed as a Delaware limited liability company on June 28, 2011, with the Company as its sole equity member. Credit II is a special purpose bankruptcy-remote entity and is a separate legal entity from the Company. Any assets conveyed to Credit II are not available to creditors of the Company or any other entity other than Credit II’s lenders.

The Company formed Horizon Funding 2019‑1 LLC (“2019‑1 LLC”) as a Delaware limited liability company on May 2, 2019 and Horizon Funding Trust 2019‑1 on May 15, 2019 (“2019‑1 Trust” and, together with the 2019‑1 LLC, the “2019‑1 Entities”). The 2019‑1 Entities are special purpose bankruptcy remote entities and are separate legal entities from the Company. The Company formed the 2019‑1 Entities for purposes of securitizing the 2019 Asset-Backed Notes.

Horizon Funding I, LLC (“HFI”) was formed as a Delaware limited liability company on May 9, 2018, with Horizon Secured Loan Fund I LLC, a Delaware limited liability company (“HSLFI”) as its sole member. HFI is a special purpose bankruptcy-remote entity and is a separate legal entity from HSLFI. Any assets conveyed to HFI are not available to creditors of HSLFI or any other entity other than HFI’s lenders. As of April 21, 2020, HSLFI and its subsidiary, HFI, are consolidated by the Company.

The Company formed Horizon Funding 2022‑1 LLC (“2022‑1 LLC”) as a Delaware limited liability company on September 30, 2022 and Horizon Funding Trust 2022‑1 on October 18, 2022 (“2022‑1 Trust” and, together with the 2022‑1 LLC, the “2022‑1 Entities”). The 2022‑1 Entities are special purpose bankruptcy remote entities and are separate legal entities from the Company. The Company formed the 2022‑1 Entities for purposes of securitizing the 2022 Asset-Backed Notes.

The Company has also established an additional wholly owned subsidiary, which is structured as a Delaware limited liability company, to hold the assets of a portfolio company acquired in connection with foreclosure or bankruptcy, which is a separate legal entity from the Company.

The Company’s investment strategy is to maximize the investment portfolio’s return by generating current income from the debt investments the Company makes and capital appreciation from the warrants the Company receives when making such debt investments. The Company has entered into an investment management agreement (the “Investment Management Agreement”) with Horizon Technology Finance Management LLC (the “Advisor”) under which the Advisor manages the day-to-day operations of, and provides investment advisory services to, the Company.

XML

Note 2 - Basis of Presentation and Significant Accounting Policies

3 Months Ended

Mar. 31, 2023

Notes to Financial Statements

Basis of Presentation and Significant Accounting Policies [Text Block]

Note 2. Basis of presentation and significant accounting policies

The consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and pursuant to the requirements for reporting on Form 10‑Q and Articles 6 and 10 of Regulation S-X (“Regulation S-X”) under the Securities Act of 1933, as amended (the “Securities Act”). In the opinion of management, the consolidated financial statements reflect all adjustments and reclassifications, consisting solely of normal recurring accruals, that are necessary for the fair presentation of financial results as of and for the periods presented. All intercompany balances and transactions have been eliminated. The current period’s results of operations are not necessarily indicative of results that ultimately may be achieved for the year. Therefore, the unaudited financial statements and notes should be read in conjunction with the audited financial statements and notes thereto for the year ended December 31, 2022.

Principles of consolidation

As required under GAAP and Regulation S-X, the Company will generally consolidate its investment in a company that is an investment company subsidiary or a controlled operating company whose business consists of providing services to the Company. Accordingly, the Company consolidated the results of the Company’s wholly-owned subsidiaries in its consolidated financial statements.

Assets related to transactions that do not meet Accounting Standards Codification (“ASC”) Topic 860, Transfers and Servicing requirements for accounting sale treatment are reflected in the Company’s Consolidated Statements of Assets and Liabilities as investments. Those assets are owned by special purpose entities, including 2019‑1 Entities and 2022-1 Entities, that are consolidated in the Company’s consolidated financial statements. The creditors of the special purpose entities have received security interests in such assets and such assets are not intended to be available to the creditors of the Company (or any affiliate of the Company).

Use of estimates

In preparing the consolidated financial statements in accordance with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosures of contingent assets and liabilities, as of the date of the balance sheet and income and expenses for the period. Actual results could differ from those estimates. Material estimates that are particularly susceptible to significant change in the near term relate to the valuation of investments.

Fair value

The Company records all of its investments at fair value in accordance with relevant GAAP, which establishes a framework used to measure fair value and requires disclosures for fair value measurements. The Company has categorized its investments carried at fair value, based on the priority of the valuation technique, into a three-level fair value hierarchy as more fully described in Note 6. Fair value is a market-based measure considered from the perspective of the market participant who holds the financial instrument rather than an entity specific measure. Therefore, when market assumptions are not readily available, the Company’s own assumptions are set to reflect those that management believes market participants would use in pricing the financial instrument at the measurement date.

The availability of observable inputs can vary depending on the financial instrument and is affected by a wide variety of factors, including, for example, the type of product, whether the product is new, whether the product is traded on an active exchange or in the secondary market and the current market conditions. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for financial instruments classified as Level 3.

See Note 6 for additional information regarding fair value.

Segments

The Company has determined that it has a single reporting segment and operating unit structure. The Company lends to and invests in portfolio companies in various technology, life science, healthcare information and services and sustainability industries. The Company separately evaluates the performance of each of its lending and investment relationships. However, because each of these debt investments and investment relationships has similar business and economic characteristics, they have been aggregated into a single lending and investment segment.

Investments

Investments are recorded at fair value. Pursuant to the amended SEC Rule 2a-5 of the 1940 Act, on July 29, 2022, the Company's board of directors (the “Board”) designated the Advisor as the Company’s “valuation designee.” The valuation designee determines the fair value of the Company’s portfolio investments and the Board oversees the valuation designee. The Company has the intent to hold its debt investments for the foreseeable future or until maturity or payoff.

Interest on debt investments is accrued and included in income based on contractual rates applied to principal amounts outstanding. Interest income is determined using a method that results in a level rate of return on principal amounts outstanding. Generally, when a debt investment becomes 90 days or more past due, or if the Company otherwise does not expect to receive interest and principal repayments, the debt investment is placed on non-accrual status and the recognition of interest income may be discontinued. Interest payments received on non-accrual debt investments may be recognized as income, on a cash basis, or applied to principal depending upon management’s judgment at the time the debt investment is placed on non-accrual status. As of March 31, 2023, there were three investments on nonaccrual status with a cost of $20.3 million and a fair value of $5.3 million. As of December 31, 2022, there were three investments on non-accrual status with a cost of $20.9 million and a fair value of $8.3 million. For the three months ended March 31, 2023 and 2022, the Company did not recognize any interest income received from debt investments on non-accrual status.

The Company receives a variety of fees from borrowers in the ordinary course of conducting its business, including advisory fees, commitment fees, amendment fees, non-utilization fees, success fees and prepayment fees. In a limited number of cases, the Company may also receive a non-refundable deposit earned upon the termination of a transaction. Debt investment origination fees, net of certain direct origination costs, are deferred and, along with unearned income, are amortized as a level-yield adjustment over the respective term of the debt investment. All other income is recognized when earned. Fees for counterparty debt investment commitments with multiple debt investments are allocated to each debt investment based upon each debt investment’s relative fair value. When a debt investment is placed on non-accrual status, the amortization of the related fees and unearned income is discontinued until the debt investment is returned to accrual status.

Certain debt investment agreements also require the borrower to make an ETP, that is accrued into interest receivable and taken into income over the life of the debt investment to the extent such amounts are expected to be collected. The Company will generally cease accruing the income if there is insufficient value to support the accrual or the Company does not expect the borrower to be able to pay the ETP when due. The proportion of the Company’s total investment income that resulted from the portion of ETPs not received in cash for the three months ended  March 31, 2023 and 2022 was 6.3% and 9.5%, respectively. 

In connection with substantially all lending arrangements, the Company receives warrants to purchase shares of stock from the borrower. The warrants are recorded as assets at estimated fair value on the grant date using the Black-Scholes valuation model. The warrants are considered loan fees and are recorded as unearned income on the grant date. The unearned income is recognized as interest income over the contractual life of the related debt investment in accordance with the Company’s income recognition policy. Subsequent to debt investment origination, the fair value of the warrants is determined using the Black-Scholes valuation model. Any adjustment to fair value is recorded through earnings as net unrealized appreciation or depreciation on investments. Gains and losses from the disposition of the warrants or stock acquired from the exercise of warrants are recognized as realized gains and losses on investments.

Realized gains or losses on the sale of investments, or upon the determination that an investment balance, or portion thereof, is not recoverable, are calculated using the specific identification method. The Company measures realized gains or losses by calculating the difference between the net proceeds from the repayment or sale and the amortized cost basis of the investment. Net change in unrealized appreciation or depreciation reflects the change in the fair values of the Company’s portfolio investments during the reporting period, including any reversal of previously recorded unrealized appreciation or depreciation when gains or losses are realized.

Debt issuance costs

Debt issuance costs are fees and other direct incremental costs incurred by the Company in obtaining debt financing from its lenders and issuing debt securities. The unamortized balance of debt issuance costs as of  March 31, 2023 and  December 31, 2022 was $6.6 million and $7.1 million, respectively. These amounts are amortized and included in interest expense in the consolidated statements of operations over the life of the borrowings. The accumulated amortization balances as of March 31, 2023 and  December 31, 2022 were $5.3 million and $4.8 million, respectively. The amortization expense for the three months ended March 31, 2023 and 2022 was $0.5 million and $0.3 million, respectively. 

Income taxes

As a BDC, the Company has elected to be treated as a RIC under Subchapter M of the Code and operates in a manner so as to qualify for the tax treatment applicable to RICs. In order to qualify as a RIC and to avoid the imposition of corporate-level income tax on the portion of its taxable income distributed to stockholders, among other things, the Company is required to meet certain source of income and asset diversification requirements and to timely distribute dividends out of assets legally available for distribution to its stockholders of an amount generally at least equal to 90% of its investment company taxable income, as defined by the Code and determined without regard to any deduction for dividends paid, for each tax year. The Company, among other things, has made and intends to continue to make the requisite distributions to its stockholders, which generally relieves the Company from corporate-level U.S. federal income taxes. Accordingly, no provision for federal income tax has been recorded in the financial statements. Differences between taxable income and net increase in net assets resulting from operations either can be temporary, meaning they will reverse in the future, or permanent. In accordance with ASC Topic 946, Financial Services—Investment Companies, as amended, of the Financial Accounting Standards Board (“FASB”), permanent tax differences, such as non-deductible excise taxes paid, are reclassified from distributions in excess of net investment income and net realized loss on investments to paid-in-capital at the end of each fiscal year. These permanent book-to-tax differences are reclassified on the consolidated statements of changes in net assets to reflect their tax character but have no impact on total net assets. 

Depending on the level of taxable income earned in a tax year, the Company may choose to carry forward taxable income in excess of current year distributions into the next tax year and incur a 4% U.S. federal excise tax on such income, as required. To the extent that the Company determines that its estimated current year annual taxable income will be in excess of estimated current year distributions, the Company accrues excise tax, if any, on estimated excess taxable income as taxable income is earned. For the three months ended March 31, 2023 and 2022, $0.2 million and $0.1 million, respectively, was accrued for U.S. federal excise tax. 

The Company evaluates tax positions taken in the course of preparing the Company’s tax returns to determine whether the tax positions are “more-likely-than-not” to be sustained by the applicable tax authority in accordance with ASC Topic 740, Income Taxes, as modified by ASC Topic 946. Tax benefits of positions not deemed to meet the more-likely-than-not threshold, or uncertain tax positions, would be recorded as a tax expense in the current year. It is the Company’s policy to recognize accrued interest and penalties related to uncertain tax benefits in income tax expense. The Company had no material uncertain tax positions at March 31, 2023 and  December 31, 2022. The Company’s income tax returns for the 2021, 2020 and 2019 tax years remain subject to examination by U.S. federal and state tax authorities.

Distributions

Distributions to common stockholders are recorded on the declaration date. The amount to be paid out as distributions is determined by the Board. Net realized capital gains, if any, may be distributed, although the Company may decide to retain such net realized gains for investment.

The Company has adopted a dividend reinvestment plan that provides for reinvestment of cash distributions on behalf of its stockholders, unless a stockholder elects to receive cash. As a result, if the Board declares a cash distribution, then stockholders who have not “opted out” of the dividend reinvestment plan will have their cash distributions automatically reinvested in additional shares of the Company’s common stock, rather than receiving the cash distribution. The Company may issue new shares or purchase shares in the open market to fulfill its obligations under the plan.

Stockholders’ Equity

On August 2, 2021, the Company entered into an At-The-Market (“ATM”) sales agreement (the “2021 Equity Distribution Agreement”), with Goldman Sachs & Co. LLC and B. Riley FBR, Inc. (each a “Sales Agent” and, collectively, the “Sales Agents”). The 2021 Equity Distribution Agreement provides that the Company may offer and sell its shares from time to time through the Sales Agents up to $100.0 million worth of its common stock, in amounts and at times to be determined by the Company. Sales of the Company’s common stock, if any, may be made in negotiated transactions or transactions that are deemed to be “at-the-market,” as defined in Rule 415 under the Securities Act, including sales made directly on the Nasdaq or similar securities exchange or sales made to or through a market maker other than on an exchange, at prices related to the prevailing market prices or at negotiated prices.

During the three months ended March 31, 2023, the Company sold 605,848 shares of common stock under the 2021 Equity Distribution Agreement. For the same period, the Company received total accumulated net proceeds of approximately $7.2 million, including $0.2 million of offering expenses, from these sales.

During the three months ended March 31, 2022, the Company sold 250,171 shares of common stock under the 2021 Equity Distribution Agreement. For the same period, the Company received total accumulated net proceeds of approximately $3.9 million, including $0.1 million of offering expenses, from these sales.

On  March 14, 2022, the Company completed a follow-on public offering of 2,500,000 shares of its common stock at a public offering price of $14.35 per share, for total net proceeds to the Company of $34.3 million, after deducting underwriting commission and discounts and other offering expenses.

The Company generally uses net proceeds from these offerings to make investments, to pay down liabilities and for general corporate purposes. As of March 31, 2023, shares representing approximately $24.1 million of its common stock remain available for issuance and sale under the 2021 Equity Distribution Agreement.

Stock Repurchase Program

On April 28, 2023, the Board extended a previously authorized stock repurchase program which allows the Company to repurchase up to $5.0 million of its common stock at prices below the Company’s net asset value per share as reported in its most recent consolidated financial statements. Under the repurchase program, the Company may, but is not obligated to, repurchase shares of its outstanding common stock in the open market or in privately negotiated transactions from time to time. Any repurchases by the Company will comply with the requirements of Rule 10b‑18 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and any applicable requirements of the 1940 Act. Unless extended by the Board, the repurchase program will terminate on the earlier of June 30, 2024 or the repurchase of $5.0 million of the Company’s common stock. During the three months ended March 31, 2023 and 2022, the Company did not make any repurchases of its common stock. From the inception of the stock repurchase program through March 31, 2023, the Company repurchased 167,465 shares of its common stock at an average price of $11.22 on the open market at a total cost of $1.9 million.

Transfers of financial assets

Assets related to transactions that do not meet the requirements under ASC Topic 860, Transfers and Servicing for sale treatment under GAAP are reflected in the Company’s consolidated statements of assets and liabilities as investments. Those assets are owned by special purpose entities that are consolidated in the Company’s financial statements. The creditors of the special purpose entities have received security interests in such assets and such assets are not intended to be available to the creditors of the Company (or any other affiliate of the Company).

Transfers of financial assets are accounted for as sales when control over the assets has been surrendered. Control over transferred assets is deemed to be surrendered when (1) the assets have been isolated from the Company — put presumptively beyond the reach of the transferor and its creditors, even in bankruptcy or other receivership, (2) the transferee obtains the right (free of conditions that constrain it from taking advantage of that right) to pledge or exchange the transferred assets and (3) the transferor does not maintain effective control over the transferred assets through either (a) an agreement that both entitles and obligates the transferor to repurchase or redeem the assets before maturity or (b) the ability to unilaterally cause the holder to return specific assets, other than through a cleanup call.

Recently issued accounting pronouncement

In June 2022, the FASB issued Accounting Standards Update No. 2022-03, Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU 2022-03”). ASU 2022-03 clarifies the guidance when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of the security. The amendments in ASU 2022-03 are effective for public companies for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The Company is currently assessing the impact of ASU 2022-03 on its consolidated financial statements.

XML

Note 3 - Related Party Transactions

3 Months Ended

Mar. 31, 2023

Notes to Financial Statements

Related Party Transactions Disclosure [Text Block]

Note 3. Related party transactions

Investment Management Agreement

At a special meeting of the stockholders on October 30, 2018, the stockholders approved a new Investment Management Agreement which became effective on March 7, 2019. The new Investment Management Agreement replaced the previously effective Amended and Restated Investment Management Agreement dated as of October 28, 2010 and amended effective July 1, 2014. On October 28, 2022, the Board unanimously approved the renewal of the Investment Management Agreement. Under the terms of the Investment Management Agreement, the Advisor determines the composition of the Company’s investment portfolio, the nature and timing of the changes to the investment portfolio and the manner of implementing such changes; identifies, evaluates and negotiates the structure of the investments the Company makes (including performing due diligence on the Company’s prospective portfolio companies); and closes, monitors and administers the investments the Company makes, including the exercise of any voting or consent rights.

On February 23, 2023, the Company announced that an affiliate of Monroe Capital LLC (“Monroe Capital”) has entered into a definitive purchase agreement to acquire one hundred percent (100%) of the membership interests of the Advisor and that the Company’s Board has unanimously approved a new investment management agreement with the Advisor, subject to stockholder approval at the annual meeting of stockholders to be held on May 25, 2023 and the closing of the purchase transaction. The Company is not a party to the definitive purchase agreement. Additional information on the approval of the new investment management agreement can be found in the Company’s proxy statement mailed to stockholders on or around April 6, 2023, and is available on the SEC’s website at http://www.sec.gov, or on the Company’s website at http://www.horizontechfinance.com.  

The Advisor’s services under the Investment Management Agreement are not exclusive to the Company, and the Advisor is free to furnish similar services to other entities so long as its services to the Company are not impaired. The Advisor is a registered investment adviser with the SEC. The Advisor receives fees for providing services to the Company under the Investment Management Agreement, consisting of two components, a base management fee and an incentive fee.

The base management fee was and will be calculated at an annual rate of 2.00% of the Company’s gross assets (less cash and cash equivalents) including any assets acquired with the proceeds of leverage; provided, that, to the extent the Company’s gross assets (less cash and cash equivalents) exceed $250 million, the base management fee on the amount of such excess over $250 million will be calculated at an annual rate of 1.60% of the Company’s gross assets (less cash and cash equivalents) including any assets acquired with the proceeds of leverage. The base management fee is payable monthly in arrears and is prorated for any partial month.

The base management fee payable at March 31, 2023 and  December 31, 2022 was $1.1 million. The base management fee expense was $3.2 million and $2.2 million for the three months ended March 31, 2023 and 2022, respectively. 

The incentive fee has two parts, as follows:

The first part, which is subject to the Incentive Fee Cap and Deferral Mechanism, as defined below, is calculated and payable quarterly in arrears based on the Company’s Pre-Incentive Fee Net Investment Income for the immediately preceding calendar quarter. For this purpose, “Pre-Incentive Fee Net Investment Income” means interest income, dividend income and any other income (including any other fees (other than fees for providing managerial assistance), such as commitment, origination, structuring, diligence and consulting fees or other fees received from portfolio companies) accrued during the calendar quarter, minus expenses for the quarter (including the base management fee, expenses payable under the Administration Agreement (as defined below), and any interest expense and any dividends paid on any issued and outstanding preferred stock, but excluding the incentive fee). Pre-Incentive Fee Net Investment Income includes, in the case of investments with a deferred interest feature (such as original issue discount, debt instruments with PIK interest and zero coupon securities), accrued income the Company has not yet received in cash. The incentive fee with respect to the Pre-Incentive Fee Net Investment Income is 20.00% of the amount, if any, by which the Pre-Incentive Fee Net Investment Income for the immediately preceding calendar quarter exceeds a hurdle rate of 1.75% (which is 7.00% annualized) of the Company’s net assets at the end of the immediately preceding calendar quarter, adjusted for any share issuances or repurchases during the relevant quarter, subject to a “catch-up” provision measured as of the end of each calendar quarter. Under this provision, in any calendar quarter, the Advisor receives no incentive fee until the Pre-Incentive Fee Net Investment Income equals the hurdle rate of 1.75%, but then receives, as a “catch-up,” 100.00% of the Pre-Incentive Fee Net Investment Income with respect to that portion of such Pre-Incentive Fee Net Investment Income, if any, that exceeds the hurdle rate but is less than 2.1875% quarterly (which is 8.75% annualized). The effect of this “catch-up” provision is that, if Pre-Incentive Fee Net Investment Income exceeds 2.1875% in any calendar quarter, the Advisor will receive 20.00% of the Pre-Incentive Fee Net Investment Income as if the hurdle rate did not apply.

Pre-Incentive Fee Net Investment Income does not include any realized capital gains, realized capital losses or unrealized capital appreciation or depreciation. Because of the structure of the incentive fee, it is possible that the Company may pay an incentive fee in a quarter in which the Company incurs a loss. For example, if the Company receives Pre-Incentive Fee Net Investment Income in excess of the quarterly minimum hurdle rate, the Company will pay the applicable incentive fee up to the Incentive Fee Cap, defined below, even if the Company has incurred a loss in that quarter due to realized and unrealized capital losses. The Company’s net investment income used to calculate this part of the incentive fee is also included in the amount of the Company’s gross assets used to calculate the 2.00% base management fee. These calculations are appropriately prorated for any period of less than three months and adjusted for any share issuances or repurchases during the current quarter.

The incentive fee on Pre-Incentive Fee Net Investment Income is subject to a fee cap and deferral mechanism which is determined based upon a look-back period of up to three years and is expensed when incurred. For this purpose, the look-back period for the incentive fee based on Pre-Incentive Fee Net Investment Income (the “Incentive Fee Look-back Period”) includes the relevant calendar quarter and the 11 preceding full calendar quarters. Each quarterly incentive fee payable on Pre-Incentive Fee Net Investment Income is subject to a cap (the “Incentive Fee Cap”) and a deferral mechanism through which the Advisor may recoup a portion of such deferred incentive fees (collectively, the “Incentive Fee Cap and Deferral Mechanism”). The Incentive Fee Cap is equal to (a) 20.00% of Cumulative Pre-Incentive Fee Net Return (as defined below) during the Incentive Fee Look-back Period less (b) cumulative incentive fees of any kind paid to the Advisor during the Incentive Fee Look-back Period. To the extent the Incentive Fee Cap is zero or a negative value in any calendar quarter, the Company will not pay an incentive fee on Pre-Incentive Fee Net Investment Income to the Advisor in that quarter. To the extent that the payment of incentive fees on Pre-Incentive Fee Net Investment Income is limited by the Incentive Fee Cap, the payment of such fees will be deferred and paid in subsequent calendar quarters up to three years after their date of deferment, subject to certain limitations, which are set forth in the Investment Management Agreement. The Company only pays incentive fees on Pre-Incentive Fee Net Investment Income to the extent allowed by the Incentive Fee Cap and Deferral Mechanism. “Cumulative Pre-Incentive Fee Net Return” during any Incentive Fee Look-back Period means the sum of (a) Pre-Incentive Fee Net Investment Income and the base management fee for each calendar quarter during the Incentive Fee Look-back Period and (b) the sum of cumulative realized capital gains and losses, cumulative unrealized capital appreciation and cumulative unrealized capital depreciation during the applicable Incentive Fee Look-back Period.

The second part of the incentive fee is determined and payable in arrears as of the end of each calendar year (or, upon termination of the Investment Management Agreement, as of the termination date), and equals 20.00% of the Company’s realized capital gains, if any, on a cumulative basis from the date of the election to be a BDC through the end of each calendar year, computed net of all realized capital losses and unrealized capital depreciation on a cumulative basis through the end of such year, less all previous amounts paid in respect of the capital gain incentive fee. However, in accordance with GAAP, the Company is required to include the aggregate unrealized capital appreciation on investments in the calculation and accrue a capital gain incentive fee on a quarterly basis, as if such unrealized capital appreciation were realized, even though such unrealized capital appreciation is not permitted to be considered in calculating the fee actually payable under the Investment Management Agreement.

The performance based incentive fee expense was $3.0 million and $1.4 million for the three months ended March 31, 2023 and 2022, respectively. The incentive fee on Pre-Incentive Fee Net Investment Income was subject to the Incentive Fee Cap and Deferral Mechanism for the three months ended March 31, 2023, which resulted in $0.2 million of reduced expense and additional net investment income. This deferral represents a contingent future liability and may be paid up to three years after the date of deferment. The total contingent future liability as of March 31, 2023 was $1.3 million. The incentive fee on Pre-Incentive Fee Net Investment Income was not subject to the Incentive Fee Cap and Deferral Mechanism for the three months ended March 31, 2022. The performance based incentive fee payable as of March 31, 2023 and  December 31, 2022 was $3.0 million and $1.4 million, respectively. The entire incentive fee payable as of March 31, 2023 and  December 31, 2022 represented part one of the incentive fee.

Administration Agreement

The Company entered into an administration agreement (the “Administration Agreement”) with the Advisor to provide administrative services to the Company. For providing these services, facilities and personnel, the Company reimburses the Advisor for the Company’s allocable portion of overhead and other expenses incurred by the Advisor in performing its obligations under the Administration Agreement, including rent, the fees and expenses associated with performing compliance functions and the Company’s allocable portion of the costs of compensation and related expenses of the Company’s Chief Financial Officer and Chief Compliance Officer and their respective staffs. The administrative fee expense was $0.4 million for the three months ended March 31, 2023 and 2022. 

XML

Note 4 - Investments

3 Months Ended

Mar. 31, 2023

Notes to Financial Statements

Investment Holdings [Text Block]

Note 4. Investments

The following table shows the Company’s investments as of March 31, 2023 and  December 31, 2022:

	March 31, 2023				December 31, 2022
	Cost		Fair Value		Cost		Fair Value
	(In thousands)
Investments
Debt	$	703,781	$	684,554	$	701,074	$	686,458
Warrants		14,735		25,658		14,790		29,712
Other		1,200		1,300		1,200		1,300
Equity		4,446		3,800		4,184		2,556
Total investments	$	724,162	$	715,312	$	721,248	$	720,026

The following table shows the Company’s investments by industry sector as of March 31, 2023 and  December 31, 2022:

	March 31, 2023				December 31, 2022
	Cost		Fair Value		Cost		Fair Value
	(In thousands)
Life Science
Biotechnology	$	187,970	$	186,981	$	193,372	$	195,006
Medical Device		129,102		131,823		132,803		135,960
Technology
Communications		22,913		26,168		22,892		26,176
Consumer-Related		107,802		99,140		121,961		114,050
Data Storage		476		1,302		476		1,316
Internet and Media		329		1,583		329		1,159
Networking		10,111		9,984		11,831		11,710
Power Management		1,585		2,808		1,585		2,610
Semiconductors		57		—		56		—
Software		145,706		143,680		120,157		118,716
Sustainability
Energy Efficiency		8		27		8		27
Other Sustainability		84,753		83,734		84,633		85,524
Healthcare Information and Services
Diagnostics		9,862		9,868		9,851		9,858
Other		6,990		1,414		7,559		3,870
Software		16,498		16,800		13,735		14,044
Total investments	$	724,162	$	715,312	$	721,248	$	720,026

XML

Note 5 - Transactions With Affiliated Companies

3 Months Ended

Mar. 31, 2023

Notes to Financial Statements

Investments in and Advances to Affiliates, Schedule of Investments [Text Block]

Note 5. Transactions with affiliated companies

A non-controlled affiliated company is generally a portfolio company in which the Company owns 5% or more of such portfolio company’s voting securities but not more than 25% of such portfolio company’s voting securities.

Transactions related to investments in non-controlled affiliated companies for the three months ended March 31, 2023 were as follows:  

					Three months ended March 31, 2023
	Fair value at						Transfers				Net				Fair value at
Portfolio	December 31,				Principal		in/(out) at		Discount		unrealized		Net realized		March 31,		Interest
Company	2022		Purchases		Payments		fair value		accretion		gain/(loss)		gain/(loss)		2023		income
	(In thousands)
Cadrenal Therapeutics, Inc.	$	—	$	—	$	—	$	—	$	—	$	846	$	—	$	846	$	—
Total non-controlled affiliates	$	—	$	—	$	—	$	—	$	—	$	846	$	—	$	846	$	—

For the three months ended March 31, 2022, there were no transactions related to investments in non-controlled affiliated companies.

A controlled affiliated company is generally a portfolio company in which the Company owns more than 25% of such portfolio company’s voting securities or has the power to exercise control over management or policies of such portfolio company (including through a management agreement).

For the three months ended March 31, 2023, there were no transactions related to investments in controlled affiliated companies. 

Transactions related to investments in controlled affiliated companies for the three months ended March 31, 2022 were as follows:

					Three months ended March 31, 2022
	Fair value at							Transfers				Net				Fair value at
Portfolio	December 31,							in/(out) at		Dividends		unrealized		Net realized		March 31,		Dividend
Company	2021		Purchases		Sales			fair value		declared		gain/(loss)		gain/(loss)		2022		income
	(In thousands)
HESP LLC		—		—		(50	)		—		—		50		—		—		—
Total controlled affiliates	$	—	$	—	$	(50	)	$	—	$	—	$	50	$	—	$	—	$	—

XML

Note 6 - Fair Value

3 Months Ended

Mar. 31, 2023

Notes to Financial Statements

Fair Value Disclosures [Text Block]

Note 6. Fair value

Prior to July 30, 2022, the Board determined the fair value of the Company’s investments. Pursuant to the amended SEC Rule 2a-5 of the 1940 Act, on July 29, 2022, the Board designated the Advisor as the Company’s “valuation designee.” The Board is responsible for oversight of the valuation designee. The valuation designee has established a Valuation Committee to determine in good faith the fair value of the Company’s investments, based on input from the Advisor’s management and personnel and independent valuation firms which are engaged at the direction of the Valuation Committee to assist in the valuation of certain portfolio investments lacking a readily available market quotation at least once during a trailing twelve-month period. The Valuation Committee determines fair values pursuant to a valuation policy approved by the Board and pursuant to a consistently applied valuation process. This valuation process is conducted at the end of each fiscal quarter, with at least 25% (based on fair value) of the Company’s valuation of portfolio companies lacking readily available market quotations subject to review by an independent valuation firm.

The Company uses fair value measurements made by the valuation designee to record fair value adjustments to certain assets and liabilities and to determine fair value disclosures. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is best determined based upon quoted market prices. However, in certain instances, there are no quoted market prices for certain assets or liabilities. In cases where quoted market prices are not available, fair values are based on estimates using present value or other valuation techniques. Those techniques are significantly affected by the assumptions used, including the discount rate and estimates of future cash flows. Accordingly, the fair value estimates may not be realized in an immediate settlement of the asset or liability.

Fair value measurements focus on exit prices in an orderly transaction (that is, not a forced liquidation or distressed sale) between market participants at the measurement date under current market conditions. If there has been a significant decrease in the volume and level of activity for the asset or liability, a change in valuation technique or the use of multiple valuation techniques may be appropriate. In such instances, determining the price at which willing market participants would transact at the measurement date under current market conditions depends on the facts and circumstances and requires the use of significant judgment.

The Company’s fair value measurements are classified into a fair value hierarchy in accordance with ASC Topic 820, Fair Value Measurement, based on the markets in which the assets and liabilities are traded and the reliability of the assumptions used to determine fair value. The three categories within the hierarchy are as follows:

Level 1 Quoted prices in active markets for identical assets and liabilities.

Level 2 Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities in active markets, quoted prices in markets that are not active, and model-based valuation techniques for which all significant inputs are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation.

Due to the inherent uncertainty of determining the fair value of investments that do not have a readily available market value, the fair value of the Company’s investments may fluctuate from period to period. Additionally, the fair value of the Company’s investments may differ significantly from the values that would have been used had a ready market existed for such investments and may differ materially from the values that the Company may ultimately realize. Further, such investments are generally subject to legal and other restrictions on resale or otherwise are less liquid than publicly traded securities. If the Company was required to liquidate a portfolio investment in a forced or liquidation sale, the Company could realize significantly less than the value at which the Company has recorded such portfolio investment.

Cash and interest receivable: The carrying amount is a reasonable estimate of fair value. These financial instruments are not recorded at fair value on a recurring basis and are categorized as Level 1 within the fair value hierarchy described above.

Money market funds:  The carrying amounts are valued at their net asset value as of the close of business on the day of valuation. These financial instruments are recorded at fair value on a recurring basis and are categorized as Level 2 within the fair value hierarchy described above as these funds can be redeemed daily.

Debt investments: The fair value of debt investments is estimated by discounting the expected future cash flows using the period end rates at which similar debt investments would be made to borrowers with similar credit ratings and for the same remaining maturities. Significant increases (decreases) in this unobservable input would result in a significantly lower (higher) fair value measurement. These assets are recorded at fair value on a recurring basis and are categorized as Level 3 within the fair value hierarchy described above.

Under certain circumstances, the Company  may use an alternative technique to value debt investments that better reflects its fair value such as the use of multiple probability weighted cash flow models when the expected future cash flows contain elements of variability.

Warrant investments: The Company values its warrants using the Black-Scholes valuation model incorporating the following material assumptions:

● Underlying asset value of the issuer is estimated based on information available, including any information regarding the most recent rounds of borrower funding. Significant increases (decreases) in this unobservable input would result in a significantly higher (lower) fair value measurement.

● Volatility, or the amount of uncertainty or risk about the size of the changes in the warrant price, is based on indices of publicly traded companies similar in nature to the underlying company issuing the warrant. A total of seven such indices are used. Significant increases (decreases) in this unobservable input would result in a significantly higher (lower) fair value measurement.

● The risk-free interest rates are derived from the U.S. Treasury yield curve. The risk-free interest rates are calculated based on a weighted average of the risk-free interest rates that correspond closest to the expected remaining life of the warrant.

● Other adjustments, including a marketability discount on private company warrants, are estimated based on management’s judgment about the general industry environment.

● Historical portfolio experience on cancellations and exercises of the Company’s warrants are utilized as the basis for determining the estimated time to exit of the warrants in each financial reporting period. Warrants may be exercised in the event of acquisitions, mergers or initial public offerings, and cancelled due to events such as bankruptcies, restructuring activities or additional financings. These events cause the expected remaining life assumption to be shorter than the contractual term of the warrants. Significant increases (decreases) in this unobservable input would result in significantly higher (lower) fair value measurement.

Under certain circumstances the Company may use an alternative technique to value warrants that better reflects the warrants’ fair value, such as an expected settlement of a warrant in the near term or a model that incorporates a put feature associated with the warrant. The fair value may be determined based on the expected proceeds to be received from such settlement or based on the net present value of the expected proceeds from the put option.

The fair value of the Company’s warrants held in publicly traded companies is determined based on inputs that are readily available in public markets or can be derived from information available in public markets. Therefore, the Company has categorized these warrants as Level 2 within the fair value hierarchy described above. The fair value of the Company’s warrants held in private companies is determined using both observable and unobservable inputs and represents management’s best estimate of what market participants would use in pricing the warrants at the measurement date. Therefore, the Company has categorized these warrants as Level 3 within the fair value hierarchy described above. These assets are recorded at fair value on a recurring basis.

Equity investments: The fair value of an equity investment in a privately held company is initially the face value of the amount invested. The Company adjusts the fair value of equity investments in private companies upon the completion of a new third-party round of equity financing. The Company may make adjustments to fair value, absent a new equity financing event, based upon positive or negative changes in a portfolio company’s financial or operational performance. Significant increases (decreases) in this unobservable input would result in a significantly higher (lower) fair value measurement. The Company has categorized these equity investments as Level 3 within the fair value hierarchy described above. The fair value of an equity investment in a publicly traded company is based upon the closing public share price on the date of measurement. Therefore, the Company has categorized these equity investments as Level 1 within the fair value hierarchy described above. These assets are recorded at fair value on a recurring basis.

Other investments: Other investments are valued based on the facts and circumstances of the underlying contractual agreement. The Company currently values these contractual agreements using a multiple probability weighted cash flow model as the contractual future cash flows contain elements of variability. Significant changes in the estimated cash flows and probability weightings would result in a significantly higher or lower fair value measurement. The Company has categorized these other investments as Level 3 within the fair value hierarchy described above. These other investments are recorded at fair value on a recurring basis.

The following tables detail the investments that are carried at fair value and measured at fair value on a recurring basis as of March 31, 2023 and  December 31, 2022 and indicate the fair value hierarchy of the valuation techniques utilized by the Company to determine the fair value:

	March 31, 2023
	Level 1		Level 2		Level 3		Total
	(In thousands)
Debt investments	$	—	$	—	$	684,554	$	684,554
Warrant investments		—		1,020		24,638		25,658
Other investments		—		—		1,300		1,300
Equity investments		885		—		2,915		3,800
Total investments	$	885	$	1,020	$	713,407	$	715,312

 

	December 31, 2022
	Level 1		Level 2		Level 3		Total
	(In thousands)
Debt investments	$	—	$	—	$	686,458	$	686,458
Warrant investments		—		3,567		26,145		29,712
Other investments		—		—		1,300		1,300
Equity investments		140		—		2,416		2,556
Total investments	$	140	$	3,567	$	716,319	$	720,026

The following tables provide a summary of quantitative information about the Company’s Level 3 fair value measurements of the Company’s investments as of March 31, 2023 and  December 31, 2022. In addition to the techniques and inputs noted in the table below, according to the Company’s valuation policy, the Company may also use other valuation techniques and methodologies when determining its fair value measurements.

The following table is not intended to be all-inclusive, but rather provides information on the significant Level 3 inputs as they relate to the Company’s fair value measurements as of March 31, 2023:

March 31, 2023
	Fair		Valuation Techniques/	Unobservable		Weighted
Investment Type	Value		Methodologies	Input	Range	Average(1)
			(Dollars in thousands, except per share data)
Debt investments	$	644,854	Discounted Expected Future Cash Flows	Hypothetical Market Yield	11% – 20%		14	%
		39,700	Multiple Probability Weighted Cash Flow Model	Probability Weighting	10% - 100%		43	%
Warrant investments		24,638	Black-Scholes Valuation Model	Price Per Share	0.100 –1,89999	$	62.82
				Average Industry Volatility	28%		28	%
				Marketability Discount	20%		20	%
				Estimated Time to Exit (in years)	1 to 5		3
Other investments		1,300	Multiple Probability Weighted Cash Flow Model	Discount Rate	25%		25	%
				Probability Weighting	100%		100	%
Equity investments		2,915	Last Equity Financing	Price Per Share	$1.00– $215.03	$	40.27
Total Level 3 investments	$	713,407

(1) Weighted average is calculated by multiplying (a) the unobservable input for each investment in the investment type by (b) (1) the fair value of the related investment in the investment type divided by (2) the total fair value of the investment type.

The following table is not intended to be all-inclusive, but rather provides information on the significant Level 3 inputs as they relate to the Company’s fair value measurements as of December 31, 2022:

December 31, 2022
	Fair		Valuation Techniques/	Unobservable		Weighted
Investment Type	Value		Methodologies	Input	Range	Average(1)
			(Dollars in thousands, except per share data)
Debt investments	$	669,617	Discounted Expected Future Cash Flows	Hypothetical Market Yield	3% – 22%		14	%
		16,545	Multiple Probability Weighted Cash Flow Model	Probability Weighting	10% - 75%		31	%
		296	Convertible Note Analysis	Price Per Share	$168.93	$	168.93
Warrant investments		26,145	Black-Scholes Valuation Model	Price Per Share	0.000 –1.89999	$	58.52
				Average Industry Volatility	28%		28	%
				Marketability Discount	20%		20	%
				Estimated Time to Exit (in years)	1 to 5		3
Other investments		1,300	Multiple Probability Weighted Cash Flow Model	Discount Rate	25%		25	%
				Probability Weighting	100%		100	%
Equity investments		2,416	Last Equity Financing	Price Per Share	$1.00– $215.03	$	26.93
Total Level 3 investments	$	716,319

(1) Weighted average is calculated by multiplying (a) the unobservable input for each investment in the investment type by (b) (1) the fair value of the related investment in the investment type divided by (2) the total fair value of the investment type.

Borrowings: The Key Facility and the NYL Facility approximate fair value due to the variable interest rate of the facilities and are categorized as Level 2 within the fair value hierarchy described above. Additionally, the Company considers its creditworthiness in determining the fair value of such borrowings. The fair value of the fixed-rate 2026 Notes (as defined in Note 7) is based on the closing public share price on the date of measurement. On March 31, 2023, the closing price of the 2026 Notes on the New York Stock Exchange was $23.39 per note and had an aggregate fair value of $53.8 million. Therefore, the Company has categorized this borrowing as Level 1 within the fair value hierarchy described above. The fair value of the fixed-rate 2027 Notes (as defined in Note 7) is based on the closing public share price on the date of measurement. On March 31, 2023, the closing price of the 2027 Notes on the New York Stock Exchange was $24.00 per note and had an aggregate fair value of $55.2 million. Therefore, the Company has categorized this borrowing as Level 1 within the fair value hierarchy described above. Based on market quotations on March 31, 2023, the 2019 Asset-Backed Notes were trading at par value, or $37.8 million, and are categorized as Level 3 within the fair value hierarchy described above. Based on market quotations on March 31, 2023, the 2022 Asset-Backed Notes were trading at par value, or $100.0 million, and are categorized as Level 3 within the fair value hierarchy described above. These borrowings are not recorded at fair value on a recurring basis.

Off-balance-sheet instruments: Fair values for off-balance-sheet lending commitments are based on fees currently charged to enter into similar agreements, taking into account the remaining terms of the agreements and the counterparties’ credit standings. Therefore, the Company has categorized these instruments as Level 3 within the fair value hierarchy described above.

The following table shows a reconciliation of the beginning and ending balances for Level 3 assets measured at fair value on a recurring basis for the three months ended March 31, 2023:

	Three months ended March 31, 2023
	Debt			Warrant			Equity		Other
	Investments			Investments			Investments		Investments		Total
	(In thousands)
Level 3 assets, beginning of period	$	686,458		$	26,145		$	2,416	$	1,300	$	716,319
Purchase of investments		46,998			—			10		—		47,008
Warrants received and classified as Level 3		—			141			—		—		141
Principal payments received on investments		(39,756	)		—			—		—		(39,756	)
Payment-in-kind interest on investments		1,204			—			—		—		1,204
Proceeds from sale of investments		(6,508	)		(12	)		—		—		(6,520	)
Net realized gain (loss) on investments		7			(141	)		—		—		(134	)
Unrealized (depreciation) appreciation included in earnings		(4,566	)		(1,490	)		189		—		(5,867	)
Transfer out of debt investments		(295	)		(5	)		300		—		—
Other		1,012			—			—		—		1,012
Level 3 assets, end of period	$	684,554		$	24,638		$	2,915	$	1,300	$	713,407

During the three months ended March 31, 2023, there were no transfers in or out of Level 3.

The change in unrealized depreciation included in the consolidated statement of operations attributable to Level 3 investments still held at March 31, 2023 includes $4.6 million in unrealized depreciation on debt and other investments, $1.4 million in unrealized depreciation on warrant investments and $0.2 million in unrealized appreciation on equity investments.

The following table shows a reconciliation of the beginning and ending balances for Level 3 assets measured at fair value on a recurring basis for the three months ended March 31, 2022:

	Three months ended March 31, 2022
	Debt			Warrant			Equity		Other
	Investments			Investments			Investments		Investments			Total
	(In thousands)
Level 3 assets, beginning of period	$	437,317		$	19,837		$	203	$	200		$	457,557
Purchase of investments		94,485			—			—		—			94,485
Warrants received and classified as Level 3		—			808			—		—			808
Principal payments received on investments		(14,095	)		—			—		(50	)		(14,145	)
Proceeds from sale of investments		(21,250	)		(30	)		—		—			(21,280	)
Net realized gain on investments		—			30			—		—			30
Unrealized (depreciation) appreciation included in earnings		(3,170	)		1,000			—		50			(2,120	)
Other		(1,093	)		—			—		—			(1,093	)
Level 3 assets, end of period	$	492,194		$	21,645		$	203	$	200		$	514,242

During the three months ended March 31, 2022, there were no transfers in or out of Level 3.

The change in unrealized depreciation included in the consolidated statement of operations attributable to Level 3 investments still held at March 31, 2022 includes $3.3 million in unrealized depreciation on debt and other investments and $1.0 million in unrealized appreciation on warrant investments.

The Company discloses fair value information about financial instruments, whether or not recognized in the consolidated statement of assets and liabilities, for which it is practicable to estimate that value. Certain financial instruments are excluded from the disclosure requirements. Accordingly, the aggregate fair value amounts presented do not represent the underlying value of the Company.

The fair value amounts have been measured as of the reporting date and have not been reevaluated or updated for purposes of these financial statements subsequent to that date. As such, the fair values of these financial instruments subsequent to the reporting date may be different than amounts reported.

As of March 31, 2023 and  December 31, 2022, all of the balances of all the Company’s financial instruments were recorded at fair value, except for the Company’s borrowings, as previously described.

Market risk

The Company assumes interest rate risk (the risk that general interest rate levels will change) as a result of its normal operations. As a result, the fair values of the Company’s financial instruments will change when interest rate levels change, and that change may be either favorable or unfavorable to the Company. Management attempts to match maturities of assets and liabilities to the extent believed necessary to minimize interest rate risk. Management monitors rates and maturities of assets and liabilities and attempts to minimize interest rate risk by adjusting terms of new debt investments and by investing in securities with terms that mitigate the Company’s overall interest rate risk.

XML

Note 7 - Borrowings

3 Months Ended

Mar. 31, 2023

Notes to Financial Statements

Debt Disclosure [Text Block]

Note 7. Borrowings

The following table shows the Company’s borrowings as of March 31, 2023 and  December 31, 2022:

	March 31, 2023							December 31, 2022
	Total		Balance			Unused		Total		Balance			Unused
	Commitment		Outstanding			Commitment		Commitment		Outstanding			Commitment
	(In thousands)
Key Facility	$	125,000	$	15,000		$	110,000	$	125,000	$	5,000		$	120,000
NYL Facility		200,000		176,750			23,250		200,000		176,750			23,250
2019 Asset-Backed Notes		37,791		37,791			—		42,573		42,573			—
2022 Asset-Backed Notes		100,000		100,000			—		100,000		100,000			—
2027 Notes		57,500		57,500			—		57,500		57,500			—
2026 Notes		57,500		57,500			—		57,500		57,500			—
Total before debt issuance costs		577,791		444,541			133,250		582,573		439,323			143,250
Unamortized debt issuance costs attributable to term borrowings		—		(4,896	)		—		—		(5,245	)		—
Total borrowings outstanding, net	$	577,791	$	439,645		$	133,250	$	582,573	$	434,078		$	143,250

As of March 31, 2023, with certain limited exceptions, the Company, as a BDC, is only allowed to borrow amounts such that the Company’s asset coverage, as defined in the 1940 Act, is at least 150% after such borrowings. As of March 31, 2023, the asset coverage for borrowed amounts was 172%.

Credit Facilities

Key Facility

The Company entered into the Key Facility with Key effective November 4, 2013. On June 22, 2021, the Company amended the Key Facility, among other things, to amend the interest rate applied to the outstanding principal balance and to extend the period during which the Company  may request advances under the Key Facility to June 22, 2024. The Key Facility has an accordion feature which allows for an increase in the total loan commitment to $150 million from the $125 million commitment. The Key Facility is collateralized by all debt investments and warrants held by Credit II and permits an advance rate of up to 60% of eligible debt investments held by Credit II. The Key Facility contains covenants that, among other things, require the Company to maintain a minimum net worth and to restrict the debt investments securing the Key Facility to certain criteria for qualified debt investments and includes portfolio company concentration limits as defined in the related loan agreement. The Key Facility is scheduled to mature on June 22, 2026. The interest rate on the Key Facility is based on the rate of interest published in The Wall Street Journal as the prime rate in the United States plus 0.25%, with a prime rate floor of 4.25%. The prime rate was 8.00% and 7.50% on March 31, 2023 and  December 31, 2022, respectively. The average interest rate on the Key Facility for the three months ended March 31, 2023 and 2022 was 7.94% and 4.25%, respectively. The Key Facility requires the payment of an unused line fee in an amount up to 0.50% on an annualized basis of any unborrowed amount available under the facility. As of March 31, 2023 and  December 31, 2022, the Company had borrowing capacity under the Key Facility of $110.0 million and $120.0 million, respectively. At March 31, 2023 and  December 31, 2022, $47.7 million and $40.2 million, respectively, was available for borrowing, subject to existing terms and advance rates.

NYL Facility

On April 21, 2020, the Company purchased all of the limited liability company interests of Arena in HSLFI, which is a party to the NYL Facility. HFI entered into the NYL Facility with the NYL Noteholders for an aggregate purchase price of up to $100.0 million, with an accordion feature of up to $200.0 million at the mutual discretion and agreement of HSLFI and the NYL Noteholders. On June 1, 2018, HSLFI sold or contributed to HFI certain secured loans made to certain portfolio companies pursuant to the Sale and Servicing Agreement. Any notes issued by HFI are collateralized by all investments held by HFI and permit an advance rate of up to 67% of the aggregate principal amount of eligible debt investments. The notes were issued pursuant to the Indenture. The interest rate on the notes issued under the NYL Facility was based on the three year USD mid-market swap rate plus a margin of between 3.55% and 5.15% with an interest rate floor, depending on the rating of such notes at the time of issuance.

On February 25, 2022, the Company amended its NYL Facility, increasing the commitment by $100.0 million to enable its wholly-owned subsidiary to issue up to $200.0 million of secured notes. The amendment to the NYL Facility extends the investment period to June 2023 and the maturity date to June 2028. In addition, the amendment, among other things, reduces the applicable margin used to calculate the credit facility’s interest rate on the Company’s borrowings above $100.0 million. Such borrowings will be priced at the three-year USD mid-market swap rate plus 3.00%.

There were $176.8 million in advances made by the NYL Noteholders as of March 31, 2023 and  December 31, 2022. The interest rate as of March 31, 2023 and  December 31, 2022 was 5.57%. As of March 31, 2023 and  December 31, 2022, the Company had borrowing capacity under the NYL Facility of $23.2 million. At March 31, 2023 and  December 31, 2022, $21.1 million and $23.2 million, respectively, was available for borrowing, subject to existing terms and advance rates.

Under the terms of the NYL Facility, the Company is required to maintain a reserve cash balance, which may be used to pay monthly interest and principal payments on the NYL Facility. The Company has segregated these funds and classified them as restricted investments in money market funds. At  March 31, 2023 and December 31, 2022, there were approximately $1.3 million and $1.0 million, respectively, of restricted investments.

Securitizations

2019 Asset-Backed Notes

On August 13, 2019, the Company completed a term debt securitization in connection with which an affiliate of the Company made an offering of the 2019 Asset-Backed Notes. The 2019 Asset-Backed Notes were rated A+(sf) by Morningstar Credit Ratings, LLC. There has been no change in the rating since August 13, 2019.

The 2019 Asset-Backed Notes were issued by the 2019‑1 Trust pursuant to a note purchase agreement, dated as of August 13, 2019, by and among the Company and Keybanc Capital Markets Inc. as Initial Purchaser, and are backed by a pool of loans made to certain portfolio companies of the Company and secured by certain assets of those portfolio companies and are to be serviced by the Company. Interest on the 2019 Asset-Backed Notes will be paid, to the extent of funds available, at a fixed rate of 4.21% per annum. The reinvestment period of the 2019 Asset-Backed Notes ended July 15, 2021 and the maturity date is September 15, 2027.

As of March 31, 2023 and  December 31, 2022, the 2019 Asset-Backed Notes had an outstanding principal balance of $37.8 million and $42.6 million, respectively.

Under the terms of the 2019 Asset-Backed Notes, the Company is required to maintain a reserve cash balance, funded through proceeds from the sale of the 2019 Asset-Backed Notes, which may be used to pay monthly interest and principal payments on the 2019 Asset-Backed Notes. The Company has segregated these funds and classified them as restricted investments in money market funds. At March 31, 2023 and  December 31, 2022, there were approximately $0.5 million and $0.6 million of restricted investments, respectively.

2022 Asset-Backed Notes

On November 9, 2022, the Company completed a term debt securitization in connection with which an affiliate of the Company made an offering of the 2022 Asset-Backed Notes. The 2022 Asset-Backed Notes were rated A by DRBS, Inc. There has been no change in the rating since November 9, 2022.

The 2022 Asset-Backed Notes were issued by the 2022‑1 Trust pursuant to a note purchase agreement, dated as of November 9, 2022, by and among the Company and Keybanc Capital Markets Inc. as Initial Purchaser, and are backed by a pool of loans made to certain portfolio companies of the Company and secured by certain assets of those portfolio companies and are to be serviced by the Company. Interest on the 2022 Asset-Backed Notes will be paid, to the extent of funds available, at a fixed rate of 7.56% per annum. The reinvestment period of the 2022 Asset-Backed Notes ends November 15, 2024 and the maturity date is November 15, 2030.

As of  March 31, 2023 and  December 31, 2022, the 2022 Asset-Backed Notes had an outstanding principal balance of $100.0 million.

Under the terms of the 2022 Asset-Backed Notes, the Company is required to maintain a reserve cash balance, funded through proceeds from the sale of the 2022 Asset-Backed Notes, which may be used to pay monthly interest and principal payments on the 2022 Asset-Backed Notes. The Company has segregated these funds and classified them as restricted investments in money market funds. At  March 31, 2023 and  December 31, 2022, there were approximately $1.1 million and $1.0 million of restricted investments, respectively.

Unsecured Notes

2026 Notes

On March 30, 2021, the Company issued and sold an aggregate principal amount of $57.5 million of 4.875% notes due in 2026 (the “2026 Notes”). The amount of 2026 Notes issued and sold included the full exercise by the underwriters of their option to purchase $7.5 million in aggregate principal of additional notes. The 2026 Notes have a stated maturity of March 30, 2026 and may be redeemed in whole or in part at the Company’s option at any time or from time to time on or after March 30, 2023 at a redemption price of $25 per security plus accrued and unpaid interest. The 2026 Notes bear interest at a rate of 4.875% per year, payable quarterly on March 30, June 30, September 30 and December 30 of each year. The 2026 Notes are the Company’s direct unsecured obligations and (i) rank equally in right of payment with the Company’s current and future unsecured indebtedness; (ii) are senior in right of payment to any of the Company’s future indebtedness that expressly provides it is subordinated to the 2026 Notes; (iii) are effectively subordinated to all of the Company’s existing and future secured indebtedness (including indebtedness that is initially unsecured to which the Company subsequently grants security), to the extent of the value of the assets securing such indebtedness, and (iv) are structurally subordinated to all existing and future indebtedness and other obligations of any of the Company’s subsidiaries. As of March 31, 2023, the Company was in material compliance with the terms of the 2026 Notes. The 2026 Notes are listed on the New York Stock Exchange under the symbol “HTFB”.

2027 Notes

On June 15, 2022, the Company issued and sold an aggregate principal amount of $50.0 million of 6.25% notes due in 2027 and on July 11, 2022, pursuant to the underwriters’ 30 day option to purchase additional notes, the Company sold an additional $7.5 million of such notes (collectively, the “2027 Notes”). The 2027 Notes have a stated maturity of June 15, 2027 and may be redeemed in whole or in part at the Company’s option at any time or from time to time on or after June 15, 2024 at a redemption price of $25 per security plus accrued and unpaid interest. The 2027 Notes bear interest at a rate of 6.25% per year, payable quarterly on March 30, June 30, September 30 and December 30 of each year, commencing on September 30, 2022. The 2027 Notes are the Company’s direct unsecured obligations and (i) rank equally in right of payment with the Company’s current and future unsecured indebtedness; (ii) are senior in right of payment to any of the Company’s future indebtedness that expressly provides it is subordinated to the 2027 Notes; (iii) are effectively subordinated to all of the Company’s existing and future secured indebtedness (including indebtedness that is initially unsecured to which the Company subsequently grants security), to the extent of the value of the assets securing such indebtedness, and (iv) are structurally subordinated to all existing and future indebtedness and other obligations of any of the Company’s subsidiaries. As of March 31, 2023, the Company was in material compliance with the terms of the 2027 Notes. The 2027 Notes are listed on the New York Stock Exchange under the symbol “HTFC”.

XML

Note 8 - Financial Instruments With Off-balance-sheet Risk

3 Months Ended

Mar. 31, 2023

Notes to Financial Statements

Financial Instruments Disclosure [Text Block]

Note 8. Financial instruments with off-balance-sheet risk

In the normal course of business, the Company is party to financial instruments with off-balance-sheet risk to meet the financing needs of its borrowers. These financial instruments include commitments to extend credit and involve, to varying degrees, elements of credit risk in excess of the amount recognized in the consolidated statement of assets and liabilities. The Company attempts to limit its credit risk by conducting extensive due diligence and obtaining collateral where appropriate.

The balance of unfunded commitments to extend credit was $166.2 million and $190.0 million as of March 31, 2023 and  December 31, 2022, respectively. Commitments to extend credit consist principally of the unused portions of commitments that obligate the Company to extend credit, often subject to financial or non-financial milestones and other conditions to borrow that must be achieved before the commitment can be drawn. In addition, the commitments generally have fixed expiration dates or other termination clauses. Since commitments may expire without being drawn upon, the total commitment amounts do not necessarily represent future cash requirements. 

The following table provides the Company’s unfunded commitments by portfolio company as of March 31, 2023:

	March 31, 2023				December 31, 2022
			Fair Value of				Fair Value of
			Unfunded				Unfunded
	Principal		Commitment		Principal		Commitment
	Balance		Liability		Balance		Liability
	(In thousands)				(In thousands)
BrightInsight, Inc.	$	18,250	$	241	$	21,000	$	278
Britecore Holdings, Inc.		—		—		5,000		66
Castle Creek Biosciences		4,000		72		4,000		72
Corinth Medtech, Inc.		200		—		—		—
Divergent Technologies, Inc.		18,750		197		22,500		236
Engage3, LLC		8,000		40		8,000		40
Groundspeed Analytics, Inc.		15,500		150		15,000		150
Hound Labs, Inc.		7,500		88		7,500		88
KSQ Therapeutics, Inc.		10,000		100		10,000		100
Lytics, Inc.		4,000		52		5,000		65
Native Microbials, Inc.		—		—		7,500		72
Noodle Partners, Inc.		10,000		123		—		—
Optoro, Inc.		15,000		38		15,000		38
PDS Biotechnology Corporation		10,000		158		10,000		158
Robin Healthcare, Inc.		5,000		50		10,000		100
Scientia Vascular, Inc.		10,000		110		10,000		110
Slingshot Aerospace, Inc.		5,000		63		5,000		64
Swift Health Systems Inc.		18,500		—		25,500		105
Temperpack Technologies, Inc.		6,500		14		9,000		19
Total	$	166,200	$	1,496	$	190,000	$	1,761

The table above also provides the fair value of the Company’s unfunded commitment liability as of March 31, 2023 and December 31, 2022, which totaled $1.5 million and $1.8 million, respectively. The fair value at inception of the delay draw credit agreements is equal to the fees and/or warrants received to enter into these agreements, taking into account the remaining terms of the agreements and the counterparties’ credit profile. The unfunded commitment liability reflects the fair value of these future funding commitments and is included in the Company’s consolidated statement of assets and liabilities.

XML

Note 9 - Concentrations of Credit Risk

3 Months Ended

Mar. 31, 2023

Notes to Financial Statements

Concentration Risk Disclosure [Text Block]

Note 9. Concentrations of credit risk

The Company’s debt investments consist primarily of loans to development-stage companies at various stages of development in the technology, life science, healthcare information and services and sustainability industries. Many of these companies may have relatively limited operating histories and also may experience variation in operating results. Many of these companies conduct business in regulated industries and could be affected by changes in government regulations. Most of the Company’s borrowers will need additional capital to satisfy their continuing working capital needs and other requirements, and in many instances, to service the interest and principal payments on the loans.

The Company’s largest debt investments may vary from period to period as new debt investments are recorded and existing debt investments are repaid. The Company’s five largest debt investments, at cost and fair value, represented 23% of total debt investments outstanding as of March 31, 2023 and  December 31, 2022. No single debt investment represented more than 10% of the total debt investments at cost or fair value as of March 31, 2023 and  December 31, 2022. Investment income, consisting of interest and fees, can fluctuate significantly upon repayment of large debt investments. Interest income from the five largest debt investments at cost and fair value accounted for 22% and 26% of total interest and fee income on investments for the three months ended March 31, 2023 and 2022, respectively. 

XML

Note 10 - Distributions

3 Months Ended

Mar. 31, 2023

Notes to Financial Statements

Equity [Text Block]

Note 10. Distributions

The Company’s distributions are recorded on the declaration date. The following table summarizes the Company’s distribution activity for the three months ended March 31, 2023 and for the year ended December 31, 2022:

							DRIP		DRIP
Date			Amount		Cash		Shares		Share
Declared	Record Date	Payment Date	Per Share		Distribution		Issued		Value
			(In thousands, except share and per share data)
Three Months Ended March 31, 2023
2/23/2023	5/18/23	6/14/23	$	0.11	$	—		—	$	—
2/23/2023	4/18/23	5/16/23		0.11		—		—		—
2/23/2023	3/17/23	4/14/23		0.11		3,035		6,894		81
			$	0.33	$	3,035		6,894	$	81
Year Ended December 31, 2022
10/28/2022	2/17/23	3/15/23	$	0.11	$	3,040		6,764	$	75
10/28/2022	1/18/23	2/15/23		0.11		3,021		5,754		74
10/28/2022	12/19/22	1/13/23		0.11		2,978		5,618		69
10/28/2022	11/17/22	12/15/22		0.05		1,319		2,171		27
7/29/2022	11/17/22	12/15/22		0.10		2,638		4,341		57
7/29/2022	10/18/22	11/15/22		0.10		2,580		4,621		60
7/29/2022	9/19/22	10/14/22		0.10		2,558		7,703		81
4/29/2022	8/18/22	9/15/22		0.10		2,528		4,925		60
4/29/2022	7/19/22	8/16/22		0.10		2,484		3,939		55
4/29/2022	6/17/22	7/15/22		0.10		2,434		4,286		51
2/25/2022	5/18/22	6/15/22		0.10		2,378		4,428		50
2/25/2022	4/19/22	5/16/22		0.10		2,349		4,088		49
2/25/2022	3/18/22	4/14/22		0.10		2,352		3,221		46
			$	1.28	$	32,659		61,859	$	754

On April 28, 2023, the Board declared monthly distributions per share, payable as set forth in the following table:

Monthly distributions

Ex-Dividend Date	Record Date	Payment Date	Distributions Declared
June 15, 2023	June 16, 2023	July 14, 2023	$	0.11
July 17, 2023	July 18, 2023	August 15, 2023	$	0.11
August 16, 2023	August 17, 2023	September 15, 2023	$	0.11

After paying distributions of $0.33 per share and earning net investment income of $0.46 per share for the quarter, the Company’s undistributed spillover income as of March 31, 2023 was $0.81 per share. Spillover income includes any ordinary income and net capital gains from the preceding tax years that were not distributed during such tax years.

XML

Note 11 - Financial Highlights

3 Months Ended

Mar. 31, 2023

Notes to Financial Statements

Investment Company, Financial Highlights [Text Block]

Note 11. Financial highlights

The following table shows financial highlights for the Company:

	Three months ended March 31,
	2023				2022
	(In thousands, except share and per share data)
Per share data:
Net asset value at beginning of period	$	11.47			$	11.56
Net investment income		0.46				0.26
Realized loss		(0.01	)			—
Unrealized depreciation on investments		(0.26	)			(0.10	)
Net increase in net assets resulting from operations		0.19				0.16
Distributions declared (1)		(0.33	)			(0.30	)
From net investment income		(0.33	)			(0.30	)
From net realized gain on investments		—				—
Return of capital		—				—
Other (2)		0.01				0.26
Net asset value at end of period	$	11.34			$	11.68
Per share market value, beginning of period	$	11.60			$	15.92
Per share market value, end of period	$	11.28			$	13.90
Total return based on a market value (3)		0.1	%			(10.8	)%
Shares outstanding at end of period		28,377,357				23,977,137
Ratios to average net assets:
Expenses without incentive value (4)		14.8	%			10.6	%
Incentive fees (4)		3.7	%			2.2	%
Net expenses (4)		18.5	%			12.8	%
Net investment income with incentive fees (4)		16.3	%			8.7	%
Net assets at the end of the period	$	321,683			$	279,989
Average net asset value	$	320,066			$	262,662
Average debt per share	$	15.61			$	12.21
Portfolio turnover ratio		4.2	%	(5)		2.6	%	(5)

(1) Distributions are determined based on taxable income calculated in accordance with income tax regulations, which may differ from amounts determined under GAAP due to (i) changes in unrealized appreciation and depreciation, (ii) temporary and permanent differences in income and expense recognition, and (iii) the amount of spillover income carried over from a given tax year for distribution in the following tax year. The final determination of taxable income for each tax year, as well as the tax attributes for distributions in such tax year, will be made after the close of the tax year.

(2) Includes the impact of the different share amounts as a result of calculating per share data based on the weighted average basic shares outstanding during the period and certain per share data based on the shares outstanding as of a period end or transaction date. The issuance of common stock on a per share basis reflects the incremental net asset value changes as a result of the issuance of common stock in the Company’s continuous public offering and pursuant to the Company’s distribution reinvestment plan. The issuance of common stock at an offering price, net of sales commissions and dealer manager fees, that is greater than the net asset value per share results in an increase in net asset value per share.

(3) The total return equals the change in the ending market value over the beginning of period price per share plus distributions paid per share during the period, divided by the beginning price.

(4) Annualized.

(5) Calculated by dividing the lesser of purchases or the sum of (1) principal prepayments and (2) maturities by the monthly average debt investment balance.

XML

Note 12 - Subsequent Events

3 Months Ended

Mar. 31, 2023

Notes to Financial Statements

Subsequent Events [Text Block]

Note 12. Subsequent Events

In  April 2023, the Company sold 272,303 shares of common stock under the 2021 Equity Distribution Agreement. For the same period, the Company received total accumulated net proceeds of approximately $3.1 million, including $0.1 million of offering expenses, from these sales.

IMV Inc. (“IMV”) (NASDAQ: IMV; TSX: IMV), announced on May 1, 2023 that the Nova Scotia Supreme Court has issued an initial order (the “Initial Order”) granting IMV and its subsidiaries protection under the Companies’ Creditors Arrangement Act (R.S.C., 1985, c. C-36) and IMV will seek the recognition of the Initial Order in the United States by filing a petition commencing proceedings under the Chapter 15 of the United States Bankruptcy Code.

XML

Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2023

Accounting Policies [Abstract]

Consolidation, Policy [Policy Text Block]

Principles of consolidation

As required under GAAP and Regulation S-X, the Company will generally consolidate its investment in a company that is an investment company subsidiary or a controlled operating company whose business consists of providing services to the Company. Accordingly, the Company consolidated the results of the Company’s wholly-owned subsidiaries in its consolidated financial statements.

Assets related to transactions that do not meet Accounting Standards Codification (“ASC”) Topic 860, Transfers and Servicing requirements for accounting sale treatment are reflected in the Company’s Consolidated Statements of Assets and Liabilities as investments. Those assets are owned by special purpose entities, including 2019‑1 Entities and 2022-1 Entities, that are consolidated in the Company’s consolidated financial statements. The creditors of the special purpose entities have received security interests in such assets and such assets are not intended to be available to the creditors of the Company (or any affiliate of the Company).

Use of Estimates, Policy [Policy Text Block]

Use of estimates

In preparing the consolidated financial statements in accordance with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosures of contingent assets and liabilities, as of the date of the balance sheet and income and expenses for the period. Actual results could differ from those estimates. Material estimates that are particularly susceptible to significant change in the near term relate to the valuation of investments.

Fair Value Measurement, Policy [Policy Text Block]

Fair value

The Company records all of its investments at fair value in accordance with relevant GAAP, which establishes a framework used to measure fair value and requires disclosures for fair value measurements. The Company has categorized its investments carried at fair value, based on the priority of the valuation technique, into a three-level fair value hierarchy as more fully described in Note 6. Fair value is a market-based measure considered from the perspective of the market participant who holds the financial instrument rather than an entity specific measure. Therefore, when market assumptions are not readily available, the Company’s own assumptions are set to reflect those that management believes market participants would use in pricing the financial instrument at the measurement date.

The availability of observable inputs can vary depending on the financial instrument and is affected by a wide variety of factors, including, for example, the type of product, whether the product is new, whether the product is traded on an active exchange or in the secondary market and the current market conditions. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for financial instruments classified as Level 3.

See Note 6 for additional information regarding fair value.

Segment Reporting, Policy [Policy Text Block]

Segments

The Company has determined that it has a single reporting segment and operating unit structure. The Company lends to and invests in portfolio companies in various technology, life science, healthcare information and services and sustainability industries. The Company separately evaluates the performance of each of its lending and investment relationships. However, because each of these debt investments and investment relationships has similar business and economic characteristics, they have been aggregated into a single lending and investment segment.

Investment, Policy [Policy Text Block]

Investments

Investments are recorded at fair value. Pursuant to the amended SEC Rule 2a-5 of the 1940 Act, on July 29, 2022, the Company's board of directors (the “Board”) designated the Advisor as the Company’s “valuation designee.” The valuation designee determines the fair value of the Company’s portfolio investments and the Board oversees the valuation designee. The Company has the intent to hold its debt investments for the foreseeable future or until maturity or payoff.

Interest on debt investments is accrued and included in income based on contractual rates applied to principal amounts outstanding. Interest income is determined using a method that results in a level rate of return on principal amounts outstanding. Generally, when a debt investment becomes 90 days or more past due, or if the Company otherwise does not expect to receive interest and principal repayments, the debt investment is placed on non-accrual status and the recognition of interest income may be discontinued. Interest payments received on non-accrual debt investments may be recognized as income, on a cash basis, or applied to principal depending upon management’s judgment at the time the debt investment is placed on non-accrual status. As of March 31, 2023, there were three investments on nonaccrual status with a cost of $20.3 million and a fair value of $5.3 million. As of December 31, 2022, there were three investments on non-accrual status with a cost of $20.9 million and a fair value of $8.3 million. For the three months ended March 31, 2023 and 2022, the Company did not recognize any interest income received from debt investments on non-accrual status.

The Company receives a variety of fees from borrowers in the ordinary course of conducting its business, including advisory fees, commitment fees, amendment fees, non-utilization fees, success fees and prepayment fees. In a limited number of cases, the Company may also receive a non-refundable deposit earned upon the termination of a transaction. Debt investment origination fees, net of certain direct origination costs, are deferred and, along with unearned income, are amortized as a level-yield adjustment over the respective term of the debt investment. All other income is recognized when earned. Fees for counterparty debt investment commitments with multiple debt investments are allocated to each debt investment based upon each debt investment’s relative fair value. When a debt investment is placed on non-accrual status, the amortization of the related fees and unearned income is discontinued until the debt investment is returned to accrual status.

Certain debt investment agreements also require the borrower to make an ETP, that is accrued into interest receivable and taken into income over the life of the debt investment to the extent such amounts are expected to be collected. The Company will generally cease accruing the income if there is insufficient value to support the accrual or the Company does not expect the borrower to be able to pay the ETP when due. The proportion of the Company’s total investment income that resulted from the portion of ETPs not received in cash for the three months ended  March 31, 2023 and 2022 was 6.3% and 9.5%, respectively. 

In connection with substantially all lending arrangements, the Company receives warrants to purchase shares of stock from the borrower. The warrants are recorded as assets at estimated fair value on the grant date using the Black-Scholes valuation model. The warrants are considered loan fees and are recorded as unearned income on the grant date. The unearned income is recognized as interest income over the contractual life of the related debt investment in accordance with the Company’s income recognition policy. Subsequent to debt investment origination, the fair value of the warrants is determined using the Black-Scholes valuation model. Any adjustment to fair value is recorded through earnings as net unrealized appreciation or depreciation on investments. Gains and losses from the disposition of the warrants or stock acquired from the exercise of warrants are recognized as realized gains and losses on investments.

Realized gains or losses on the sale of investments, or upon the determination that an investment balance, or portion thereof, is not recoverable, are calculated using the specific identification method. The Company measures realized gains or losses by calculating the difference between the net proceeds from the repayment or sale and the amortized cost basis of the investment. Net change in unrealized appreciation or depreciation reflects the change in the fair values of the Company’s portfolio investments during the reporting period, including any reversal of previously recorded unrealized appreciation or depreciation when gains or losses are realized.

Debt, Policy [Policy Text Block]

Debt issuance costs

Debt issuance costs are fees and other direct incremental costs incurred by the Company in obtaining debt financing from its lenders and issuing debt securities. The unamortized balance of debt issuance costs as of  March 31, 2023 and  December 31, 2022 was $6.6 million and $7.1 million, respectively. These amounts are amortized and included in interest expense in the consolidated statements of operations over the life of the borrowings. The accumulated amortization balances as of March 31, 2023 and  December 31, 2022 were $5.3 million and $4.8 million, respectively. The amortization expense for the three months ended March 31, 2023 and 2022 was $0.5 million and $0.3 million, respectively. 

Income Tax, Policy [Policy Text Block]

Income taxes

As a BDC, the Company has elected to be treated as a RIC under Subchapter M of the Code and operates in a manner so as to qualify for the tax treatment applicable to RICs. In order to qualify as a RIC and to avoid the imposition of corporate-level income tax on the portion of its taxable income distributed to stockholders, among other things, the Company is required to meet certain source of income and asset diversification requirements and to timely distribute dividends out of assets legally available for distribution to its stockholders of an amount generally at least equal to 90% of its investment company taxable income, as defined by the Code and determined without regard to any deduction for dividends paid, for each tax year. The Company, among other things, has made and intends to continue to make the requisite distributions to its stockholders, which generally relieves the Company from corporate-level U.S. federal income taxes. Accordingly, no provision for federal income tax has been recorded in the financial statements. Differences between taxable income and net increase in net assets resulting from operations either can be temporary, meaning they will reverse in the future, or permanent. In accordance with ASC Topic 946, Financial Services—Investment Companies, as amended, of the Financial Accounting Standards Board (“FASB”), permanent tax differences, such as non-deductible excise taxes paid, are reclassified from distributions in excess of net investment income and net realized loss on investments to paid-in-capital at the end of each fiscal year. These permanent book-to-tax differences are reclassified on the consolidated statements of changes in net assets to reflect their tax character but have no impact on total net assets. 

Depending on the level of taxable income earned in a tax year, the Company may choose to carry forward taxable income in excess of current year distributions into the next tax year and incur a 4% U.S. federal excise tax on such income, as required. To the extent that the Company determines that its estimated current year annual taxable income will be in excess of estimated current year distributions, the Company accrues excise tax, if any, on estimated excess taxable income as taxable income is earned. For the three months ended March 31, 2023 and 2022, $0.2 million and $0.1 million, respectively, was accrued for U.S. federal excise tax. 

The Company evaluates tax positions taken in the course of preparing the Company’s tax returns to determine whether the tax positions are “more-likely-than-not” to be sustained by the applicable tax authority in accordance with ASC Topic 740, Income Taxes, as modified by ASC Topic 946. Tax benefits of positions not deemed to meet the more-likely-than-not threshold, or uncertain tax positions, would be recorded as a tax expense in the current year. It is the Company’s policy to recognize accrued interest and penalties related to uncertain tax benefits in income tax expense. The Company had no material uncertain tax positions at March 31, 2023 and  December 31, 2022. The Company’s income tax returns for the 2021, 2020 and 2019 tax years remain subject to examination by U.S. federal and state tax authorities.

Distributions [Policy Text Block]

Distributions

Distributions to common stockholders are recorded on the declaration date. The amount to be paid out as distributions is determined by the Board. Net realized capital gains, if any, may be distributed, although the Company may decide to retain such net realized gains for investment.

The Company has adopted a dividend reinvestment plan that provides for reinvestment of cash distributions on behalf of its stockholders, unless a stockholder elects to receive cash. As a result, if the Board declares a cash distribution, then stockholders who have not “opted out” of the dividend reinvestment plan will have their cash distributions automatically reinvested in additional shares of the Company’s common stock, rather than receiving the cash distribution. The Company may issue new shares or purchase shares in the open market to fulfill its obligations under the plan.

Stockholders' Equity, Policy [Policy Text Block]

Stockholders’ Equity

On August 2, 2021, the Company entered into an At-The-Market (“ATM”) sales agreement (the “2021 Equity Distribution Agreement”), with Goldman Sachs & Co. LLC and B. Riley FBR, Inc. (each a “Sales Agent” and, collectively, the “Sales Agents”). The 2021 Equity Distribution Agreement provides that the Company may offer and sell its shares from time to time through the Sales Agents up to $100.0 million worth of its common stock, in amounts and at times to be determined by the Company. Sales of the Company’s common stock, if any, may be made in negotiated transactions or transactions that are deemed to be “at-the-market,” as defined in Rule 415 under the Securities Act, including sales made directly on the Nasdaq or similar securities exchange or sales made to or through a market maker other than on an exchange, at prices related to the prevailing market prices or at negotiated prices.

During the three months ended March 31, 2023, the Company sold 605,848 shares of common stock under the 2021 Equity Distribution Agreement. For the same period, the Company received total accumulated net proceeds of approximately $7.2 million, including $0.2 million of offering expenses, from these sales.

During the three months ended March 31, 2022, the Company sold 250,171 shares of common stock under the 2021 Equity Distribution Agreement. For the same period, the Company received total accumulated net proceeds of approximately $3.9 million, including $0.1 million of offering expenses, from these sales.

On  March 14, 2022, the Company completed a follow-on public offering of 2,500,000 shares of its common stock at a public offering price of $14.35 per share, for total net proceeds to the Company of $34.3 million, after deducting underwriting commission and discounts and other offering expenses.

The Company generally uses net proceeds from these offerings to make investments, to pay down liabilities and for general corporate purposes. As of March 31, 2023, shares representing approximately $24.1 million of its common stock remain available for issuance and sale under the 2021 Equity Distribution Agreement.

Stock Repurchase Program [Policy Text Block]

Stock Repurchase Program

On April 28, 2023, the Board extended a previously authorized stock repurchase program which allows the Company to repurchase up to $5.0 million of its common stock at prices below the Company’s net asset value per share as reported in its most recent consolidated financial statements. Under the repurchase program, the Company may, but is not obligated to, repurchase shares of its outstanding common stock in the open market or in privately negotiated transactions from time to time. Any repurchases by the Company will comply with the requirements of Rule 10b‑18 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and any applicable requirements of the 1940 Act. Unless extended by the Board, the repurchase program will terminate on the earlier of June 30, 2024 or the repurchase of $5.0 million of the Company’s common stock. During the three months ended March 31, 2023 and 2022, the Company did not make any repurchases of its common stock. From the inception of the stock repurchase program through March 31, 2023, the Company repurchased 167,465 shares of its common stock at an average price of $11.22 on the open market at a total cost of $1.9 million.

Transfers and Servicing of Financial Assets, Policy [Policy Text Block]

Transfers of financial assets

Assets related to transactions that do not meet the requirements under ASC Topic 860, Transfers and Servicing for sale treatment under GAAP are reflected in the Company’s consolidated statements of assets and liabilities as investments. Those assets are owned by special purpose entities that are consolidated in the Company’s financial statements. The creditors of the special purpose entities have received security interests in such assets and such assets are not intended to be available to the creditors of the Company (or any other affiliate of the Company).

Transfers of financial assets are accounted for as sales when control over the assets has been surrendered. Control over transferred assets is deemed to be surrendered when (1) the assets have been isolated from the Company — put presumptively beyond the reach of the transferor and its creditors, even in bankruptcy or other receivership, (2) the transferee obtains the right (free of conditions that constrain it from taking advantage of that right) to pledge or exchange the transferred assets and (3) the transferor does not maintain effective control over the transferred assets through either (a) an agreement that both entitles and obligates the transferor to repurchase or redeem the assets before maturity or (b) the ability to unilaterally cause the holder to return specific assets, other than through a cleanup call.

New Accounting Pronouncements, Policy [Policy Text Block]

Recently issued accounting pronouncement

In June 2022, the FASB issued Accounting Standards Update No. 2022-03, Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU 2022-03”). ASU 2022-03 clarifies the guidance when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of the security. The amendments in ASU 2022-03 are effective for public companies for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The Company is currently assessing the impact of ASU 2022-03 on its consolidated financial statements.

XML

Consolidated Schedule of Investments (Unaudited) (Tables)

3 Months Ended

Mar. 31, 2023

Notes Tables

Investment [Table Text Block]

Portfolio Company (1)(3)	Sector	Type of Investment (7)	Cash Rate (4)			Index	Margin			Floor			Ceiling			ETP (10)			Maturity Date	Principal Amount		Cost of Investments (6)(9)		Fair Value (9)
Non-Affiliate Investments — 222.1% (8)
Non-Affiliate Debt Investments — 212.8% (8)
Non-Affiliate Debt Investments — Life Science — 95.7% (8)
Avalo Therapeutics, Inc. (2)(5)(12)	Biotechnology	Term Loan		14.25	%	Prime		6.25	%		9.50	%		-			3.00	%	January 1, 2025	$	2,913	$	2,860	$	2,779
		Term Loan		14.25	%	Prime		6.25	%		9.50	%		-			3.00	%	January 1, 2025		2,885		2,832		2,752
		Term Loan		14.25	%	Prime		6.25	%		9.50	%		-			3.00	%	January 1, 2025		1,442		1,416		1,375
		Term Loan		14.25	%	Prime		6.25	%		9.50	%		-			3.00	%	February 1, 2025		2,885		2,829		2,749
		Term Loan		14.25	%	Prime		6.25	%		9.50	%		-			3.00	%	February 1, 2025		2,885		2,829		2,749
		Term Loan		14.25	%	Prime		6.25	%		9.50	%		-			3.00	%	April 1, 2025		1,442		1,412		1,370
		Term Loan		14.25	%	Prime		6.25	%		9.50	%		-			3.00	%	April 1, 2025		1,442		1,412		1,370
Castle Creek Biosciences, Inc. (2)(12)	Biotechnology	Term Loan		12.88	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		5,000		4,895		4,895
		Term Loan		12.88	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		5,000		4,967		4,967
		Term Loan		12.88	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		3,000		2,977		2,977
		Term Loan		12.88	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		5,000		4,967		4,967
		Term Loan		12.88	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		5,000		4,970		4,970
		Term Loan		12.88	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		3,000		2,980		2,980
Emalex Biosciences, Inc. (2)(12)	Biotechnology	Term Loan		12.57	%	Libor		4.72	%		9.75	%		-			5.00	%	June 1, 2024		1,979		1,965		1,965
		Term Loan		12.57	%	Libor		4.72	%		9.75	%		-			5.00	%	June 1, 2024		1,979		1,966		1,966
		Term Loan		12.57	%	Libor		4.72	%		9.75	%		-			5.00	%	November 1, 2025		5,000		4,930		4,930
		Term Loan		12.57	%	Libor		4.72	%		9.75	%		-			5.00	%	May 1, 2026		5,000		4,921		4,921
Evelo Biosciences, Inc. (2)(5)(12)	Biotechnology	Term Loan		12.25	%	Prime		4.25	%		11.00	%		-			4.25	%	January 1, 2028		10,000		9,880		9,880
		Term Loan		12.25	%	Prime		4.25	%		11.00	%		-			4.25	%	January 1, 2028		15,000		14,819		14,819
		Term Loan		12.25	%	Prime		4.25	%		11.00	%		-			4.25	%	January 1, 2028		6,000		5,928		5,928
		Term Loan		12.25	%	Prime		4.25	%		11.00	%		-			4.25	%	January 1, 2028		6,000		5,928		5,928
		Term Loan		12.25	%	Prime		4.25	%		11.00	%		-			4.25	%	January 1, 2028		4,000		3,952		3,952
		Term Loan		12.25	%	Prime		4.25	%		11.00	%		-			4.25	%	January 1, 2028		4,000		3,952		3,952
Greenlight Biosciences, Inc. (2)(5)(12)	Biotechnology	Term Loan		13.75	%	Prime		5.75	%		9.00	%		-			3.00	%	July 1, 2025		4,500		4,371		4,352
		Term Loan		13.75	%	Prime		5.75	%		9.00	%		-			3.00	%	July 1, 2025		2,250		2,187		2,177
IMV Inc. (2)(5)(12)	Biotechnology	Term Loan		13.75	%	Prime		5.75	%		9.00	%		-			5.00	%	July 1, 2025		5,000		4,951		4,759
		Term Loan		13.75	%	Prime		5.75	%		9.00	%		-			5.00	%	July 1, 2025		2,500		2,476		2,380
		Term Loan		13.75	%	Prime		5.75	%		9.00	%		-			5.00	%	January 1, 2026		5,000		4,953		4,761
		Term Loan		13.75	%	Prime		5.75	%		9.00	%		-			5.00	%	January 1, 2026		5,000		4,953		4,761
KSQ Therapeutics, Inc. (2) (12)	Biotechnology	Term Loan		12.75	%	Prime		4.75	%		8.50	%		-			5.50	%	May 1, 2027		6,250		6,082		6,082
		Term Loan		12.75	%	Prime		4.75	%		8.50	%		-			5.50	%	May 1, 2027		6,250		6,182		6,182
Native Microbials, Inc (2) (12)	Biotechnology	Term Loan		13.25	%	Prime		5.25	%		8.50	%		-			5.00	%	November 1, 2026		3,750		3,707		3,707
		Term Loan		13.25	%	Prime		5.25	%		8.50	%		-			5.00	%	November 1, 2026		2,500		2,472		2,472
PDS Biotechnology Corporation (2)(5)(12)	Biotechnology	Term Loan		13.75	%	Prime		5.75	%		9.75	%		-			3.75	%	September 1, 2026		10,000		9,714		9,714
		Term Loan		13.75	%	Prime		5.75	%		9.75	%		-			3.75	%	September 1, 2026		3,750		3,702		3,702
		Term Loan		13.75	%	Prime		5.75	%		9.75	%		-			3.75	%	September 1, 2026		3,750		3,702		3,702
Provivi, Inc. (2)(12)	Biotechnology	Term Loan		13.17	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		4,667		4,606		4,606
		Term Loan		13.17	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		4,667		4,606		4,606
		Term Loan		13.17	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		2,333		2,287		2,287
		Term Loan		13.17	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		2,333		2,287		2,287
		Term Loan		13.17	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		2,333		2,282		2,282
		Term Loan		13.17	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		2,333		2,282		2,282

Portfolio Company (1)(3)	Sector	Type of Investment (7)	Cash Rate (4)			Index	Margin			Floor			Ceiling		ETP (10)			Maturity Date	Principal Amount		Cost of Investments (6)(9)		Fair Value (9)
Stealth Biotherapeutics Inc. (2)(12)	Biotechnology	Term Loan		13.50	%	Prime		5.50	%		8.75	%		-		6.00	%	October 1, 2025		5,000		4,922		4,922
		Term Loan		13.50	%	Prime		5.50	%		8.75	%		-		6.00	%	October 1, 2025		2,500		2,461		2,461
Aerobiotix, LLC (2)(12)	Medical Device	Term Loan		14.25	%	Prime		6.25	%		9.50	%		-		6.00	%	April 1, 2026		2,500		2,467		2,361
		Term Loan		14.25	%	Prime		6.25	%		9.50	%		-		6.00	%	April 1, 2026		2,500		2,467		2,361
Ceribell, Inc. (2)(12)	Medical Device	Term Loan		11.25	%	Prime		3.50	%		8.25	%		-		5.50	%	October 1, 2024		5,000		4,977		4,977
		Term Loan		11.25	%	Prime		3.50	%		8.25	%		-		5.50	%	October 1, 2024		5,000		4,977		4,977
		Term Loan		11.25	%	Prime		3.50	%		8.25	%		-		5.50	%	October 1, 2024		2,500		2,481		2,481
		Term Loan		11.25	%	Prime		3.50	%		8.25	%		-		5.50	%	October 1, 2024		2,500		2,481		2,481
Cognoa, Inc. (2)(12)	Medical Device	Term Loan		13.50	%	Prime		5.50	%		8.75	%		-		6.00	%	August 1, 2026		5,000		4,940		4,940
		Term Loan		13.50	%	Prime		5.50	%		8.75	%		-		6.00	%	August 1, 2026		2,500		2,470		2,470
Conventus Orthopaedics, Inc. (2)(12)	Medical Device	Term Loan		12.67	%	Libor		8.00	%		9.25	%		-		10.36	%	July 1, 2025		3,960		3,904		3,904
		Term Loan		12.67	%	Libor		8.00	%		9.25	%		-		10.36	%	July 1, 2025		3,960		3,904		3,904
Corinth Medtech, Inc. (2)(12)	Medical Device	Term Loan		13.00	% (11)	Prime		5.25	%		8.50	%		-		20.00	%	June 30, 2023		2,528		2,528		2,528
		Term Loan		13.00	% (11)	Prime		5.25	%		8.50	%		-		20.00	%	June 30, 2023		2,528		2,528		2,528
		Term Loan		13.00	% (11)	Prime		5.25	%		8.50	%		-		50.00	%	June 30, 2023		200		200		200
CSA Medical, Inc. (2)(12)	Medical Device	Term Loan		12.87	%	Libor		8.20	%		10.00	%		-		5.00	%	January 1, 2024		1,250		1,239		1,239
		Term Loan		12.87	%	Libor		8.20	%		10.00	%		-		5.00	%	January 1, 2024		83		83		83
		Term Loan		12.87	%	Libor		8.20	%		10.00	%		-		5.00	%	March 1, 2024		1,600		1,587		1,587
InfoBionic, Inc. (2)(12)	Medical Device	Term Loan		14.00	%	Prime		6.25	%		9.50	%		-		4.00	%	October 1, 2024		2,771		2,715		2,715
		Term Loan		14.00	%	Prime		6.25	%		9.50	%		-		4.00	%	June 1, 2025		1,000		977		977
Magnolia Medical Technologies, Inc. (2)(12)	Medical Device	Term Loan		12.75	%	Prime		5.00	%		9.75	%		-		4.00	%	March 1, 2025		5,000		4,946		4,946
		Term Loan		12.75	%	Prime		5.00	%		9.75	%		-		4.00	%	March 1, 2025		5,000		4,946		4,946
		Term Loan		12.75	%	Prime		5.00	%		9.75	%		-		4.00	%	March 1, 2025		5,000		4,940		4,940
		Term Loan		12.75	%	Prime		5.00	%		9.75	%		-		4.00	%	March 1, 2025		5,000		4,941		4,941
		Term Loan		12.75	%	Prime		5.00	%		9.75	%		-		4.00	%	January 1, 2027		5,000		4,920		4,920
		Term Loan		12.75	%	Prime		5.00	%		9.75	%		-		4.00	%	January 1, 2027		5,000		4,920		4,920
Robin Healthcare, Inc. (2)(12)	Medical Device	Term Loan		13.50	%	Prime		5.50	%		10.25	%		-		4.00	%	November 1, 2026		3,500		3,413		3,413
		Term Loan		13.50	%	Prime		5.50	%		10.25	%		-		4.00	%	November 1, 2026		3,500		3,463		3,463
Scientia Vascular, Inc. (2)(12)	Medical Device	Term Loan		12.50	%	Prime		4.75	%		8.50	%		-		5.00	%	January 1, 2027		3,750		3,601		3,601
		Term Loan		12.50	%	Prime		4.75	%		8.50	%		-		5.00	%	January 1, 2027		3,750		3,710		3,710
Sonex Health, Inc. (2)(12)	Medical Device	Term Loan		14.25	%	Prime		6.50	%		9.75	%		-		8.00	%	June 1, 2025		2,500		2,478		2,478
		Term Loan		14.25	%	Prime		6.50	%		9.75	%		-		8.00	%	June 1, 2025		2,500		2,478		2,478
		Term Loan		14.25	%	Prime		6.50	%		9.75	%		-		8.00	%	June 1, 2025		2,500		2,478		2,478
		Term Loan		14.25	%	Prime		6.50	%		9.75	%		-		8.00	%	April 1, 2026		2,500		2,459		2,459
		Term Loan		14.25	%	Prime		6.50	%		9.75	%		-		8.00	%	May 1, 2026		2,500		2,458		2,458
Spineology, Inc. (2)(12)	Medical Device	Term Loan		15.00	%	Prime		7.00	%		10.25	%		-		1.00	%	October 1, 2025		5,000		4,969		4,969
		Term Loan		15.00	%	Prime		7.00	%		10.25	%		-		1.00	%	April 1, 2026		2,500		2,483		2,483

Portfolio Company (1)(3)	Sector	Type of Investment (7)	Cash Rate (4)			Index	Margin			Floor			Ceiling		ETP (10)			Maturity Date	Principal Amount		Cost of Investments (6)(9)		Fair Value (9)
Swift Health Systems Inc. (2)(12)	Medical Device	Term Loan		13.00	%	Prime		5.25	%		9.00	%		-		5.00	%	July 1, 2027		3,500		3,457		3,457
		Term Loan		13.00	%	Prime		5.25	%		9.00	%		-		5.00	%	July 1, 2027		3,500		3,457		3,457
		Term Loan		13.25	%	Prime		5.25	%		9.00	%		-		5.00	%	July 1, 2027		3,500		3,447		3,447
		Term Loan		13.25	%	Prime		5.25	%		9.00	%		-		5.00	%	July 1, 2027		3,500		3,447		3,447
Total Non-Affiliate Debt Investments — Life Science																						309,108		307,749
Non-Affiliate Debt Investments — Sustainability — 25.8% (8)
Aerofarms, Inc. (2)(12)	Other Sustainability	Term Loan		14.75	%	Prime		6.75	%		10.00	%		-		3.00	%	April 1, 2026		3,750		3,704		3,585
		Term Loan		14.75	%	Prime		6.75	%		10.00	%		-		3.00	%	April 1, 2026		3,750		3,704		3,585
Nexii Building Solutions, Inc. (2)(12)	Other Sustainability	Term Loan		15.00	%	Prime		7.00	%		10.25	%		-		2.50	%	September 1, 2025		7,500		7,383		7,245
		Term Loan		15.00	%	Prime		7.00	%		10.25	%		-		2.50	%	September 1, 2025		7,500		7,383		7,245
		Term Loan		15.00	%	Prime		7.00	%		10.25	%		-		2.50	%	September 1, 2025		7,500		7,383		7,245
		Term Loan		15.00	%	Prime		7.00	%		10.25	%		-		2.50	%	July 1, 2026		5,000		4,912		4,820
		Term Loan		15.00	%	Prime		7.00	%		10.25	%		-		2.50	%	July 1, 2026		5,000		4,912		4,820
Soli Organic, Inc. (2)(12)	Other Sustainability	Term Loan		14.75	%	Prime		6.75	%		10.00	%		-		2.75	%	April 1, 2026		5,000		4,935		4,935
		Term Loan		14.75	%	Prime		6.75	%		10.00	%		-		2.75	%	April 1, 2026		2,500		2,467		2,467
		Term Loan		14.75	%	Prime		6.75	%		10.00	%		-		2.75	%	May 1, 2026		5,000		4,932		4,932
		Term Loan		14.75	%	Prime		6.75	%		10.00	%		-		2.75	%	May 1, 2026		2,500		2,466		2,466
		Term Loan		13.50	%	Prime		5.50	%		11.75	%		-		2.75	%	December 1, 2026		5,000		4,909		4,909
		Term Loan		13.50	%	Prime		5.50	%		11.75	%		-		2.75	%	December 1, 2026		2,500		2,454		2,454
Temperpack Technologies, Inc. (2)(12)	Other Sustainability	Term Loan		14.75	%	Prime		6.75	%		10.00	%		-		2.50	%	June 1, 2025		3,750		3,706		3,706
		Term Loan		14.75	%	Prime		6.75	%		10.00	%		-		2.50	%	June 1, 2025		3,750		3,720		3,720
		Term Loan		14.75	%	Prime		6.75	%		10.00	%		-		2.50	%	October 1, 2025		7,500		7,431		7,431
		Term Loan		14.75	%	Prime		6.75	%		10.00	%		-		2.50	%	October 1, 2025		3,750		3,715		3,715
		Term Loan		14.75	%	Prime		6.75	%		10.00	%		-		2.50	%	October 1, 2025		3,750		3,715		3,715
Total Non-Affiliate Debt Investments — Sustainability																						83,831		82,995
Non-Affiliate Debt Investments — Technology — 83.2% (8)
Axiom Space, Inc. (2)(12)	Communications	Term Loan		13.75	%	Prime		6.00	%		9.25	%		-		2.50	%	June 1, 2026		7,500		7,459		7,459
		Term Loan		13.75	%	Prime		6.00	%		9.25	%		-		2.50	%	June 1, 2026		7,500		7,459		7,459
		Term Loan		13.75	%	Prime		6.00	%		9.25	%		-		2.50	%	June 1, 2026		7,500		7,459		7,459
Better Place Forests Co. (12)(13)	Consumer-related Technologies	Term Loan		14.25	%	Prime		6.25	%		9.50	%		-		1.85	%	July 1, 2025		5,000		4,951		3,467
		Term Loan		14.25	%	Prime		6.25	%		9.50	%		-		1.85	%	October 1, 2025		2,500		2,474		1,733
CAMP NYC, Inc. (2)(12)	Consumer-related Technologies	Term Loan		15.25	%	Prime		7.25	%		10.50	%		-		3.00	%	May 1, 2026		3,500		3,464		3,464
Clara Foods Co. (2)(12)	Consumer-related Technologies	Term Loan		13.50	%	Prime		5.75	%		9.00	%		-		5.50	%	August 1, 2025		2,333		2,318		2,318
		Term Loan		13.50	%	Prime		5.75	%		9.00	%		-		5.50	%	August 1, 2025		2,333		2,318		2,318

Portfolio Company (1)(3)	Sector	Type of Investment (7)	Cash Rate (4)			Index	Margin			Floor			Ceiling			ETP (10)			Maturity Date	Principal Amount		Cost of Investments (6)(9)		Fair Value (9)
Divergent Technologies, Inc. (2)(12)	Consumer-related Technologies	Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		3,750		3,520		3,520
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		1,250		1,239		1,239
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		3,750		3,717		3,717
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		1,250		1,239		1,239
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		3,750		3,717		3,717
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		1,250		1,239		1,239
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	January 1, 2028		3,750		3,701		3,701
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	January 1, 2028		3,750		3,701		3,701
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	April 1, 2028		3,750		3,698		3,698
Havenly, Inc. (2)(12)	Consumer-related Technologies	Term Loan		13.00	%	Prime		5.00	%		5.00	%		-			4.00	%	March 1, 2027		2,000		1,165		1,165
		Term Loan		13.00	%	Prime		5.00	%		5.00	%		-			4.00	%	March 1, 2027		3,000		1,748		1,748
		Term Loan		11.50	%	Prime		3.50	%		10.50	%		-			7.78	%	February 1, 2028		2,813		2,813		2,813
		Term Loan		11.50	%	Prime		3.50	%		10.50	%		-			7.78	%	February 1, 2028		2,813		2,813		2,813
Interior Define, Inc. (2)(12)(13)	Consumer-related Technologies	Term Loan		14.50	%	Prime		6.50	%		9.75	%		-			4.00	%	January 1, 2026		3,246		3,162		—
		Term Loan		14.50	%	Prime		6.50	%		9.75	%		-			4.00	%	January 1, 2026		2,963		2,886		—
Lyrical Foods, Inc. (2)(12)	Consumer-related Technologies	Term Loan		10.50	%	Prime		2.50	%		8.00	%		-			-		September 1, 2027		2,598		2,586		2,330
MyForest Foods Co. (2)(12)	Consumer-related Technologies	Term Loan		14.75	%	Prime		6.75	%		10.00	%		-			3.00	%	October 1, 2025		5,000		4,961		4,961
		Term Loan		14.75	%	Prime		6.75	%		10.00	%		-			3.00	%	October 1, 2025		2,500		2,480		2,480
NextCar Holding Company, Inc. (2)(12)	Consumer-related Technologies	Term Loan		13.50	% (11)	Prime		5.75	%		9.00	%		-			5.25	%	October 31, 2023		5,169		5,121		4,883
		Term Loan		13.50	% (11)	Prime		5.75	%		9.00	%		-			5.25	%	October 31, 2023		2,067		2,050		1,955
		Term Loan		13.50	% (11)	Prime		5.75	%		9.00	%		-			5.25	%	October 31, 2023		2,584		2,564		2,446
		Term Loan		13.50	% (11)	Prime		5.75	%		9.00	%		-			5.25	%	October 31, 2023		3,101		3,076		2,934
		Term Loan		13.50	% (11)	Prime		5.75	%		9.00	%		-			5.25	%	October 31, 2023		2,584		2,548		2,430
		Term Loan		13.50	% (11)	Prime		5.75	%		9.00	%		-			5.25	%	October 31, 2023		2,584		2,548		2,430
		Term Loan		13.50	% (11)	Prime		5.75	%		9.00	%		-			5.25	%	October 31, 2023		5,169		5,093		4,859
		Term Loan		13.50	% (11)	Prime		5.75	%		9.00	%		-			5.25	%	October 31, 2023		2,584		2,545		2,428
Optoro, Inc. (2)(12)	Consumer-related Technologies	Term Loan		14.00	%	Prime		6.25	%		9.50	%		-			4.00	%	August 1, 2027		2,500		2,355		2,355
Primary Kids, Inc. (2)(12)	Consumer-related Technologies	Term Loan		15.00	%	Prime		7.25	%		10.50	%		-			3.00	%	March 1, 2025		2,300		2,277		2,277
		Term Loan		15.00	%	Prime		7.25	%		10.50	%		-			3.00	%	March 1, 2025		2,300		2,277		2,277
		Term Loan		15.00	%	Prime		7.25	%		10.50	%		-			3.00	%	September 1, 2025		2,900		2,870		2,870
Unagi, Inc. (2)(12)	Consumer-related Technologies	Term Loan		15.75	% (11)	Prime		7.75	%		11.00	%		-			-		May 1, 2027		1,065		1,041		1,041
		Term Loan		15.75	% (11)	Prime		7.75	%		11.00	%		-			-		May 1, 2027		533		520		520
		Term Loan		15.75	% (11)	Prime		7.75	%		11.00	%		-			-		May 1, 2027		533		521		521
Liqid, Inc. (2)(12)	Networking	Term Loan		14.00	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		2,833		2,793		2,793
		Term Loan		14.00	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		2,833		2,793		2,793
		Term Loan		14.00	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		1,417		1,395		1,395
		Term Loan		14.00	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		1,417		1,395		1,395
		Term Loan		14.00	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		1,417		1,371		1,371
BriteCore Holdings, Inc. (2)(12)	Software	Term Loan		14.50	%	Prime		6.75	%		10.00	%		-			5.00	%	March 1, 2026		2,500		2,488		2,488
		Term Loan		14.50	%	Prime		6.75	%		10.00	%		-			5.00	%	March 1, 2026		2,500		2,488		2,488
		Term Loan		14.50	%	Prime		6.75	%		10.00	%		-			3.00	%	March 1, 2027		2,500		2,467		2,467
		Term Loan		14.50	%	Prime		6.75	%		10.00	%		-			3.00	%	March 1, 2027		2,500		2,467		2,467
Decisyon, Inc. (12)	Software	Term Loan		17.43	%	Prime		9.43	%		12.68	%		-			50.43	%	December 31, 2022		3,284		3,284		2,750

Portfolio Company (1)(3)	Sector	Type of Investment (7)	Cash Rate (4)			Index	Margin			Floor			Ceiling			ETP (10)			Maturity Date	Principal Amount		Cost of Investments (6)(9)		Fair Value (9)
Dropoff, Inc. (2)(12)	Software	Term Loan		14.50	%	Prime		6.50	%		9.75	%		-			3.50	%	April 1, 2026		6,500		6,359		6,359
		Term Loan		14.50	%	Prime		6.50	%		9.75	%		-			3.50	%	April 1, 2026		6,000		5,869		5,869
		Term Loan		14.50	%	Prime		6.50	%		9.75	%		-			3.50	%	August 1, 2026		2,500		2,442		2,442
Engage3, LLC (2)(12)	Software	Term Loan		14.00	%	Prime		6.25	%		9.75	%		-			4.50	%	July 1, 2027		3,750		3,680		3,680
		Term Loan		14.00	%	Prime		6.25	%		9.75	%		-			4.50	%	July 1, 2027		3,750		3,720		3,720
Groundspeed Analytics, Inc. (2)(12)	Software	Term Loan		13.50	%	Prime		5.50	%		11.00	%		18.00	%		3.00	%	December 1, 2026		5,000		4,802		4,802
		Term Loan		13.50	%	Prime		5.50	%		11.00	%		18.00	%		3.00	%	December 1, 2026		5,000		4,953		4,953
		Convertible Note		15.00	%														September 10,2024		500		500		500
Kodiak Robotics, Inc. (2)(12)	Software	Term Loan		13.50	%	Prime		5.50	%		10.25	%		-			4.00	%	April 1, 2026		10,000		9,843		9,843
		Term Loan		13.50	%	Prime		5.50	%		10.25	%		-			4.00	%	April 1, 2026		10,000		9,843		9,843
		Term Loan		13.50	%	Prime		5.50	%		10.25	%		-			4.00	%	April 1, 2026		5,000		4,921		4,921
		Term Loan		13.50	%	Prime		5.50	%		10.25	%		-			4.00	%	April 1, 2026		5,000		4,921		4,921
Lemongrass Holdings, Inc. (2)(12)	Software	Term Loan		14.50	%	Prime		6.50	%		9.75	%		-			2.50	%	March 1, 2026		5,000		4,953		4,953
		Term Loan		14.50	%	Prime		6.50	%		9.75	%		-			2.50	%	March 1, 2026		2,500		2,477		2,477
Lytics, Inc. (2)(12)	Software	Term Loan		13.75	%	Prime		6.00	%		9.25	%		-			3.00	%	November 1, 2026		2,500		2,411		2,411
		Term Loan		13.75	%	Prime		6.00	%		12.25	%		-			3.00	%	December 1, 2026		1,250		1,232		1,232
		Term Loan		13.75	%	Prime		6.00	%		12.25	%		-			3.00	%	April 1, 2027		1,000		984		984
Noodle Partners, Inc. (2)(12)	Software	Term Loan		13.00	%	Prime		5.00	%		12.00	%		-			3.00	%	March 1, 2027		10,000		9,733		9,733
		Term Loan		13.00	%	Prime		5.00	%		12.00	%		-			3.00	%	March 1, 2027		5,000		4,928		4,928
		Term Loan		13.00	%	Prime		5.00	%		12.00	%		-			3.00	%	March 1, 2027		5,000		4,928		4,928
Reputation Institute, Inc. (2)(12)	Software	Term Loan		15.00	%	Prime		7.25	%		10.50	%		-			3.00	%	August 1, 2025		4,833		4,772		4,772
Slingshot Aerospace, Inc. (2)(12)	Software	Term Loan		13.75	%	Prime		5.75	%		9.75	%		-			5.00	%	August 1, 2026		5,000		4,940		4,940
		Term Loan		13.75	%	Prime		5.75	%		9.75	%		-			5.00	%	August 1, 2026		5,000		4,940		4,940
		Term Loan		13.75	%	Prime		5.75	%		9.75	%		-			5.00	%	August 1, 2026		5,000		4,875		4,875
		Term Loan		13.75	%	Prime		5.75	%		9.75	%		-			5.00	%	August 1, 2026		5,000		4,940		4,940
Supply Network Visibility Holdings LLC (2)(12)	Software	Term Loan		14.25	%	Prime		6.50	%		9.75	%		-			4.00	%	February 1, 2025		3,208		3,183		3,183
		Term Loan		14.25	%	Prime		6.50	%		9.75	%		-			4.00	%	February 1, 2025		3,208		3,183		3,183
		Term Loan		14.25	%	Prime		6.50	%		9.75	%		-			4.00	%	December 1, 2025		2,500		2,475		2,475
		Term Loan		14.25	%	Prime		6.50	%		9.75	%		-			4.00	%	December 1, 2025		2,500		2,475		2,475
Total Non-Affiliate Debt Investments — Technology																							277,916		267,673
Non-Affiliate Debt Investments — Healthcare information and services — 8.1% (8)
Hound Labs inc. (2) (12)	Diagnostics	Term Loan		14.00	%	Prime		6.00	%		9.25	%		-			3.50	%	June 1, 2026		2,500		2,388		2,388
		Term Loan		14.00	%	Prime		6.00	%		9.25	%		-			3.50	%	June 1, 2026		2,500		2,476		2,476
		Term Loan		14.00	%	Prime		6.00	%		9.25	%		-			3.50	%	June 1, 2026		5,000		4,951		4,951
Secure Transfusion Services, Inc. (12)(13)	Other Healthcare	Term Loan		13.75	%	Prime		5.75	%		9.00	%		-			4.00	%	October 1, 2025		4,719		4,658		46
		Term Loan		13.75	%	Prime		5.75	%		9.00	%		-			4.00	%	December 31, 2025		2,217		2,182		5
BrightInsight, Inc. (2)(12)	Software	Term Loan		13.25	%	Prime		5.50	%		9.50	%		-			3.00	%	August 1, 2027		7,000		6,663		6,663
		Term Loan		13.25	%	Prime		5.50	%		9.50	%		-			3.00	%	August 1, 2027		3,500		3,452		3,452
		Term Loan		13.25	%	Prime		5.50	%		9.50	%		-			3.00	%	August 1, 2027		3,500		3,452		3,452
		Term Loan		13.50	%	Prime		5.50	%		9.50	%		-			3.00	%	April 1, 2028		2,750		2,704		2,704
Total Non-Affiliate Debt Investments — Healthcare information and services																							32,926		26,137
Total Non- Affiliate Debt Investments																							703,781		684,554

					Cost of		Fair
Portfolio Company (1)(3)	Sector	Type of Investment (7)	Number of Shares		Investments (6)(9)		Value (9)
Non-Affiliate Warrant Investments — 8.0% (8)
Non-Affiliate Warrants — Life Science — 2.1% (8)
Avalo Therapeutics, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		26,444		311		—
Castle Creek Biosciences, Inc. (2)(12)	Biotechnology	Preferred Stock Warrant		7,404		214		329
Corvium, Inc. (2)(12)	Biotechnology	Preferred Stock Warrant		661,956		53		—
Emalex Biosciences, Inc. (2)(12)	Biotechnology	Preferred Stock Warrant		110,402		176		256
Evelo Biosciences, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		463,915		126		—
Greenlight Biosciences, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		47,452		366		—
Imunon, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		19,671		66		—
IMV Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		39,774		67		—
KSQ Therapeutics, Inc. (2) (12)	Biotechnology	Preferred Stock Warrant		48,076		50		56
Mustang Bio, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		252,161		141		—
Native Microbials, Inc (2)(12)	Biotechnology	Preferred Stock Warrant		103,679		64		159
PDS Biotechnology Corporation (2)(5)(12)	Biotechnology	Common Stock Warrant		299,848		160		937
Provivi, Inc. (2)(12)	Biotechnology	Preferred Stock Warrant		254,609		401		128
Rocket Pharmaceuticals Corporation (5)(12)	Biotechnology	Common Stock Warrant		7,051		17		2
Stealth Biotherapeutics Inc. (2)(12)	Biotechnology	Common Stock Warrant		318,181		264		28
vTv Therapeutics Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		95,293		44		—
Xeris Pharmaceuticals, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		126,000		72		9
AccuVein Inc. (2)(12)	Medical Device	Common Stock Warrant		1,175		24		—
Aerin Medical, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		1,818,183		66		1,196
Aerobiotix, LLC (2)(12)	Medical Device	Preferred Stock Warrant		27,330		48		31
Canary Medical Inc. (2)(12)	Medical Device	Preferred Stock Warrant		12,153		86		1,862
Ceribell, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		145,483		69		206
Cognoa, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		775,000		144		173
Conventus Orthopaedics, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		7,972,222		221		221
CSA Medical, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		1,375,727		153		148
CVRx, Inc. (2)(5)(12)	Medical Device	Common Stock Warrant		47,410		76		72
Infobionic, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		317,647		124		51

					Cost of		Fair
Portfolio Company (1)(3)	Sector	Type of Investment (7)	Number of Shares		Investments (6)(9)		Value (9)
Magnolia Medical Technologies, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		809,931		194		379
Meditrina, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		233,993		83		98
Robin Healthcare, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		86,066		16		15
Scientia Vascular, Inc (2)(12)	Medical Device	Preferred Stock Warrant		19,662		40		45
Sonex Health, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		605,313		98		120
VERO Biotech LLC (2)(12)	Medical Device	Preferred Stock Warrant		408		53		1
Swift Health Systems Inc. (2)(12)	Medical Device	Preferred Stock Warrant		135,484		71		81
Total Non-Affiliate Warrants — Life Science						4,158		6,603
Non-Affiliate Warrants — Sustainability — 0.2% (8)
Aerofarms, Inc. (2)(12)	Other Sustainability	Preferred Stock Warrant		201,537		61		72
LiquiGlide, Inc. (2)(12)	Other Sustainability	Common Stock Warrant		61,359		39		53
Nexii Building Solutions, Inc. (2)(12)	Other Sustainability	Common Stock Warrant		204,195		490		1
Soli Organic, Inc. (2)(12)	Other Sustainability	Preferred Stock Warrant		681		214		354
Temperpack Technologies, Inc. (2)(12)	Other Sustainability	Preferred Stock Warrant		34,604		118		259
Total Non-Affiliate Warrants — Sustainability						922		739
Non-Affiliate Warrants — Technology — 5.1% (8)
Axiom Space, Inc. (2)(12)	Communications	Common Stock Warrant		1,991		46		64
Intelepeer Holdings, Inc. (2)(12)	Communications	Preferred Stock Warrant		2,936,535		138		3,251
PebblePost, Inc. (2)(12)	Communications	Preferred Stock Warrant		598,850		91		170
Alula Holdings, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		20,000		93		64
Aterian, Inc. (2)(5)(12)	Consumer-related Technologies	Common Stock Warrant		76,923		195		—
Better Place Forests Co. (12)	Consumer-related Technologies	Preferred Stock Warrant		2,672		26		—
Caastle, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		268,591		68		1,057
CAMP NYC, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		17,605		22		—
Clara Foods Co. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		46,745		30		124
Divergent Technologies, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		33,742		70		237
Havenly, Inc. (2)(12)	Consumer-related Technologies	Common Stock Warrant		1,312,500		2,942		2,674
MyForest Foods Co. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		143		29		36
NextCar Holding Company, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		1,261,253		197		17
Optoro, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		6,600		104		104
Primary Kids, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		553,778		57		427
Quip NYC Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		6,191		325		532
Unagi, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		171,081		32		111
Updater, Inc.(2)(12)	Consumer-related Technologies	Common Stock Warrant		108,333		34		42
CPG Beyond, Inc. (2)(12)	Data Storage	Preferred Stock Warrant		500,000		242		903
Silk, Inc. (2)(12)	Data Storage	Preferred and Common Stock Warrant		442,110		234		399
Global Worldwide LLC (2)(12)	Internet and Media	Preferred Stock Warrant		245,810		75		—
Rocket Lawyer Incorporated (2)(12)	Internet and Media	Preferred Stock Warrant		261,721		92		352
Skillshare, Inc. (2)(12)	Internet and Media	Preferred Stock Warrant		139,074		162		1,231
Liqid, Inc. (2)(12)	Networking	Preferred Stock Warrant		344,102		364		237
Halio, Inc. (2)(12)	Power Management	Preferred Stock Warrant		5,002,574		1,585		2,808
Avalanche Technology, Inc. (2)(12)	Semiconductors	Preferred and Common Stock Warrants		6,081		57		—
BriteCore Holdings, Inc. (2)(12)	Software	Preferred Stock Warrant		77,828		21		67
Decisyon, Inc. (12)	Software	Common Stock Warrant		82,967		46		—
Dropoff, Inc. (2)(12)	Software	Common Stock Warrant		516,732		455		196
E La Carte, Inc. (2)(5)(12)	Software	Common Stock Warrant		147,361		60		—
Groundspeed Analytics, Inc. (2)(12)	Software	Preferred Stock Warrant		86,300		7		1
Kodiak Robotics, Inc. (2)(12)	Software	Preferred Stock Warrant		639,918		275		287
Lemongrass Holdings, Inc. (2)(12)	Software	Preferred Stock Warrant		101,308		35		40
Lotame Solutions, Inc. (2)(12)	Software	Preferred Stock Warrant		71,305		19		53
Lytics, Inc. (2)(12)	Software	Preferred Stock Warrant		85,543		43		46
Noodle Partners, Inc. (2)(12)	Software	Preferred Stock Warrant		84,037		116		116
Reputation Institute, Inc. (2)(12)	Software	Preferred Stock Warrant		3,731		61		46
Revinate Holdings, Inc. (2)(12)	Software	Preferred Stock Warrant		682,034		44		97
Riv Data Corp. (2)(12)	Software	Preferred Stock Warrant		321,428		12		296
SIGNiX, Inc. (12)	Software	Preferred Stock Warrant		186,235		225		—
Slingshot Aerospace, Inc. (2)(12)	Software	Preferred Stock Warrant		309,208		123		135
Supply Network Visibility Holdings LLC (2)(12)	Software	Preferred Stock Warrant		682		64		140
Topia Mobility, Inc. (2)(12)	Software	Preferred Stock Warrant		3,049,607		138		—
xAd, Inc. (2)(12)	Software	Preferred Stock Warrant		4,343,348		177		11
Total Non-Affiliate Warrants — Technology						9,231		16,371

					Cost of		Fair
Portfolio Company (1)(3)	Sector	Type of Investment (7)	Number of Shares		Investments (6)(9)		Value (9)
Non-Affiliate Warrants — Healthcare information and services — 0.6% (8)
Hound Labs, Inc (2) (12)	Diagnostics	Preferred Stock Warrant		159,893		47		53
Kate Farms, Inc. (2)(12)	Other Healthcare	Preferred Stock Warrant		82,965		102		1,363
Secure Transfusion Services, Inc. (12)	Other Healthcare	Preferred Stock Warrant		77,690		48		—
BrightInsight, Inc. (2)(12)	Software	Preferred Stock Warrant		85,066		167		175
Medsphere Systems Corporation (2)(12)	Software	Preferred Stock Warrant		7,097,792		60		354
Total Non-Affiliate Warrants — Healthcare information and services						424		1,945
Total Non-Affiliate Warrants						14,735		25,658
Non-Affiliate Other Investments — 0.4% (8)
Lumithera, Inc. (12)	Medical Device	Royalty Agreement				1,200		1,100
ZetrOZ, Inc. (12)	Medical Device	Royalty Agreement				—		200
Total Non-Affiliate Other Investments						1,200		1,300
Non-Affiliate Equity — 0.9% (8)
Castle Creek Biosciences, Inc. (12)	Biotechnology	Common Stock		1,162		250		250
Emalex Biosciences, Inc. (12)	Biotechnology	Common Stock		32,831		356		356
Getaround, Inc. (2)(5)	Consumer-related Technologies	Common Stock		87,082		253		25
SnagAJob.com, Inc. (12)	Consumer-related Technologies	Common Stock		82,974		9		83
Lumithera, Inc. (12)	Medical Device	Common Stock		392,651		2,000		1,700
Tigo Energy, Inc. (12)	Other Sustainability	Preferred Stock		22,313		8		27
Branded Online, Inc. (2)(5)	Software	Common Stock		5,398		1,075		14
Decisyon, Inc. (12)	Software	Preferred and Common Stock		72,638,663		229		—
Lotame, Inc. (12)	Software	Preferred Stock		66,127		5		193
Axiom Space, Inc. (12)	Technology	Preferred Stock		1,810		261		306
Total Non-Affiliate Equity						4,446		2,954
Total Non-Affiliate Portfolio Investment Assets					$	724,162	$	714,466
Non-controlled Affiliate Investments — 0.3% (8)
Non-controlled Affiliate Equity — Life Science —0.3% (8)
Cadrenal Therapeutics, Inc. (5)	Biotechnology	Common Stock		600,000		—		846
Total Non-Controlled Affiliate Equity					$	—		846
Total Non-Controlled Affiliate Portfolio Investment Assets					$	—		846
Total Portfolio Investment Assets — 222.4% (8)					$	724,162	$	715,312

Portfolio Company (1)(3)	Sector	Type of Investment (7)	Cash Rate (4)			Index	Margin			Floor			Ceiling			ETP (10)			Maturity Date	Principal Amount		Cost of Investments (6)(9)		Fair Value (9)
Non-Affiliate Investments — 226.1% (8)
Non-Affiliate Debt Investments — 215.5% (8)
Non-Affiliate Debt Investments — Life Science — 99.7% (8)
Avalo Therapeutics, Inc. (2)(5)(12)	Biotechnology	Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			3.00	%	January 1, 2025	$	2,885	$	2,853	$	2,777
		Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			3.00	%	January 1, 2025		2,885		2,823		2,750
		Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			3.00	%	January 1, 2025		1,442		1,411		1,374
		Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			3.00	%	February 1, 2025		2,885		2,821		2,748
		Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			3.00	%	February 1, 2025		2,885		2,821		2,748
		Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			3.00	%	April 1, 2025		1,442		1,408		1,371
		Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			3.00	%	April 1, 2025		1,442		1,408		1,371
Castle Creek Biosciences, Inc. (2)(12)	Biotechnology	Term Loan		12.50	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		5,000		4,891		4,891
		Term Loan		12.50	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		5,000		4,963		4,963
		Term Loan		12.50	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		3,000		2,978		2,978
		Term Loan		12.50	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		5,000		4,963		4,963
		Term Loan		12.50	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		5,000		4,963		4,963
		Term Loan		12.50	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		3,000		2,978		2,978
Emalex Biosciences, Inc. (2)(12)	Biotechnology	Term Loan		12.07	%	Libor		7.90	%		9.75	%		-			5.00	%	June 1, 2024		1,979		1,962		1,962
		Term Loan		12.07	%	Libor		7.90	%		9.75	%		-			5.00	%	June 1, 2024		1,979		1,963		1,963
		Term Loan		12.07	%	Libor		7.90	%		9.75	%		-			5.00	%	November 1, 2025		5,000		4,923		4,923
		Term Loan		12.07	%	Libor		7.90	%		9.75	%		-			5.00	%	May 1, 2026		5,000		4,912		4,912
Evelo Biosciences, Inc. (2)(5)(12)	Biotechnology	Term Loan		11.75	%	Prime		4.75	%		11.00	%		-			4.25	%	January 1, 2028		10,000		9,872		9,872
		Term Loan		11.75	%	Prime		4.75	%		11.00	%		-			4.25	%	January 1, 2028		15,000		14,808		14,808
		Term Loan		11.75	%	Prime		4.75	%		11.00	%		-			4.25	%	January 1, 2028		6,000		5,923		5,923
		Term Loan		11.75	%	Prime		4.75	%		11.00	%		-			4.25	%	January 1, 2028		6,000		5,923		5,923
		Term Loan		11.75	%	Prime		4.75	%		11.00	%		-			4.25	%	January 1, 2028		4,000		3,949		3,949
		Term Loan		11.75	%	Prime		4.75	%		11.00	%		-			4.25	%	January 1, 2028		4,000		3,949		3,949
F-Star Therapeutics, Inc. (2)(5)(12)	Biotechnology	Term Loan		13.25	%	Prime		6.25	%		9.50	%		-			4.00	%	April 1, 2025		2,500		2,476		2,476
		Term Loan		13.25	%	Prime		6.25	%		9.50	%		-			4.00	%	July 1, 2025		2,500		2,473		2,473
Greenlight Biosciences, Inc. (2)(5)(12)	Biotechnology	Term Loan		13.25	%	Prime		5.75	%		9.00	%		-			3.00	%	July 1, 2025		5,000		4,857		4,857
		Term Loan		13.25	%	Prime		5.75	%		9.00	%		-			3.00	%	July 1, 2025		2,500		2,430		2,430
IMV Inc. (2)(5)(12)	Biotechnology	Term Loan		13.25	%	Prime		5.75	%		9.00	%		-			5.00	%	July 1, 2025		5,000		4,946		4,946
		Term Loan		13.25	%	Prime		5.75	%		9.00	%		-			5.00	%	July 1, 2025		2,500		2,473		2,473
		Term Loan		13.25	%	Prime		5.75	%		9.00	%		-			5.00	%	January 1, 2026		5,000		4,947		4,947
		Term Loan		13.25	%	Prime		5.75	%		9.00	%		-			5.00	%	January 1, 2026		5,000		4,947		4,947
KSQ Therapeutics, Inc. (2) (12)	Biotechnology	Term Loan		12.25	%	Prime		4.75	%		8.50	%		-			5.50	%	May 1, 2027		6,250		6,077		6,077
		Term Loan		12.25	%	Prime		4.75	%		8.50	%		-			5.50	%	May 1, 2027		6,250		6,177		6,177
Native Microbials, Inc (2) (12)	Biotechnology	Term Loan		12.75	%	Prime		5.25	%		8.50	%		-			5.00	%	November 1, 2026		3,750		3,630		3,630
		Term Loan		12.75	%	Prime		5.25	%		8.50	%		-			5.00	%	November 1, 2026		2,500		2,469		2,469
PDS Biotechnology Corporation (2)(5)(12)	Biotechnology	Term Loan		13.25	%	Prime		5.75	%		9.75	%		-			3.75	%	September 1, 2026		10,000		9,701		9,701
		Term Loan		13.25	%	Prime		5.75	%		9.75	%		-			3.75	%	September 1, 2026		3,750		3,697		3,697
		Term Loan		13.25	%	Prime		5.75	%		9.75	%		-			3.75	%	September 1, 2026		3,750		3,697		3,697
Provivi, Inc. (2)(12)	Biotechnology	Term Loan		12.67	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		4,667		4,597		4,597
		Term Loan		12.67	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		4,667		4,597		4,597
		Term Loan		12.67	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		2,333		2,280		2,280
		Term Loan		12.67	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		2,333		2,280		2,280
		Term Loan		12.67	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		2,333		2,274		2,274
		Term Loan		12.67	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		2,333		2,274		2,274
Stealth Biotherapeutics Inc. (2)(12)	Biotechnology	Term Loan		13.00	%	Prime		5.50	%		8.75	%		-			6.00	%	October 1, 2025		5,000		4,914		4,914
		Term Loan		13.00	%	Prime		5.50	%		8.75	%		-			6.00	%	October 1, 2025		2,500		2,457		2,457
Aerobiotix, LLC (2)(12)	Medical Device	Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			6.00	%	April 1, 2026		2,500		2,463		2,364
		Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			6.00	%	April 1, 2026		2,500		2,463		2,364
Canary Medical Inc. (2)(12)	Medical Device	Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			7.00	%	November 1, 2024		2,500		2,475		2,475
		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			7.00	%	November 1, 2024		2,500		2,489		2,489
		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			7.00	%	November 1, 2024		2,500		2,473		2,473
Ceribell, Inc. (2)(12)	Medical Device	Term Loan		10.50	%	Prime		3.50	%		8.25	%		-			5.50	%	October 1, 2024		5,000		4,973		4,973
		Term Loan		10.50	%	Prime		3.50	%		8.25	%		-			5.50	%	October 1, 2024		5,000		4,973		4,973
		Term Loan		10.50	%	Prime		3.50	%		8.25	%		-			5.50	%	October 1, 2024		2,500		2,478		2,478
		Term Loan		10.50	%	Prime		3.50	%		8.25	%		-			5.50	%	October 1, 2024		2,500		2,478		2,478
Cognoa, Inc. (2)(12)	Medical Device	Term Loan		13.00	%	Prime		5.50	%		8.75	%		-			6.00	%	August 1, 2026		2,500		2,466		2,466
		Term Loan		13.00	%	Prime		5.50	%		8.75	%		-			6.00	%	August 1, 2026		5,000		4,932		4,932
Conventus Orthopaedics, Inc. (2)(12)	Medical Device	Term Loan		12.17	%	Libor		8.00	%		9.25	%		-			10.36	%	July 1, 2025		3,960		3,898		3,898
		Term Loan		12.17	%	Libor		8.00	%		9.25	%		-			10.36	%	July 1, 2025		3,960		3,898		3,898

Portfolio Company (1)(3)	Sector	Type of Investment (7)	Cash Rate (4)			Index	Margin			Floor			Ceiling		ETP (10)			Maturity Date	Principal Amount		Cost of Investments (6)(9)		Fair Value (9)
Corinth Medtech, Inc. (2)(12)	Medical Device	Term Loan		12.25	%	Prime		5.25	%		8.50	%		-		20.00	%	September 15, 2022		2,500		2,500		2,500
		Term Loan		12.25	%	Prime		5.25	%		8.50	%		-		20.00	%	September 15, 2022		2,500		2,500		2,500
CSA Medical, Inc. (2)(12)	Medical Device	Term Loan		12.37	%	Libor		8.20	%		10.00	%		-		5.00	%	January 1, 2024		1,625		1,610		1,610
		Term Loan		12.37	%	Libor		8.20	%		10.00	%		-		5.00	%	January 1, 2024		108		107		107
		Term Loan		12.37	%	Libor		8.20	%		10.00	%		-		5.00	%	March 1, 2024		2,000		1,983		1,983
Embody, Inc. (2)(12)	Medical Device	Term Loan		14.00	%	Prime		6.50	%		9.75	%		-		28.00	%	August 1, 2026		2,500		2,482		2,482
InfoBionic, Inc. (2)(12)	Medical Device	Term Loan		13.25	%	Prime		6.25	%		9.50	%		-		4.00	%	October 1, 2024		3,208		3,143		3,143
		Term Loan		13.25	%	Prime		6.25	%		9.50	%		-		4.00	%	June 1, 2025		1,000		974		974
Magnolia Medical Technologies, Inc. (2)(12)	Medical Device	Term Loan		12.00	%	Prime		5.00	%		9.75	%		-		4.00	%	March 1, 2025		5,000		4,939		4,939
		Term Loan		12.00	%	Prime		5.00	%		9.75	%		-		4.00	%	March 1, 2025		5,000		4,939		4,939
		Term Loan		12.00	%	Prime		5.00	%		9.75	%		-		4.00	%	March 1, 2025		5,000		4,933		4,933
		Term Loan		12.00	%	Prime		5.00	%		9.75	%		-		4.00	%	March 1, 2025		5,000		4,933		4,933
		Term Loan		12.50	%	Prime		5.00	%		9.75	%		-		4.00	%	January 1, 2027		5,000		4,913		4,913
		Term Loan		12.50	%	Prime		5.00	%		9.75	%		-		4.00	%	January 1, 2027		5,000		4,913		4,913
Robin Healthcare, Inc. (2)(12)	Medical Device	Term Loan		13.00	%	Prime		5.50	%		10.25	%		-		4.00	%	November 1, 2026		3,500		3,360		3,360
		Term Loan		13.00	%	Prime		5.50	%		10.25	%		-		4.00	%	November 1, 2026		3,500		3,460		3,460
Scientia Vascular, Inc. (2)(12)	Medical Device	Term Loan		11.75	%	Prime		4.75	%		8.50	%		-		5.00	%	January 1, 2027		3,750		3,597		3,597
		Term Loan		11.75	%	Prime		4.75	%		8.50	%		-		5.00	%	January 1, 2027		3,750		3,706		3,706
Sonex Health, Inc. (2)(12)	Medical Device	Term Loan		13.50	%	Prime		6.50	%		9.75	%		-		8.00	%	June 1, 2025		2,500		2,476		2,476
		Term Loan		13.50	%	Prime		6.50	%		9.75	%		-		8.00	%	June 1, 2025		2,500		2,476		2,476
		Term Loan		13.50	%	Prime		6.50	%		9.75	%		-		8.00	%	June 1, 2025		2,500		2,476		2,476
		Term Loan		13.50	%	Prime		6.50	%		9.75	%		-		8.00	%	April 1, 2026		2,500		2,453		2,453
		Term Loan		13.50	%	Prime		6.50	%		9.75	%		-		8.00	%	May 1, 2026		2,500		2,455		2,455
Spineology, Inc. (2)(12)	Medical Device	Term Loan		14.50	%	Prime		7.00	%		10.25	%		-		1.00	%	October 1, 2025		5,000		4,966		4,966
		Term Loan		14.50	%	Prime		7.00	%		10.25	%		-		1.00	%	April 1, 2026		2,500		2,481		2,481
Swift Health Systems Inc. (2)(12)	Medical Device	Term Loan		12.25	%	Prime		5.25	%		9.00	%		-		5.00	%	July 1, 2027		3,500		3,349		3,349
		Term Loan		12.25	%	Prime		5.25	%		9.00	%		-		5.00	%	July 1, 2027		3,500		3,454		3,454
Total Non-Affiliate Debt Investments — Life Science																						318,172		317,568
Non-Affiliate Debt Investments — Sustainability — 26.3% (8)
Aerofarms, Inc. (2)(12)	Other Sustainability	Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		3.00	%	April 1, 2026		3,750		3,699		3,699
		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		3.00	%	April 1, 2026		3,750		3,699		3,699
Nexii Building Solutions, Inc. (2)(12)	Other Sustainability	Term Loan		14.50	%	Prime		7.00	%		10.25	%		-		2.50	%	September 1, 2025		7,500		7,371		7,371
		Term Loan		14.50	%	Prime		7.00	%		10.25	%		-		2.50	%	September 1, 2025		7,500		7,371		7,371
		Term Loan		14.50	%	Prime		7.00	%		10.25	%		-		2.50	%	September 1, 2025		7,500		7,371		7,371
		Term Loan		14.50	%	Prime		7.00	%		10.25	%		-		2.50	%	July 1, 2026		5,000		4,903		4,903
		Term Loan		14.50	%	Prime		7.00	%		10.25	%		-		2.50	%	July 1, 2026		5,000		4,903		4,903
Soli Organic, Inc. (2)(12)	Other Sustainability	Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.75	%	April 1, 2026		2,500		2,463		2,463
		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.75	%	April 1, 2026		5,000		4,927		4,927
		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.75	%	May 1, 2026		5,000		4,924		4,924
		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.75	%	May 1, 2026		2,500		2,462		2,462
		Term Loan		13.00	%	Prime		5.50	%		10.00	%		-		2.75	%	December 1, 2026		5,000		4,900		4,900
		Term Loan		13.00	%	Prime		5.50	%		10.00	%		-		2.75	%	December 1, 2026		2,500		2,450		2,450
Temperpack Technologies, Inc. (2)(12)	Other Sustainability	Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.50	%	June 1, 2025		3,750		3,697		3,697
		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.50	%	June 1, 2025		3,750		3,717		3,717
		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.50	%	October 1, 2025		7,500		7,424		7,424
		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.50	%	October 1, 2025		3,750		3,712		3,712
		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.50	%	October 1, 2025		3,750		3,712		3,712
Total Non-Affiliate Debt Investments — Sustainability																						83,705		83,705
Non-Affiliate Debt Investments — Technology — 81.4% (8)
Axiom Space, Inc. (2)(12)	Communications	Term Loan		13.00	%	Prime		6.00	%		9.25	%		-		2.50	%	June 1, 2026		7,500		7,455		7,455
		Term Loan		13.00	%	Prime		6.00	%		9.25	%		-		2.50	%	June 1, 2026		7,500		7,455		7,455
		Term Loan		13.00	%	Prime		6.00	%		9.25	%		-		2.50	%	June 1, 2026		7,500		7,455		7,455
		Convertible Note		3.00	%													July 1, 2023		250		250		306
Alula Holdings, Inc. (2)(12)	Consumer-related Technologies	Term Loan		13.75	%	Prime		6.75	%		10.00	%		-		3.00	%	January 1, 2025		5,000		4,966		4,966
		Term Loan		13.75	%	Prime		6.75	%		10.00	%		-		3.00	%	January 1, 2025		5,000		4,966		4,966
		Term Loan		13.75	%	Prime		6.75	%		10.00	%		-		3.00	%	January 1, 2025		3,000		2,979		2,979
		Term Loan		13.75	%	Prime		6.75	%		10.00	%		-		3.00	%	December 1, 2025		1,000		976		976
		Term Loan		13.75	%	Prime		6.75	%		10.00	%		-		3.00	%	February 1, 2026		1,000		977		977
Better Place Forests Co. (2)(12)(13)	Consumer-related Technologies	Term Loan		13.75	%	Prime		6.25	%		9.50	%		-		1.85	%	July 1, 2025		5,000		4,951		3,834
		Term Loan		13.75	%	Prime		6.25	%		9.50	%		-		1.85	%	October 1, 2025		2,500		2,474		1,916
CAMP NYC, Inc. (2)(12)	Consumer-related Technologies	Term Loan		14.75	%	Prime		7.25	%		10.50	%		-		3.00	%	May 1, 2026		3,500		3,461		3,461
Clara Foods Co. (2)(12)	Consumer-related Technologies	Term Loan		12.75	%	Prime		5.75	%		9.00	%		-		5.50	%	August 1, 2025		2,500		2,482		2,482
		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-		5.50	%	August 1, 2025		2,500		2,482		2,482

Portfolio Company (1)(3)	Sector	Type of Investment (7)	Cash Rate (4)			Index	Margin			Floor			Ceiling			ETP (10)			Maturity Date	Principal Amount		Cost of Investments (6)(9)		Fair Value (9)
Divergent Technologies, Inc. (2)(12)	Consumer-related Technologies	Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		3,750		3,478		3,478
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		1,250		1,238		1,238
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		3,750		3,715		3,715
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		1,250		1,238		1,238
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		3,750		3,715		3,715
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		1,250		1,238		1,238
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	January 1, 2028		3,750		3,698		3,698
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	January 1, 2028		3,750		3,698		3,698
Havenly, Inc. (2)(12)	Consumer-related Technologies	Term Loan		12.50	%	Prime		5.00	%		5.00	%		-			4.00	%	March 1, 2027		2,000		1,082		1,082
		Term Loan		12.50	%	Prime		5.00	%		5.00	%		-			4.00	%	March 1, 2027		3,000		1,623		1,623
		Term Loan		11.00	%	Prime		3.50	%		10.50	%		-			7.78	%	February 1, 2028		2,813		2,813		2,813
		Term Loan		11.00	%	Prime		3.50	%		10.50	%		-			7.78	%	February 1, 2028		2,813		2,813		2,813
Interior Define, Inc. (2)(12)(13)	Consumer-related Technologies	Term Loan		13.50	%	Prime		6.50	%		9.75	%		-			4.00	%	January 1, 2026		3,210		3,151		—
		Term Loan		13.50	%	Prime		6.50	%		9.75	%		-			4.00	%	January 1, 2026		2,963		2,886		—
Lyrical Foods, Inc. (2)(12)	Consumer-related Technologies	Term Loan		10.00	%	Prime		6.75	%		10.00	%		-			-		September 1, 2027		2,500		2,588		2,279
MyForest Foods Co. (2)(12)	Consumer-related Technologies	Term Loan		14.25	%	Prime		6.75	%		10.00	%		-			3.00	%	October 1, 2025		5,000		4,954		4,954
		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-			3.00	%	October 1, 2025		2,500		2,477		2,477
NextCar Holding Company, Inc. (2)(12)	Consumer-related Technologies	Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			2.00	%	December 30, 2022		5,000		4,943		4,715
		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			2.00	%	December 30, 2022		2,000		1,981		1,890
		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			2.00	%	December 30, 2022		2,500		2,477		2,363
		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			2.00	%	December 30, 2022		3,000		2,971		2,835
		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			2.00	%	December 30, 2022		2,500		2,459		2,345
		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			2.00	%	December 30, 2022		2,500		2,459		2,345
		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			2.00	%	December 30, 2022		5,000		4,914		4,688
		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			2.00	%	December 30, 2022		2,500		2,456		2,342
Optoro, Inc. (2)(12)	Consumer-related Technologies	Term Loan		13.25	%	Prime		6.25	%		9.50	%		-			4.00	%	August 1, 2027		2,500		2,347		2,347
Primary Kids, Inc. (2)(12)	Consumer-related Technologies	Term Loan		14.25	%	Prime		7.25	%		10.50	%		-			3.00	%	March 1, 2025		2,700		2,673		2,673
		Term Loan		14.25	%	Prime		7.25	%		10.50	%		-			3.00	%	March 1, 2025		2,700		2,673		2,673
		Term Loan		14.25	%	Prime		7.25	%		10.50	%		-			3.00	%	September 1, 2025		3,000		2,967		2,967
Unagi, Inc. (2)(12)	Consumer-related Technologies	Term Loan		15.25	%	Prime		7.75	%		11.00	%		-			-		July 1, 2025		2,500		2,473		2,473
		Term Loan		15.25	%	Prime		7.75	%		11.00	%		-			-		July 1, 2025		1,250		1,236		1,236
		Term Loan		15.25	%	Prime		7.75	%		11.00	%		-			-		July 1, 2025		1,250		1,236		1,236
Liqid, Inc. (2)(12)	Networking	Term Loan		13.25	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		3,333		3,286		3,286
		Term Loan		13.25	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		3,333		3,286		3,286
		Term Loan		13.25	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		1,667		1,641		1,641
		Term Loan		13.25	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		1,667		1,641		1,641
		Term Loan		13.25	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		1,667		1,613		1,613
BriteCore Holdings, Inc. (2)(12)	Software	Term Loan		13.75	%	Prime		6.75	%		10.00	%		-			5.00	%	March 1, 2026		2,500		2,421		2,421
		Term Loan		13.75	%	Prime		6.75	%		10.00	%		-			5.00	%	March 1, 2026		2,500		2,487		2,487
Decisyon, Inc. (12)	Software	Term Loan		16.93	%	Prime		9.43	%		12.68	%		-			50.43	%	December 31, 2022		3,295		3,295		3,295
Dropoff, Inc. (2)(12)	Software	Term Loan		14.00	%	Prime		6.50	%		9.75	%		-			3.50	%	April 1, 2026		6,500		6,347		6,347
		Term Loan		14.00	%	Prime		6.50	%		9.75	%		-			3.50	%	April 1, 2026		6,000		5,859		5,859
		Term Loan		14.00	%	Prime		6.50	%		9.75	%		-			3.50	%	August 1, 2026		2,500		2,436		2,436
Engage3, LLC (2)(12)	Software	Term Loan		13.25	%	Prime		6.25	%		9.75	%		-			4.50	%	July 1, 2027		3,750		3,678		3,678
		Term Loan		13.25	%	Prime		6.25	%		9.75	%		-			4.50	%	July 1, 2027		3,750		3,718		3,718
Groundspeed Analytics, Inc. (2)(12)	Software	Term Loan		13.00	%	Prime		5.50	%		11.00	%		18.00	%		3.00	%	December 1, 2026		5,000		4,798		4,798
		Term Loan		13.00	%	Prime		5.50	%		11.00	%		18.00	%		3.00	%	December 1, 2026		5,000		4,948		4,948
Kodiak Robotics, Inc. (2)(12)	Software	Term Loan		13.00	%	Prime		5.50	%		10.25	%		-			4.00	%	April 1, 2026		10,000		9,826		9,826
		Term Loan		13.00	%	Prime		5.50	%		10.25	%		-			4.00	%	April 1, 2026		10,000		9,826		9,826
		Term Loan		13.00	%	Prime		5.50	%		10.25	%		-			4.00	%	April 1, 2026		5,000		4,913		4,913
		Term Loan		13.00	%	Prime		5.50	%		10.25	%		-			4.00	%	April 1, 2026		5,000		4,913		4,913
Lemongrass Holdings, Inc. (2)(12)	Software	Term Loan		14.00	%	Prime		6.50	%		9.75	%		-			2.50	%	March 1, 2026		5,000		4,947		4,947
		Term Loan		14.00	%	Prime		6.50	%		9.75	%		-			2.50	%	March 1, 2026		2,500		2,474		2,474
Lytics, Inc. (2)(12)	Software	Term Loan		13.00	%	Prime		6.00	%		9.25	%		-			3.00	%	July 1, 2025		2,500		2,396		2,396
		Term Loan		13.00	%	Prime		6.00	%		12.25	%		-			3.00	%	December 1, 2026		1,250		1,231		1,231
Reputation Institute, Inc. (2)(12)	Software	Term Loan		14.25	%	Prime		7.25	%		10.50	%		-			3.00	%	August 1, 2025		5,000		4,932		4,932
Slingshot Aerospace, Inc. (2)(12)	Software	Term Loan		13.25	%	Prime		5.75	%		9.75	%		-			5.00	%	August 1, 2026		5,000		4,870		4,870
		Term Loan		13.25	%	Prime		5.75	%		9.75	%		-			5.00	%	August 1, 2026		5,000		4,933		4,933
		Term Loan		13.25	%	Prime		5.75	%		9.75	%		-			5.00	%	August 1, 2026		5,000		4,933		4,933
		Term Loan		13.25	%	Prime		5.75	%		9.75	%		-			5.00	%	August 1, 2026		5,000		4,933		4,933
Supply Network Visiblity Holdings LLC (2)(12)	Software	Term Loan		13.50	%	Prime		6.50	%		9.75	%		-			4.00	%	February 1, 2025		3,500		3,472		3,472
		Term Loan		13.50	%	Prime		6.50	%		9.75	%		-			4.00	%	February 1, 2025		3,500		3,472		3,472
		Term Loan		13.50	%	Prime		6.50	%		9.75	%		-			4.00	%	December 1, 2025		2,500		2,472		2,472
		Term Loan		13.50	%	Prime		6.50	%		9.75	%		-			4.00	%	December 1, 2025		2,500		2,472		2,472
Total Non-Affiliate Debt Investments — Technology																							268,468		259,366
Non-Affiliate Debt Investments — Healthcare information and services — 8.1% (8)
Hound Labs inc. (2) (12)	Diagnostics	Term Loan		13.50	%	Prime		6.00	%		9.25	%		-			3.50	%	June 1, 2026		2,500		2,385		2,385
		Term Loan		13.50	%	Prime		6.00	%		9.25	%		-			3.50	%	June 1, 2026		2,500		2,473		2,473
		Term Loan		13.50	%	Prime		6.00	%		9.25	%		-			3.50	%	June 1, 2026		5,000		4,946		4,946
Secure Transfusion Services, Inc. (2)(12)(13)	Other Healthcare	Term Loan		13.25	%	Prime		5.75	%		9.00	%		-			4.00	%	October 1, 2025		4,943		4,943		1,668
		Term Loan		13.25	%	Prime		5.75	%		9.00	%		-			4.00	%	December 31, 2025		2,500		2,467		832
BrightInsight, Inc. (2)(12)	Software	Term Loan		12.50	%	Prime		5.50	%		9.50	%		-			3.00	%	August 1, 2027		7,000		6,619		6,619
		Term Loan		12.50	%	Prime		5.50	%		9.50	%		-			3.00	%	August 1, 2027		3,500		3,448		3,448
		Term Loan		12.50	%	Prime		5.50	%		9.50	%		-			3.00	%	August 1, 2027		3,500		3,448		3,448
Total Non-Affiliate Debt Investments — Healthcare information and services																							30,729		25,819
Total Non- Affiliate Debt Investments																							701,074		686,458

					Cost of		Fair
Portfolio Company (1)(3)	Sector	Type of Investment (7)	Number of Shares		Investments (6)(9)		Value (9)
Non-Affiliate Warrant Investments — 9.4% (8)
Non-Affiliate Warrants — Life Science — 3.1% (8)
Avalo Therapeutics, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		26,442		311		—
Castle Creek Biosciences, Inc. (2)(12)	Biotechnology	Preferred Stock Warrant		7,404		214		335
Corvium, Inc. (2)(12)	Biotechnology	Preferred Stock Warrant		661,956		53		—
Emalex Biosciences, Inc. (2)(12)	Biotechnology	Preferred Stock Warrant		110,402		176		263
Evelo Biosciences, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		463,915		126		125
F-Star Therapeutics, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		21,120		35		—
Greenlight Biosciences, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		47,452		366		—
Imunon, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		16,502		66		—
IMV Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		39,774		67		—
KSQ Therapeutics, Inc. (2) (12)	Biotechnology	Preferred Stock Warrant		48,077		51		60
Mustang Bio, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		252,161		146		—
Native Microbials, Inc (2) (12)	Biotechnology	Preferred Stock Warrant		103,679		64		162
PDS Biotechnology Corporation (2)(5)(12)	Biotechnology	Common Stock Warrant		299,848		160		3,024
Provivi, Inc. (2)(12)	Biotechnology	Preferred Stock Warrant		203,017		399		648
Rocket Pharmaceuticals Corporation (5)(12)	Biotechnology	Common Stock Warrant		7,051		17		14
Stealth Biotherapeutics Inc. (2)(12)	Biotechnology	Common Stock Warrant		318,181		264		37
vTv Therapeutics Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		95,293		44		—
Xeris Pharmaceuticals, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		126,000		72		3
AccuVein Inc. (2)(12)	Medical Device	Common Stock Warrant		1,175		24		—
Aerin Medical, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		1,818,183		64		1,200
Aerobiotix, LLC (2)(12)	Medical Device	Preferred Stock Warrant		27,330		48		31
Canary Medical Inc. (2)(12)	Medical Device	Preferred Stock Warrant		12,153		84		1,864
Ceribell, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		145,483		69		209
Cognoa, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		775,000		148		179
Conventus Orthopaedics, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		7,972,222		221		226
CSA Medical, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		1,375,727		153		150
CVRx, Inc. (2)(5)(12)	Medical Device	Common Stock Warrant		47,410		76		394
Infobionic, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		317,647		124		113
Magnolia Medical Technologies, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		809,931		194		385
Meditrina, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		233,993		83		101
Robin Healthcare, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		86,066		16		16
Scientia Vascular, Inc (2)(12)	Medical Device	Preferred Stock Warrant		19,662		40		46
Sonex Health, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		605,313		98		123
VERO Biotech LLC (2)(12)	Medical Device	Preferred Stock Warrant		408		53		1
Swift Health Systems Inc. (2)(12)	Medical Device	Preferred Stock Warrant		135,484		71		83
Total Non-Affiliate Warrants — Life Science						4,197		9,792
Non-Affiliate Warrants — Sustainability — 0.6% (8)
Aerofarms, Inc. (2)(12)	Other Sustainability	Preferred Stock Warrant		201,537		61		74
LiquiGlide, Inc. (2)(12)	Other Sustainability	Common Stock Warrant		61,539		39		55
Nexii Building Solutions, Inc. (2)(12)	Other Sustainability	Common Stock Warrant		204,832		488		1,061
Soli Organic, Inc. (2)(12)	Other Sustainability	Preferred Stock Warrant		681		214		361
Temperpack Technologies, Inc. (2)(12)	Other Sustainability	Preferred Stock Warrant		35,906		126		268
Total Non-Affiliate Warrants — Sustainability						928		1,819

					Cost of		Fair
Portfolio Company (1)(3)	Sector	Type of Investment (7)	Number of Shares		Investments (6)(9)		Value (9)
Non-Affiliate Warrants — Technology — 5.1% (8)
Axiom Space, Inc. (2)(12)	Communications	Common Stock Warrant		1,991		46		67
Intelepeer Holdings, Inc. (2)(12)	Communications	Preferred Stock Warrant		2,936,535		139		3,265
PebblePost, Inc. (2)(12)	Communications	Preferred Stock Warrant		598,850		92		173
Alula Holdings, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		20,000		93		64
Aterian, Inc. (2)(5)(12)	Consumer-related Technologies	Common Stock Warrant		76,923		195		—
Better Place Forests Co. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		10,690		26		—
Caastle, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		268,591		68		1,069
CAMP NYC, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		17,605		20		61
Clara Foods Co. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		46,745		30		125
Divergent Technologies, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		31,966		56		233
Havenly, Inc. (2)(12)	Consumer-related Technologies	Common Stock Warrant		1,312,500		2,947		2,947
Interior Define, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		553,710		103		—
MyForest Foods Co. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		143		29		37
NextCar Holding Company, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		1,261,253		197		17
Optoro, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		6,600		104		104
Primary Kids, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		553,778		57		429
Quip NYC Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		6,191		325		534
Unagi, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		171,081		32		22
Updater, Inc.(2)(12)	Consumer-related Technologies	Common Stock Warrant		108,333		34		42
CPG Beyond, Inc. (2)(12)	Data Storage	Preferred Stock Warrant		500,000		242		909
Silk, Inc. (2)(12)	Data Storage	Preferred Stock Warrant		442,110		234		407
Global Worldwide LLC (2)(12)	Internet and Media	Preferred Stock Warrant		245,810		75		—
Rocket Lawyer Incorporated (2)(12)	Internet and Media	Preferred Stock Warrant		261,721		92		357
Skillshare, Inc. (2)(12)	Internet and Media	Preferred Stock Warrant		139,074		162		802
Liqid, Inc. (2)(12)	Networking	Preferred Stock Warrant		344,102		364		243
Halio, Inc. (2)(12)	Power Management	Preferred Stock Warrant		5,002,574		1,585		2,610
Avalanche Technology, Inc. (2)(12)	Semiconductors	Preferred and Common Stock Warrants		6,081		56		—
BriteCore Holdings, Inc. (2)(12)	Software	Preferred Stock Warrant		77,828		21		69
Decisyon, Inc. (12)	Software	Common Stock Warrant		82,967		46		—
Dropoff, Inc. (2)(12)	Software	Common Stock Warrant		516,732		455		197
E La Carte, Inc. (2)(5)(12)	Software	Common Stock Warrant		147,361		60		3
Groundspeed Analytics, Inc. (2)(12)	Software	Preferred Stock Warrant		86,300		6		6
Kodiak Robotics, Inc. (2)(12)	Software	Preferred Stock Warrant		639,918		273		296
Lemongrass Holdings, Inc. (2)(12)	Software	Preferred Stock Warrant		101,308		34		41
Lotame Solutions, Inc. (2)(12)	Software	Preferred Stock Warrant		288,115		22		312
Lytics, Inc. (2)(12)	Software	Preferred Stock Warrant		80,197		40		44
Reputation Institute, Inc. (2)(12)	Software	Preferred Stock Warrant		3,731		56		39
Revinate Holdings, Inc. (2)(12)	Software	Preferred Stock Warrant		682,034		46		99
Riv Data Corp. (2)(12)	Software	Preferred Stock Warrant		321,428		12		296
SIGNiX, Inc. (12)	Software	Preferred Stock Warrant		186,235		225		—
Skyword, Inc. (12)	Software	Preferred and Common Stock Warrants		301,055		48		1
Slingshot Aerospace, Inc. (2)(12)	Software	Preferred Stock Warrant		309,208		123		133
Supply Network Visiblity Holdings LLC (2)(12)	Software	Preferred Stock Warrant		682		64		83
Topia Mobility, Inc. (2)(12)	Software	Preferred Stock Warrant		3,049,607		138		—
xAd, Inc. (2)(12)	Software	Preferred Stock Warrant		4,343,348		177		12
Total Non-Affiliate Warrants — Technology						9,249		16,148
Non-Affiliate Warrants — Healthcare information and services — 0.6% (8)
Hound Labs, Inc (2) (12)	Diagnostics	Preferred Stock Warrant		159,893		47		54
Kate Farms, Inc. (2)(12)	Other Healthcare	Preferred Stock Warrant		82,965		102		1,370
Secure Transfusion Services, Inc. (2)(12)	Other Healthcare	Preferred Stock Warrant		77,690		47		—
BrightInsight, Inc. (2)(12)	Software	Preferred Stock Warrant		80,544		160		170
Medsphere Systems Corporation (2)(12)	Software	Preferred Stock Warrant		7,097,792		60		359
Total Non-Affiliate Warrants — Healthcare information and services						416		1,953
Total Non-Affiliate Warrants						14,790		29,712
Non-Affiliate Other Investments — 0.4% (8)
Lumithera, Inc. (2)	Medical Device	Royalty Agreement				1,200		1,100
ZetrOZ, Inc. (12)	Medical Device	Royalty Agreement				—		200
Total Non-Affiliate Other Investments						1,200		1,300
Non-Affiliate Equity — 0.8% (8)
Castle Creek Biosciences, Inc. (12)	Biotechnology	Common Stock		1,162		250		250
Emalex Biosciences, Inc. (2)(12)	Biotechnology	Common Stock		32,831		356		356
Getaround, Inc. (2)(5)	Consumer-related Technologies	Common Stock		87,082		253		57
SnagAJob.com, Inc. (12)	Consumer-related Technologies	Common Stock		82,974		8		83
Lumithera, Inc. (2)	Medical Device	Common Stock		392,651		2,000		1,700
Tigo Energy, Inc. (2)	Other Sustainability	Preferred		22,313		8		27
Branded Online, Inc. (2)(5)	Software	Common Stock		108,004		1,079		83
Decisyon, Inc. (12)	Software	Preferred and Common Stock		72,638,663		230		—
Total Non-Affiliate Equity						4,184		2,556
Total Non-Affiliate Portfolio Investment Assets					$	721,248	$	720,026
Total Portfolio Investment Assets — 226.1% (8)					$	721,248	$	720,026

XML

Note 4 - Investments (Tables)

3 Months Ended

Mar. 31, 2023

Notes Tables

Investment Holdings, Schedule of Investments [Table Text Block]

	March 31, 2023				December 31, 2022
	Cost		Fair Value		Cost		Fair Value
	(In thousands)
Investments
Debt	$	703,781	$	684,554	$	701,074	$	686,458
Warrants		14,735		25,658		14,790		29,712
Other		1,200		1,300		1,200		1,300
Equity		4,446		3,800		4,184		2,556
Total investments	$	724,162	$	715,312	$	721,248	$	720,026

	March 31, 2023				December 31, 2022
	Cost		Fair Value		Cost		Fair Value
	(In thousands)
Life Science
Biotechnology	$	187,970	$	186,981	$	193,372	$	195,006
Medical Device		129,102		131,823		132,803		135,960
Technology
Communications		22,913		26,168		22,892		26,176
Consumer-Related		107,802		99,140		121,961		114,050
Data Storage		476		1,302		476		1,316
Internet and Media		329		1,583		329		1,159
Networking		10,111		9,984		11,831		11,710
Power Management		1,585		2,808		1,585		2,610
Semiconductors		57		—		56		—
Software		145,706		143,680		120,157		118,716
Sustainability
Energy Efficiency		8		27		8		27
Other Sustainability		84,753		83,734		84,633		85,524
Healthcare Information and Services
Diagnostics		9,862		9,868		9,851		9,858
Other		6,990		1,414		7,559		3,870
Software		16,498		16,800		13,735		14,044
Total investments	$	724,162	$	715,312	$	721,248	$	720,026

XML

Note 5 - Transactions With Affiliated Companies (Tables)

3 Months Ended

Mar. 31, 2023

Notes Tables

Investments in and Advances to Affiliates [Table Text Block]

					Three months ended March 31, 2023
	Fair value at						Transfers				Net				Fair value at
Portfolio	December 31,				Principal		in/(out) at		Discount		unrealized		Net realized		March 31,		Interest
Company	2022		Purchases		Payments		fair value		accretion		gain/(loss)		gain/(loss)		2023		income
	(In thousands)
Cadrenal Therapeutics, Inc.	$	—	$	—	$	—	$	—	$	—	$	846	$	—	$	846	$	—
Total non-controlled affiliates	$	—	$	—	$	—	$	—	$	—	$	846	$	—	$	846	$	—

					Three months ended March 31, 2022
	Fair value at							Transfers				Net				Fair value at
Portfolio	December 31,							in/(out) at		Dividends		unrealized		Net realized		March 31,		Dividend
Company	2021		Purchases		Sales			fair value		declared		gain/(loss)		gain/(loss)		2022		income
	(In thousands)
HESP LLC		—		—		(50	)		—		—		50		—		—		—
Total controlled affiliates	$	—	$	—	$	(50	)	$	—	$	—	$	50	$	—	$	—	$	—

XML

Note 6 - Fair Value (Tables)

3 Months Ended

Mar. 31, 2023

Notes Tables

Fair Value, Assets Measured on Recurring Basis [Table Text Block]

	March 31, 2023
	Level 1		Level 2		Level 3		Total
	(In thousands)
Debt investments	$	—	$	—	$	684,554	$	684,554
Warrant investments		—		1,020		24,638		25,658
Other investments		—		—		1,300		1,300
Equity investments		885		—		2,915		3,800
Total investments	$	885	$	1,020	$	713,407	$	715,312

	December 31, 2022
	Level 1		Level 2		Level 3		Total
	(In thousands)
Debt investments	$	—	$	—	$	686,458	$	686,458
Warrant investments		—		3,567		26,145		29,712
Other investments		—		—		1,300		1,300
Equity investments		140		—		2,416		2,556
Total investments	$	140	$	3,567	$	716,319	$	720,026

Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]

March 31, 2023
	Fair		Valuation Techniques/	Unobservable		Weighted
Investment Type	Value		Methodologies	Input	Range	Average(1)
			(Dollars in thousands, except per share data)
Debt investments	$	644,854	Discounted Expected Future Cash Flows	Hypothetical Market Yield	11% – 20%		14	%
		39,700	Multiple Probability Weighted Cash Flow Model	Probability Weighting	10% - 100%		43	%
Warrant investments		24,638	Black-Scholes Valuation Model	Price Per Share	0.100 –1,89999	$	62.82
				Average Industry Volatility	28%		28	%
				Marketability Discount	20%		20	%
				Estimated Time to Exit (in years)	1 to 5		3
Other investments		1,300	Multiple Probability Weighted Cash Flow Model	Discount Rate	25%		25	%
				Probability Weighting	100%		100	%
Equity investments		2,915	Last Equity Financing	Price Per Share	$1.00– $215.03	$	40.27
Total Level 3 investments	$	713,407

December 31, 2022
	Fair		Valuation Techniques/	Unobservable		Weighted
Investment Type	Value		Methodologies	Input	Range	Average(1)
			(Dollars in thousands, except per share data)
Debt investments	$	669,617	Discounted Expected Future Cash Flows	Hypothetical Market Yield	3% – 22%		14	%
		16,545	Multiple Probability Weighted Cash Flow Model	Probability Weighting	10% - 75%		31	%
		296	Convertible Note Analysis	Price Per Share	$168.93	$	168.93
Warrant investments		26,145	Black-Scholes Valuation Model	Price Per Share	0.000 –1.89999	$	58.52
				Average Industry Volatility	28%		28	%
				Marketability Discount	20%		20	%
				Estimated Time to Exit (in years)	1 to 5		3
Other investments		1,300	Multiple Probability Weighted Cash Flow Model	Discount Rate	25%		25	%
				Probability Weighting	100%		100	%
Equity investments		2,416	Last Equity Financing	Price Per Share	$1.00– $215.03	$	26.93
Total Level 3 investments	$	716,319

Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

	Three months ended March 31, 2023
	Debt			Warrant			Equity		Other
	Investments			Investments			Investments		Investments		Total
	(In thousands)
Level 3 assets, beginning of period	$	686,458		$	26,145		$	2,416	$	1,300	$	716,319
Purchase of investments		46,998			—			10		—		47,008
Warrants received and classified as Level 3		—			141			—		—		141
Principal payments received on investments		(39,756	)		—			—		—		(39,756	)
Payment-in-kind interest on investments		1,204			—			—		—		1,204
Proceeds from sale of investments		(6,508	)		(12	)		—		—		(6,520	)
Net realized gain (loss) on investments		7			(141	)		—		—		(134	)
Unrealized (depreciation) appreciation included in earnings		(4,566	)		(1,490	)		189		—		(5,867	)
Transfer out of debt investments		(295	)		(5	)		300		—		—
Other		1,012			—			—		—		1,012
Level 3 assets, end of period	$	684,554		$	24,638		$	2,915	$	1,300	$	713,407

	Three months ended March 31, 2022
	Debt			Warrant			Equity		Other
	Investments			Investments			Investments		Investments			Total
	(In thousands)
Level 3 assets, beginning of period	$	437,317		$	19,837		$	203	$	200		$	457,557
Purchase of investments		94,485			—			—		—			94,485
Warrants received and classified as Level 3		—			808			—		—			808
Principal payments received on investments		(14,095	)		—			—		(50	)		(14,145	)
Proceeds from sale of investments		(21,250	)		(30	)		—		—			(21,280	)
Net realized gain on investments		—			30			—		—			30
Unrealized (depreciation) appreciation included in earnings		(3,170	)		1,000			—		50			(2,120	)
Other		(1,093	)		—			—		—			(1,093	)
Level 3 assets, end of period	$	492,194		$	21,645		$	203	$	200		$	514,242

XML

Note 7 - Borrowings (Tables)

3 Months Ended

Mar. 31, 2023

Notes Tables

Schedule of Debt [Table Text Block]

	March 31, 2023							December 31, 2022
	Total		Balance			Unused		Total		Balance			Unused
	Commitment		Outstanding			Commitment		Commitment		Outstanding			Commitment
	(In thousands)
Key Facility	$	125,000	$	15,000		$	110,000	$	125,000	$	5,000		$	120,000
NYL Facility		200,000		176,750			23,250		200,000		176,750			23,250
2019 Asset-Backed Notes		37,791		37,791			—		42,573		42,573			—
2022 Asset-Backed Notes		100,000		100,000			—		100,000		100,000			—
2027 Notes		57,500		57,500			—		57,500		57,500			—
2026 Notes		57,500		57,500			—		57,500		57,500			—
Total before debt issuance costs		577,791		444,541			133,250		582,573		439,323			143,250
Unamortized debt issuance costs attributable to term borrowings		—		(4,896	)		—		—		(5,245	)		—
Total borrowings outstanding, net	$	577,791	$	439,645		$	133,250	$	582,573	$	434,078		$	143,250

XML

Note 8 - Financial Instruments With Off-balance-sheet Risk (Tables)

3 Months Ended

Mar. 31, 2023

Notes Tables

Schedule of Fair Value, off-Balance-Sheet Risks [Table Text Block]

	March 31, 2023				December 31, 2022
			Fair Value of				Fair Value of
			Unfunded				Unfunded
	Principal		Commitment		Principal		Commitment
	Balance		Liability		Balance		Liability
	(In thousands)				(In thousands)
BrightInsight, Inc.	$	18,250	$	241	$	21,000	$	278
Britecore Holdings, Inc.		—		—		5,000		66
Castle Creek Biosciences		4,000		72		4,000		72
Corinth Medtech, Inc.		200		—		—		—
Divergent Technologies, Inc.		18,750		197		22,500		236
Engage3, LLC		8,000		40		8,000		40
Groundspeed Analytics, Inc.		15,500		150		15,000		150
Hound Labs, Inc.		7,500		88		7,500		88
KSQ Therapeutics, Inc.		10,000		100		10,000		100
Lytics, Inc.		4,000		52		5,000		65
Native Microbials, Inc.		—		—		7,500		72
Noodle Partners, Inc.		10,000		123		—		—
Optoro, Inc.		15,000		38		15,000		38
PDS Biotechnology Corporation		10,000		158		10,000		158
Robin Healthcare, Inc.		5,000		50		10,000		100
Scientia Vascular, Inc.		10,000		110		10,000		110
Slingshot Aerospace, Inc.		5,000		63		5,000		64
Swift Health Systems Inc.		18,500		—		25,500		105
Temperpack Technologies, Inc.		6,500		14		9,000		19
Total	$	166,200	$	1,496	$	190,000	$	1,761

XML

Note 10 - Distributions (Tables)

3 Months Ended

Mar. 31, 2023

Notes Tables

Dividends Declared [Table Text Block]

							DRIP		DRIP
Date			Amount		Cash		Shares		Share
Declared	Record Date	Payment Date	Per Share		Distribution		Issued		Value
			(In thousands, except share and per share data)
Three Months Ended March 31, 2023
2/23/2023	5/18/23	6/14/23	$	0.11	$	—		—	$	—
2/23/2023	4/18/23	5/16/23		0.11		—		—		—
2/23/2023	3/17/23	4/14/23		0.11		3,035		6,894		81
			$	0.33	$	3,035		6,894	$	81
Year Ended December 31, 2022
10/28/2022	2/17/23	3/15/23	$	0.11	$	3,040		6,764	$	75
10/28/2022	1/18/23	2/15/23		0.11		3,021		5,754		74
10/28/2022	12/19/22	1/13/23		0.11		2,978		5,618		69
10/28/2022	11/17/22	12/15/22		0.05		1,319		2,171		27
7/29/2022	11/17/22	12/15/22		0.10		2,638		4,341		57
7/29/2022	10/18/22	11/15/22		0.10		2,580		4,621		60
7/29/2022	9/19/22	10/14/22		0.10		2,558		7,703		81
4/29/2022	8/18/22	9/15/22		0.10		2,528		4,925		60
4/29/2022	7/19/22	8/16/22		0.10		2,484		3,939		55
4/29/2022	6/17/22	7/15/22		0.10		2,434		4,286		51
2/25/2022	5/18/22	6/15/22		0.10		2,378		4,428		50
2/25/2022	4/19/22	5/16/22		0.10		2,349		4,088		49
2/25/2022	3/18/22	4/14/22		0.10		2,352		3,221		46
			$	1.28	$	32,659		61,859	$	754

Ex-Dividend Date	Record Date	Payment Date	Distributions Declared
June 15, 2023	June 16, 2023	July 14, 2023	$	0.11
July 17, 2023	July 18, 2023	August 15, 2023	$	0.11
August 16, 2023	August 17, 2023	September 15, 2023	$	0.11

XML

Note 11 - Financial Highlights (Tables)

3 Months Ended

Mar. 31, 2023

Notes Tables

Investment Company, Financial Highlights [Table Text Block]

	Three months ended March 31,
	2023				2022
	(In thousands, except share and per share data)
Per share data:
Net asset value at beginning of period	$	11.47			$	11.56
Net investment income		0.46				0.26
Realized loss		(0.01	)			—
Unrealized depreciation on investments		(0.26	)			(0.10	)
Net increase in net assets resulting from operations		0.19				0.16
Distributions declared (1)		(0.33	)			(0.30	)
From net investment income		(0.33	)			(0.30	)
From net realized gain on investments		—				—
Return of capital		—				—
Other (2)		0.01				0.26
Net asset value at end of period	$	11.34			$	11.68
Per share market value, beginning of period	$	11.60			$	15.92
Per share market value, end of period	$	11.28			$	13.90
Total return based on a market value (3)		0.1	%			(10.8	)%
Shares outstanding at end of period		28,377,357				23,977,137
Ratios to average net assets:
Expenses without incentive value (4)		14.8	%			10.6	%
Incentive fees (4)		3.7	%			2.2	%
Net expenses (4)		18.5	%			12.8	%
Net investment income with incentive fees (4)		16.3	%			8.7	%
Net assets at the end of the period	$	321,683			$	279,989
Average net asset value	$	320,066			$	262,662
Average debt per share	$	15.61			$	12.21
Portfolio turnover ratio		4.2	%	(5)		2.6	%	(5)

XML

Consolidated Schedule of Investments (Unaudited) (Details Textual) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022	Nov. 09, 2022	Aug. 13, 2019
Debt Instrument, Face Amount	$ 577,791	$ 582,573
Percentage of Nonqualifying Assets on a Cost Basis	6.30%	6.50%
Percentage of Nonqualifying Assets on a Fair Value Basis	6.20%	6.60%
Asset-backed Notes 2019 [Member]
Debt Instrument, Face Amount	$ 37,791	$ 42,573		$ 160,000
Asset-backed Notes 2019 [Member] | Affiliated Entity [Member]
Debt Instrument, Face Amount				$ 100,000
Asset-backed Notes 2022 [Member]
Debt Instrument, Face Amount	$ 100,000	$ 100,000	$ 157,800
Asset-backed Notes 2022 [Member] | Affiliated Entity [Member]
Debt Instrument, Face Amount			$ 100,000

XML

Consolidated Schedule of Investments (Unaudited) - Investments (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Investments at cost	$ 724,162	$ 721,248
Investments at fair value	715,312	720,026
Investment, Unaffiliated Issuer [Member]
Investments at cost	724,162	721,248
Investments at fair value	714,466	720,026
Investment, Unaffiliated Issuer [Member] | Debt Securities [Member]
Principal Amount
Investments at cost	703,781	701,074
Investments at fair value	684,554	686,458
Investment, Unaffiliated Issuer [Member] | Warrant [Member]
Investments at cost	14,735	14,790
Investments at fair value	25,658	29,712
Investment, Unaffiliated Issuer [Member] | Other Long-Term Investments [Member]
Investments at cost	1,200	1,200
Investments at fair value	1,300	1,300
Investment, Unaffiliated Issuer [Member] | Equity Securities [Member]
Investments at cost	4,446	4,184
Investments at fair value	2,954	2,556
Investment, Affiliated Issuer, Noncontrolled [Member]
Investments at cost	0	0
Investments at fair value	846	0
Investment, Affiliated Issuer, Noncontrolled [Member] | Equity Securities [Member]
Investments at cost	0
Investments at fair value	846
Biotechnology Sector [Member]
Investments at cost	187,970	193,372
Investments at fair value	186,981	195,006
Medical Device Sector [Member]
Investments at cost	129,102	132,803
Investments at fair value	131,823	135,960
Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Warrant [Member]
Investments at cost	4,158
Investments at fair value	6,603
Software Sector [Member]
Investments at cost	145,706	120,157
Investments at fair value	143,680	118,716
Diagnostics Sector [Member]
Investments at cost	9,862	9,851
Investments at fair value	9,868	9,858
Communications Sector [Member]
Investments at cost	22,913	22,892
Investments at fair value	26,168	26,176
Other Healthcare Sector [Member]
Investments at cost	6,990	7,559
Investments at fair value	1,414	3,870
Life Science [Member] | Investment, Unaffiliated Issuer [Member] | Debt Securities [Member]
Investments at cost	309,108	318,172
Investments at fair value	307,749	317,568
Life Science [Member] | Investment, Unaffiliated Issuer [Member] | Warrant [Member]
Investments at cost		4,197
Investments at fair value		$ 9,792
Number of shares (in shares)
Other Sustainability Sector [Member]
Investments at cost	84,753	$ 84,633
Investments at fair value	83,734	85,524
Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Warrant [Member]
Investments at cost	922
Investments at fair value	739
Healthcare Sector [Member] | Investment, Unaffiliated Issuer [Member] | Debt Securities [Member]
Investments at cost	32,926	30,729
Investments at fair value	26,137	25,819
Healthcare Sector [Member] | Investment, Unaffiliated Issuer [Member] | Warrant [Member]
Investments at cost	424	416
Investments at fair value	1,945	1,953
Technology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Debt Securities [Member]
Investments at cost	277,916	268,468
Investments at fair value	267,673	259,366
Technology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Warrant [Member]
Investments at cost	9,231	9,249
Investments at fair value	$ 16,371	16,148
Number of shares (in shares)
Data Storage Sector [Member]
Investments at cost	$ 476	476
Investments at fair value	1,302	1,316
Internet and Media Sector [Member]
Investments at cost	329	329
Investments at fair value	1,583	1,159
Sustainability Segment [Member] | Investment, Unaffiliated Issuer [Member] | Debt Securities [Member]
Investments at cost	83,831	83,705
Investments at fair value	82,995	83,705
Sustainability Segment [Member] | Investment, Unaffiliated Issuer [Member] | Warrant [Member]
Investments at cost		928
Investments at fair value		$ 1,819
Number of shares (in shares)
Networking Sector [Member]
Investments at cost	10,111	$ 11,831
Investments at fair value	9,984	11,710
Power Management Sector [Member]
Investments at cost	1,585	1,585
Investments at fair value	2,808	2,610
Semiconductor Sector [Member]
Investments at cost	57	56
Investments at fair value	0	0
Software, Healthcare Information and Service [Member]
Investments at cost	16,498	13,735
Investments at fair value	$ 16,800	$ 14,044
Avalo Therapeutics, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	14.25%	13.75%
Margin	6.25%	6.25%
Floor	9.50%	9.50%
Ceiling	0.00%	0.00%
ETP	3.00%	3.00%
Maturity Date	Jan. 01, 2025	Jan. 01, 2025
Principal Amount	$ 2,913	$ 2,885
Investments at cost	2,860	2,853
Investments at fair value	$ 2,779	$ 2,777
Avalo Therapeutics, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	14.25%	13.75%
Margin	6.25%	6.25%
Floor	9.50%	9.50%
Ceiling	0.00%	0.00%
ETP	3.00%	3.00%
Maturity Date	Jan. 01, 2025	Jan. 01, 2025
Principal Amount	$ 2,885	$ 2,885
Investments at cost	2,832	2,823
Investments at fair value	2,752	2,750
Avalo Therapeutics, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member]
Investments at cost	311	311
Investments at fair value	$ 0	$ 0
Number of shares (in shares)	26,444	26,442
Avalo Therapeutics, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	14.25%	13.75%
Margin	6.25%	6.25%
Floor	9.50%	9.50%
Ceiling	0.00%	0.00%
ETP	3.00%	3.00%
Maturity Date	Jan. 01, 2025	Jan. 01, 2025
Principal Amount	$ 1,442	$ 1,442
Investments at cost	1,416	1,411
Investments at fair value	$ 1,375	$ 1,374
Avalo Therapeutics, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate	14.25%	13.75%
Margin	6.25%	6.25%
Floor	9.50%	9.50%
Ceiling	0.00%	0.00%
ETP	3.00%	3.00%
Maturity Date	Feb. 01, 2025	Feb. 01, 2025
Principal Amount	$ 2,885	$ 2,885
Investments at cost	2,829	2,821
Investments at fair value	$ 2,749	$ 2,748
Avalo Therapeutics, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Five [Member]
Cash Rate	14.25%	13.75%
Margin	6.25%	6.25%
Floor	9.50%	9.50%
Ceiling	0.00%	0.00%
ETP	3.00%	3.00%
Maturity Date	Feb. 01, 2025	Feb. 01, 2025
Principal Amount	$ 2,885	$ 2,885
Investments at cost	2,829	2,821
Investments at fair value	$ 2,749	$ 2,748
Avalo Therapeutics, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Six [Member]
Cash Rate	14.25%	13.75%
Margin	6.25%	6.25%
Floor	9.50%	9.50%
Ceiling	0.00%	0.00%
ETP	3.00%	3.00%
Maturity Date	Apr. 01, 2025	Apr. 01, 2025
Principal Amount	$ 1,442	$ 1,442
Investments at cost	1,412	1,408
Investments at fair value	$ 1,370	$ 1,371
Avalo Therapeutics, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Seven [Member]
Cash Rate	14.25%	13.75%
Margin	6.25%	6.25%
Floor	9.50%	9.50%
Ceiling	0.00%	0.00%
ETP	3.00%	3.00%
Maturity Date	Apr. 01, 2025	Apr. 01, 2025
Principal Amount	$ 1,442	$ 1,442
Investments at cost	1,412	1,408
Investments at fair value	$ 1,370	$ 1,371
Stealth BioTherapeutics Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13.50%	13.00%
Margin	5.50%	5.50%
Floor	8.75%	8.75%
Ceiling	0.00%	0.00%
ETP	6.00%	6.00%
Maturity Date	Oct. 01, 2025	Oct. 01, 2025
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,922	4,914
Investments at fair value	$ 4,922	$ 4,914
Stealth BioTherapeutics Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	13.50%	13.00%
Margin	5.50%	5.50%
Floor	8.75%	8.75%
Ceiling	0.00%	0.00%
ETP	6.00%	6.00%
Maturity Date	Oct. 01, 2025	Oct. 01, 2025
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,461	2,457
Investments at fair value	2,461	2,457
Stealth BioTherapeutics Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member]
Investments at cost	264	264
Investments at fair value	$ 28	$ 37
Number of shares (in shares)	318,181	318,181
Swift Health Systems Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13.00%	12.25%
Margin	5.25%	5.25%
Floor	9.00%	9.00%
Ceiling	0.00%	0.00%
ETP	5.00%	5.00%
Maturity Date	Jul. 01, 2027	Jul. 01, 2027
Principal Amount	$ 3,500	$ 3,500
Investments at cost	3,457	3,349
Investments at fair value	$ 3,457	$ 3,349
Swift Health Systems Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	13.00%	12.25%
Margin	5.25%	5.25%
Floor	9.00%	9.00%
Ceiling	0.00%	0.00%
ETP	5.00%	5.00%
Maturity Date	Jul. 01, 2027	Jul. 01, 2027
Principal Amount	$ 3,500	$ 3,500
Investments at cost	3,457	3,454
Investments at fair value	3,457	3,454
Swift Health Systems Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	71	71
Investments at fair value	$ 81	$ 83
Number of shares (in shares)	135,484	135,484
Swift Health Systems Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	13.25%
Margin	5.25%
Floor	9.00%
Ceiling	0.00%
ETP	5.00%
Maturity Date	Jul. 01, 2027
Principal Amount	$ 3,500
Investments at cost	3,447
Investments at fair value	$ 3,447
Swift Health Systems Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate	13.25%
Margin	5.25%
Floor	9.00%
Ceiling	0.00%
ETP	5.00%
Maturity Date	Jul. 01, 2027
Principal Amount	$ 3,500
Investments at cost	3,447
Investments at fair value	$ 3,447
Divergent Technologies, Inc. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	11.25%	11.25%
Margin	6.00%	6.00%
Floor	9.50%	9.50%
Ceiling	11.25%	11.25%
ETP	3.00%	3.00%
Maturity Date	Jul. 01, 2027	Jul. 01, 2027
Principal Amount	$ 3,750	$ 3,750
Investments at cost	3,520	3,478
Investments at fair value	$ 3,520	$ 3,478
Divergent Technologies, Inc. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	11.25%	11.25%
Margin	6.00%	6.00%
Floor	9.50%	9.50%
Ceiling	11.25%	11.25%
ETP	3.00%	3.00%
Maturity Date	Jul. 01, 2027	Jul. 01, 2027
Principal Amount	$ 1,250	$ 1,250
Investments at cost	1,239	1,238
Investments at fair value	1,239	1,238
Divergent Technologies, Inc. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	70	56
Investments at fair value	$ 237	$ 233
Number of shares (in shares)	33,742	31,966
Divergent Technologies, Inc. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	11.25%	11.25%
Margin	6.00%	6.00%
Floor	9.50%	9.50%
Ceiling	11.25%	11.25%
ETP	3.00%	3.00%
Maturity Date	Jul. 01, 2027	Jul. 01, 2027
Principal Amount	$ 3,750	$ 3,750
Investments at cost	3,717	3,715
Investments at fair value	$ 3,717	$ 3,715
Divergent Technologies, Inc. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate	11.25%	11.25%
Margin	6.00%	6.00%
Floor	9.50%	9.50%
Ceiling	11.25%	11.25%
ETP	3.00%	3.00%
Maturity Date	Jul. 01, 2027	Jul. 01, 2027
Principal Amount	$ 1,250	$ 1,250
Investments at cost	1,239	1,238
Investments at fair value	$ 1,239	$ 1,238
Divergent Technologies, Inc. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Five [Member]
Cash Rate	11.25%	11.25%
Margin	6.00%	6.00%
Floor	9.50%	9.50%
Ceiling	11.25%	11.25%
ETP	3.00%	3.00%
Maturity Date	Jul. 01, 2027	Jul. 01, 2027
Principal Amount	$ 3,750	$ 3,750
Investments at cost	3,717	3,715
Investments at fair value	$ 3,717	$ 3,715
Divergent Technologies, Inc. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Six [Member]
Cash Rate	11.25%	11.25%
Margin	6.00%	6.00%
Floor	9.50%	9.50%
Ceiling	11.25%	11.25%
ETP	3.00%	3.00%
Maturity Date	Jul. 01, 2027	Jul. 01, 2027
Principal Amount	$ 1,250	$ 1,250
Investments at cost	1,239	1,238
Investments at fair value	$ 1,239	$ 1,238
Divergent Technologies, Inc. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Seven [Member]
Cash Rate	11.25%	11.25%
Margin	6.00%	6.00%
Floor	9.50%	9.50%
Ceiling	11.25%	11.25%
ETP	3.00%	3.00%
Maturity Date	Jan. 01, 2028	Jan. 01, 2028
Principal Amount	$ 3,750	$ 3,750
Investments at cost	3,701	3,698
Investments at fair value	$ 3,701	$ 3,698
Divergent Technologies, Inc. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Eight [Member]
Cash Rate	11.25%	11.25%
Margin	6.00%	6.00%
Floor	9.50%	9.50%
Ceiling	11.25%	11.25%
ETP	3.00%	3.00%
Maturity Date	Jan. 01, 2028	Jan. 01, 2028
Principal Amount	$ 3,750	$ 3,750
Investments at cost	3,701	3,698
Investments at fair value	$ 3,701	$ 3,698
Divergent Technologies, Inc. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Nine [Member]
Cash Rate	11.25%
Margin	6.00%
Floor	9.50%
Ceiling	11.25%
ETP	3.00%
Maturity Date	Apr. 01, 2028
Principal Amount	$ 3,750
Investments at cost	3,698
Investments at fair value	$ 3,698
DropOff, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	14.50%	14.00%
Margin	6.50%	6.50%
Floor	9.75%	9.75%
Ceiling	0.00%	0.00%
ETP	3.50%	3.50%
Maturity Date	Apr. 01, 2026	Apr. 01, 2026
Principal Amount	$ 6,500	$ 6,500
Investments at cost	6,359	6,347
Investments at fair value	$ 6,359	$ 6,347
DropOff, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	14.50%	14.00%
Margin	6.50%	6.50%
Floor	9.75%	9.75%
Ceiling	0.00%	0.00%
ETP	3.50%	3.50%
Maturity Date	Apr. 01, 2026	Apr. 01, 2026
Principal Amount	$ 6,000	$ 6,000
Investments at cost	5,869	5,859
Investments at fair value	5,869	5,859
DropOff, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member]
Investments at cost	455	455
Investments at fair value	$ 196	$ 197
Number of shares (in shares)	516,732	516,732
DropOff, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	14.50%	14.00%
Margin	6.50%	6.50%
Floor	9.75%	9.75%
Ceiling	0.00%	0.00%
ETP	3.50%	3.50%
Maturity Date	Aug. 01, 2026	Aug. 01, 2026
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,442	2,436
Investments at fair value	$ 2,442	$ 2,436
Corinth Medtech, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13.00%	12.25%
Margin	5.25%	5.25%
Floor	8.50%	8.50%
Ceiling	0.00%	0.00%
ETP	20.00%	20.00%
Maturity Date	Jun. 30, 2023	Sep. 15, 2022
Principal Amount	$ 2,528	$ 2,500
Investments at cost	2,528	2,500
Investments at fair value	$ 2,528	$ 2,500
Corinth Medtech, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	13.00%	12.25%
Margin	5.25%	5.25%
Floor	8.50%	8.50%
Ceiling	0.00%	0.00%
ETP	20.00%	20.00%
Maturity Date	Jun. 30, 2023	Sep. 15, 2022
Principal Amount	$ 2,528	$ 2,500
Investments at cost	2,528	2,500
Investments at fair value	$ 2,528	$ 2,500
Corinth Medtech, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	13.00%
Margin	5.25%
Floor	8.50%
Ceiling	0.00%
ETP	50.00%
Maturity Date	Jun. 30, 2023
Principal Amount	$ 200
Investments at cost	200
Investments at fair value	$ 200
Magnolia Medical Technologies, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	12.75%	12.00%
Margin	5.00%	5.00%
Floor	9.75%	9.75%
Ceiling	0.00%	0.00%
ETP	4.00%	4.00%
Maturity Date	Mar. 01, 2025	Mar. 01, 2025
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,946	4,939
Investments at fair value	$ 4,946	$ 4,939
Magnolia Medical Technologies, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	12.75%	12.00%
Margin	5.00%	5.00%
Floor	9.75%	9.75%
Ceiling	0.00%	0.00%
ETP	4.00%	4.00%
Maturity Date	Mar. 01, 2025	Mar. 01, 2025
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,946	4,939
Investments at fair value	4,946	4,939
Magnolia Medical Technologies, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	194	194
Investments at fair value	$ 379	$ 385
Number of shares (in shares)	809,931	809,931
Magnolia Medical Technologies, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	12.75%	12.00%
Margin	5.00%	5.00%
Floor	9.75%	9.75%
Ceiling	0.00%	0.00%
ETP	4.00%	4.00%
Maturity Date	Mar. 01, 2025	Mar. 01, 2025
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,940	4,933
Investments at fair value	$ 4,940	$ 4,933
Magnolia Medical Technologies, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate	12.75%	12.00%
Margin	5.00%	5.00%
Floor	9.75%	9.75%
Ceiling	0.00%	0.00%
ETP	4.00%	4.00%
Maturity Date	Mar. 01, 2025	Mar. 01, 2025
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,941	4,933
Investments at fair value	$ 4,941	$ 4,933
Magnolia Medical Technologies, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Five [Member]
Cash Rate	12.75%	12.50%
Margin	5.00%	5.00%
Floor	9.75%	9.75%
Ceiling	0.00%	0.00%
ETP	4.00%	4.00%
Maturity Date	Jan. 01, 2027	Jan. 01, 2027
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,920	4,913
Investments at fair value	$ 4,920	$ 4,913
Magnolia Medical Technologies, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Six [Member]
Cash Rate	12.75%	12.50%
Margin	5.00%	5.00%
Floor	9.75%	9.75%
Ceiling	0.00%	0.00%
ETP	4.00%	4.00%
Maturity Date	Jan. 01, 2027	Jan. 01, 2027
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,920	4,913
Investments at fair value	$ 4,920	$ 4,913
Hound Labs, Inc. [Member] | Diagnostics Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	14.00%	13.50%
Margin	6.00%	6.00%
Floor	9.25%	9.25%
Ceiling	0.00%	0.00%
ETP	3.50%	3.50%
Maturity Date	Jun. 01, 2026	Jun. 01, 2026
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,388	2,385
Investments at fair value	$ 2,388	$ 2,385
Hound Labs, Inc. [Member] | Diagnostics Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	14.00%	13.50%
Margin	6.00%	6.00%
Floor	9.25%	9.25%
Ceiling	0.00%	0.00%
ETP	3.50%	3.50%
Maturity Date	Jun. 01, 2026	Jun. 01, 2026
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,476	2,473
Investments at fair value	2,476	2,473
Hound Labs, Inc. [Member] | Diagnostics Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	47	47
Investments at fair value	$ 53	$ 54
Number of shares (in shares)	159,893	159,893
Hound Labs, Inc. [Member] | Diagnostics Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	14.00%	13.50%
Margin	6.00%	6.00%
Floor	9.25%	9.25%
Ceiling	0.00%	0.00%
ETP	3.50%	3.50%
Maturity Date	Jun. 01, 2026	Jun. 01, 2026
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,951	4,946
Investments at fair value	$ 4,951	$ 4,946
Axiom Space, Inc [Member] | Communications Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13.75%	13.00%
Margin	6.00%	6.00%
Floor	9.25%	9.25%
Ceiling	0.00%	0.00%
ETP	2.50%	2.50%
Maturity Date	Jun. 01, 2026	Jun. 01, 2026
Principal Amount	$ 7,500	$ 7,500
Investments at cost	7,459	7,455
Investments at fair value	$ 7,459	$ 7,455
Axiom Space, Inc [Member] | Communications Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	13.75%	13.00%
Margin	6.00%	6.00%
Floor	9.25%	9.25%
Ceiling	0.00%	0.00%
ETP	2.50%	2.50%
Maturity Date	Jun. 01, 2026	Jun. 01, 2026
Principal Amount	$ 7,500	$ 7,500
Investments at cost	7,459	7,455
Investments at fair value	7,459	7,455
Axiom Space, Inc [Member] | Communications Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member]
Investments at cost	46	46
Investments at fair value	$ 64	$ 67
Number of shares (in shares)	1,991	1,991
Axiom Space, Inc [Member] | Communications Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	13.75%	13.00%
Margin	6.00%	6.00%
Floor	9.25%	9.25%
Ceiling	0.00%	0.00%
ETP	2.50%	2.50%
Maturity Date	Jun. 01, 2026	Jun. 01, 2026
Principal Amount	$ 7,500	$ 7,500
Investments at cost	7,459	7,455
Investments at fair value	7,459	$ 7,455
Axiom Space, Inc [Member] | Communications Sector [Member] | Investment, Unaffiliated Issuer [Member] | Convertible Debt Securities [Member]
Cash Rate		3.00%
Maturity Date		Jul. 01, 2023
Principal Amount		$ 250
Investments at cost		250
Investments at fair value		$ 306
Axiom Space, Inc [Member] | Technology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock [Member]
Investments at cost	261
Investments at fair value	$ 306
Number of shares (in shares)	1,810
Aerobiotix, LLC [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	14.25%	13.75%
Margin	6.25%	6.25%
Floor	9.50%	9.50%
Ceiling	0.00%	0.00%
ETP	6.00%	6.00%
Maturity Date	Apr. 01, 2026	Apr. 01, 2026
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,467	2,463
Investments at fair value	$ 2,361	$ 2,364
Aerobiotix, LLC [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	14.25%	13.75%
Margin	6.25%	6.25%
Floor	9.50%	9.50%
Ceiling	0.00%	0.00%
ETP	6.00%	6.00%
Maturity Date	Apr. 01, 2026	Apr. 01, 2026
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,467	2,463
Investments at fair value	2,361	2,364
Aerobiotix, LLC [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	48	48
Investments at fair value	$ 31	$ 31
Number of shares (in shares)	27,330	27,330
Castle Creek Biosciences, Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	12.88%	12.50%
Margin	6.05%	6.05%
Floor	9.55%	9.55%
Ceiling	13.50%	13.50%
ETP	5.50%	5.50%
Maturity Date	May 01, 2026	May 01, 2026
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,895	4,891
Investments at fair value	$ 4,895	$ 4,891
Castle Creek Biosciences, Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	12.88%	12.50%
Margin	6.05%	6.05%
Floor	9.55%	9.55%
Ceiling	13.50%	13.50%
ETP	5.50%	5.50%
Maturity Date	May 01, 2026	May 01, 2026
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,967	4,963
Investments at fair value	4,967	4,963
Castle Creek Biosciences, Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	214	214
Investments at fair value	$ 329	$ 335
Number of shares (in shares)	7,404	7,404
Castle Creek Biosciences, Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	12.88%	12.50%
Margin	6.05%	6.05%
Floor	9.55%	9.55%
Ceiling	13.50%	13.50%
ETP	5.50%	5.50%
Maturity Date	May 01, 2026	May 01, 2026
Principal Amount	$ 3,000	$ 3,000
Investments at cost	2,977	2,978
Investments at fair value	$ 2,977	$ 2,978
Castle Creek Biosciences, Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate	12.88%	12.50%
Margin	6.05%	6.05%
Floor	9.55%	9.55%
Ceiling	13.50%	13.50%
ETP	5.50%	5.50%
Maturity Date	May 01, 2026	May 01, 2026
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,967	4,963
Investments at fair value	$ 4,967	$ 4,963
Castle Creek Biosciences, Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Five [Member]
Cash Rate	12.88%	12.50%
Margin	6.05%	6.05%
Floor	9.55%	9.55%
Ceiling	13.50%	13.50%
ETP	5.50%	5.50%
Maturity Date	May 01, 2026	May 01, 2026
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,970	4,963
Investments at fair value	$ 4,970	$ 4,963
Castle Creek Biosciences, Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Six [Member]
Cash Rate	12.88%	12.50%
Margin	6.05%	6.05%
Floor	9.55%	9.55%
Ceiling	13.50%	13.50%
ETP	5.50%	5.50%
Maturity Date	May 01, 2026	May 01, 2026
Principal Amount	$ 3,000	$ 3,000
Investments at cost	2,980	2,978
Investments at fair value	2,980	2,978
Castle Creek Biosciences, Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock [Member]
Investments at cost	250	250
Investments at fair value	$ 250	$ 250
Number of shares (in shares)	1,162	1,162
Meditrina, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	$ 83	$ 83
Investments at fair value	$ 98	$ 101
Number of shares (in shares)	233,993	233,993
Kate Farms, Inc [Member] | Other Healthcare Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	$ 102	$ 102
Investments at fair value	$ 1,363	$ 1,370
Number of shares (in shares)	82,965	82,965
CSA Medical, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	$ 153	$ 153
Investments at fair value	$ 148	$ 150
Number of shares (in shares)	1,375,727	1,375,727
CSA Medical, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, LIBOR Index, One [Member]
Cash Rate	12.87%	12.37%
Margin	8.20%	8.20%
Floor	10.00%	10.00%
Ceiling	0.00%	0.00%
ETP	5.00%	5.00%
Maturity Date	Jan. 01, 2024	Jan. 01, 2024
Principal Amount	$ 1,250	$ 1,625
Investments at cost	1,239	1,610
Investments at fair value	$ 1,239	$ 1,610
CSA Medical, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, LIBOR Index, Two [Member]
Cash Rate	12.87%	12.37%
Margin	8.20%	8.20%
Floor	10.00%	10.00%
Ceiling	0.00%	0.00%
ETP	5.00%	5.00%
Maturity Date	Jan. 01, 2024	Jan. 01, 2024
Principal Amount	$ 83	$ 108
Investments at cost	83	107
Investments at fair value	$ 83	$ 107
CSA Medical, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, LIBOR Index, Three [Member]
Cash Rate	12.87%	12.37%
Margin	8.20%	8.20%
Floor	10.00%	10.00%
Ceiling	0.00%	0.00%
ETP	5.00%	5.00%
Maturity Date	Mar. 01, 2024	Mar. 01, 2024
Principal Amount	$ 1,600	$ 2,000
Investments at cost	1,587	1,983
Investments at fair value	1,587	1,983
Intelepeer Holdings, Inc [Member] | Communications Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	138	139
Investments at fair value	$ 3,251	$ 3,265
Number of shares (in shares)	2,936,535	2,936,535
Engage3, LLC [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	14.00%	13.25%
Margin	6.25%	6.25%
Floor	9.75%	9.75%
Ceiling	0.00%	0.00%
ETP	4.50%	4.50%
Maturity Date	Jul. 01, 2027	Jul. 01, 2027
Principal Amount	$ 3,750	$ 3,750
Investments at cost	3,680	3,678
Investments at fair value	$ 3,680	$ 3,678
Engage3, LLC [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	14.00%	13.25%
Margin	6.25%	6.25%
Floor	9.75%	9.75%
Ceiling	0.00%	0.00%
ETP	4.50%	4.50%
Maturity Date	Jul. 01, 2027	Jul. 01, 2027
Principal Amount	$ 3,750	$ 3,750
Investments at cost	3,720	3,718
Investments at fair value	3,720	3,718
Corvium, Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	53	53
Investments at fair value	$ 0	$ 0
Number of shares (in shares)	661,956	661,956
Robin Healthcare, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13.50%	13.00%
Margin	5.50%	5.50%
Floor	10.25%	10.25%
Ceiling	0.00%	0.00%
ETP	4.00%	4.00%
Maturity Date	Nov. 01, 2026	Nov. 01, 2026
Principal Amount	$ 3,500	$ 3,500
Investments at cost	3,413	3,360
Investments at fair value	$ 3,413	$ 3,360
Robin Healthcare, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	13.50%	13.00%
Margin	5.50%	5.50%
Floor	10.25%	10.25%
Ceiling	0.00%	0.00%
ETP	4.00%	4.00%
Maturity Date	Nov. 01, 2026	Nov. 01, 2026
Principal Amount	$ 3,500	$ 3,500
Investments at cost	3,463	3,460
Investments at fair value	3,463	3,460
Robin Healthcare, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	16	16
Investments at fair value	$ 15	$ 16
Number of shares (in shares)	86,066	86,066
Secure Transfusion Services, Inc [Member] | Other Healthcare Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13.75%	13.25%
Margin	5.75%	5.75%
Floor	9.00%	9.00%
Ceiling	0.00%	0.00%
ETP	4.00%	4.00%
Maturity Date	Oct. 01, 2025	Oct. 01, 2025
Principal Amount	$ 4,719	$ 4,943
Investments at cost	4,658	4,943
Investments at fair value	$ 46	$ 1,668
Secure Transfusion Services, Inc [Member] | Other Healthcare Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	13.75%	13.25%
Margin	5.75%	5.75%
Floor	9.00%	9.00%
Ceiling	0.00%	0.00%
ETP	4.00%	4.00%
Maturity Date	Dec. 31, 2025	Dec. 31, 2025
Principal Amount	$ 2,217	$ 2,500
Investments at cost	2,182	2,467
Investments at fair value	5	832
Secure Transfusion Services, Inc [Member] | Other Healthcare Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	48	47
Investments at fair value	$ 0	$ 0
Number of shares (in shares)	77,690	77,690
PebblePost, Inc [Member] | Communications Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	$ 91	$ 92
Investments at fair value	$ 170	$ 173
Number of shares (in shares)	598,850	598,850
Ceribell, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	11.25%	10.50%
Margin	3.50%	3.50%
Floor	8.25%	8.25%
Ceiling	0.00%	0.00%
ETP	5.50%	5.50%
Maturity Date	Oct. 01, 2024	Oct. 01, 2024
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,977	4,973
Investments at fair value	$ 4,977	$ 4,973
Ceribell, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	11.25%	10.50%
Margin	3.50%	3.50%
Floor	8.25%	8.25%
Ceiling	0.00%	0.00%
ETP	5.50%	5.50%
Maturity Date	Oct. 01, 2024	Oct. 01, 2024
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,977	4,973
Investments at fair value	4,977	4,973
Ceribell, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	69	69
Investments at fair value	$ 206	$ 209
Number of shares (in shares)	145,483	145,483
Ceribell, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	11.25%	10.50%
Margin	3.50%	3.50%
Floor	8.25%	8.25%
Ceiling	0.00%	0.00%
ETP	5.50%	5.50%
Maturity Date	Oct. 01, 2024	Oct. 01, 2024
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,481	2,478
Investments at fair value	$ 2,481	$ 2,478
Ceribell, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate	11.25%	10.50%
Margin	3.50%	3.50%
Floor	8.25%	8.25%
Ceiling	0.00%	0.00%
ETP	5.50%	5.50%
Maturity Date	Oct. 01, 2024	Oct. 01, 2024
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,481	2,478
Investments at fair value	2,481	2,478
Emalex Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	176	176
Investments at fair value	$ 256	$ 263
Number of shares (in shares)	110,402	110,402
Emalex Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, LIBOR Index, One [Member]
Cash Rate	12.57%	12.07%
Margin	4.72%	7.90%
Floor	9.75%	9.75%
Ceiling	0.00%	0.00%
ETP	5.00%	5.00%
Maturity Date	Jun. 01, 2024	Jun. 01, 2024
Principal Amount	$ 1,979	$ 1,979
Investments at cost	1,965	1,962
Investments at fair value	$ 1,965	$ 1,962
Emalex Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, LIBOR Index, Two [Member]
Cash Rate	12.57%	12.07%
Margin	4.72%	7.90%
Floor	9.75%	9.75%
Ceiling	0.00%	0.00%
ETP	5.00%	5.00%
Maturity Date	Jun. 01, 2024	Jun. 01, 2024
Principal Amount	$ 1,979	$ 1,979
Investments at cost	1,966	1,963
Investments at fair value	$ 1,966	$ 1,963
Emalex Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, LIBOR Index, Three [Member]
Cash Rate	12.57%	12.07%
Margin	4.72%	7.90%
Floor	9.75%	9.75%
Ceiling	0.00%	0.00%
ETP	5.00%	5.00%
Maturity Date	Nov. 01, 2025	Nov. 01, 2025
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,930	4,923
Investments at fair value	4,930	4,923
Emalex Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock [Member]
Investments at cost	356	356
Investments at fair value	$ 356	$ 356
Number of shares (in shares)	32,831	32,831
Emalex Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, LIBOR Index, Four [Member]
Cash Rate	12.57%	12.07%
Margin	4.72%	7.90%
Floor	9.75%	9.75%
Ceiling	0.00%	0.00%
ETP	5.00%	5.00%
Maturity Date	May 01, 2026	May 01, 2026
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,921	4,912
Investments at fair value	$ 4,921	$ 4,912
Scientia Vascular, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	12.50%	11.75%
Margin	4.75%	4.75%
Floor	8.50%	8.50%
Ceiling	0.00%	0.00%
ETP	5.00%	5.00%
Maturity Date	Jan. 01, 2027	Jan. 01, 2027
Principal Amount	$ 3,750	$ 3,750
Investments at cost	3,601	3,597
Investments at fair value	$ 3,601	$ 3,597
Scientia Vascular, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	12.50%	11.75%
Margin	4.75%	4.75%
Floor	8.50%	8.50%
Ceiling	0.00%	0.00%
ETP	5.00%	5.00%
Maturity Date	Jan. 01, 2027	Jan. 01, 2027
Principal Amount	$ 3,750	$ 3,750
Investments at cost	3,710	3,706
Investments at fair value	3,710	3,706
Scientia Vascular, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	40	40
Investments at fair value	$ 45	$ 46
Number of shares (in shares)	19,662	19,662
BrightInsight, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	$ 167
Investments at fair value	$ 175
Number of shares (in shares)	85,066
BrightInsight, Inc. [Member] | Software, Healthcare Information and Service [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13.25%	12.50%
Margin	5.50%	5.50%
Floor	9.50%	9.50%
Ceiling	0.00%	0.00%
ETP	3.00%	3.00%
Maturity Date	Aug. 01, 2027	Aug. 01, 2027
Principal Amount	$ 7,000	$ 7,000
Investments at cost	6,663	6,619
Investments at fair value	$ 6,663	$ 6,619
BrightInsight, Inc. [Member] | Software, Healthcare Information and Service [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	13.25%	12.50%
Margin	5.50%	5.50%
Floor	9.50%	9.50%
Ceiling	0.00%	0.00%
ETP	3.00%	3.00%
Maturity Date	Aug. 01, 2027	Aug. 01, 2027
Principal Amount	$ 3,500	$ 3,500
Investments at cost	3,452	3,448
Investments at fair value	$ 3,452	3,448
BrightInsight, Inc. [Member] | Software, Healthcare Information and Service [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost		160
Investments at fair value		$ 170
Number of shares (in shares)		80,544
BrightInsight, Inc. [Member] | Software, Healthcare Information and Service [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	13.25%	12.50%
Margin	5.50%	5.50%
Floor	9.50%	9.50%
Ceiling	0.00%	0.00%
ETP	3.00%	3.00%
Maturity Date	Aug. 01, 2027	Aug. 01, 2027
Principal Amount	$ 3,500	$ 3,500
Investments at cost	3,452	3,448
Investments at fair value	$ 3,452	$ 3,448
BrightInsight, Inc. [Member] | Software, Healthcare Information and Service [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate	13.50%
Margin	5.50%
Floor	9.50%
Ceiling	0.00%
ETP	3.00%
Maturity Date	Apr. 01, 2028
Principal Amount	$ 2,750
Investments at cost	2,704
Investments at fair value	2,704
Alula Holdings, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		13.75%
Margin		6.75%
Floor		10.00%
Ceiling		0.00%
ETP		3.00%
Maturity Date		Jan. 01, 2025
Principal Amount		$ 5,000
Investments at cost		4,966
Investments at fair value		$ 4,966
Alula Holdings, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate		13.75%
Margin		6.75%
Floor		10.00%
Ceiling		0.00%
ETP		3.00%
Maturity Date		Jan. 01, 2025
Principal Amount		$ 5,000
Investments at cost		4,966
Investments at fair value		4,966
Alula Holdings, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	93	93
Investments at fair value	$ 64	$ 64
Number of shares (in shares)	20,000	20,000
Alula Holdings, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member]
Cash Rate		13.75%
Margin		6.75%
Floor		10.00%
Ceiling		0.00%
ETP		3.00%
Maturity Date		Jan. 01, 2025
Principal Amount		$ 3,000
Investments at cost		2,979
Investments at fair value		$ 2,979
Alula Holdings, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate		13.75%
Margin		6.75%
Floor		10.00%
Ceiling		0.00%
ETP		3.00%
Maturity Date		Dec. 01, 2025
Principal Amount		$ 1,000
Investments at cost		976
Investments at fair value		$ 976
Alula Holdings, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Five [Member]
Cash Rate		13.75%
Margin		6.75%
Floor		10.00%
Ceiling		0.00%
ETP		3.00%
Maturity Date		Feb. 01, 2026
Principal Amount		$ 1,000
Investments at cost		977
Investments at fair value		$ 977
Aerofarms, Inc. [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	14.75%	14.25%
Margin	6.75%	6.75%
Floor	10.00%	10.00%
Ceiling	0.00%	0.00%
ETP	3.00%	3.00%
Maturity Date	Apr. 01, 2026	Apr. 01, 2026
Principal Amount	$ 3,750	$ 3,750
Investments at cost	3,704	3,699
Investments at fair value	$ 3,585	$ 3,699
Aerofarms, Inc. [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	14.75%	14.25%
Margin	6.75%	6.75%
Floor	10.00%	10.00%
Ceiling	0.00%	0.00%
ETP	3.00%	3.00%
Maturity Date	Apr. 01, 2026	Apr. 01, 2026
Principal Amount	$ 3,750	$ 3,750
Investments at cost	3,704	3,699
Investments at fair value	3,585	3,699
Aerofarms, Inc. [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	61	61
Investments at fair value	$ 72	$ 74
Number of shares (in shares)	201,537	201,537
Groundspeed Analytics, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13.50%	13.00%
Margin	5.50%	5.50%
Floor	11.00%	11.00%
Ceiling	18.00%	18.00%
ETP	3.00%	3.00%
Maturity Date	Dec. 01, 2026	Dec. 01, 2026
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,802	4,798
Investments at fair value	$ 4,802	$ 4,798
Groundspeed Analytics, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	13.50%	13.00%
Margin	5.50%	5.50%
Floor	11.00%	11.00%
Ceiling	18.00%	18.00%
ETP	3.00%	3.00%
Maturity Date	Dec. 01, 2026	Dec. 01, 2026
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,953	4,948
Investments at fair value	4,953	4,948
Groundspeed Analytics, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	7	6
Investments at fair value	$ 1	$ 6
Number of shares (in shares)	86,300	86,300
Groundspeed Analytics, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Convertible Debt Securities [Member]
Cash Rate	15.00%
Maturity Date	Sep. 10, 2024
Principal Amount	$ 500
Investments at cost	500
Investments at fair value	$ 500
Evelo Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	12.25%	11.75%
Margin	4.25%	4.75%
Floor	11.00%	11.00%
Ceiling	0.00%	0.00%
ETP	4.25%	4.25%
Maturity Date	Jan. 01, 2028	Jan. 01, 2028
Principal Amount	$ 10,000	$ 10,000
Investments at cost	9,880	9,872
Investments at fair value	$ 9,880	$ 9,872
Evelo Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	12.25%	11.75%
Margin	4.25%	4.75%
Floor	11.00%	11.00%
Ceiling	0.00%	0.00%
ETP	4.25%	4.25%
Maturity Date	Jan. 01, 2028	Jan. 01, 2028
Principal Amount	$ 15,000	$ 15,000
Investments at cost	14,819	14,808
Investments at fair value	14,819	14,808
Evelo Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member]
Investments at cost	126	126
Investments at fair value	$ 0	$ 125
Number of shares (in shares)	463,915	463,915
Evelo Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	12.25%	11.75%
Margin	4.25%	4.75%
Floor	11.00%	11.00%
Ceiling	0.00%	0.00%
ETP	4.25%	4.25%
Maturity Date	Jan. 01, 2028	Jan. 01, 2028
Principal Amount	$ 6,000	$ 6,000
Investments at cost	5,928	5,923
Investments at fair value	$ 5,928	$ 5,923
Evelo Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate	12.25%	11.75%
Margin	4.25%	4.75%
Floor	11.00%	11.00%
Ceiling	0.00%	0.00%
ETP	4.25%	4.25%
Maturity Date	Jan. 01, 2028	Jan. 01, 2028
Principal Amount	$ 6,000	$ 6,000
Investments at cost	5,928	5,923
Investments at fair value	$ 5,928	$ 5,923
Evelo Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Five [Member]
Cash Rate	12.25%	11.75%
Margin	4.25%	4.75%
Floor	11.00%	11.00%
Ceiling	0.00%	0.00%
ETP	4.25%	4.25%
Maturity Date	Jan. 01, 2028	Jan. 01, 2028
Principal Amount	$ 4,000	$ 4,000
Investments at cost	3,952	3,949
Investments at fair value	$ 3,952	$ 3,949
Evelo Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Six [Member]
Cash Rate	12.25%	11.75%
Margin	4.25%	4.75%
Floor	11.00%	11.00%
Ceiling	0.00%	0.00%
ETP	4.25%	4.25%
Maturity Date	Jan. 01, 2028	Jan. 01, 2028
Principal Amount	$ 4,000	$ 4,000
Investments at cost	3,952	3,949
Investments at fair value	$ 3,952	$ 3,949
Sonex Health, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	14.25%	13.50%
Margin	6.50%	6.50%
Floor	9.75%	9.75%
Ceiling	0.00%	0.00%
ETP	8.00%	8.00%
Maturity Date	Jun. 01, 2025	Jun. 01, 2025
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,478	2,476
Investments at fair value	$ 2,478	$ 2,476
Sonex Health, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	14.25%	13.50%
Margin	6.50%	6.50%
Floor	9.75%	9.75%
Ceiling	0.00%	0.00%
ETP	8.00%	8.00%
Maturity Date	Jun. 01, 2025	Jun. 01, 2025
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,478	2,476
Investments at fair value	2,478	2,476
Sonex Health, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	98	98
Investments at fair value	$ 120	$ 123
Number of shares (in shares)	605,313	605,313
Sonex Health, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	14.25%	13.50%
Margin	6.50%	6.50%
Floor	9.75%	9.75%
Ceiling	0.00%	0.00%
ETP	8.00%	8.00%
Maturity Date	Jun. 01, 2025	Jun. 01, 2025
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,478	2,476
Investments at fair value	$ 2,478	$ 2,476
Sonex Health, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate	14.25%	13.50%
Margin	6.50%	6.50%
Floor	9.75%	9.75%
Ceiling	0.00%	0.00%
ETP	8.00%	8.00%
Maturity Date	Apr. 01, 2026	Apr. 01, 2026
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,459	2,453
Investments at fair value	$ 2,459	$ 2,453
Sonex Health, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Five [Member]
Cash Rate	14.25%	13.50%
Margin	6.50%	6.50%
Floor	9.75%	9.75%
Ceiling	0.00%	0.00%
ETP	8.00%	8.00%
Maturity Date	May 01, 2026	May 01, 2026
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,458	2,455
Investments at fair value	2,458	2,455
Medsphere Systems Corporation [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	60
Investments at fair value	$ 354
Number of shares (in shares)	7,097,792
Medsphere Systems Corporation [Member] | Software, Healthcare Information and Service [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost		60
Investments at fair value		$ 359
Number of shares (in shares)		7,097,792
Embody, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		14.00%
Margin		6.50%
Floor		9.75%
Ceiling		0.00%
ETP		28.00%
Maturity Date		Aug. 01, 2026
Principal Amount		$ 2,500
Investments at cost		2,482
Investments at fair value		2,482
Aterian, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member]
Investments at cost	$ 195	195
Investments at fair value	$ 0	$ 0
Number of shares (in shares)	76,923	76,923
Greenlight Biosciences, Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13.75%	13.25%
Margin	5.75%	5.75%
Floor	9.00%	9.00%
Ceiling	0.00%	0.00%
ETP	3.00%	3.00%
Maturity Date	Jul. 01, 2025	Jul. 01, 2025
Principal Amount	$ 4,500	$ 5,000
Investments at cost	4,371	4,857
Investments at fair value	$ 4,352	$ 4,857
Greenlight Biosciences, Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	13.75%	13.25%
Margin	5.75%	5.75%
Floor	9.00%	9.00%
Ceiling	0.00%	0.00%
ETP	3.00%	3.00%
Maturity Date	Jul. 01, 2025	Jul. 01, 2025
Principal Amount	$ 2,250	$ 2,500
Investments at cost	2,187	2,430
Investments at fair value	2,177	2,430
Greenlight Biosciences, Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member]
Investments at cost	366	366
Investments at fair value	$ 0	$ 0
Number of shares (in shares)	47,452	47,452
VERO Biotech LLC [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	$ 53	$ 53
Investments at fair value	$ 1	$ 1
Number of shares (in shares)	408	408
InfoBionic, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	14.00%	13.25%
Margin	6.25%	6.25%
Floor	9.50%	9.50%
Ceiling	0.00%	0.00%
ETP	4.00%	4.00%
Maturity Date	Oct. 01, 2024	Oct. 01, 2024
Principal Amount	$ 2,771	$ 3,208
Investments at cost	2,715	3,143
Investments at fair value	$ 2,715	$ 3,143
InfoBionic, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	14.00%	13.25%
Margin	6.25%	6.25%
Floor	9.50%	9.50%
Ceiling	0.00%	0.00%
ETP	4.00%	4.00%
Maturity Date	Jun. 01, 2025	Jun. 01, 2025
Principal Amount	$ 1,000	$ 1,000
Investments at cost	977	974
Investments at fair value	977	974
InfoBionic, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	124	124
Investments at fair value	$ 51	$ 113
Number of shares (in shares)	317,647	317,647
F-Star Therapeutics, Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		13.25%
Margin		6.25%
Floor		9.50%
Ceiling		0.00%
ETP		4.00%
Maturity Date		Apr. 01, 2025
Principal Amount		$ 2,500
Investments at cost		2,476
Investments at fair value		$ 2,476
F-Star Therapeutics, Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate		13.25%
Margin		6.25%
Floor		9.50%
Ceiling		0.00%
ETP		4.00%
Maturity Date		Jul. 01, 2025
Principal Amount		$ 2,500
Investments at cost		2,473
Investments at fair value		2,473
F-Star Therapeutics, Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member]
Investments at cost		35
Investments at fair value		$ 0
Number of shares (in shares)		21,120
Better Place Forests Co. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	14.25%	13.75%
Margin	6.25%	6.25%
Floor	9.50%	9.50%
Ceiling	0.00%	0.00%
ETP	1.85%	1.85%
Maturity Date	Jul. 01, 2025	Jul. 01, 2025
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,951	4,951
Investments at fair value	$ 3,467	$ 3,834
Better Place Forests Co. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	14.25%	13.75%
Margin	6.25%	6.25%
Floor	9.50%	9.50%
Ceiling	0.00%	0.00%
ETP	1.85%	1.85%
Maturity Date	Oct. 01, 2025	Oct. 01, 2025
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,474	2,474
Investments at fair value	1,733	1,916
Better Place Forests Co. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	26	26
Investments at fair value	$ 0	$ 0
Number of shares (in shares)	2,672	10,690
Nexii Building Solutions, Inc [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	15.00%	14.50%
Margin	7.00%	7.00%
Floor	10.25%	10.25%
Ceiling	0.00%	0.00%
ETP	2.50%	2.50%
Maturity Date	Sep. 01, 2025	Sep. 01, 2025
Principal Amount	$ 7,500	$ 7,500
Investments at cost	7,383	7,371
Investments at fair value	$ 7,245	$ 7,371
Nexii Building Solutions, Inc [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	15.00%	14.50%
Margin	7.00%	7.00%
Floor	10.25%	10.25%
Ceiling	0.00%	0.00%
ETP	2.50%	2.50%
Maturity Date	Sep. 01, 2025	Sep. 01, 2025
Principal Amount	$ 7,500	$ 7,500
Investments at cost	7,383	7,371
Investments at fair value	7,245	7,371
Nexii Building Solutions, Inc [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member]
Investments at cost	490	488
Investments at fair value	$ 1	$ 1,061
Number of shares (in shares)	204,195	204,832
Nexii Building Solutions, Inc [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	15.00%	14.50%
Margin	7.00%	7.00%
Floor	10.25%	10.25%
Ceiling	0.00%	0.00%
ETP	2.50%	2.50%
Maturity Date	Sep. 01, 2025	Sep. 01, 2025
Principal Amount	$ 7,500	$ 7,500
Investments at cost	7,383	7,371
Investments at fair value	$ 7,245	$ 7,371
Nexii Building Solutions, Inc [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate	15.00%	14.50%
Margin	7.00%	7.00%
Floor	10.25%	10.25%
Ceiling	0.00%	0.00%
ETP	2.50%	2.50%
Maturity Date	Jul. 01, 2026	Jul. 01, 2026
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,912	4,903
Investments at fair value	$ 4,820	$ 4,903
Nexii Building Solutions, Inc [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Five [Member]
Cash Rate	15.00%	14.50%
Margin	7.00%	7.00%
Floor	10.25%	10.25%
Ceiling	0.00%	0.00%
ETP	2.50%	2.50%
Maturity Date	Jul. 01, 2026	Jul. 01, 2026
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,912	4,903
Investments at fair value	4,820	4,903
Imunon, Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member]
Investments at cost	66	66
Investments at fair value	$ 0	$ 0
Number of shares (in shares)	19,671	16,502
Caastle, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	$ 68	$ 68
Investments at fair value	$ 1,057	$ 1,069
Number of shares (in shares)	268,591	268,591
Cognoa, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13.50%	13.00%
Margin	5.50%	5.50%
Floor	8.75%	8.75%
Ceiling	0.00%	0.00%
ETP	6.00%	6.00%
Maturity Date	Aug. 01, 2026	Aug. 01, 2026
Principal Amount	$ 5,000	$ 2,500
Investments at cost	4,940	2,466
Investments at fair value	$ 4,940	$ 2,466
Cognoa, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	13.50%	13.00%
Margin	5.50%	5.50%
Floor	8.75%	8.75%
Ceiling	0.00%	0.00%
ETP	6.00%	6.00%
Maturity Date	Aug. 01, 2026	Aug. 01, 2026
Principal Amount	$ 2,500	$ 5,000
Investments at cost	2,470	4,932
Investments at fair value	2,470	4,932
Cognoa, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	144	148
Investments at fair value	$ 173	$ 179
Number of shares (in shares)	775,000	775,000
Kodiak Robotics, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13.50%	13.00%
Margin	5.50%	5.50%
Floor	10.25%	10.25%
Ceiling	0.00%	0.00%
ETP	4.00%	4.00%
Maturity Date	Apr. 01, 2026	Apr. 01, 2026
Principal Amount	$ 10,000	$ 10,000
Investments at cost	9,843	9,826
Investments at fair value	$ 9,843	$ 9,826
Kodiak Robotics, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	13.50%	13.00%
Margin	5.50%	5.50%
Floor	10.25%	10.25%
Ceiling	0.00%	0.00%
ETP	4.00%	4.00%
Maturity Date	Apr. 01, 2026	Apr. 01, 2026
Principal Amount	$ 10,000	$ 10,000
Investments at cost	9,843	9,826
Investments at fair value	9,843	9,826
Kodiak Robotics, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	275	273
Investments at fair value	$ 287	$ 296
Number of shares (in shares)	639,918	639,918
Kodiak Robotics, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	13.50%	13.00%
Margin	5.50%	5.50%
Floor	10.25%	10.25%
Ceiling	0.00%	0.00%
ETP	4.00%	4.00%
Maturity Date	Apr. 01, 2026	Apr. 01, 2026
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,921	4,913
Investments at fair value	$ 4,921	$ 4,913
Kodiak Robotics, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate	13.50%	13.00%
Margin	5.50%	5.50%
Floor	10.25%	10.25%
Ceiling	0.00%	0.00%
ETP	4.00%	4.00%
Maturity Date	Apr. 01, 2026	Apr. 01, 2026
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,921	4,913
Investments at fair value	$ 4,921	$ 4,913
IMV Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13.75%	13.25%
Margin	5.75%	5.75%
Floor	9.00%	9.00%
Ceiling	0.00%	0.00%
ETP	5.00%	5.00%
Maturity Date	Jul. 01, 2025	Jul. 01, 2025
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,951	4,946
Investments at fair value	$ 4,759	$ 4,946
IMV Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	13.75%	13.25%
Margin	5.75%	5.75%
Floor	9.00%	9.00%
Ceiling	0.00%	0.00%
ETP	5.00%	5.00%
Maturity Date	Jul. 01, 2025	Jul. 01, 2025
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,476	2,473
Investments at fair value	2,380	2,473
IMV Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member]
Investments at cost	67	67
Investments at fair value	$ 0	$ 0
Number of shares (in shares)	39,774	39,774
IMV Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	13.75%	13.25%
Margin	5.75%	5.75%
Floor	9.00%	9.00%
Ceiling	0.00%	0.00%
ETP	5.00%	5.00%
Maturity Date	Jan. 01, 2026	Jan. 01, 2026
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,953	4,947
Investments at fair value	$ 4,761	$ 4,947
IMV Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate	13.75%	13.25%
Margin	5.75%	5.75%
Floor	9.00%	9.00%
Ceiling	0.00%	0.00%
ETP	5.00%	5.00%
Maturity Date	Jan. 01, 2026	Jan. 01, 2026
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,953	4,947
Investments at fair value	4,761	4,947
Lumithera, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Royalty Agreement [Member]
Investments at cost	1,200	1,200
Investments at fair value	1,100	1,100
Lumithera, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock [Member]
Investments at cost	2,000	2,000
Investments at fair value	$ 1,700	$ 1,700
Number of shares (in shares)	392,651	392,651
Havenly, Inc. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13.00%	12.50%
Margin	5.00%	5.00%
Floor	5.00%	5.00%
Ceiling	0.00%	0.00%
ETP	4.00%	4.00%
Maturity Date	Mar. 01, 2027	Mar. 01, 2027
Principal Amount	$ 2,000	$ 2,000
Investments at cost	1,165	1,082
Investments at fair value	$ 1,165	$ 1,082
Havenly, Inc. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	13.00%	12.50%
Margin	5.00%	5.00%
Floor	5.00%	5.00%
Ceiling	0.00%	0.00%
ETP	4.00%	4.00%
Maturity Date	Mar. 01, 2027	Mar. 01, 2027
Principal Amount	$ 3,000	$ 3,000
Investments at cost	1,748	1,623
Investments at fair value	1,748	1,623
Havenly, Inc. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member]
Investments at cost	2,942	2,947
Investments at fair value	$ 2,674	$ 2,947
Number of shares (in shares)	1,312,500	1,312,500
Havenly, Inc. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	11.50%	11.00%
Margin	3.50%	3.50%
Floor	10.50%	10.50%
Ceiling	0.00%	0.00%
ETP	7.78%	7.78%
Maturity Date	Feb. 01, 2028	Feb. 01, 2028
Principal Amount	$ 2,813	$ 2,813
Investments at cost	2,813	2,813
Investments at fair value	$ 2,813	$ 2,813
Havenly, Inc. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate	11.50%	11.00%
Margin	3.50%	3.50%
Floor	10.50%	10.50%
Ceiling	0.00%	0.00%
ETP	7.78%	7.78%
Maturity Date	Feb. 01, 2028	Feb. 01, 2028
Principal Amount	$ 2,813	$ 2,813
Investments at cost	2,813	2,813
Investments at fair value	$ 2,813	$ 2,813
CAMP NYC, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	15.25%	14.75%
Margin	7.25%	7.25%
Floor	10.50%	10.50%
Ceiling	0.00%	0.00%
ETP	3.00%	3.00%
Maturity Date	May 01, 2026	May 01, 2026
Principal Amount	$ 3,500	$ 3,500
Investments at cost	3,464	3,461
Investments at fair value	3,464	3,461
CAMP NYC, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	22	20
Investments at fair value	$ 0	$ 61
Number of shares (in shares)	17,605	17,605
KSQ Therapeutics, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	12.75%	12.25%
Margin	4.75%	4.75%
Floor	8.50%	8.50%
Ceiling	0.00%	0.00%
ETP	5.50%	5.50%
Maturity Date	May 01, 2027	May 01, 2027
Principal Amount	$ 6,250	$ 6,250
Investments at cost	6,082	6,077
Investments at fair value	$ 6,082	$ 6,077
KSQ Therapeutics, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	12.75%	12.25%
Margin	4.75%	4.75%
Floor	8.50%	8.50%
Ceiling	0.00%	0.00%
ETP	5.50%	5.50%
Maturity Date	May 01, 2027	May 01, 2027
Principal Amount	$ 6,250	$ 6,250
Investments at cost	6,182	6,177
Investments at fair value	6,182	6,177
KSQ Therapeutics, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	50	51
Investments at fair value	$ 56	$ 60
Number of shares (in shares)	48,076	48,077
ZetrOZ, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Royalty Agreement [Member]
Investments at cost	$ 0	$ 0
Investments at fair value	$ 200	$ 200
Clara Foods Co [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13.50%	12.75%
Margin	5.75%	5.75%
Floor	9.00%	9.00%
Ceiling	0.00%	0.00%
ETP	5.50%	5.50%
Maturity Date	Aug. 01, 2025	Aug. 01, 2025
Principal Amount	$ 2,333	$ 2,500
Investments at cost	2,318	2,482
Investments at fair value	$ 2,318	$ 2,482
Clara Foods Co [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	13.50%	12.75%
Margin	5.75%	5.75%
Floor	9.00%	9.00%
Ceiling	0.00%	0.00%
ETP	5.50%	5.50%
Maturity Date	Aug. 01, 2025	Aug. 01, 2025
Principal Amount	$ 2,333	$ 2,500
Investments at cost	2,318	2,482
Investments at fair value	2,318	2,482
Clara Foods Co [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	30	30
Investments at fair value	$ 124	$ 125
Number of shares (in shares)	46,745	46,745
Conventus Orthopaedics, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	$ 221	$ 221
Investments at fair value	$ 221	$ 226
Number of shares (in shares)	7,972,222	7,972,222
Conventus Orthopaedics, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, LIBOR Index, One [Member]
Cash Rate	12.67%	12.17%
Margin	8.00%	8.00%
Floor	9.25%	9.25%
Ceiling	0.00%	0.00%
ETP	10.36%	10.36%
Maturity Date	Jul. 01, 2025	Jul. 01, 2025
Principal Amount	$ 3,960	$ 3,960
Investments at cost	3,904	3,898
Investments at fair value	$ 3,904	$ 3,898
Conventus Orthopaedics, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, LIBOR Index, Two [Member]
Cash Rate	12.67%	12.17%
Margin	8.00%	8.00%
Floor	9.25%	9.25%
Ceiling	0.00%	0.00%
ETP	10.36%	10.36%
Maturity Date	Jul. 01, 2025	Jul. 01, 2025
Principal Amount	$ 3,960	$ 3,960
Investments at cost	3,904	3,898
Investments at fair value	3,904	3,898
Mustang Bio, Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member]
Investments at cost	141	146
Investments at fair value	$ 0	$ 0
Number of shares (in shares)	252,161	252,161
LiquiGlide, Inc [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member]
Investments at cost	$ 39	$ 39
Investments at fair value	$ 53	$ 55
Number of shares (in shares)	61,359	61,539
Native Microbials, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13.25%	12.75%
Margin	5.25%	5.25%
Floor	8.50%	8.50%
Ceiling	0.00%	0.00%
ETP	5.00%	5.00%
Maturity Date	Nov. 01, 2026	Nov. 01, 2026
Principal Amount	$ 3,750	$ 3,750
Investments at cost	3,707	3,630
Investments at fair value	$ 3,707	$ 3,630
Native Microbials, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	13.25%	12.75%
Margin	5.25%	5.25%
Floor	8.50%	8.50%
Ceiling	0.00%	0.00%
ETP	5.00%	5.00%
Maturity Date	Nov. 01, 2026	Nov. 01, 2026
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,472	2,469
Investments at fair value	2,472	2,469
Native Microbials, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	64	64
Investments at fair value	$ 159	$ 162
Number of shares (in shares)	103,679	103,679
Soli Organic, Inc [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	14.75%	14.25%
Margin	6.75%	6.75%
Floor	10.00%	10.00%
Ceiling	0.00%	0.00%
ETP	2.75%	2.75%
Maturity Date	Apr. 01, 2026	Apr. 01, 2026
Principal Amount	$ 5,000	$ 2,500
Investments at cost	4,935	2,463
Investments at fair value	$ 4,935	$ 2,463
Soli Organic, Inc [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	14.75%	14.25%
Margin	6.75%	6.75%
Floor	10.00%	10.00%
Ceiling	0.00%	0.00%
ETP	2.75%	2.75%
Maturity Date	Apr. 01, 2026	Apr. 01, 2026
Principal Amount	$ 2,500	$ 5,000
Investments at cost	2,467	4,927
Investments at fair value	2,467	4,927
Soli Organic, Inc [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	214	214
Investments at fair value	$ 354	$ 361
Number of shares (in shares)	681	681
Soli Organic, Inc [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	14.75%	14.25%
Margin	6.75%	6.75%
Floor	10.00%	10.00%
Ceiling	0.00%	0.00%
ETP	2.75%	2.75%
Maturity Date	May 01, 2026	May 01, 2026
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,932	4,924
Investments at fair value	$ 4,932	$ 4,924
Soli Organic, Inc [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate	14.75%	14.25%
Margin	6.75%	6.75%
Floor	10.00%	10.00%
Ceiling	0.00%	0.00%
ETP	2.75%	2.75%
Maturity Date	May 01, 2026	May 01, 2026
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,466	2,462
Investments at fair value	$ 2,466	$ 2,462
Soli Organic, Inc [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Five [Member]
Cash Rate	13.50%	13.00%
Margin	5.50%	5.50%
Floor	11.75%	10.00%
Ceiling	0.00%	0.00%
ETP	2.75%	2.75%
Maturity Date	Dec. 01, 2026	Dec. 01, 2026
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,909	4,900
Investments at fair value	$ 4,909	$ 4,900
Soli Organic, Inc [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Six [Member]
Cash Rate	13.50%	13.00%
Margin	5.50%	5.50%
Floor	11.75%	10.00%
Ceiling	0.00%	0.00%
ETP	2.75%	2.75%
Maturity Date	Dec. 01, 2026	Dec. 01, 2026
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,454	2,450
Investments at fair value	$ 2,454	$ 2,450
Lemongrass Holdings, Inc [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	14.50%	14.00%
Margin	6.50%	6.50%
Floor	9.75%	9.75%
Ceiling	0.00%	0.00%
ETP	2.50%	2.50%
Maturity Date	Mar. 01, 2026	Mar. 01, 2026
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,953	4,947
Investments at fair value	$ 4,953	$ 4,947
Lemongrass Holdings, Inc [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	14.50%	14.00%
Margin	6.50%	6.50%
Floor	9.75%	9.75%
Ceiling	0.00%	0.00%
ETP	2.50%	2.50%
Maturity Date	Mar. 01, 2026	Mar. 01, 2026
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,477	2,474
Investments at fair value	2,477	2,474
Lemongrass Holdings, Inc [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	35	34
Investments at fair value	$ 40	$ 41
Number of shares (in shares)	101,308	101,308
PDS Biotechnology Corporation [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13.75%	13.25%
Margin	5.75%	5.75%
Floor	9.75%	9.75%
Ceiling	0.00%	0.00%
ETP	3.75%	3.75%
Maturity Date	Sep. 01, 2026	Sep. 01, 2026
Principal Amount	$ 10,000	$ 10,000
Investments at cost	9,714	9,701
Investments at fair value	$ 9,714	$ 9,701
PDS Biotechnology Corporation [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	13.75%	13.25%
Margin	5.75%	5.75%
Floor	9.75%	9.75%
Ceiling	0.00%	0.00%
ETP	3.75%	3.75%
Maturity Date	Sep. 01, 2026	Sep. 01, 2026
Principal Amount	$ 3,750	$ 3,750
Investments at cost	3,702	3,697
Investments at fair value	3,702	3,697
PDS Biotechnology Corporation [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member]
Investments at cost	160	160
Investments at fair value	$ 937	$ 3,024
Number of shares (in shares)	299,848	299,848
PDS Biotechnology Corporation [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	13.75%	13.25%
Margin	5.75%	5.75%
Floor	9.75%	9.75%
Ceiling	0.00%	0.00%
ETP	3.75%	3.75%
Maturity Date	Sep. 01, 2026	Sep. 01, 2026
Principal Amount	$ 3,750	$ 3,750
Investments at cost	3,702	3,697
Investments at fair value	$ 3,702	$ 3,697
Interior Define, Inc. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	14.50%	13.50%
Margin	6.50%	6.50%
Floor	9.75%	9.75%
Ceiling	0.00%	0.00%
ETP	4.00%	4.00%
Maturity Date	Jan. 01, 2026	Jan. 01, 2026
Principal Amount	$ 3,246	$ 3,210
Investments at cost	3,162	3,151
Investments at fair value	$ 0	$ 0
Interior Define, Inc. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	14.50%	13.50%
Margin	6.50%	6.50%
Floor	9.75%	9.75%
Ceiling	0.00%	0.00%
ETP	4.00%	4.00%
Maturity Date	Jan. 01, 2026	Jan. 01, 2026
Principal Amount	$ 2,963	$ 2,963
Investments at cost	2,886	2,886
Investments at fair value	0	0
Interior Define, Inc. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost		103
Investments at fair value		$ 0
Number of shares (in shares)		553,710
Provivi, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	401	$ 399
Investments at fair value	$ 128	$ 648
Number of shares (in shares)	254,609	203,017
Provivi, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, LIBOR Index, One [Member]
Cash Rate	13.17%	12.67%
Margin	8.50%	8.50%
Floor	9.50%	9.50%
Ceiling	0.00%	0.00%
ETP	5.50%	5.50%
Maturity Date	Dec. 01, 2024	Dec. 01, 2024
Principal Amount	$ 4,667	$ 4,667
Investments at cost	4,606	4,597
Investments at fair value	$ 4,606	$ 4,597
Provivi, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, LIBOR Index, Two [Member]
Cash Rate	13.17%	12.67%
Margin	8.50%	8.50%
Floor	9.50%	9.50%
Ceiling	0.00%	0.00%
ETP	5.50%	5.50%
Maturity Date	Dec. 01, 2024	Dec. 01, 2024
Principal Amount	$ 4,667	$ 4,667
Investments at cost	4,606	4,597
Investments at fair value	$ 4,606	$ 4,597
Provivi, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, LIBOR Index, Three [Member]
Cash Rate	13.17%	12.67%
Margin	8.50%	8.50%
Floor	9.50%	9.50%
Ceiling	0.00%	0.00%
ETP	5.50%	5.50%
Maturity Date	Dec. 01, 2024	Dec. 01, 2024
Principal Amount	$ 2,333	$ 2,333
Investments at cost	2,287	2,280
Investments at fair value	$ 2,287	$ 2,280
Provivi, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, LIBOR Index, Four [Member]
Cash Rate	13.17%	12.67%
Margin	8.50%	8.50%
Floor	9.50%	9.50%
Ceiling	0.00%	0.00%
ETP	5.50%	5.50%
Maturity Date	Dec. 01, 2024	Dec. 01, 2024
Principal Amount	$ 2,333	$ 2,333
Investments at cost	2,287	2,280
Investments at fair value	$ 2,287	$ 2,280
Provivi, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, LIBOR Index, Five [Member]
Cash Rate	13.17%	12.67%
Margin	8.50%	8.50%
Floor	9.50%	9.50%
Ceiling	0.00%	0.00%
ETP	5.50%	5.50%
Maturity Date	Dec. 01, 2024	Dec. 01, 2024
Principal Amount	$ 2,333	$ 2,333
Investments at cost	2,282	2,274
Investments at fair value	$ 2,282	$ 2,274
Provivi, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, LIBOR Index, Six [Member]
Cash Rate	13.17%	12.67%
Margin	8.50%	8.50%
Floor	9.50%	9.50%
Ceiling	0.00%	0.00%
ETP	5.50%	5.50%
Maturity Date	Dec. 01, 2024	Dec. 01, 2024
Principal Amount	$ 2,333	$ 2,333
Investments at cost	2,282	2,274
Investments at fair value	$ 2,282	$ 2,274
Temperpack Technologies, Inc [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	14.75%	14.25%
Margin	6.75%	6.75%
Floor	10.00%	10.00%
Ceiling	0.00%	0.00%
ETP	2.50%	2.50%
Maturity Date	Jun. 01, 2025	Jun. 01, 2025
Principal Amount	$ 3,750	$ 3,750
Investments at cost	3,706	3,697
Investments at fair value	$ 3,706	$ 3,697
Temperpack Technologies, Inc [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	14.75%	14.25%
Margin	6.75%	6.75%
Floor	10.00%	10.00%
Ceiling	0.00%	0.00%
ETP	2.50%	2.50%
Maturity Date	Jun. 01, 2025	Jun. 01, 2025
Principal Amount	$ 3,750	$ 3,750
Investments at cost	3,720	3,717
Investments at fair value	3,720	3,717
Temperpack Technologies, Inc [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	118	126
Investments at fair value	$ 259	$ 268
Number of shares (in shares)	34,604	35,906
Temperpack Technologies, Inc [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	14.75%	14.25%
Margin	6.75%	6.75%
Floor	10.00%	10.00%
Ceiling	0.00%	0.00%
ETP	2.50%	2.50%
Maturity Date	Oct. 01, 2025	Oct. 01, 2025
Principal Amount	$ 7,500	$ 7,500
Investments at cost	7,431	7,424
Investments at fair value	$ 7,431	$ 7,424
Temperpack Technologies, Inc [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate	14.75%	14.25%
Margin	6.75%	6.75%
Floor	10.00%	10.00%
Ceiling	0.00%	0.00%
ETP	2.50%	2.50%
Maturity Date	Oct. 01, 2025	Oct. 01, 2025
Principal Amount	$ 3,750	$ 3,750
Investments at cost	3,715	3,712
Investments at fair value	$ 3,715	$ 3,712
Temperpack Technologies, Inc [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Five [Member]
Cash Rate	14.75%	14.25%
Margin	6.75%	6.75%
Floor	10.00%	10.00%
Ceiling	0.00%	0.00%
ETP	2.50%	2.50%
Maturity Date	Oct. 01, 2025	Oct. 01, 2025
Principal Amount	$ 3,750	$ 3,750
Investments at cost	3,715	3,712
Investments at fair value	3,715	3,712
Getaround, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock [Member]
Investments at cost	253	253
Investments at fair value	$ 25	$ 57
Number of shares (in shares)	87,082	87,082
MyForest Foods Co [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	14.75%	14.25%
Margin	6.75%	6.75%
Floor	10.00%	10.00%
Ceiling	0.00%	0.00%
ETP	3.00%	3.00%
Maturity Date	Oct. 01, 2025	Oct. 01, 2025
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,961	4,954
Investments at fair value	$ 4,961	$ 4,954
MyForest Foods Co [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	14.75%	14.25%
Margin	6.75%	6.75%
Floor	10.00%	10.00%
Ceiling	0.00%	0.00%
ETP	3.00%	3.00%
Maturity Date	Oct. 01, 2025	Oct. 01, 2025
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,480	2,477
Investments at fair value	2,480	2,477
MyForest Foods Co [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	29	29
Investments at fair value	$ 36	$ 37
Number of shares (in shares)	143	143
Lytics, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13.75%	13.00%
Margin	6.00%	6.00%
Floor	9.25%	9.25%
Ceiling	0.00%	0.00%
ETP	3.00%	3.00%
Maturity Date	Nov. 01, 2026	Jul. 01, 2025
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,411	2,396
Investments at fair value	$ 2,411	$ 2,396
Lytics, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	13.75%	13.00%
Margin	6.00%	6.00%
Floor	12.25%	12.25%
Ceiling	0.00%	0.00%
ETP	3.00%	3.00%
Maturity Date	Dec. 01, 2026	Dec. 01, 2026
Principal Amount	$ 1,250	$ 1,250
Investments at cost	1,232	1,231
Investments at fair value	1,232	1,231
Lytics, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	43	40
Investments at fair value	$ 46	$ 44
Number of shares (in shares)	85,543	80,197
Lytics, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	13.75%
Margin	6.00%
Floor	12.25%
Ceiling	0.00%
ETP	3.00%
Maturity Date	Apr. 01, 2027
Principal Amount	$ 1,000
Investments at cost	984
Investments at fair value	984
Rocket Pharmaceuticals Corporation [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member]
Investments at cost	17	$ 17
Investments at fair value	$ 2	$ 14
Number of shares (in shares)	7,051	7,051
SnagAJob.com, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock [Member]
Investments at cost	$ 9	$ 8
Investments at fair value	$ 83	$ 83
Number of shares (in shares)	82,974	82,974
Lyrical Foods, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	10.50%	10.00%
Margin	2.50%	6.75%
Floor	8.00%	10.00%
Ceiling	0.00%	0.00%
ETP	0.00%	0.00%
Maturity Date	Sep. 01, 2027	Sep. 01, 2027
Principal Amount	$ 2,598	$ 2,500
Investments at cost	2,586	2,588
Investments at fair value	$ 2,330	$ 2,279
NextCar Holding Company, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13.50%	12.75%
Margin	5.75%	5.75%
Floor	9.00%	9.00%
Ceiling	0.00%	0.00%
ETP	5.25%	2.00%
Maturity Date	Oct. 31, 2023	Dec. 30, 2022
Principal Amount	$ 5,169	$ 5,000
Investments at cost	5,121	4,943
Investments at fair value	$ 4,883	$ 4,715
NextCar Holding Company, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	13.50%	12.75%
Margin	5.75%	5.75%
Floor	9.00%	9.00%
Ceiling	0.00%	0.00%
ETP	5.25%	2.00%
Maturity Date	Oct. 31, 2023	Dec. 30, 2022
Principal Amount	$ 2,067	$ 2,000
Investments at cost	2,050	1,981
Investments at fair value	1,955	1,890
NextCar Holding Company, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	197	197
Investments at fair value	$ 17	$ 17
Number of shares (in shares)	1,261,253	1,261,253
NextCar Holding Company, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	13.50%	12.75%
Margin	5.75%	5.75%
Floor	9.00%	9.00%
Ceiling	0.00%	0.00%
ETP	5.25%	2.00%
Maturity Date	Oct. 31, 2023	Dec. 30, 2022
Principal Amount	$ 2,584	$ 2,500
Investments at cost	2,564	2,477
Investments at fair value	$ 2,446	$ 2,363
NextCar Holding Company, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate	13.50%	12.75%
Margin	5.75%	5.75%
Floor	9.00%	9.00%
Ceiling	0.00%	0.00%
ETP	5.25%	2.00%
Maturity Date	Oct. 31, 2023	Dec. 30, 2022
Principal Amount	$ 3,101	$ 3,000
Investments at cost	3,076	2,971
Investments at fair value	$ 2,934	$ 2,835
NextCar Holding Company, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Five [Member]
Cash Rate	13.50%	12.75%
Margin	5.75%	5.75%
Floor	9.00%	9.00%
Ceiling	0.00%	0.00%
ETP	5.25%	2.00%
Maturity Date	Oct. 31, 2023	Dec. 30, 2022
Principal Amount	$ 2,584	$ 2,500
Investments at cost	2,548	2,459
Investments at fair value	$ 2,430	$ 2,345
NextCar Holding Company, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Six [Member]
Cash Rate	13.50%	12.75%
Margin	5.75%	5.75%
Floor	9.00%	9.00%
Ceiling	0.00%	0.00%
ETP	5.25%	2.00%
Maturity Date	Oct. 31, 2023	Dec. 30, 2022
Principal Amount	$ 2,584	$ 2,500
Investments at cost	2,548	2,459
Investments at fair value	$ 2,430	$ 2,345
NextCar Holding Company, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Seven [Member]
Cash Rate	13.50%	12.75%
Margin	5.75%	5.75%
Floor	9.00%	9.00%
Ceiling	0.00%	0.00%
ETP	5.25%	2.00%
Maturity Date	Oct. 31, 2023	Dec. 30, 2022
Principal Amount	$ 5,169	$ 5,000
Investments at cost	5,093	4,914
Investments at fair value	$ 4,859	$ 4,688
NextCar Holding Company, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Eight [Member]
Cash Rate	13.50%	12.75%
Margin	5.75%	5.75%
Floor	9.00%	9.00%
Ceiling	0.00%	0.00%
ETP	5.25%	2.00%
Maturity Date	Oct. 31, 2023	Dec. 30, 2022
Principal Amount	$ 2,584	$ 2,500
Investments at cost	2,545	2,456
Investments at fair value	$ 2,428	$ 2,342
Optoro, Inc. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	14.00%	13.25%
Margin	6.25%	6.25%
Floor	9.50%	9.50%
Ceiling	0.00%	0.00%
ETP	4.00%	4.00%
Maturity Date	Aug. 01, 2027	Aug. 01, 2027
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,355	2,347
Investments at fair value	2,355	2,347
Optoro, Inc. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	104	104
Investments at fair value	$ 104	$ 104
Number of shares (in shares)	6,600	6,600
vTv Therapeutics Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member]
Investments at cost	$ 44	$ 44
Investments at fair value	$ 0	$ 0
Number of shares (in shares)	95,293	95,293
Tigo Energy, Inc. [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock [Member]
Investments at cost	$ 8	$ 8
Investments at fair value	$ 27	$ 27
Number of shares (in shares)	22,313	22,313
Primary Kids, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	15.00%	14.25%
Margin	7.25%	7.25%
Floor	10.50%	10.50%
Ceiling	0.00%	0.00%
ETP	3.00%	3.00%
Maturity Date	Mar. 01, 2025	Mar. 01, 2025
Principal Amount	$ 2,300	$ 2,700
Investments at cost	2,277	2,673
Investments at fair value	$ 2,277	$ 2,673
Primary Kids, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	15.00%	14.25%
Margin	7.25%	7.25%
Floor	10.50%	10.50%
Ceiling	0.00%	0.00%
ETP	3.00%	3.00%
Maturity Date	Mar. 01, 2025	Mar. 01, 2025
Principal Amount	$ 2,300	$ 2,700
Investments at cost	2,277	2,673
Investments at fair value	2,277	2,673
Primary Kids, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	57	57
Investments at fair value	$ 427	$ 429
Number of shares (in shares)	553,778	553,778
Primary Kids, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	15.00%	14.25%
Margin	7.25%	7.25%
Floor	10.50%	10.50%
Ceiling	0.00%	0.00%
ETP	3.00%	3.00%
Maturity Date	Sep. 01, 2025	Sep. 01, 2025
Principal Amount	$ 2,900	$ 3,000
Investments at cost	2,870	2,967
Investments at fair value	$ 2,870	2,967
Noodle Partners, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13.00%
Margin	5.00%
Floor	12.00%
Ceiling	0.00%
ETP	3.00%
Maturity Date	Mar. 01, 2027
Principal Amount	$ 10,000
Investments at cost	9,733
Investments at fair value	$ 9,733
Noodle Partners, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	13.00%
Margin	5.00%
Floor	12.00%
Ceiling	0.00%
ETP	3.00%
Maturity Date	Mar. 01, 2027
Principal Amount	$ 5,000
Investments at cost	4,928
Investments at fair value	4,928
Noodle Partners, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	116
Investments at fair value	$ 116
Number of shares (in shares)	84,037
Noodle Partners, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	13.00%
Margin	5.00%
Floor	12.00%
Ceiling	0.00%
ETP	3.00%
Maturity Date	Mar. 01, 2027
Principal Amount	$ 5,000
Investments at cost	4,928
Investments at fair value	4,928
Xeris Pharmaceuticals, Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member]
Investments at cost	72	72
Investments at fair value	$ 9	$ 3
Number of shares (in shares)	126,000	126,000
Branded Online, Inc [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock [Member]
Investments at cost	$ 1,075	$ 1,079
Investments at fair value	$ 14	$ 83
Number of shares (in shares)	5,398	108,004
Quip NYC Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	$ 325	$ 325
Investments at fair value	$ 532	$ 534
Number of shares (in shares)	6,191	6,191
AccuVein Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member]
Investments at cost	$ 24	$ 24
Investments at fair value	$ 0	$ 0
Number of shares (in shares)	1,175	1,175
Decisyon, Inc [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	17.43%	16.93%
Margin	9.43%	9.43%
Floor	12.68%	12.68%
Ceiling	0.00%	0.00%
ETP	50.43%	50.43%
Maturity Date	Dec. 31, 2022	Dec. 31, 2022
Principal Amount	$ 3,284	$ 3,295
Investments at cost	3,284	3,295
Investments at fair value	2,750	3,295
Decisyon, Inc [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member]
Investments at cost	46	46
Investments at fair value	$ 0	$ 0
Number of shares (in shares)	82,967	82,967
Decisyon, Inc [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred and Common Stock [Member]
Investments at cost	$ 229
Investments at fair value	$ 0
Number of shares (in shares)	72,638,663
Decisyon, Inc [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Equity Securities [Member]
Investments at cost		$ 230
Investments at fair value		$ 0
Number of shares (in shares)		72,638,663
Unagi, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	15.75%	15.25%
Margin	7.75%	7.75%
Floor	11.00%	11.00%
Ceiling	0.00%	0.00%
ETP	0.00%	0.00%
Maturity Date	May 01, 2027	Jul. 01, 2025
Principal Amount	$ 1,065	$ 2,500
Investments at cost	1,041	2,473
Investments at fair value	$ 1,041	$ 2,473
Unagi, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	15.75%	15.25%
Margin	7.75%	7.75%
Floor	11.00%	11.00%
Ceiling	0.00%	0.00%
ETP	0.00%	0.00%
Maturity Date	May 01, 2027	Jul. 01, 2025
Principal Amount	$ 533	$ 1,250
Investments at cost	520	1,236
Investments at fair value	520	1,236
Unagi, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	32	32
Investments at fair value	$ 111	$ 22
Number of shares (in shares)	171,081	171,081
Unagi, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	15.75%	15.25%
Margin	7.75%	7.75%
Floor	11.00%	11.00%
Ceiling	0.00%	0.00%
ETP	0.00%	0.00%
Maturity Date	May 01, 2027	Jul. 01, 2025
Principal Amount	$ 533	$ 1,250
Investments at cost	521	1,236
Investments at fair value	521	1,236
Aerin Medical, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	66	64
Investments at fair value	$ 1,196	$ 1,200
Number of shares (in shares)	1,818,183	1,818,183
Lotame Solutions, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	$ 19	$ 22
Investments at fair value	$ 53	$ 312
Number of shares (in shares)	71,305	288,115
Lotame Solutions, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock [Member]
Investments at cost	$ 5
Investments at fair value	$ 193
Number of shares (in shares)	66,127
Updater, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member]
Investments at cost	$ 34	$ 34
Investments at fair value	$ 42	$ 42
Number of shares (in shares)	108,333	108,333
Reputation Institute, Inc [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	15.00%	14.25%
Margin	7.25%	7.25%
Floor	10.50%	10.50%
Ceiling	0.00%	0.00%
ETP	3.00%	3.00%
Maturity Date	Aug. 01, 2025	Aug. 01, 2025
Principal Amount	$ 4,833	$ 5,000
Investments at cost	4,772	4,932
Investments at fair value	4,772	4,932
Reputation Institute, Inc [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	61	56
Investments at fair value	$ 46	$ 39
Number of shares (in shares)	3,731	3,731
CPG Beyond, Inc [Member] | Data Storage Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	$ 242	$ 242
Investments at fair value	$ 903	$ 909
Number of shares (in shares)	500,000	500,000
Slingshot Aerospace, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13.75%	13.25%
Margin	5.75%	5.75%
Floor	9.75%	9.75%
Ceiling	0.00%	0.00%
ETP	5.00%	5.00%
Maturity Date	Aug. 01, 2026	Aug. 01, 2026
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,940	4,870
Investments at fair value	$ 4,940	$ 4,870
Slingshot Aerospace, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	13.75%	13.25%
Margin	5.75%	5.75%
Floor	9.75%	9.75%
Ceiling	0.00%	0.00%
ETP	5.00%	5.00%
Maturity Date	Aug. 01, 2026	Aug. 01, 2026
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,940	4,933
Investments at fair value	4,940	4,933
Slingshot Aerospace, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	123	123
Investments at fair value	$ 135	$ 133
Number of shares (in shares)	309,208	309,208
Slingshot Aerospace, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	13.75%	13.25%
Margin	5.75%	5.75%
Floor	9.75%	9.75%
Ceiling	0.00%	0.00%
ETP	5.00%	5.00%
Maturity Date	Aug. 01, 2026	Aug. 01, 2026
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,875	4,933
Investments at fair value	$ 4,875	$ 4,933
Slingshot Aerospace, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate	13.75%	13.25%
Margin	5.75%	5.75%
Floor	9.75%	9.75%
Ceiling	0.00%	0.00%
ETP	5.00%	5.00%
Maturity Date	Aug. 01, 2026	Aug. 01, 2026
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,940	4,933
Investments at fair value	4,940	$ 4,933
Canary Medical Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		12.75%
Margin		5.75%
Floor		9.00%
Ceiling		0.00%
ETP		7.00%
Maturity Date		Nov. 01, 2024
Principal Amount		$ 2,500
Investments at cost		2,475
Investments at fair value		$ 2,475
Canary Medical Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate		12.75%
Margin		5.75%
Floor		9.00%
Ceiling		0.00%
ETP		7.00%
Maturity Date		Nov. 01, 2024
Principal Amount		$ 2,500
Investments at cost		2,489
Investments at fair value		2,489
Canary Medical Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	86	84
Investments at fair value	$ 1,862	$ 1,864
Number of shares (in shares)	12,153	12,153
Canary Medical Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member]
Cash Rate		12.75%
Margin		5.75%
Floor		9.00%
Ceiling		0.00%
ETP		7.00%
Maturity Date		Nov. 01, 2024
Principal Amount		$ 2,500
Investments at cost		2,473
Investments at fair value		2,473
Silk, Inc [Member] | Data Storage Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost		234
Investments at fair value		$ 407
Number of shares (in shares)		442,110
Silk, Inc [Member] | Data Storage Sector [Member] | Investment, Unaffiliated Issuer [Member] | Warrant [Member]
Investments at cost	$ 234
Investments at fair value	$ 399
Number of shares (in shares)	442,110
Global Worldwide LLC [Member] | Internet and Media Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	$ 75	$ 75
Investments at fair value	$ 0	$ 0
Number of shares (in shares)	245,810	245,810
Cadrenal Therapeutics, Inc. [Member] | Investment, Affiliated Issuer, Noncontrolled [Member]
Investments at fair value	$ 846	$ 0
Cadrenal Therapeutics, Inc. [Member] | Biotechnology Sector [Member] | Investment, Affiliated Issuer, Noncontrolled [Member] | Common Stock [Member]
Investments at cost	0
Investments at fair value	$ 846
Number of shares (in shares)	600,000
Spineology, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	15.00%	14.50%
Margin	7.00%	7.00%
Floor	10.25%	10.25%
Ceiling	0.00%	0.00%
ETP	1.00%	1.00%
Maturity Date	Oct. 01, 2025	Oct. 01, 2025
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,969	4,966
Investments at fair value	$ 4,969	$ 4,966
Spineology, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	15.00%	14.50%
Margin	7.00%	7.00%
Floor	10.25%	10.25%
Ceiling	0.00%	0.00%
ETP	1.00%	1.00%
Maturity Date	Apr. 01, 2026	Apr. 01, 2026
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,483	2,481
Investments at fair value	2,483	2,481
Rocket Lawyer Incorporated [Member] | Internet and Media Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	92	92
Investments at fair value	$ 352	$ 357
Number of shares (in shares)	261,721	261,721
Skillshare, Inc [Member] | Internet and Media Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	$ 162	$ 162
Investments at fair value	$ 1,231	$ 802
Number of shares (in shares)	139,074	139,074
Supply Network Visiblity Holdings LLC [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	14.25%	13.50%
Margin	6.50%	6.50%
Floor	9.75%	9.75%
Ceiling	0.00%	0.00%
ETP	4.00%	4.00%
Maturity Date	Feb. 01, 2025	Feb. 01, 2025
Principal Amount	$ 3,208	$ 3,500
Investments at cost	3,183	3,472
Investments at fair value	$ 3,183	$ 3,472
Supply Network Visiblity Holdings LLC [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	14.25%	13.50%
Margin	6.50%	6.50%
Floor	9.75%	9.75%
Ceiling	0.00%	0.00%
ETP	4.00%	4.00%
Maturity Date	Feb. 01, 2025	Dec. 01, 2025
Principal Amount	$ 3,208	$ 2,500
Investments at cost	3,183	2,472
Investments at fair value	3,183	2,472
Supply Network Visiblity Holdings LLC [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	64	64
Investments at fair value	$ 140	$ 83
Number of shares (in shares)	682	682
Supply Network Visiblity Holdings LLC [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	14.25%	13.50%
Margin	6.50%	6.50%
Floor	9.75%	9.75%
Ceiling	0.00%	0.00%
ETP	4.00%	4.00%
Maturity Date	Dec. 01, 2025	Dec. 01, 2025
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,475	2,472
Investments at fair value	$ 2,475	$ 2,472
Supply Network Visiblity Holdings LLC [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate	14.25%
Margin	6.50%
Floor	9.75%
Ceiling	0.00%
ETP	4.00%
Maturity Date	Dec. 01, 2025
Principal Amount	$ 2,500
Investments at cost	2,475
Investments at fair value	$ 2,475
Liqid, Inc [Member] | Networking Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	14.00%	13.25%
Margin	6.25%	6.25%
Floor	9.50%	9.50%
Ceiling	0.00%	0.00%
ETP	4.00%	4.00%
Maturity Date	Sep. 01, 2024	Sep. 01, 2024
Principal Amount	$ 2,833	$ 3,333
Investments at cost	2,793	3,286
Investments at fair value	$ 2,793	$ 3,286
Liqid, Inc [Member] | Networking Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	14.00%	13.25%
Margin	6.25%	6.25%
Floor	9.50%	9.50%
Ceiling	0.00%	0.00%
ETP	4.00%	4.00%
Maturity Date	Sep. 01, 2024	Sep. 01, 2024
Principal Amount	$ 2,833	$ 3,333
Investments at cost	2,793	3,286
Investments at fair value	2,793	3,286
Liqid, Inc [Member] | Networking Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	364	364
Investments at fair value	$ 237	$ 243
Number of shares (in shares)	344,102	344,102
Liqid, Inc [Member] | Networking Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	14.00%	13.25%
Margin	6.25%	6.25%
Floor	9.50%	9.50%
Ceiling	0.00%	0.00%
ETP	4.00%	4.00%
Maturity Date	Sep. 01, 2024	Sep. 01, 2024
Principal Amount	$ 1,417	$ 1,667
Investments at cost	1,395	1,641
Investments at fair value	$ 1,395	$ 1,641
Liqid, Inc [Member] | Networking Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate	14.00%	13.25%
Margin	6.25%	6.25%
Floor	9.50%	9.50%
Ceiling	0.00%	0.00%
ETP	4.00%	4.00%
Maturity Date	Sep. 01, 2024	Sep. 01, 2024
Principal Amount	$ 1,417	$ 1,667
Investments at cost	1,395	1,641
Investments at fair value	$ 1,395	$ 1,641
Liqid, Inc [Member] | Networking Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Five [Member]
Cash Rate	14.00%	13.25%
Margin	6.25%	6.25%
Floor	9.50%	9.50%
Ceiling	0.00%	0.00%
ETP	4.00%	4.00%
Maturity Date	Sep. 01, 2024	Sep. 01, 2024
Principal Amount	$ 1,417	$ 1,667
Investments at cost	1,371	1,613
Investments at fair value	1,371	1,613
CVRx, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member]
Investments at cost	76	76
Investments at fair value	$ 72	$ 394
Number of shares (in shares)	47,410	47,410
Halio, Inc [Member] | Power Management Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	$ 1,585	$ 1,585
Investments at fair value	$ 2,808	$ 2,610
Number of shares (in shares)	5,002,574	5,002,574
Avalanche Technology, Inc [Member] | Semiconductor Sector [Member] | Investment, Unaffiliated Issuer [Member] | Warrant [Member]
Investments at cost	$ 57	$ 56
Investments at fair value	$ 0	$ 0
Number of shares (in shares)	6,081	6,081
Britecore Holdings, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	14.50%	13.75%
Margin	6.75%	6.75%
Floor	10.00%	10.00%
Ceiling	0.00%	0.00%
ETP	5.00%	5.00%
Maturity Date	Mar. 01, 2026	Mar. 01, 2026
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,488	2,421
Investments at fair value	$ 2,488	$ 2,421
Britecore Holdings, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	14.50%	13.75%
Margin	6.75%	6.75%
Floor	10.00%	10.00%
Ceiling	0.00%	0.00%
ETP	5.00%	5.00%
Maturity Date	Mar. 01, 2026	Mar. 01, 2026
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,488	2,487
Investments at fair value	2,488	2,487
Britecore Holdings, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	21	21
Investments at fair value	$ 67	$ 69
Number of shares (in shares)	77,828	77,828
Britecore Holdings, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	14.50%
Margin	6.75%
Floor	10.00%
Ceiling	0.00%
ETP	3.00%
Maturity Date	Mar. 01, 2027
Principal Amount	$ 2,500
Investments at cost	2,467
Investments at fair value	$ 2,467
Britecore Holdings, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate	14.50%
Margin	6.75%
Floor	10.00%
Ceiling	0.00%
ETP	3.00%
Maturity Date	Mar. 01, 2027
Principal Amount	$ 2,500
Investments at cost	2,467
Investments at fair value	2,467
E La Carte, Inc [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member]
Investments at cost	60	$ 60
Investments at fair value	$ 0	$ 3
Number of shares (in shares)	147,361	147,361
Revinate Holdings, Inc [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	$ 44	$ 46
Investments at fair value	$ 97	$ 99
Number of shares (in shares)	682,034	682,034
Riv Data Corp [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	$ 12	$ 12
Investments at fair value	$ 296	$ 296
Number of shares (in shares)	321,428	321,428
SIGNiX, Inc [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	$ 225	$ 225
Investments at fair value	$ 0	$ 0
Number of shares (in shares)	186,235	186,235
Skyword, Inc [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Warrant [Member]
Investments at cost		$ 48
Investments at fair value		$ 1
Number of shares (in shares)		301,055
Topia Mobility, Inc [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	$ 138	$ 138
Investments at fair value	$ 0	$ 0
Number of shares (in shares)	3,049,607	3,049,607
xAd, Inc [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	$ 177	$ 177
Investments at fair value	$ 11	$ 12
Number of shares (in shares)	4,343,348	4,343,348

XML

Consolidated Schedule of Investments (Unaudited) - Investments (Details) (Parentheticals)	Mar. 31, 2023	Dec. 31, 2022
NAV %	222.40%	226.10%
Investment, Unaffiliated Issuer [Member]
NAV %	221.10%	226.10%
Investment, Unaffiliated Issuer [Member] | Warrant [Member]
NAV %	8.00%	9.40%
Investment, Unaffiliated Issuer [Member] | Warrant [Member] | Healthcare Sector [Member]
NAV %	0.60%	0.60%
Investment, Unaffiliated Issuer [Member] | Warrant [Member] | Life Science [Member]
NAV %	2.10%	3.10%
Investment, Unaffiliated Issuer [Member] | Warrant [Member] | Sustainability Segment [Member]
NAV %	0.20%	0.60%
Investment, Unaffiliated Issuer [Member] | Warrant [Member] | Technology Sector [Member]
NAV %	5.10%	5.10%
Investment, Unaffiliated Issuer [Member] | Other Long-Term Investments [Member]
NAV %	0.40%	0.40%
Investment, Unaffiliated Issuer [Member] | Equity Securities [Member]
NAV %	0.90%	0.80%
Investment, Unaffiliated Issuer [Member] | Debt Securities [Member]
NAV %	212.80%	215.50%
Investment, Unaffiliated Issuer [Member] | Debt Securities [Member] | Healthcare Sector [Member]
NAV %	8.10%	8.10%
Investment, Unaffiliated Issuer [Member] | Debt Securities [Member] | Life Science [Member]
NAV %	95.70%	99.70%
Investment, Unaffiliated Issuer [Member] | Debt Securities [Member] | Sustainability Segment [Member]
NAV %	25.80%	26.30%
Investment, Unaffiliated Issuer [Member] | Debt Securities [Member] | Technology Sector [Member]
NAV %	83.20%	81.40%
Investment, Affiliated Issuer, Noncontrolled [Member]
NAV %	0.30%
Investment, Affiliated Issuer, Noncontrolled [Member] | Equity Securities [Member] | Life Science [Member]
NAV %	0.30%

XML

Note 2 - Basis of Presentation and Significant Accounting Policies (Details Textual) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended		23 Months Ended
	Mar. 14, 2022	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Dec. 31, 2022	Apr. 28, 2022	Aug. 02, 2021
Investments, Nonaccrual, Interest Income		$ 0	$ 0
Investment, Nonaccrual, Income Not Received in Cash, Percent		6.30%	9.50%
Debt Issuance Costs, Net		$ 6,600		$ 6,600	$ 7,100
Accumulated Amortization, Debt Issuance Costs		5,300		$ 5,300	4,800
Amortization of Debt Issuance Costs		$ 478	$ 336
Federal Excise Tax, Percent		4.00%		4.00%
Investment Income, Operating, Tax Expense (Benefit)		$ 184	100
Unrecognized Tax Benefits, Ending Balance		$ 0		$ 0	0
Open Tax Year		2019 2020 2021
Proceeds from Issuance of Common Stock		$ 7,174	$ 38,187
Stock Repurchase Program, Remaining Authorized Repurchase Amount						$ 5,000
Stock Repurchased During Period, Shares (in shares)		0	0	167,465
Stock Repurchased During Period, Per Share (in dollars per share)				$ 11.22
Stock Repurchased During Period, Value				$ 1,900
The 2021 Equity Distribution Agreement [Member]
Equity Sales Agreement, Maximum Value							$ 100,000
Stock Issued During Period, Shares, New Issues (in shares)		605,848	250,171
Proceeds from Issuance of Common Stock		$ 7,200	$ 3,900
Payments of Stock Issuance Costs		200	$ 100
Equity Sales Agreement, Remaining Amount Available for Issuance		24,100		24,100
Public Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)	2,500,000
Proceeds from Issuance of Common Stock	$ 34,300
Shares Issued, Price Per Share (in dollars per share)	$ 14.35
Three Investments [Member]
Investments, Cost, Nonaccrual Status		20,300		20,300	20,900
Investments, Fair Value, Nonaccrual Status		$ 5,300		$ 5,300	$ 8,300

XML

Note 3 - Related Party Transactions (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	May 25, 2023	Dec. 31, 2022
Management Fee Payable	$ 1,059			$ 1,065
Management Fee Expense	3,201	$ 2,244
Incentive Fee Payable	2,978			1,392
Administrative Fees Expense	$ 440	362
Investment Management Agreement [Member]
Base Management Fee, Annual, Percent	2.00%
Base Management Fee, Annual, Percent, Gross Assets Exceeding $250 Million	1.60%
Management Fee Payable	$ 1,100			1,100
Management Fee Expense	$ 3,200	2,200
Incentive Fee to Pre-incentive Net Investment Income	20.00%
Pre-Incentive Fee Net Investment Income, Hurdle Rate	1.75%
Pre-Incentive Fee Net Investment Income, Hurdle Rate, Annualized	7.00%
Pre-Incentive Fee Net Investment Income, Catch-up, Percent	100.00%
Pre-Incentive Fee Net Investment Income, Maximum Rate to Trigger Catch-up	2.1875%
Pre-Incentive Fee Net Investment Income, Maximum Rate to Trigger Catch-up, Annualized	8.75%
Incentive Fee Expense	$ 3,000	1,400
Incentive Fee Cap and Deferral Mechanism Reduction to Expense	200
Incentive Fee Cap and Deferral Mechanism, Contingent Future Liability	1,300
Incentive Fee Payable	3,000			$ 1,400
Administration Agreement [Member]
Administrative Fees Expense	$ 400	$ 400
Affiliate of Monroe Capital LLC [Member] | Forecast [Member] | Horizon Technology Finance Management LLC (the Advisor) [Member]
Subsidiary, Ownership Percentage, Parent			100.00%

XML

Note 4 - Investments - Investments (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Investments at cost	$ 724,162	$ 721,248
Investments at fair value	715,312	720,026
Biotechnology Sector [Member]
Investments at cost	187,970	193,372
Investments at fair value	186,981	195,006
Medical Device Sector [Member]
Investments at cost	129,102	132,803
Investments at fair value	131,823	135,960
Communications Sector [Member]
Investments at cost	22,913	22,892
Investments at fair value	26,168	26,176
Consumer-related Sector [Member]
Investments at cost	107,802	121,961
Investments at fair value	99,140	114,050
Data Storage Sector [Member]
Investments at cost	476	476
Investments at fair value	1,302	1,316
Internet and Media Sector [Member]
Investments at cost	329	329
Investments at fair value	1,583	1,159
Networking Sector [Member]
Investments at cost	10,111	11,831
Investments at fair value	9,984	11,710
Power Management Sector [Member]
Investments at cost	1,585	1,585
Investments at fair value	2,808	2,610
Semiconductor Sector [Member]
Investments at cost	57	56
Investments at fair value	0	0
Software Sector [Member]
Investments at cost	145,706	120,157
Investments at fair value	143,680	118,716
Energy Efficiency [Member]
Investments at cost	8	8
Investments at fair value	27	27
Other Sustainability Sector [Member]
Investments at cost	84,753	84,633
Investments at fair value	83,734	85,524
Diagnostics Sector [Member]
Investments at cost	9,862	9,851
Investments at fair value	9,868	9,858
Other Healthcare Sector [Member]
Investments at cost	6,990	7,559
Investments at fair value	1,414	3,870
Software, Healthcare Information and Service [Member]
Investments at cost	16,498	13,735
Investments at fair value	16,800	14,044
Debt [Member]
Investments at cost	703,781	701,074
Investments at fair value	684,554	686,458
Warrant [Member]
Investments at cost	14,735	14,790
Investments at fair value	25,658	29,712
Other Debt Obligations [Member]
Investments at cost	1,200	1,200
Investments at fair value	1,300	1,300
Equity Securities [Member]
Investments at cost	4,446	4,184
Investments at fair value	$ 3,800	$ 2,556

XML

Note 5 - Transactions With Affiliated Companies (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Investment, Affiliated Issuer, Noncontrolled [Member]
Investments in and Advances to Affiliates, at Fair Value, Period Increase (Decrease)		$ 0
Investment, Affiliated Issuer, Controlled [Member]
Investments in and Advances to Affiliates, at Fair Value, Period Increase (Decrease)	$ 0

XML

Note 5 - Transactions With Affiliated Companies - Investments in Affiliated Companies (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Investments, fair value	$ 720,026
Unrealized Gain (Loss) on Investments	(7,537)	$ (2,237)
Net realized gain (loss) on investments	(168)	30
Investments, fair value	715,312
Investment, Affiliated Issuer, Noncontrolled [Member]
Investments, fair value	0
Purchases	0
Principal payments	0
Transfers in/(out) at fair value	0
Discount accretion	0
Unrealized Gain (Loss) on Investments	846	0
Net realized gain (loss) on investments	0
Investments, fair value	846
Interest income	0
Investment, Affiliated Issuer, Noncontrolled [Member] | Cadrenal Therapeutics, Inc. [Member]
Investments, fair value	0
Purchases	0
Principal payments	0
Transfers in/(out) at fair value	0
Discount accretion	0
Unrealized Gain (Loss) on Investments	846
Net realized gain (loss) on investments	0
Investments, fair value	846
Interest income	0
Investment, Affiliated Issuer, Controlled [Member]
Investments, fair value		0
Purchases		0
Principal payments		(50)
Transfers in/(out) at fair value		0
Discount accretion		0
Unrealized Gain (Loss) on Investments	$ 0	50
Net realized gain (loss) on investments		0
Investments, fair value		0
Interest income		0
Investment, Affiliated Issuer, Controlled [Member] | HESP LLC [Member]
Investments, fair value		0
Purchases		0
Principal payments		(50)
Transfers in/(out) at fair value		0
Discount accretion		0
Unrealized Gain (Loss) on Investments		50
Net realized gain (loss) on investments		0
Investments, fair value		0
Interest income		$ 0

XML

Note 6 - Fair Value (Details Textual) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($) $ / shares	Mar. 31, 2022 USD ($)	Dec. 31, 2022
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net	$ 0	$ 0
Unrealized Gain (Loss) on Investments	(7,537)	(2,237)
Fair Value, Inputs, Level 3 [Member] | Debt [Member]
Unrealized Gain (Loss) on Investments	(4,600)	(3,300)
Fair Value, Inputs, Level 3 [Member] | Warrant [Member]
Unrealized Gain (Loss) on Investments	(1,400)	$ 1,000
Fair Value, Inputs, Level 3 [Member] | Equity Securities [Member]
Unrealized Gain (Loss) on Investments	$ 200
The 2026 Notes [Member]
Debt Instrument, Share Price (in dollars per share) | $ / shares	$ 23.39
The 2026 Notes [Member] | Fair Value, Inputs, Level 1 [Member]
Debt Instrument, Fair Value Disclosure	$ 53,800
The 2027 Notes [Member]
Debt Instrument, Share Price (in dollars per share) | $ / shares	$ 24.00
The 2027 Notes [Member] | Fair Value, Inputs, Level 1 [Member]
Debt Instrument, Fair Value Disclosure	$ 55,200
Asset-backed Notes 2019 [Member] | Fair Value, Inputs, Level 3 [Member]
Debt Instrument, Fair Value Disclosure	37,800
Asset-backed Notes 2022 [Member] | Fair Value, Inputs, Level 3 [Member]
Debt Instrument, Fair Value Disclosure	$ 100,000
Measurement Input, Hypothetical Market Yields [Member]
Debt Instrument, Measurement Input			0.25

XML

Note 6 - Fair Value - Assets at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Fair Value, Recurring [Member]
Investments, fair value	$ 715,312	$ 720,026
Fair Value, Recurring [Member] | Debt [Member]
Investments, fair value	684,554	686,458
Fair Value, Recurring [Member] | Warrant [Member]
Investments, fair value	25,658	29,712
Fair Value, Recurring [Member] | Other Investments [Member]
Investments, fair value	1,300	1,300
Fair Value, Recurring [Member] | Equity Securities [Member]
Investments, fair value	3,800	2,556
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member]
Investments, fair value	885	140
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | Debt [Member]
Investments, fair value	0	0
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | Warrant [Member]
Investments, fair value	0	0
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | Other Investments [Member]
Investments, fair value	0	0
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | Equity Securities [Member]
Investments, fair value	885	140
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member]
Investments, fair value	1,020	3,567
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | Debt [Member]
Investments, fair value	0	0
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | Warrant [Member]
Investments, fair value	1,020	3,567
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | Other Investments [Member]
Investments, fair value	0	0
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | Equity Securities [Member]
Investments, fair value	0	0
Fair Value, Inputs, Level 3 [Member]
Investments, fair value	713,407	716,319
Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member]
Investments, fair value	713,407	716,319
Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member] | Debt [Member]
Investments, fair value	684,554	686,458
Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member] | Warrant [Member]
Investments, fair value	24,638	26,145
Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member] | Other Investments [Member]
Investments, fair value	1,300	1,300
Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member] | Equity Securities [Member]
Investments, fair value	$ 2,915	$ 2,416

XML

Note 6 - Fair Value - Significant Level 3 Fair Value Measurement Inputs (Details) - Fair Value, Inputs, Level 3 [Member]		Mar. 31, 2023 USD ($)		Dec. 31, 2022 USD ($)
Investments, fair value		$ 713,407,000		$ 716,319,000
Debt [Member] | Valuation Technique, Discounted Cash Flow [Member]
Investments, fair value		$ 644,854,000		$ 669,617,000
Debt [Member] | Valuation Technique, Discounted Cash Flow [Member] | Minimum [Member] | Hypothetical Market Yield [Member]
Investments, measurement input		0.11		0.03
Debt [Member] | Valuation Technique, Discounted Cash Flow [Member] | Maximum [Member] | Hypothetical Market Yield [Member]
Investments, measurement input		0.20	[1]	0.22
Debt [Member] | Valuation Technique, Discounted Cash Flow [Member] | Weighted Average [Member] | Hypothetical Market Yield [Member]
Investments, measurement input		0.14		0.14	[1]
Debt [Member] | Multiple Probability Weighted Cash Flow Model [Member]
Investments, fair value		$ 39,700,000		$ 16,545,000
Debt [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Minimum [Member] | Probability Weighting [Member]
Investments, measurement input		0.10		0.10
Debt [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Maximum [Member] | Probability Weighting [Member]
Investments, measurement input		1	[1]	0.75
Debt [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Weighted Average [Member] | Probability Weighting [Member]
Investments, measurement input		0.43		0.31	[1]
Debt [Member] | Black-scholes Valuation Model [Member]
Investments, fair value				$ 26,145,000
Debt [Member] | Black-scholes Valuation Model [Member] | Measurement Input, Price Volatility [Member]
Investments, measurement input				0.28
Debt [Member] | Black-scholes Valuation Model [Member] | Measurement Input, Discount for Lack of Marketability [Member]
Investments, measurement input				0.20
Debt [Member] | Black-scholes Valuation Model [Member] | Minimum [Member] | Measurement Input, Share Price [Member]
Investments, measurement input				0.00
Debt [Member] | Black-scholes Valuation Model [Member] | Minimum [Member] | Estimated Time to Exit [Member]
Investments, measurement input				1
Debt [Member] | Black-scholes Valuation Model [Member] | Maximum [Member] | Measurement Input, Share Price [Member]
Investments, measurement input				1.899
Debt [Member] | Black-scholes Valuation Model [Member] | Maximum [Member] | Estimated Time to Exit [Member]
Investments, measurement input				5
Debt [Member] | Black-scholes Valuation Model [Member] | Weighted Average [Member] | Measurement Input, Share Price [Member]
Investments, measurement input	[1]			58.52
Debt [Member] | Black-scholes Valuation Model [Member] | Weighted Average [Member] | Measurement Input, Price Volatility [Member]
Investments, measurement input	[1]			0.28
Debt [Member] | Black-scholes Valuation Model [Member] | Weighted Average [Member] | Measurement Input, Discount for Lack of Marketability [Member]
Investments, measurement input	[1]			0.20
Debt [Member] | Black-scholes Valuation Model [Member] | Weighted Average [Member] | Estimated Time to Exit [Member]
Investments, measurement input	[1]			3
Debt [Member] | Convertible Note Analysis [Member]
Investments, fair value				$ 296,000
Debt [Member] | Convertible Note Analysis [Member] | Measurement Input, Share Price [Member]
Investments, measurement input				168.93
Debt [Member] | Convertible Note Analysis [Member] | Weighted Average [Member] | Measurement Input, Share Price [Member]
Investments, measurement input	[1]			168.93
Warrant [Member] | Black-scholes Valuation Model [Member]
Investments, fair value		$ 24,638,000
Warrant [Member] | Black-scholes Valuation Model [Member] | Measurement Input, Price Volatility [Member]
Investments, measurement input		0.28
Warrant [Member] | Black-scholes Valuation Model [Member] | Measurement Input, Discount for Lack of Marketability [Member]
Investments, measurement input		0.20
Warrant [Member] | Black-scholes Valuation Model [Member] | Minimum [Member] | Measurement Input, Share Price [Member]
Investments, measurement input		0.10
Warrant [Member] | Black-scholes Valuation Model [Member] | Minimum [Member] | Measurement Input, Discount for Lack of Marketability [Member]
Investments, measurement input		0.20
Warrant [Member] | Black-scholes Valuation Model [Member] | Minimum [Member] | Estimated Time to Exit [Member]
Investments, measurement input		1
Warrant [Member] | Black-scholes Valuation Model [Member] | Maximum [Member] | Measurement Input, Share Price [Member]
Investments, measurement input	[1]	1,899
Warrant [Member] | Black-scholes Valuation Model [Member] | Maximum [Member] | Estimated Time to Exit [Member]
Investments, measurement input	[1]	5
Warrant [Member] | Black-scholes Valuation Model [Member] | Weighted Average [Member] | Measurement Input, Share Price [Member]
Investments, measurement input		62.82
Warrant [Member] | Black-scholes Valuation Model [Member] | Weighted Average [Member] | Measurement Input, Price Volatility [Member]
Investments, measurement input		0.28
Warrant [Member] | Black-scholes Valuation Model [Member] | Weighted Average [Member] | Estimated Time to Exit [Member]
Investments, measurement input		3
Other Investments [Member] | Multiple Probability Weighted Cash Flow Model [Member]
Investments, fair value		$ 1,300,000		$ 1,300,000
Other Investments [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Probability Weighting [Member]
Investments, measurement input		1		1
Other Investments [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Measurement Input, Discount Rate [Member]
Investments, measurement input		0.25		0.25
Other Investments [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Weighted Average [Member] | Probability Weighting [Member]
Investments, measurement input		1		1	[1]
Other Investments [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Weighted Average [Member] | Measurement Input, Discount Rate [Member]
Investments, measurement input		0.25		0.25	[1]
Equity Securities [Member] | Last Equity Financing [Member]
Investments, fair value		$ 2,915,000		$ 24.16
Equity Securities [Member] | Last Equity Financing [Member] | Weighted Average [Member] | Measurement Input, Share Price [Member]
Investments, measurement input		40.27		26.93	[1]

[1] Weighted average is calculated by multiplying (a) the unobservable input for each investment in the investment type by (b) (1) the fair value of the related investment in the investment type divided by (2) the total fair value of the investment type.

XML

Note 6 - Fair Value - Reconciliation of Level 3 Assets Measured on a Recurring Basis (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Balance	$ 716,319	$ 457,557
Purchase of investments	47,008	94,485
Warrants received and classified as Level 3	141	808
Principal payments received on investments	(39,756)	14,145
Payment-in-kind interest on investments	1,204
Proceeds from sale of investments	(6,520)	21,280
Net realized gain (loss) on investments	(134)	30
Unrealized (depreciation) appreciation included in earnings	(5,867)	(2,120)
Transfer out of debt investments	0
Other	1,012	(1,093)
Balance	713,407	514,242
Principal payments received on investments	39,756	(14,145)
Proceeds from sale of investments	6,520	(21,280)
Debt [Member]
Balance	686,458	437,317
Purchase of investments	46,998	94,485
Warrants received and classified as Level 3	0	0
Principal payments received on investments	(39,756)	14,095
Payment-in-kind interest on investments	1,204
Proceeds from sale of investments	(6,508)	21,250
Net realized gain (loss) on investments	7	0
Unrealized (depreciation) appreciation included in earnings	(4,566)	(3,170)
Transfer out of debt investments	(295)
Other	1,012	(1,093)
Balance	684,554	492,194
Principal payments received on investments	39,756	(14,095)
Proceeds from sale of investments	6,508	(21,250)
Warrant [Member]
Balance	26,145	19,837
Purchase of investments	0	0
Warrants received and classified as Level 3	141	808
Principal payments received on investments	0	0
Payment-in-kind interest on investments	0
Proceeds from sale of investments	(12)	30
Net realized gain (loss) on investments	(141)	30
Unrealized (depreciation) appreciation included in earnings	(1,490)	1,000
Transfer out of debt investments	(5)
Other	0	0
Balance	24,638	21,645
Principal payments received on investments	(0)	0
Proceeds from sale of investments	12	(30)
Equity Securities [Member]
Balance	2,416	203
Purchase of investments	10	0
Warrants received and classified as Level 3	0	0
Principal payments received on investments	0	0
Payment-in-kind interest on investments	0
Proceeds from sale of investments	0	0
Net realized gain (loss) on investments	0	0
Unrealized (depreciation) appreciation included in earnings	189	0
Transfer out of debt investments	300
Other	0	0
Balance	2,915	203
Principal payments received on investments	(0)	0
Proceeds from sale of investments	(0)	0
Other Investments [Member]
Balance	1,300	200
Purchase of investments	0	0
Warrants received and classified as Level 3	0	0
Principal payments received on investments	0	50
Payment-in-kind interest on investments	0
Proceeds from sale of investments	0	0
Net realized gain (loss) on investments	0	0
Unrealized (depreciation) appreciation included in earnings	0	50
Transfer out of debt investments	0
Other	0	0
Balance	1,300	200
Principal payments received on investments	(0)	(50)
Proceeds from sale of investments	$ (0)	$ 0

XML

Note 7 - Borrowings (Details Textual) - USD ($) $ / shares in Units, $ in Thousands			3 Months Ended	12 Months Ended	21840 Months Ended
	Feb. 25, 2022	Apr. 21, 2020	Mar. 31, 2023	Dec. 31, 2021	Feb. 25, 2022	Dec. 31, 2022	Nov. 09, 2022	Jun. 15, 2022	Jun. 22, 2021	Mar. 30, 2021	Aug. 13, 2019
Asset Coverage to Borrowings, Ratio, Percent			172.00%
Restricted Investments			$ 2,987			$ 2,788
Long-Term Debt, Gross			444,541			439,323
Debt Instrument, Face Amount			$ 577,791			582,573
Key Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity, Accordian Feature									$ 150,000
Line of Credit Facility, Maximum Borrowing Capacity									$ 125,000
Line of Credit Facility, Advance Rate of Eligible Debt Investments									60.00%
Long-Term Debt, Weighted Average Interest Rate, over Time			7.94%	4.25%
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage			0.50%
Line of Credit Facility, Current Borrowing Capacity			$ 110,000			120,000
Line of Credit Facility, Remaining Borrowing Capacity			47,700			40,200
Long-Term Debt, Gross			15,000			5,000
Debt Instrument, Face Amount			$ 125,000			$ 125,000
Key Facility [Member] | Prime Rate [Member]
Debt Instrument, Basis Spread on Variable Rate			0.25%
Debt Instrument, Variable Rate			8.00%			7.50%
NYL Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity	$ 200,000	$ 100,000			$ 200,000
Line of Credit Facility, Current Borrowing Capacity			$ 23,200			$ 23,200
Line of Credit Facility, Remaining Borrowing Capacity			21,100			23,200
Line of Credit Facility, Maximum Borrowing Capacity, Accordion Feature		$ 200,000
Line of Credit Facility, Advance Rate		67.00%
Line of Credit Facility, Change in Maximum Borrowing Capacity	$ 100,000
Long-Term Line of Credit			$ 176,800			$ 176,800
Line of Credit Facility, Interest Rate at Period End			5.57%			5.57%
Restricted Investments			$ 1,300			$ 1,000
Long-Term Debt, Gross			176,750			176,750
Debt Instrument, Face Amount			200,000			200,000
NYL Facility [Member] | USD Mid-market Wwap Rate [Member]
Debt Instrument, Basis Spread on Variable Rate					3.00%
Asset-backed Notes 2019 [Member]
Restricted Investments			500			600
Debt Instrument, Interest Rate, Stated Percentage											4.21%
Long-Term Debt, Gross			37,791			42,573
Debt Instrument, Face Amount			37,791			42,573					$ 160,000
Asset-backed Notes 2022 [Member]
Restricted Investments			1,100			1,000
Debt Instrument, Interest Rate, Stated Percentage							7.56%
Long-Term Debt, Gross			100,000			100,000
Debt Instrument, Face Amount			100,000			100,000	$ 157,800
The 2026 Notes [Member]
Debt Instrument, Interest Rate, Stated Percentage										4.875%
Long-Term Debt, Gross			57,500			57,500
Debt Instrument, Face Amount			57,500			57,500				$ 57,500
The 2026 Notes Underwriter Option [Member]
Debt Instrument, Face Amount										$ 7,500
Debt Instrument, Convertible, Conversion Price (in dollars per share)										$ 25
The 2027 Notes [Member]
Debt Instrument, Interest Rate, Stated Percentage								6.25%
Long-Term Debt, Gross			57,500			57,500
Debt Instrument, Face Amount			$ 57,500			$ 57,500		$ 50,000
The 2027 Notes Underwriter Option [Member]
Debt Instrument, Face Amount								$ 7,500
Debt Instrument, Convertible, Conversion Price (in dollars per share)								$ 25
Minimum [Member]
Asset Coverage to Borrowings, Ratio, Percent			150.00%
Minimum [Member] | Key Facility [Member] | Prime Rate [Member]
Debt Instrument, Basis Spread on Variable Rate			4.25%
Minimum [Member] | NYL Facility [Member] | USD Mid-market Wwap Rate [Member]
Debt Instrument, Basis Spread on Variable Rate		3.55%
Maximum [Member] | NYL Facility [Member] | USD Mid-market Wwap Rate [Member]
Debt Instrument, Basis Spread on Variable Rate		5.15%

XML

Note 7 - Borrowings - Borrowings (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022	Nov. 09, 2022	Jun. 15, 2022	Mar. 30, 2021	Aug. 13, 2019
Total commitment	$ 577,791	$ 582,573
Balance outstanding	444,541	439,323
Unused commitment	133,250	143,250
Unamortized debt issuance costs attributable to term borrowings	(4,896)	(5,245)
Total borrowings outstanding, net	439,645	434,078
Key Facility [Member]
Total commitment	125,000	125,000
Balance outstanding	15,000	5,000
Unused commitment	110,000	120,000
NYL Facility [Member]
Total commitment	200,000	200,000
Balance outstanding	176,750	176,750
Unused commitment	23,250	23,250
Asset-backed Notes 2019 [Member]
Total commitment	37,791	42,573				$ 160,000
Balance outstanding	37,791	42,573
Unused commitment	0	0
Asset-backed Notes 2022 [Member]
Total commitment	100,000	100,000	$ 157,800
Balance outstanding	100,000	100,000
Unused commitment	0	0
The 2027 Notes [Member]
Total commitment	57,500	57,500		$ 50,000
Balance outstanding	57,500	57,500
Unused commitment	0	0
The 2026 Notes [Member]
Total commitment	57,500	57,500			$ 57,500
Balance outstanding	57,500	57,500
Unused commitment	$ 0	$ 0

XML

Note 8 - Financial Instruments With Off-balance-sheet Risk (Details Textual) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Fair Value Disclosure, off-Balance-Sheet Risks, Amount, Liability	$ 1,496	$ 1,761
Commitments to Extend Credit [Member]
Other Commitment	$ 166,200	$ 190,000

XML

Note 8 - Financial Instruments With Off-balance-sheet Risk - Unfunded Commitments (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Unfunded commitments, principal balance	$ 166,200	$ 190,000
Fair value of unfunded commitment liability	1,496	1,761
BrightInsight, Inc. [Member]
Unfunded commitments, principal balance	18,250	21,000
Fair value of unfunded commitment liability	241	278
Britecore Holdings, Inc. [Member]
Unfunded commitments, principal balance	0	5,000
Fair value of unfunded commitment liability	0	66
Castle Creek Biosciences [Member]
Unfunded commitments, principal balance	4,000	4,000
Fair value of unfunded commitment liability	72	72
Corinth Medtech, Inc [Member]
Unfunded commitments, principal balance	200	0
Fair value of unfunded commitment liability	0	0
Divergent Technologies, Inc. [Member]
Unfunded commitments, principal balance	18,750	22,500
Fair value of unfunded commitment liability	197	236
Engage3, LLC [Member]
Unfunded commitments, principal balance	8,000	8,000
Fair value of unfunded commitment liability	40	40
Groundspeed Analytics, Inc. [Member]
Unfunded commitments, principal balance	15,500	15,000
Fair value of unfunded commitment liability	150	150
Hound Labs, Inc. [Member]
Unfunded commitments, principal balance	7,500	7,500
Fair value of unfunded commitment liability	88	88
KSQ Therapeutics, Inc. [Member]
Unfunded commitments, principal balance	10,000	10,000
Fair value of unfunded commitment liability	100	100
Lytics, Inc. [Member]
Unfunded commitments, principal balance	4,000	5,000
Fair value of unfunded commitment liability	52	65
Native Microbials, Inc. [Member]
Unfunded commitments, principal balance	0	7,500
Fair value of unfunded commitment liability	0	72
Noodle Partners, Inc. [Member]
Unfunded commitments, principal balance	10,000	0
Fair value of unfunded commitment liability	123	0
Optoro, Inc. [Member]
Unfunded commitments, principal balance	15,000	15,000
Fair value of unfunded commitment liability	38	38
PDS Biotechnology Corporation [Member]
Unfunded commitments, principal balance	10,000	10,000
Fair value of unfunded commitment liability	158	158
Robin Healthcare, Inc. [Member]
Unfunded commitments, principal balance	5,000	10,000
Fair value of unfunded commitment liability	50	100
Scientia Vascular, Inc. [Member]
Unfunded commitments, principal balance	10,000	10,000
Fair value of unfunded commitment liability	110	110
Slingshot Aerospace, Inc. [Member]
Unfunded commitments, principal balance	5,000	5,000
Fair value of unfunded commitment liability	63	64
Swift Health Systems Inc. [Member]
Unfunded commitments, principal balance	18,500	25,500
Fair value of unfunded commitment liability	0	105
Temperpack Technologies, Inc [Member]
Unfunded commitments, principal balance	6,500	9,000
Fair value of unfunded commitment liability	$ 14	$ 19

XML

Note 9 - Concentrations of Credit Risk (Details Textual) - Debt Investments [Member] - Five Largest Debt Investments [Member]	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Investment Concentration Risk [Member]
Concentration Risk, Percentage	23.00%		23.00%
Investment Income Concentration Risk [Member]
Concentration Risk, Percentage	22.00%	26.00%

XML

Note 10 - Distributions (Details Textual) - $ / shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Common Stock, Dividends, Per Share, Cash Paid (in dollars per share)	$ 0.33
Earnings Per Share, Basic (in dollars per share)	0.46	$ 0.26
Earnings Per Share, Basic, Undistributed (in dollars per share)	$ 0.81

XML

Note 10 - Distributions - Distribution Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Distributions declared per share (in dollars per share)	$ 0.33	$ 0.30		$ 1.28
Dividends, cash	$ 3,035			$ 32,659
Dividends, shares (in shares)	6,894			61,859
Dividends, stock	$ 81			$ 754
June 15, 2023 Dividend [Member] | Forecast [Member]
Distributions declared per share (in dollars per share)			$ 0.11
July 17, 2023 Dividend [Member] | Forecast [Member]
Distributions declared per share (in dollars per share)			0.11
First 2/23/2023 Dividend [Member]
Record date	May 18, 2023
Payment date	Jun. 14, 2023
Distributions declared per share (in dollars per share)	$ 0.11
Dividends, cash	$ 0
Dividends, shares (in shares)	0
Dividends, stock	$ 0
August 16, 2023 Dividend [Member] | Forecast [Member]
Distributions declared per share (in dollars per share)			$ 0.11
Second 2/23/2023 Dividend [Member]
Record date	Apr. 18, 2023
Payment date	May 16, 2023
Distributions declared per share (in dollars per share)	$ 0.11
Dividends, cash	$ 0
Dividends, shares (in shares)	0
Dividends, stock	$ 0
Third 2/23/2023 Dividend [Member]
Record date	Mar. 17, 2023
Payment date	Apr. 14, 2023
Distributions declared per share (in dollars per share)	$ 0.11
Dividends, cash	$ 3,035
Dividends, shares (in shares)	6,894
Dividends, stock	$ 81
First 10/28/2022 Dividend [Member]
Record date				Feb. 17, 2023
Payment date				Mar. 15, 2023
Distributions declared per share (in dollars per share)				$ 0.11
Dividends, cash				$ 3,040
Dividends, shares (in shares)				6,764
Dividends, stock				$ 75
Second 10/28/2022 Dividend [Member]
Record date				Jan. 18, 2023
Payment date				Feb. 15, 2023
Distributions declared per share (in dollars per share)				$ 0.11
Dividends, cash				$ 3,021
Dividends, shares (in shares)				5,754
Dividends, stock				$ 74
Third 10/28/2022 Dividend [Member]
Record date				Dec. 19, 2022
Payment date				Jan. 13, 2023
Distributions declared per share (in dollars per share)				$ 0.11
Dividends, cash				$ 2,978
Dividends, shares (in shares)				5,618
Dividends, stock				$ 69
Fourth 10/28/2022 Dividend [Member]
Record date				Nov. 17, 2022
Payment date				Dec. 15, 2022
Distributions declared per share (in dollars per share)				$ 0.05
Dividends, cash				$ 1,319
Dividends, shares (in shares)				2,171
Dividends, stock				$ 27
First 7/29/2022 Dividend [Member]
Record date				Nov. 17, 2022
Payment date				Dec. 15, 2022
Distributions declared per share (in dollars per share)				$ 0.10
Dividends, cash				$ 2,638
Dividends, shares (in shares)				4,341
Dividends, stock				$ 57
Second 7/29/2022 Dividend [Member]
Record date				Oct. 18, 2022
Payment date				Nov. 15, 2022
Distributions declared per share (in dollars per share)				$ 0.10
Dividends, cash				$ 2,580
Dividends, shares (in shares)				4,621
Dividends, stock				$ 60
Third 7/29/2022 Dividend [Member]
Record date				Sep. 19, 2022
Payment date				Oct. 14, 2022
Distributions declared per share (in dollars per share)				$ 0.10
Dividends, cash				$ 2,558
Dividends, shares (in shares)				7,703
Dividends, stock				$ 81
First 4/29/22 Dividend [Member]
Record date				Aug. 18, 2022
Payment date				Sep. 15, 2022
Distributions declared per share (in dollars per share)				$ 0.10
Dividends, cash				$ 2,528
Dividends, shares (in shares)				4,925
Dividends, stock				$ 60
Second 4/29/2022 Dividend [Member]
Record date				Jul. 19, 2022
Payment date				Aug. 16, 2022
Distributions declared per share (in dollars per share)				$ 0.10
Dividends, cash				$ 2,484
Dividends, shares (in shares)				3,939
Dividends, stock				$ 55
Third 4/29/2022 Dividend [Member]
Record date				Jun. 17, 2022
Payment date				Jul. 15, 2022
Distributions declared per share (in dollars per share)				$ 0.10
Dividends, cash				$ 2,434
Dividends, shares (in shares)				4,286
Dividends, stock				$ 51
First 2/25/2022 Dividend [Member]
Record date				May 18, 2022
Payment date				Jun. 15, 2022
Distributions declared per share (in dollars per share)				$ 0.10
Dividends, cash				$ 2,378
Dividends, shares (in shares)				4,428
Dividends, stock				$ 50
Second 2/25/2022 Dividend [Member]
Record date				Apr. 19, 2022
Payment date				May 16, 2022
Distributions declared per share (in dollars per share)				$ 0.10
Dividends, cash				$ 2,349
Dividends, shares (in shares)				4,088
Dividends, stock				$ 49
Third 2/25/2022 Dividend [Member]
Record date				Mar. 18, 2022
Payment date				Apr. 14, 2022
Distributions declared per share (in dollars per share)				$ 0.10
Dividends, cash				$ 2,352
Dividends, shares (in shares)				3,221
Dividends, stock				$ 46

XML

Note 11 - Financial Highlights - Financial Highlights (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended
		Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Net asset value at beginning of period (in dollars per share)		$ 11.47	$ 11.56
Net investment income (in dollars per share)		0.46	0.26
Realized loss (in dollars per share)		(0.01)	0
Unrealized depreciation on investments (in dollars per share)		(0.26)	(0.10)
Net increase in net assets resulting from operations (in dollars per share)		0.19	0.16
Distributions declared (in dollars per share)	[1]	(0.33)	(0.30)
From net investment income (in dollars per share)		(0.33)	(0.30)
From net realized gain on investments (in dollars per share)		0	0
Return of capital (in dollars per share)		0	0
Other (in dollars per share)	[2]	0.01	0.26
Net asset value at end of period (in dollars per share)		11.34	11.68
Per share market value, beginning of period (in dollars per share)		11.60	15.92
Per share market value, end of period (in dollars per share)		$ 11.28	$ 13.90
Total return based on a market value	[3]	0.10%	(10.80%)
Shares outstanding at end of period (in shares)		28,377,357	23,977,137	27,753,373
Expenses without incentive value	[4]	14.80%	10.60%
Incentive fees	[4]	3.70%	2.20%
Net expenses	[4]	18.50%	12.80%
Net investment income with incentive fees	[4]	16.30%	8.70%
Net assets at the end of the period		$ 321,683	$ 279,989	$ 318,448
Average net asset value		$ 320,066	$ 262,662
Average debt per share (in dollars per share)		$ 15.61	$ 12.21
Portfolio turnover ratio	[5]	4.20%	2.60%

[1] Distributions are determined based on taxable income calculated in accordance with income tax regulations, which may differ from amounts determined under GAAP due to (i) changes in unrealized appreciation and depreciation, (ii) temporary and permanent differences in income and expense recognition, and (iii) the amount of spillover income carried over from a given tax year for distribution in the following tax year. The final determination of taxable income for each tax year, as well as the tax attributes for distributions in such tax year, will be made after the close of the tax year.

[2] Includes the impact of the different share amounts as a result of calculating per share data based on the weighted average basic shares outstanding during the period and certain per share data based on the shares outstanding as of a period end or transaction date. The issuance of common stock on a per share basis reflects the incremental net asset value changes as a result of the issuance of common stock in the Company’s continuous public offering and pursuant to the Company’s distribution reinvestment plan. The issuance of common stock at an offering price, net of sales commissions and dealer manager fees, that is greater than the net asset value per share results in an increase in net asset value per share.

[3] The total return equals the change in the ending market value over the beginning of period price per share plus distributions paid per share during the period, divided by the beginning price.

[4] Annualized.

[5] Calculated by dividing the lesser of purchases or the sum of (1) principal prepayments and (2) maturities by the monthly average debt investment balance.

XML

Note 12 - Subsequent Events (Details Textual) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended
	Apr. 30, 2023	Mar. 31, 2023	Mar. 31, 2022
Proceeds from Issuance of Common Stock		$ 7,174	$ 38,187
The 2021 Equity Distribution Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares)		605,848	250,171
Proceeds from Issuance of Common Stock		$ 7,200	$ 3,900
Payments of Stock Issuance Costs		$ 200	$ 100
Subsequent Event [Member] | The 2021 Equity Distribution Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares)	272,303
Proceeds from Issuance of Common Stock	$ 3,100
Payments of Stock Issuance Costs	$ 100